var title_f31_44_32448="Calculator: Venous segmental disease score for reflux";
var content_f31_44_32448=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"VSDSReflux_form\" name=\"VSDSReflux_form\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Venous segmental disease score for reflux",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Thigh veins",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Small saphenous (0.5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Great saphenous (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Perforator, thigh (0.5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Popliteal vein (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Femoral vein (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Deep femoral vein (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Common femoral vein or above (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Calf veins",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VSDSReflux_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Posterior tibial alone (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VSDSReflux_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           More than one calf vein (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"VSDSReflux_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Perforators, calf (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Reflux is defined by total valve incompetence in the defined segment.",
"      </li>",
"      <li>",
"       Reflux points are not assigned above the common femoral vein.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Rutherford RB, Padberg FT Jr, Comerota AJ, et. al.  Venous severity scoring: An adjunct to venous outcome assessment.",
"        <i>",
"         J Vasc Surg",
"        </i>",
"        . 2000 Jun;31(6):1307-12.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"VSDSReflux_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32448=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function VSDSReflux_fx() {",
"with(document.VSDSReflux_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 0.5;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 0.5;",
"}",
"if (cc4.checked){",
"Score = Score + 2;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"if (cc8[0].checked){",
"Score = Score + 1;",
"}",
"if (cc8[1].checked){",
"Score = Score + 2;",
"}",
"if (cc9.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"}",
"}",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f31_44_32448=null;
var title_f31_44_32449="Straddle injury3";
var content_f31_44_32449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Straddle injury on picket fence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmH0+E52wxkEZPyCopNPhOSbeIn0Ciuh+zYBK4NNEOMbl4r5/2j7nvOC7HMS6ZCxJaCJWPUbcVWl0iMjIiQHsAOtdc1sMEcHHqahe03DJAB7Fe1WqrM3TRx39nLyDGvTghRRFaqFKtFGWJ7qOK6Z7Mkgnn0PSo5bPkFVAzjqa09qR7Mw47VMjMMRx1G0VMtqnIMcR9cIK1Gt8MNx+mOlSrbnAK/oaftBchmrZwkhfKj2gddgGaeLFCM+THx/sitJLcldzD2PBqWK3+YEE89F9KlzKUDNj0+Fs5hTOMfdFWE0+EBf3MYx1ygrUihCnHP1x0q0sKthk9fSs3PzLUTPj0+3AwLePOOfkHNTw6dDkA28WAOuwdK1LeDehKL781aih454XP6VlKT7lqxlpYwhV228XtlBzVqGxtgNzW0J9B5Y61eEWCBjJPr6VMIQV4Ubu/NYuT7mmhTXT4GP8Ax7w9Mn5BViPT7ViCbeDp0EYz/KrcUC44JJP5VaigIbg4/Cp52GhSi062BIFtB/37HNTrYWqgZtYD3/1Q/wAKvxxnPOFXpxUohy54yfrUXZPMihHY20mW+yQcdjEB/SpV0y0BB+zW/Pcxr/hWpGi9xk47jpQYyCOM/UUyXIzhpto23/R4Dj/pmv8AhQNPth8wtbdTng+UD/StRFXgAE89fSl2hVwRnnGaTv3FdGSbS1T79rACf+ma4/lSpZWhOfscIHvEvP6VpsgJ4UenNR7Ch46Hv6VnzPY0uin9is93Frbnj/nkv+FSCytvui2tiP8ArktWXUElUB+ppAMd8460J26iauVPsdnk5toAw/6ZDj9KDYWoHy2tvj3jX/CrjgZySPoKackfdOB6GjmYWRVWytQObW345/1S8/pSGztck/Zbcf8AbJf8Ksk4Hv8AWkU5CjP9aOdhbyK/2S0yCbW3x3/dD/CkNnankWtv1wB5S1OSDlm4wPWlUqu0Z+ho5n3CyIVsLQj/AI9rf/v0v+FMNnb7D/otvnH/ADzX/CrIbJPIAA54pH27sgn6mjmYWRTFjakKPssGe/7oUCytOd1tAT/1yWrh+bqcDr9ajfKjcqgip5itOxWNjajH+j2/08sVDJZWucC2t8j0jH+FX9nQn73Bz6D0pBw+DjPYU+Z9w0KD2FuIyxtoM/8AXNf8KadPtiB/otvz2Ea1olegOcn3qFEUO2O1XzMEjNFhajGbaDH/AFyXP8qa9jbBubeDHvGv+Faki7cknFRsFIHAwegoUmCsZjWVpjabaEY6EIuKheytcErbwEDqPLH+FaMiDPYe9RMo5BwB0B9feqTY9DOWxtckrbwL3+4MVBNZWwBIt4dw/wCmYrUVOQB0PGD3qGSI7sVXMx6GJLZ256W0XX+4KilsYiuVt4Qvp5Y/wrdMO0bnHXqPSoZo1JKjnHT3qoya6idjnnsoUwVhiB7fIKryWcRbd5EWO/yCt2SNAFyCF69OarTwLknJxjPStVN9yWkYUllCODDDn/dAqu1lEc4hiLD/AGcVsiHcOSWGePeo3hIIKjA6HPNaqb7kuKZiPZxnIEKD/gAposok4aKNl74StowMuTtO3160wxKcEfe7+tPnZm4rsZC2EQXIjiC+hXJo+xQk8RR+x2CtfyCy8g/1pUgG3gZ45p+0YciMp7KJT9yL/vgUqWkYz+4jIHfaK1xbhVUkZJ61KkOPujk9qlzfcpQXYzIrGLd/qY+e2wVYXT4QcmGJf+AitFYgAMc1OYxtwASTWbqPuVyrsZqafblcCGL1yEFFaYi2qD3xiilzvuPlRdMW1QFXrTkgHTgCr6Jx8y/iaJI9uVGfzqbjuZslvtOWJPPakMBReANw5HuK0vLLAcADpSLCoJLcGjmEZDwK20+/IqN7cA5Bz2xWwYw2fl9qiaDa53Lx0Heq5gsY/wBnLAqoIP1qOKBg2CAcnn/GtWWMrg7TjFCoFUYUHPenzBYpfZhnlc9xipvs5UZIGzrnP86siLJyRk/TpViKDEeVyw9PehyFsUdgXBIK9MAcjNW4IieD1PU4qWODMgJXI71ehhUKScknnFTzA7EKxBDjBJHHSrUMRACkAt71NFHxl8j0J7VNsbO4HJqGRcrtb5bJOc9KcIhtBAxmrYQbQccn1o2n7pPXipZXMyCGI5JHAHrVuGM5JLcmljTHoR04qaNcjOSOcc8VKQrgEKnJ69MU+PkEDjmlOSBkkY4p0ZGPQ/zo9BCqpAJYnFPwWznpjrRux65/lShz0IzSuIFU884+lS7QByeMce1IOOGJx/Kk5yQOQPSgLDWXLADIHtSMpGcAEY70vAU/Whs4POT2rJlETE4AB4NQ7CuRUgKgkHPJ+tNYjd1w1SWhu4YAwC1JkbRjv0prcAkAAd+ahllCHAxgY/Ggq1yQkHnjFBYqCQeahD7QN5AAPFEThuRyMk0Ds0SnbgA8kevrUbScgHp7+tKCTk47jrxioy21iewHemBLGBnJbJPJNPGcDoStRhvujjPekaVFQtIcADnNFxJMeuMsxYEGhySQOvHI7VW+1o0YIdBnoexqSFwOpBY0mPla1JkDsSduAOmOaRgoOQOTxnFKkgYkLgDFOHytmgTVhuDg54z6Coj1OQKkYluScEUDHcfN0+tO4iFowyH0prIu0EfifSpCcYzwfTNREkk5JGP1poZC6YX1GfSoNoPyn149qu/Lznoar7Rvzj9KpMaIXjA68e1QlctjpVmZPnGemacse5d2enJBqguUZEY9MelNeMKuSDu7EVaYqcggc8gimlNwxnn+VUhNmfJGqgnIz2qjOCDwcitaaHqxO4L6VVkiLMdg4FVcEUvLHlhlGD7U02zMBk57+9XZo8RBhjNMSNg4ZgcY6H1q0xFKWEgHaMgjiokhJPIHPYjpWr5JycZI20x4sZ4xRzCsZpgIYBV3HpR5QyATkjjNaIiwxCnPv70hhxnOM+tPmAzzF8uB19qlhiKrjjOKsrHjp160/wAs4PHzdzUuRRURQoxjvU6JujPyjPt1NSBASRn2xmpBH8gI4K/pU3ArbCv3wKKnbJxnkDvRRcDXVRgE5z0pWQFepHOenWptuMAGnbeeBz6GmSVfLGCemaaI+Mk5bpVkDjDDkdqYyDIPA9qLgQPHgZXp6dajZQVJ5DDp71bBIA/uk/hUUiAsSCMDmmmCK8cYK4b0+tNMIPTt1q0sZZgRxTjEVIPNANkXkAnJ7dKnChQAwB5z0qRYwQM5Bxn3qfaoXnr6Gi5LKgi+bng+1TxhRgYOenrU0Y5yFwe/1pWXsuPpS5hN3Ag7lKjhfSpgueSeR1pkOQ5zzx0xUsa5J9KL3JH/AHxwAeeM0oA3deSKmC8ED9e1M4B5xkcVLYkxGXacdfrUgHf14GaQod3Jz65qQIccngc0rMYwAZHqOTTgDkcA96WM7hyRxTxwcZxx0z1pIAPB+poPAGOn0p5wQN3J6/hTCckDp3GaTGL781IQSKjG7v3680uSowO1JgKQAm7O0U122qVGWJFIzdsj8qgMgzyTx0FQ2ikriOxX73UVVknTcTg+9MupSmAWAx1OaqFwybi2QeOOhrNnTGGly5LMMEE8E/nWbPcv5pXHDcDHX61H9qIlZWUpgcE9D9DVSeZcbpG2FR26kUzaMEidrtiHAkxMBgjGeR3q5b3R4KFSQoDAnqe9YySSy3iSQk/Zwv7wYGenBqZZghzIAokOfz9fSnYuUFaxqXlzKyOkYCnIAZj196SK5XZIHIZwBgVSEn75kySF+cdyahjdjNLNnD425zgHPrRcz9n0NJpxlQrkNjI5qAXDzQLuTDEEkH9DWVazTupaQCOUZGAPlPPapZ5GVPKySZTjJP54oLVOzFEyGUx2+Cgzkk9OlbVjN5q4K4PT1NYiI3lrHGq7R6CtO2wrANnJ60kOok0an3sHoQMYqRDxxjioo/Rce2TipAeOetUcTFc4w2ec8igFS2ccClJH8WSKYVxnaMjqfagkSVRj5efrUZztyACQfTNSA5UgDGO9Rhic9R7g0xkJG9s449qXhSRgHPenA4ANRNlWYgkqaYDsbwRSIpVGx0py4C5A+aheVPUZ7U0JlTysuHbt0pWGVB6EVY2DG0cCoSp2k5wapAU3yQ2F9qi+4c4PParIR1fAII7E9RTXjyOwP86oZAdqrtH3T60ALyATgc5FWBGNo78d6RYcKQSCadxFVmxIMfd6c0rrnJIOG6AVY8ptw4HHY0kigAjd+HpTuBXWIMTg8UpXDbR+ORUyjI4HHqBS9M4Gfc0uYEVgjbiAqg0PED05J71NJuBxjORwacSQFA6e9K4yHytqfMAe3FG0bD0xUmcp82TjsKQLhQSBilcCu33scYBwPeiggkgcCihspRubqqV49fWjG0ZI/CpWX0P4Un93jJzzntVtmdyE9c9e+KNmcmpCAFJwDj1pVXjjof5VIEDqCNp4+goRABn06VOYwe/GMc0uzsPSquBBgAgkj/69IG+bIAHbFPHykgdD1qZIwARjj3ougGoV+XJ5zzUhUbTtBOad5QYAL0PtTwuGBxx60yLkbhlUEckjrTYixcfe47VaYMCMDigKu4YGcH8qljuNCNuJ6HrU8agKD2pwQBT1OfzoUHdjOFqtjJsl4bkDJ9KYMdx07U4FT1A+lIRnmkwQrABvQ4pXB28sM4pu1iQcfhTgfb5c1LGIgAHbilOSc9hUgx6fhSHHzflU2ZQoBXk9KQ4Yk9CO1OOeOPwpMgEjkfShiGKRzubPFKu0kZ796XIZgPypDkcn9ahl2GscA8nHaqsjHBPH+FSyOG4Jx161TmbripkaQiUtTR5YC8KhnU5Cno1Ykt3e2jgOiNEx2rjjn0NbrynJA49xWDrFztkzIQpQc88YpHfRV3awks4msd+1SrYYqW6Vi3upM8rZVfLQY5p7s0sJcNthUZVB/H9artHBPdQwsq4ByzDtQjqjBIvaJPHexyznfJdMMYHAAFWHR2LKu4SJnarHqR1+gxSaTbrsmcM6YIAKHA/H0q5HB5M7l5hMTwWIzu7cEVp0MpSSbsZI1GSMnz4mimV9hYfMrZ963YtrRyrtUgANycjNY+tMHMUcStu3ZCk/KDzz796e0c1hZRuk4kiZsbGXDceopNJaikua1tCW7QROmG4zyo5zWfd3R/tMSoyyxRqc7eSrVk6jqV3dsY7QeWy5UuOoBqxZ2f8AZ9jCJpC8keThMYb6mi2hooW3N2KUxRCcgkk4JQ9M1rQXOSQcjacdOtc9p86yAxFwGBwAp6A1uQxlApLHAxzSsY1YpbmvDJvHzckHvVlGz97G0e9Z8DbhgNge1WQ4woAwo9KdjjlEtDH8R60MGxheM+tRocdOvvT1bLAngDrxRYysOQEMR8uKikUBunAp7A7wcYpk+SuRz7UthDCMA5A/GmkAtj0GOKkQExkEdsVGvfAoAAMLzjilUHOMZFMBww44oYYbjj0qwB3AUjp7dqqyE/RvTFWGGDg896rv94Y/IUwRC5ZGJX06Y70cvgnjmpH+YnacccU6BQOMHb3PrTGKCFXgcVGyrncMgjpUpiyMchW7VG64O3JyOmaBDSpY5K0E7nJCArS7toOckn0pwbkKFJ7k0xClA7Kc4FNIVdw6g+lSKvBPI4pONvI4pAROowCox+NMKsxB7Zp7Aj6DtTgcHuc9sUhkJ284weKYSWQAqcetWCQMfLj0qE5LE84NAyIx7gT2FFSsF2BckGikNNmm/DcEHvUm75ajiG/JOPoKcTg8nj0qyA4boc88ipEBBAPQc0xEXs3SnP8Ac59adxBlccc/0peDwOvZqanU4wQeDx0p8jLx1B9KNxPRkbrsBU896WFmycjGR1NEu1RyfTIpY8kg8fWpKJNx4Lkge9TR8g4z+dRKw6EAn271IgAcZBb39KpEy0RI3ByRn2NIuByR0/OpBhicgYI9KkAAX5SPqTTsZtkYLGTOPbrUh4fJ6mkzhhn+XFLwzDHc8UyQYgjgcj0pVHHTGKRe+cDvTzzypwDSGmAy2DilyOB3poySAeMd6ayNyVZQemSOlZu5ZJxg88+tEY28EdefrTo+SAecdzTWBD56ntSvYLDiDnBPWgbQpIz061FJweM5HJ+lN38jk89KTk2UojjhduSF/rTWOeA3FNfcwBH3c9+tNI4IU856YqGy7DJAQeMdOpFUpGIc9MVYYjnPLelVJlPPXd2WpN4GTrOoR2sZlIY5YLwK5W8mTUXieO5yrtlkPYjtWh4i/wBMjeBQVdTna3Gcf561m6cIY7p4im2SNMA47nt+FPS1z0qMFGN+pp3CJDCqpgfTpVaPERLgD5hyPWkkJYjrwOSaq38hjhYsODwSKqKuG2hsaCd0M8zEkA4CZwSe3FWnHlbpMDcfw7ccVFpUXlWEbu7Kipx/tMelOvy0kLbnJZ/mKj+EdhVPsYPWVyK2lNxKxfcI0wOBjPv/APWo1uSKbydocyMmX3LjLdzUfh51jjvIWDOcj7pJrPnkknvSEdnEY4HUjviny2Q0vf8AQq21qn2hnj4kxtIarGpRn7GUIVmB5DcUloiidmctvbnNGrkNG58wMSMBT3NRazN1K8iC1jFk+/awDgcAcDFddaSebDG/IyOhrlPJeSGJSpUZHmKTx07Gul0yVHtk8sAKvFUjPEbXNNEKpknIz2NTb9qZAOT7VR80AZU80jz4xzkn0qkrnE0Xlm24+brVqKQ5+XHPrWIJfkz97+lT290Bjk0+UzmjZ3jo3OKaWBOccCqsUm8cGpnbC8j6VDRkOPJHcZ7etPCjGQBx36VGrLsx0PalBYKcj3FTYBhBMnH6U7b1B5+tOQZbIx05olxz27VoguQy5zjOT6ioVw5/+t1qSYsyjGeO/rTApcA+n400MikX94OeOODU0SDBwTyevpTDy3QEdDnvUoQYwNxPtTYrkhi2/wC16Go3ByMj8alRuo5IHrSOQcEE8/rSJuVpSAxxtx9KaqkRjPHPX1qyVzwVPT61DISgHHAxxQUmLtB4IyD2po+YYJxmngg4xj8aYq4GO/rSEJIOMc4NISFxwOelOkYlAAOcU1FUYL/r2oGiI42+/vUYITqMn3FTyOocEgYqJyGJ7fSkUiNstgn1opQcJxRQVojTf72MdacAFyckigc9ScCgASNt9OlV6GaEB9ORTyS2N3QUm7adrD9KSNwWYYwepJFCYrD0JOegGecCmseTgfLnrUiADnnk/hSkHt07D0qiepG5JfJwT9OKmjQEZLGoRvBIx71KJQFGRTsHQlVSOSB9PWpU4K8DB7dahWTJGSfoKljznPzZouQ7ivuU57fyqVMDdxjPrSbd2C2fXFINwHrnpkULQncUpuOM8U5vl25OCfSoyeAeQDShgW4J6UDJFAB9aUH5cUxnUrgZyPSnKRjjrUu6FYCTgY/KkLYxjvQ3X270xuXG059qiUmaRiTK/PXIoLnvyabjkD+VPZRjL881N2OyGuwwM9KjbG/oKdJt5x0/lUGc/dHfnFIuKHkEYXIx6mo5CADnOD6Uu8FvvY74FNZuD3NJlWK7ZLHC4P1qpczBM56/zq5IwVOn596wNYu/IIByCw444z71mtTopQ5mUL1NrNISWdxgE4ytZKc3BlwRvXBI6E1aW7mMWycL5uSOOQRTYk+z2iRoCy8nnnGaq1nY9FXirEAkIk2/xHHXkUy8VZLqK3YnDMG2+opkz4uo05+ZulXNHWBtYNxcHakZA556c10QjbUxnKxoeIGNlBDDG7diSOMHAOKggd4rWS4kiWRCdpIPIOOPyFUNfu01A+WvmNJknep6ZP8AhS28wjeIF8Kijdn+ID+tJrUmK9xdxunz/ZdTdN58uZBg4xz9KdZwNKt5c2+GXcwYnoB/kUmqhDJ5qgBZfusByCDwat+G/Mi0S7JdMqrbhnH1PvWkVdWFUfLqvIz0YE4HDL79qm2x3DqwTdIvbNUbQNJNJkfJx36VoRyKgcrhONoPbFY21Ntttx5tIpD83J4zyTg1p2roihU4UDqBxVG3lLRhY1+XqSe9XEjVUVc4HXrTSsZ1NVqT7hnKn5ulICTz0Pr61CJBjOQD0HFIW+fGd36YrWKOaTJJGBPyn61B5xMoJ6dMVFLlWx1AP0qIkKSTnnnNWkZy1Nyxuc854q7vLt3IrEtJVDAjvWrC2EyDn+lZyiZPcuZAwckH3p6nLEE9elV0JYAkcYqYcbcc+xrKwiZQEYY7/pSuQG+bp700Z+9kY9qc4G8dmqibakAHYgY6ZpCNrYBBFPkbbjdyKTavA3cdapWQNkZT5iSPzp0YwWIYsO9P2bl9fSlVf3ZwCSOOBmqewrhyuOBio3ycDJBPNSj72COfTFOkUBQ3Y+tSFyDcSpz2HSohzgcnnjNSbOSQOPbvSxgKenApFXGKCBignH3cHFSuq5J/IVErA9qQIiDEnkc/ypksmTkdqkOA7ZJOaZMoXHU0FLUjdsL6Z6HHWmgH5cnBPWnswZPp61Cx+YHP0pDSEd8cYyfWimu+BzjNFA+W5txrhDkjJ9OmKAu1crkc9aMAhg3IPBU9xTFbdnbkAVRkSJtwSVANOYANkjGegqMPtLcDP0p5I2ZyaQDs4XhTkdali3EY4JApicxsDkj3pqfL34xVEyFkxkkDtShSCMYPFIwUjikXOfvcnjA7VVyVsSgfMv3j7g1OBw3J/GoVbp3x79aeCWbAwBmhCZajwyDgjtTdwU8E/lQrYGRzioDIecfoetUQkPlwDyOPc1GCucA8VFNIXfA7Gpdw29OvoMUIvYmwAp59+O1Jk8ngVCGI4xnPfHSnhuOgwe9ZykUkSE85Ix9Kci5wTn61DweMZ71YGcjAzx2rK47MUEE8DFPJHA/nTOgye9DsMYBpXAim6noPaoCV/vcdsVLJ83TPvUJX+90qTaL0EAOSCMn1qKZsdBUu8ISR0PGapTSccnPXNJsuKuNlkGdpJ9RmsDWLgRxhvvqT90dTV69vhCg3EZIOFPQfWqFq3n6kvmDyoductjk4zSt2O2lHl1Ods7KVroyPyCeADwtac5SIKiD5euPSrjbAGdU2kk55681jmRjLJwTk4weprSK1N3Pn1Ird1OpqXlTais2Cep7AetRm7aOy83Cq0jsTnkYqtIQpvpnG10QYIPTPFUA0ktvGi4VGIXP411qPunM3eVje01UW0a5lR23cr9feqInSa4fbuOOCQeAfStjWv3GmQWyMVCRb2Bxkk9fwrFsImaNFRgr4zt6VBtDVcxsp5dzbmDO1l5Rj60tndtDpF9ZZInLb8dsY55qG3U20e66ViM4UgYGPWqupPDdifYH2rGodlXoe3PuaqmtTGdnp0H2LboyxOc+n0qrrFy9l5ckaM+DkqBx+NWYEZI1boCOnpVAyNNP5RJbJzwen1rE6YWbubmn3ouIkmdFV8AFM8Y7VcExdyHbB5AAFc5Zacy3CyxTMj5O5f4eOlb7HHzAZzxx0+tVuZVEk9CVgSvQc+9M84AFQ3AHc012YAZwPpVO4mKv8rDFbQick2T3FwvUtyKhM4xluc4xWdLNuk68AfnSG42jAxz1rbkOfmNm3kyU6e4res5BgA+nIHauRtZcuGI4Fb1pN0IAIFZTQbm5A2ec8jpUo+Y5X9apQORgDqauIQqZya53uD2JDkLwc1LkhSepqFSWI4JqQEgFAMkc0IhkbKzYxxUsakYyeOuKWJsLhgcdRShtxIyBntTSE2IepYEYxTVO1uefxpxTCMvA/GoGXozZK9K0jqSTAqHUgdfemyEFc8AimkAMMHjt70p5J6ECpaK0AA49D7UwKT15OealQkrkAY96jIznnBBqWMVlPAB4NRPtAAOcZ604tg4LUyTdgf3ewqRpCLgpkAgD9aryliQenbFTLhFwf51GRlm3AHNA0Rr0GR14qORSXO1TkCr8MYaSNcY5yT60yWXYskaj7x5bvinYXO72M/lsjAFFO+TnIJPrRUmppKzFvXj0pyEswBGOKYVAzzinxnJ9GpkEgbdjnHvinZIbGc454qLoxGc07eyscn8fSgmxaU8YH40HG48Y44pqngbiMmnOwPFXfoQyPeoTAB3euKk2lcEEA9etHQYUfj3pGwX464x0pp2E0Az3ycdvU1KM789setR4z9wnHY05V+TIDcdeKq+hJYjywznOfQUjKMgnj60BiP4SfYcVFIGYDIIOeaS1AdtR+rYAPpQo4YqC2KgQ56/iKmBYEbRwfU9KG0kJIdHjkt1PQUbDzg0nzdcfh60rNjqOvPWsGzRXuOXGAAMHHNSj7nX8KgTIOe3vUqHIPrUlMlIzgdxUbZJ6Aj1NOLY5I4qIuTkEcYpMEgcnbjjA9KiG5hjcCfanA4DZ6+lQklmIAx6Ed6RpFIHGQAyjaOvNUrgqN2wYH86tvyvc5PaqtwvzYIyPYc1LNYaM5HxKXM0Uagqsh2lsmp5FWS0jS0nJMMeGc8g+3FXNdtneMOq5EZ3H5uRWLIm24cwI4fYMAdVB65xVJ2R6MGpJW6EqEGyE3mMZskABug+lZEcxLuSTnOd1aLhVhkVDnamdx96x7YblclsBvX0rWCuN21M+6D/6TtXd5hWPzcHAzVpE8v7PCGD/MBu6YrOuZygCJkhpcsQeuB/Sr1mfMJnkIVENdktIpHNBXk2bXiVmlv2hQsEIUksMcADtVcRTQeVcqmAhyCaltGe7lknl+Ztny7vQDirdjvmtRFO2fM5z6GsbG692NiKfU/tMvlgFYSMhWPesgPKurGzgJWGchpVAHJTp/On3INvO0bcrnbkelGhxCXW7iYsQsaCNGPfuaqOzkjKpaKsjTvgY4ASBnHTvWaIwLhJuVYAnH+NW9VmDNtUtvX5j3FZySqlzG0pUISQdx61kawL11cMLVmbCvnPsavafOLm3jLEYA5UnGTWOZlI/ebQkY3bc8v7Vd0oObZZbrIftnsOw49qcVcipZRNCQFIm4UD1zWbcuNh+bg+3FWbmYHKmNAOvWsS6ukU4JVR9c5rspQPNqzGXMvUBlA7YpkUu5sk5x1qhNNufCkHt9KdDI4XkjArocTBO5vWcnQnIGcZrdsn6cjFcrYyHaOcnua37OT7vfNctRGqOghJ+U5GK1A+cDI6etYtnJu2Y7VqREOuCORXJLcZdgHGeMjtmpIyTJnAHvVdXIxjJxxmpkc56d6lEskIJOW96l2qUyBUZYEcDPFSBgq+/pVozbIyqkNgfMR27VE3yjBAzjFTyFQuExuqu7E8E/iatC3A7BgKKaeD15NBPykqDmmb/lyMe/NJjTH5wuAefekJ/d7icn0qPeCckjNMUjOSxqGWKz9TkYHamM5K7ic0MwLZXJUdeKGf8AdkdM9jUlIAcg8j8RQiuSGI49qjT5jjq3c1KNqJnJPaqiu5LHStJECG444zVFzlsk81PLIz8klhVNiCM+hokOKBcMW4/OikDHnGNpopJGqNd1Vu5wKGb5iBn0NBG3gfTk0AFJN5+nXrQQJtBp6nHykdaUYbnHHrTVY53ZBPQ/SgRJzxxkZwMVOrbWyw9sVABjnJB9KfnpznAwTQSyXOCWDfSiN8ucjgcc0zAVBhgR705jlCcDB9Kokc5wQSAPfNKshbPUgdDULSEnHf0p8WTgDpmrXYlonlYqMnOfQUmCwO786cwIORg8ZpCBkcEHr7CqiQxFiCjLEZNODZAGBx7U7AxknBJzSfKrEH7tZzKiNywIKE8n0oeMnGG5704gktg9uMdqEycj9DWD0NIjjhIyWOPxpIiQRjJ96VwMAYzg5NCEbsgHp0pFPYdJlBx+RpgbA5FPcjIz+NVpHBcBQTikCVxzuCQMce3ekHTg9TjFNGD2/OkY/MTn6/WkWk0BUD1GTjFVJGGTkDH1xU8jYHU7utVZAASzY4HQnOfeoe5tFXIZec/IAo5+tc7cwzWd093bYIkH7wMfyNbqsdzNvAReM1BOTISpVQAM8+lUjpptxOd1d1kB8tM71Bcr9KwoHCwyEgY42n2rZuyVhIVMrg4I6/jXPh8W8uFPUjnpXTDobdDNRxNcKuM5LYPrzVrTFR55Fk3FFb7tZdjKftjrgYHKn1yTWx4dAe/lLngHmuuqvdOeg92dtplpELLCIPNk4UH+vpRpTwSy3FpHJu8pgwbHU/4VXurpbWwd2Yrn5Rj37Ulu8NvexeUGVmgBkJ/iPrWaWgO7uZ3ihdq7lwTnniotBUx2bO5+ZuRj0xTPFNyFgkJOcdqkty1npMKP97ZnjrS2ixz1sildTGWby1yWPGTzV60ggEUryIsjqmMN7n+dVLVQ8xdg23sPQ1o2MUc0ykISwO3npWexTl2IoNOElw8uzyEAG1Qck1poB5QRRkkc56VOAEcnjpj03c1Wn/dk87TyT71UEZTqOSuzH1CUwqVbnPBrnL2UltqqcdMnnit/UQWTLncv0xXMXjFWOBlfX3r0aS0OKS5mMaQF8N/CfTrUyyg4O4c+tU2cKiF+/YjvSiRFbDDp0960ZLhY2LGZiQwroLKUkqMe4NcnaTHzBgDNb1lIxZMHGelc9SIonY2f3eDxWsjFfmUg/WsPTwHCnnHp71sqyiIBhgZ6iuCa1LZZikLNgCrgUqcnGKo2ZUu5ABBFW0GSwHHvUWEyxG24DcOO1PJxjoc1Hu2kYIzjof60rE46DtVozlq9BsoGQBnjpio5McEdSPSnOdxBIxnrxSMAFx2xTYIicgHdjB71G3zA4/OpSq84zj0pjZAO0ErSuUiuFGCT1HbNJ1Ge3pUhyFyMgU3+Lj8alsYrZAyKhyXXdj6VKzDAz931qMkDhcgGkUhiuqkbucdxUsTBi7Fif7oxUQBBKgdfagF1UjkemKYmrjZCy89AOMetV1U7CWOBVrBKDPPamOvyY7UrlRIFzkgdKKsIhxx9aKRTaRoBg5PGO+aQt17j2pQAM4zg9KasfzZU/SmybDsED29KCBk7SMU4nn5jQ6ZXC9R1pCHKSGxjj1qRSCDtOffFRxZ24JyB6inZx0OKaE1cDgD5gDz2oAJPKgDHemsTgcdfWnxKWfBBznk5qkxPQWNVCn5ST6dKmUYOc/LikyN2O56CpIt23BGB+lNMh7EoJK5DYHpTNxJ+bPToaeCFGC36UNliMYOeuKqJmxUXLAvjHtTTHnknIHSnqcD5hnJ/CkdsZJ4x6VnJlxv0FKgA8jOPWmKGLEjFKXUoQpG7vnilLBFIGCazZYrkFeuB6UxV6c07O4npio9zBsYPuR3qCgcHO0tx1qFhtORkjtinszMxJGD15phY7SO9SXG4j8qSDge1AIyMdKQH5cnGBzQwB+UNgdQaCxjk7mA5HuKpXKkJg9+OK0myVGOmOh61mSE/aR83y7cAelSzSC1ARKIyqqCDye3NZWphhA0iEK2MbT6Vq8q7EnPt/Ssi/Znt5yFyQePQD0qkzaG5kSRt5JHBJ4IPRa5TUWMMZUMcZOMeldcObbDnJxxzjHrmuN1rKI2ckZJ/Cuqn0N29zLsUkaVUO3BAxjtgmtjSGW2a4aTAKNnFZWlOftDGRcZVQv0962ns5C/nopMfG9iM7T2rsqb2OWi1a7L9revdzRPMpWNjtVW649aS8vDDqqsrEBgU556dDXOarrC2er2duqsyxnMgHXBrSv5/tEKvEVdWwee3vQ4tDU4uTF1WT7ddwws2ELAn3A5q5dy+cQozgdx/KsSz3tfSSSOrSEBVAH3R3rbj+WPII3jjpWc420BSu7ktqEG2Nct1yM9K2bF2O3oETOOMVlW0ZadDwA33iw6+1btgipFlx8x456EVzscnZXEnUF+STtYn6VVm4Y5IJPPPerF25UDnhulZ13N8gKg7wMEY/rW1NXZzybsZGqtsPJIPpzWBdSgvjZw3tWxeK8gMjlWbryeax7oHbg4APPXqK9GKsjGL1M6Qhdygsx7ZHSm/ewWJ/wAKkkjC5ZDvzz06moC2GAJ56g461RpJXNG0KlwAcH1Oea6TSVAKlmHqa5SyI3fOfpXTaU4Yx5XHpz1rKpsZJWZ3GmsrR/XpWiAQhUjJ61kadwigEA+wrZRh5YORkevevOnoxlixxsYlfrjvVqNiTlcg9BzVODIVgM/geKsQnLkgE47elQ0J7loMeh+lIGO07hkCmsQp4GCaa+SoO7J/KmQNdhuJAJx36U8HPqVxUUYAzkknHSnlgq8ZoY7CPkc5GP1qBiR948e9OkPGQDz70wqVGWb+tSNIhEhB4ApW5clcCgqQCQDk0RhUJAO760ihSAc85PcVG5IB28EnoaeQQeDlqjYBm5pDGs5DDn24p28qwOcAVED85zmpfbH4UFWHliwOcD+tNUhW+YcHrmkbK9OtKjbx81ILAVBOVoqTAB7gdhRTQmW23K2B+NIc8HoDQcA8H8+9MDc9c4oAlO0DcBk9M4pUUk5zgUkQPc8Yxk00qQTluPSgTJVPzYzx+tOcBlGBgetRxtjJPbt60FiQPXrTQhxHHJBP0p8efLZmOM+lMU7gMZx61IAqg4Hy9smqIbJccHAycZApwLYwc47VEjBlbH4Gpx257Y6UITJCBsALc9PXFQg4JweB0wakcBF5J/Km4XJxk00zMkjlLRngYxUagHBJHT9KMDbx688U9QQSMDkdaiRcWNXGSMZUHNO/3Qce9I7ZXp1701SNuB0NZMvccueuOOnWgDllyOBUSkqoyePaljc5Oc8ikVYkB4POOKikztODUjdPc+vemSfc7+gxU2KRCGVRsYHFSBRtyvQUiAbjnP40ZClSpGDzSZZHMwCgDjqemazm2ySCRl5B4q1cn5JGzjjms+1kMkO4DaD0Xrikb01ZXJpMlWBXHGR9ayr5JPs+MbVbgnPIrTeTy8AglmPFUdSbyLZ5PmJxwfTtVpFwetjnJZl/eIQSAQOetc1r5/dEnAyw6fWtzVlWIFmAOR8y85z2rkLu5dlKTKEZmBIHHeuqludU4rluP8PW2HkcsDlyTnvWlqd7MUkit5AoIG7aKrabceYj5ChQxBIGBwe9R358uF2Q5OGb0rrTvLU4GrQ0MUxRNqCSoWkc8szd2HWtG7mSytMRlS7n5Rn7vvUcaouyQqq7V3HHA9TWJcTtcTvI3OTx7AVslzSOdvkidBpknmSZ/iYjJ7k9zXSwlSSpPzVyGkO+4BSDtOMdq6i3cvEWyw9z1FctZ2kdNJXjdmrYlmDNJxjkY9K043AjAGeuCap2a4iRepHt2q6yEIqkDjp71gtRSsVbyXMeE5+b6VWumDwgchumassW24x0POO1VLnBA4UDGDnv710UzOUTCvXHmbcAnH5/Ws95FKPuIDLgBa07wMrHaGDH06EetY75Mm0h9w59a7Y6ohRsU5TsJAPynn6VSMZdspwMdDV2VTnJYsSeme9VXLHIUDGeo7VYMkg68du/rXVaSqgqOM45NcvFt3gEkD075rf00qVDs2SOxqJrQyO206RkAKkkep9K1ISzEA/Ue9czYTN5eQ3HTGa2tOkeZl+bjIx7VwTgV0ubsJ2oCcdegqbzcAfNg/TrTPLQnJYZ6ZPBpk0JjOc1lYzvdlhWUMQc+31pGJLDJGPao0UhcZyT+lOZCPm70mO4oAAyuTUseACSPzpoU7cDqeaRx0VSd3epuUNLY6AEGmHqeAPapD8qj1+tMOCQO/fvSBDMblGARg007SSR07n1qR2wMcimZ4I7e1CGRFSM4zj3owMdOacSx9Me9KUZse3oaRVyILkZzj2NO+YgdKm8k4wTgClKhVx29aQXI1A2HJoQHOT0p0ag5wOlOOccjvmgdxCNze1FSZIXge/0opk7kr4IHamMpXBH5U9mDHoDTSMvkcCmNCpnJLEgGgttbkGlG5TzyTTTISwGOaQMaGbfgc0/5ce9Jnb8xB/GnRgOSSO1BI8FSmcjp2NIpAXJAY+9NwN2B04p5wo2kZHtTvcTQ5HI2le3QHrVhRyA3B6nFVwOBjHNTqxYkHg54NK5MiYgFRk/rSs2Y8AZA7+tJ8y4wRxTSxyy4qk0ZkiHIxtx3ppOFxkgkfSkByRk4GOop7KGAAwM0pMaI8jBx+vambwwHrQ6kOSo4PvUL71K7ePes2bLYkxwAo59KPukZJ60zBLLxgUjbS3c4PNSUtC1wR1PHU0xmIPGM54zTWOcEBvUg/zoCEtz0oBCsg3FievbNJnuOo5qVeVxjaOvHSmSjOSOFzzSsUncp3Kb42GSvGayrSMwoUkzuycnNbEjbi2Me1UnBJG08k4pWNovSxG8hBBABOOPUmsrWrgxukAXJPOGPp2rSJ3nCnAHG70rF1y1mkkiltslM7T6/WqRtSS51cwNWY5LH5mUEkdmJ71w2qs4vFQ/M+5QeOhz0rvLyBkhaVwwKDpjNcffRAyxsRgbwxHue1ddB66nTNrlaRHo9wEF3Ex3APnHXk9alv5We2k3KQxXA9R/hUOjosV0oyEjkBDbvXt+NWNajWOyPOHLcGuvl96557qLkcSrqTeTYcdXIGK5yTcM9mPWtvXtxa2TPSMsw3Z6nj6Viy5aQjIHrxXQlY4r3NXRGYzYQemTjtXZ2/8AqwN2VPPXn865Pw9Ary4JIIBxz1ro1YpEyP17AV59d+8elS+FI6jT8G33ZODgcdq0BCViCncwX15A5qhpKgQRqTgYweeorV2BAQrEr71mjCb1KMifMT0Y9Pes+9+QnOQelaJyMkDIHAqnd7XLdMCt4BHU5y5kyrZGEzg5qjIhLMwBI9z2rQuVIZlBwPT1qnKSUIXCoeBn1rqiact0ZUhIl6gL3yMc1XaMDlSCDVq7DBSC3BOR7VXjAYbGGQOTg1qjmnLWw2MCR8BegwTWxZkIi5IJHrVCONQoIOPde9acFuTFuXn+I+tDM7GjBMF+5n863tImZn2qTz1FcpAA+cnaB74rqPD1sFIO7IxzzXNVVkaJaHZWoG0eYRjHaieXdlU+8PxzUKKSm7OPxp6bQDJzurksYtdRyLtIJyTVtfm+bgAnpmq0WTgsQB7irKCMsFBP1FRISJTuIy2OKhb72cHJ96lIydqnI96QD5TwQRUFJldgoz6jsKTad2OfqambbnDDH0pjsSflXC0FEchYABvu0xSMkYHPbNPClgS2eelIEIw2MDtTQ0IqsxIHHPSnFSh5I59Kev3hxnPelKbn9AKm4CMvAyc1GxBIA6Cpnj28nFIfYcUhkY4IwCad8p46U5QdhxkGmoN3LHkd6AB+2D+tFLjj5elFMRKORzimtweDg9iKCQ3Uk0cAYz06Uhikt8vfjrSKcnkYOc0E4PPSlyAMgED1oAkjZc5IJ60qLkk/ypikMuAf1qTKjgdf5UAI3ygnuexoCl2AyMDvUgGQBnNOCAfMG5zyaCSMgIRgZH1p0YyDzjnNKVYAjjnqabEoDZZjTC2hKAOPy5pFzv4JpwIwemOlIgXDcHOOlBA4EEHkipQG29evAx2qNBkZ6DrSJJye1DCxG0jBj6etKCoT5uSaVwrEfNjHp0pMKvGOepNZ3LSEOGBAOcDAFRkBMHOAefrUn3eMgetG0MQScgdO2KRQ4yDcApIHpSxk7h1wT1qJWAyRnPqe9Pjd/TAz0pXGx+Pmxnj0FQklgVUjHbNSvuIUjjPBFQ7ScouKBxK0q44b+L+EVB91RnCnp0q3KoyM8Gq02OA/3Qc5oNU7lC4YKNoPy5zjuaguXKoFAOMdD1pbl/3uR09TVS9lJkGCcYyTVI3SKl+67Wx1HQ+9cRqasdh67pB3wOtdndHMRcDkAnFcjqCOWXcoGWzha6Ke5tH4WjLaIwue4Vt459D0qDWp/MhPPJwQD25rRuU8sAfKRxyT7c81ganNid15yeM+1ehHU86elxLlhI25TywGaptEC7lueelW442Xcjg7l4PHShl3HitTnjubGgJznHzAYrpoBGzjeoJyCT9K5vQSACo5HqRXRu4TGOD0rhq7ndDY3bM4PGB9BxirwceoyenFZenPuX5iRmr/APrMbcHrnNZozkncZK5IIxgdeRnBrKvXAU7TnHfNaExCjOflPesq/kAXGRW1NCbsYd3ITLhgGYd/Wq7y5GFA988Uy5DM5OMtnt2qFgzyDGAOmSa7EiVUZHNGpdTzkevb3oSINyrDjoR3qU24PGSQeoIq2kcaLn7rY6mqvYm1yCKEKvzE+pHtUpuCpaMBiCMcDtTJ2QD5S3TJqa0iYDKkZIwOego31JbsLYL50gX5wmRXbaTAqKDuIA/WuWsI0SQBiQRzXWadtRQIyWJ55Nc1bYaehsqwAAVj/jU8aMAAwx6j1qqhAxxzVgEnBPSuVqxDJ1IOAAQKsQKA55wMVCAR8y/dqzFtcEleaykJIcMcAGpG+7kjkjtTFwp559qeeOgNSHUhkAyCTjHpULA5ITPPNWWAxk5qFzlhwKRQ1clVA6fSlYAx4OOOxpVycZ4xTyU5GMn1oYxiHOC3foacOTyPloRjkgDHpThnoetIbGOMnqQKdhguf1pWXsTTZD8oA3YoAY7HBAx+FRjKr6ip+wO36UhGBwAB70BcYG564HeilQLg9c0UxXFz1xnNKi7jgjHvSFSG9qeWAPGcnikUMYMB046U5eSVbpnikA5wx/I0oXd0yD3oAdtx05wabknB28etS5KquSPoOtBxkZB9h2NKwAD8wC9fSlcjcMEtg0DHPY01MEgDvnrRsIkOC2JG79KUBWJGQOPrSbR3ThfSpUVTyFNMTG4CnDZ6/nTwFZ8AbfcUH5g2M0qjkdc0Ey2GsQD14zjNIdivk/hQTy2Rx6U2UA9M88ZNG4JApySfamOSG3c4z+VPjXBIOOfWkOWwMZx97FSyxyqHUcnJ4qJ18tjuOQOwqRTtZgvf8qYSHkw+BUloXcrAYPJPp3py7lj+bnPp/Km+Uu3Ibn26UFinJ9euOtFmSI7NHtO3HbAHSmeYrEHBDU8uCME53HvUTBUb5skDOMCkWhJHLdcB+xqhLkFt2SAO9WpskAn7oGfp7VRuHZhnnPsaDSBmXAP3zjO7gZ7VTuJSQjEAYyAAetT3UxRlyN3XOPWqM7KU3feweMVpY6ktCO4bOAAeBx2zWC7s7AsBkZPseOhrbLZOOo9MVhzsW2v8rIjjCk4zW1PcaejM7UH2QqMBiOeBjj/Oa5HU5inI47/Suv1g43JxkEjqeRXFasGCMynqcfhXoUtZWOKtZQbLGlSkphhweD7VoGMIvPSqWmM0rh5JGfdyxbGSce1aNz0z1GecitZLVnPS6MuaSeCynvzx0raaX5MH86wdJb5cLk/WtdfmQZ5NcVVHbTN+zlCxhT1HPStKF8qQzYz6VgQzbcA+w54NaXn5QHHPfPaoSFMluWwjHBPoBWLdTb88FeOh7VpTOHUleABWTOpQnHJP61vTMGrma5KkKByTxilWFpGX+Rp7K0kuEU4H4Yqe3wrfMc44yea6LjURzW/kopKkcc1TubgiLA6H0HSpNRuJGUruYr1yazWUbeCcDmnFXCTshVXftO75RyfetC2TO4kHd1HNU4UXhWyB3xWlEwwQTjjvVtmHKy3Yh5ZCuAPf0rprLbGMHgeua521KxJmMZY1q2M5LZbaCexrmmrlbG9E7ZBU8fSrsb9i/Pp6Vn2829OCPzqxABnr371zyRLNUxhR94Gp4iBHVKNTsOefrViJlK4J5PArJoksRgEZPFEjFQNpz9aF45PT0pWPI4AHTIrMa3GFiRyOaY69Oeae2QT0xSiMkZ5x61JZGg6k5OKYRnG0fr2qdz0X86Y3ynIHNK4IFbceBinHswPIpIsY3dqfwelTcZGVOTn71OJwmCfoabgZyM0cEciqATqOW7UZIXB5+ooxhaOuO1MBN2E59aKMEDGM5opiHH5gMLwe1JjgqoGfWnKOSPSmcnnPBpWsUKSF4IyTzn0pY8nk0xQW4A6U5TtYgZP9KlgPyBk4+bt60oYlhg5x19qZGcNmpACPp7UgsKuSpyAOalTgcLz3PvTVOMcc04KCOuccU0xEijI5OR+tOPypt7UwDYwJGalbGOmBRchjBt2bcZPWn8MMgg/SmLjnJHHTFPGBjrikDGbcYzknPFMfcrrnp6elSOoLLgH1+lDAE8807jQjJxzjPvUSsY2IzjAzU45BzgnsPSmP88nI6DFTZAtBhwUyOvemqqhSG49DUs0eWUDPTORUUoATI++OPakUncjkdi21AR6GmBXY8k8DOKaofBHOR3FKGY8457CkmjRJocVMYAyfxprNlQGbp608M+ct93vUUrY+dcemT2oGtSuxGSGySeazbuX5iF6D14q9dvuxtID9jWTPkOxchsjPPNUjenHqUL1tzZGB6/SqrvmPHU+1TXhVRtySxHHoKohPlUuT06A1pE36D4X6sRkY/GsfU1KyMMhe6hVPGTj9K1Im+bJPB4PvWReymR5W8t4/JP325yQenHYVrDcnu0UdWdhM0ciEYxtdsDcOmfb6VyOslTGWCYPTjpXT6ycGTbmQu2HYjr7jPOK5i+R5ZFiXLMfQcV30t9TirK6sP0EfLgAHH3q0r5iAVQgkjr7UtlaPEF+Qoki4G055A6/Wor/csf3tx45x/P3q5yu7ijDlsifT4wgXjGSCea29wjI3LuGO3esSyI2RsDkYwa1FcupB65zmuapqdMTThkaQc5U+/pVxJDjDc4HOO9Z1sx3YDFsDHNXSQnXqeazSJmyVpBsI5HeqUyFh8hwB61MSApIGfaq82TFnsTxW0DLqMQLj5QSeTntWfcXBSRlB+bpxT5rloVwn3j+prMO5pd5OTzkVvFXE3Yf5zzZDbsgVYjiAwcjYecE0RxfMGIIPr61c8geWqnAPr61bfYS11ZAPm5RTjAyPSrkQOQxBJA9OlNFv25yfTj8KkQGNCGHIHJ9akOUt2u1STkg561bTLNxjaeayo5WOVAHPAxS/aGjYqGOenWlYmx1FpPtTHAUVp28gJDH061yVpI7uBn5u/NdBaSOGAPI9qxlGxEkb0creXjfx0qzCwA5zn9DWTHMV+6cetaNtIPlJ5J9K55IlmgjZPK1KWJ7YXNQqwBJB5/lUysCBkcHkmsJAgH3c8nninHJXHQdqTggBelKCAOeKhsbI26k9eOKjxk4zn2xT3+vH0pc9M9D3oZSIiADx+VKp+UE8Y4ocfP8ALyKaWwDnP41Ix3IHzflTsDb701CCMnpSFjuwM4qhCjltuQDTSOSOnNB+8ABj1NISVzjkUxgD82AefSim47gUUyR7jnPOPSnYUc9B2pGYgdc81Ezk4H60rFom3DgDimKwbIwTnuKbIqlgOuakYEKAuAfekMT8sZxzU0ZwAAc5pEUbPanZyPTFSDdxxB+g9aUkbgf4f50n3gDg5HNSqA67SMetIhi7lHOM46VIrZBBHHemplBjANSKOpXv60+hLQwKMk9qfHtUnP4UAgHnjPFG7GQPXoBQiR6gFMkDHoKjIUHp8314qVQRyfyHeo5MqBnrn0pvUFdDGRkOQRzTM88ZGPSpSCdu7p1pqIACQDg/jS0KQE8c/QCmyYMRzzxUijnOKhMgGSeM9qgpIq7irE5/xoVx1ON3vUoAfcACOKgMfzHdQaaDpJDtwVAP0qtc/vAenHarfmZXIAzVOYlcnuO1DKiylMHGTxwPyrMueQQcntxWjMdxG48Y6DtVG4+WMgAcHjsapHRF2RkyDzJCp7dM1DsRHYKDnJGfT6VZdyCCoxzioCC0pZsbenua02NbmfPJtRsLjAz9KxV3yCNnlk4PmHIA288kflW3foxifbn25rFjxHaFMAsTksR0A7D2rWDsUldCG1e8vN5Bdid2SOuef8Kvy6TaiSHYkquPmcEjIzWjZ2wZUuIirHAOAccfSrNxHtmMkgDLhVGeCtbxnY55wuYN5aBB8q7DG3ABzn8e9YWuR4eUpjk/d9K6rUQytKwRTnumK53U/wB5uPVj97ParUw5GZunZ8nDDGDxir24hl2nOapWgxkAcdua07ZMEHbk449KcgW1i5a5DDgAjmrpdmXI6jrVaFgJPmHzEcmrAACH1PrWdiJBJP5fJ5UDPPpWVNcbgCpxntU08rcgD26VRkJIIIAA61vBGQSHKFicMPU5psCOSMD3z6UbU3Lj7vXmpVKhQ6kk46VrcLEqnAy4w3p/jVlT92TGBVQyNIxLAk8Zqynde/XJFAxXlHmDr7nPSnsxkXC8r3pNy+WTtJPv2qASE5AOPTigCwjrH9zOT2FVSyrdHcpZSM80uSY879uepxUfmYOw7SOoIoVwsjUspSGGwjGK37OQ/e3Ej0rmrJlRl4PvW3HOCQVJHqKhiaNWKXduwTWnZvtIz0+tYlmoZW3E+1aVoDsBIJ9+xrCSE4o6KAA5KdOpJq6gJUEfjWdp+dh5z9K0EB6kkD0rjnuYtDgBjj5T6GmsccHr609vmxgdOppkuCFwflJ6H1rNoEMJBwAaHYLgHoKew+TOcEHimA8fNTKGEjvwfWmSAlQQf/r1Id23jrULMUY7sk56CkkNbChsLgrj608kqAvGaZuG3DdOtMDMeRgjHWmA9iccikBIyTSE7sDqfal3g8H8jTQB9OneikBUDAU4oqiRHcg5x+dNZhxzUYc4HAx1PNIrqJN3BU9KRokWfM3AYGD/ACpy5zljxUKcljnjtipfMJ7DHSpYEwxgjpmnFQFGCTj9KijGQec96kjJ6Dv39KkRLHgnjg+lS4+Ztx4xjiq6BhJlT+VS7ipJ6k0EskAAB5+b0FLuI6/pTFBz1OM5qQ8YAGQKLLqIcjKqkseBSlfnypwKacc4P4044VsEiixIuMDJJoOCQB6cnFPIPl4JHXOajRdxyrYoAGQkYXAHfJpqqQepNPBfjjK49KVcgHJ6+9A0Imc46A9KryR7m4x9BVkIB3PHNNcbCSKloadmVlJRgAM560kxU9OvrTyQMhup7YqOQ7gSAB2pdC1uVNuO3vxUMjKCS45I49alc7WznioSqs2dxBxQWjOkLAsMAZHpWfcK6sXUgrjoRWrnaSM7geOlUpgPNKnO3rVRN0zPdtwbg59DUKhnkU4AAOKuuoLsR27CqkiAy89+lWaJkVzErW7Fcc8jHWudjsgJW3/eOCCScE11WG8snA2Ace1Z89qSpPBY4PrVJmkJW0Ohg0VbSwclmS7RlyrthSp6EDHPesuTawZJIwjo2CzHofp+Na+h3e+2+zTMzlwEBLY246EH9Kq6kLdrwiGGfaSMhVzx7k1to0c8ZNSakYbRql4w3gHqSvP/ANasi7sFdmYscsc5xXRXKRs+VDxkDeHb2/hrGuW5wed3Prj6UkmjRyvsYItXSR8YUBuPcVctDhDHxsbnOOhqzt+ftnrVYsE5GRniuhe8ZtijBcAdup9alZ2IIHT0qtFJ8u2TIPalWVi/zjnqSKtRMJMZMGJ9cetVbkEqMHvmrcrKMgk+vSs6VgC6gnHXFbLYkMg8knA7ipk+4DtGMZxVeLB3bSQB0NWOSMnGPemUWIeGUnJBHPFK+fNLLgcU1WwAikE9/SpVkCpluDn86BjXchCyg4I796dG6LEhC/M33qieTjAHBpyKrn5uOOhoBCud06R4CKfxqpMUiuX25zzgmrsiqgOOD+dVJD5hG4Y49OtOISRqQSK0SNwc8HA61r2qKpBJwrDArnIf3ar5Zyp6j0rordRNCm08+lTNC1NCNBsUDPHc1qaWuEClyVzWTZybZxG3Pauls7cZBwcYrnm7IUnY07aIKRVzByeMgelQwgqQOvFTk9cHjr1rilqYt3GEfK2D+HrQoOBt9O9LJggDoDSIwVTnOMetQCGkkLzgimbjyCPcUsZyD2x0zSgnlhg4FBQx9xwV/WoCxB+fOB14qYnjnjFRscck5z2oGhpGV+VvfrTFxnd/FQ43A7ehpkYbaR2oKJDJjjGe+aTdnnqT0qGTIcY6DpSh+m4gMKoRIThRkGikBJTIxj3NFMllcMS2D9TUkZDNgj6DpTABhnwPYVKV3rnIxx9aV9DUkQlDgYAAwBUkYJBPY8/Sq8RG8F/oKnU8E5yPSpJJFY4wO1SIckZx71EMDml8wArz2qWIsbsA8YxS8hc9MVECS2Rg9+KkUNkjI2HsaBEi8gD05zmrCkbRngelVgQQBnIpwcqpAHHT1oJaJiAc4GMUqgY4PJqPeThscY9Kfv6BeCfXii4rEmXI55xzTVDDAOQKQli4704gnGWOKBsewJweqjimqDJ83QCpVDYVevtTPukgk8dqCLjmU7RyM1GzFgT6cjinSYbkn1qPlejckUnqUiF0xzmq5OCVwcZ4qdz0yffFV5By2F9xmkaJEVwC3TgdxUJU7eDyOeKsEgxc8mqj5Trn/GkWirdIMgpjJ65qvcR7oiX+UenrV7PmJhFHPc1XK5DBidwP1qkaKVjOePGSowMYxUUqB1LEZ4zwcVcmUjBz9cdah+UI24ck4FWjRSKiEiIAZ56moZ12ISMkDnpVqRSnlqpJJ6+9QXKkJtXkN3ppXKUtRbGdW/dqNshz1/pVS8kkXCK7rI/AwxzjtUKyGAbXXoeCOc5qOXBXcWIbPf0rSJdkncuXE0cFqI227l4wDk/nWBl/tBKgYznI7VemnUzu0kfnIRgjOD06g+tZ3msXba2PTHetktLmLeuhLKgAJcZb+7VGdGDKeq4yTV6R/wB0zDt1zVYgSBRkqauDJlIrIA2AM8c1MQd4C96RlKMVHOBz6mgNkgc5HetjCTIbr7xI4I/Ws4yZBCgDPU1q3gXYcdOoGehrKK7sLjcO4rWOwroarDaAOhNWYyC4BHy96ryRqjYVGHpnnFSQtsBDrn1FVYaZoS+UDhRgnt2pksOVHzZx+lQ7kYAnJbIqeFyVPIB+napLGLGNw5IHXJp6v17t0pXZQh2jGR1NNDBhsXaBnJx3oGiZuIj5np2rMuZNnyBeOma0H2qSQDtUd6pTg4BAyCevWnEUhtgx+4GOCa6SxBBON20+/Nc7GnlSrkHjniuk00ofnyDnse1E9hR2Oh04K8kZIJBPX0rr7WIbAVJOBXNaMis2GUYHQ11dqAqkAk+9cNVmVR3JSBgc8jIpM8nn8BUjjKgVCOByPlPGa5WZoc437eefSmlQM7vwoLAHocjikfOAc8HpSZSGK23noOmaaTndzjnvTj8py/TsKRhuGcYpFjcFWIbr7U2RcHccfjTzkcsOnrUbE4OB7mgBApHKHimBWKHBApcZGVJHtSqMZK8+tMLlTI3EHrmkkKAkkHPrU0mASeNv61H8hJBPJ6CqsMVGBViTz2oqNiI/TJ9qKGhND0CN3ORTxgLlstz6UgBBBI4PHpTsFWOOD0xQy7grZQjHTmpYTnBXFQtjB6Y+vWjLcEY6dPaoHYskjPTv1pUGXww6jP0pquUX8KcvJ3HJbt9KCRytg9C2DUm7c2Scegpgxs5+XHv1qbbldxII7UEsBnIBGAKlDHHfrTEBBJAJBp+9UXkc+lK4mPPTrx7dqeqnjAyfyqq4YklTxmpVdxgn5sU7IRJGxViAOfep4lOM9SaroCX4/HHGasLvTAB57H0pImQ9Rh/mOCOtNYDeSD7YNPKbVySPfJ5piJ7cE+tUyUNfAAIPzfSmcEEHg+9Tbdp5xzx61Cww5OSKgtEEnDE4xjpiopWO0AdfTFWbhOeOKrPyecEUmjSLIVYlGz97HpzUEi7yAxxxmrKoVb/PNBUOzEkD/Cgu6KB+UHnGeBmoZ04wpO4+nGKsTwM8gfcQi1BOwZNwHTimtyirKFKbDnd61E2NuNxPWp3b5FbI9KhfCxktkE9CPQ1aHcrKhDg4IX86gvUYrHwRyRx/WrwHTaQMDg+9VZCcjdnL9Oa0SsClqYlwp3fIe+WJ6GqdxIVYKxA6jPatS9VA53fy/Ouf1aTZCwJAHoa0po2c9CKfUkgR03gyOcKvpS2JWVlLMC2OwxiuIuLt21JFL5VeAa6zSGLhQRwT1FdE48sTmhU5pM0wu1gGBwvrSSIrTKO5Gc1d8shQx5z2prQbSOu71qIMplR4m5IHU/jUO07z0IH51oFSWUY7VG0YDfMcMT6VqmQ1czri3Z0IPXnGe1Z8KgS4kXg8Ejmtq5hLD7xNVkRIUIwd5rRSsibFaRS+I1zszu4HNMuFi2gKGz3+tWGYBgUIDAcnP6VDndIwIJ3c8VSHYjYbQBt57g8VJyGQFWJPp2qJ3d2BJBx0J7UiPN5nXIAySKdir2LlqFZgrt8npipIo18zgsQPamWM0XmhZ1J3cZzgj3q0H/eYH3R0JqWXErXG0MdjcVUnizGWDDIP3TVydleNvlG4HqKrKhZT2cnn6VSERBG2oysPfNauizBbjacYz9aouwjOF2+uPWn6aZPtG5B8ucninLVCsek6VJFIPkwAK6W2UKgbk1xvh+VXYfKVb9K7a0TKnBOOuc159ZO5hU0ZaGHGetRuuV6CmodrEdu1O3EHrgD17VzGZBLkKTt/EVACCQc5HpVybpmqrKqn07nFI0TuNkJZ+nHahwFIOSR7UgfGRng/rQqkEjNAxCcKCR3qF2y4GeT0NSYGSGPNN+UKQVyBQMjYFZTz09TxTgQxOTionDMMqOKQHB/CmgHPLtByAR34qFmJIIAx2xUhZFYt94nsaaQ2MgAcUxjNpKjknHNFDthsJx680UwsmOfccH0peCN569gKaHyp+YnnpSMBtyW5Pal5FolLh16EHHJp4/dqpY8nioediYG31PrU7E7AxOfQVLEyTgnEnUinIRvAAPA6moo8sTvA49anQndkAdPT9aCWSDnHcnoKk2cjb29e9RRPyxbmpVyFySCM0iSRSSmBjAPNKqgKS5HPrzUaNuGRmpGwwwR09KNAFGQBgGlXkgZAXHemx/MD8xHGKdGoDc8+9CYMnX5WxgkjpjpTmzneTk01SuTnse3al2rvDNggetOxnclUgqMDt1zQSccZIpCxzhCDjrgcU3zCo4YE54oshCngBs596jkyzDH4nNSZ+Qg5yfakTcRtxkdallJldsYySc9vrUTLsIzkntViRM4I5x+tQyHJ+8Mjk0noaIinBUA55FRY3IeRlalX75OM98Go/wC9vGFJ9akspu581o25A6nOMGonJK7QMe45qxPsO7aqsoz9TUFvH+6yW4HUH1quhfmVGjLPxxjnkZoKq24HGf5VJd+ZHG0ip82MVB96IEcyEc5FXATIpIycE5xnkGopS7LuUgY4AIzxUrgg5J9jzUEwxygO1f1rS4luZF8SynjHPU1x2uzFkZccrx9K7DUshTkjPrXF62AIpCOATmtoFPY4xwf7QPfvXb6G+1UAHHWuIjG68OOpNdropXYinqOa6cRsjCgtWdTEN64HQGpmTrwQR6CorDLEjkE1eMYUZx34J71yRdmbyKEyFQSMdM4NVXGArOp2ng4rRuhvIXHU9KrEjZsdeOme9bpiIo3XysjAGOfpSLZvLEXXaSD07/8A6qdiNcjA56ZqwiYAKkknrg1TkIxbqEq28r93rxxWa3mMxYYznt610N55YzkgnuKxpmR3GEwvdf8A69axYIrxxr5p3s3H8OOc0ZKyBs/L6dM091BBO04HII602JFEhZh+Zq7k2HI6kM5HzZ6Vb83zFAxz0qO2jWVztOF96mWVIVyRkZOOKRohIYmQ7WJwMnr1p0bbwwVB0waihuW8/wCUkq3ariKyFlKDaxzkc4oLRnm1ZnOAeatafBMJQpcbcdx2rRSHfgImWHb1qf8As53CuvDj0qHLTUp2Rc0JykwDA5z6/wAq7i1lGwAMR/SuTsrJlaMnIxzXW2qhAv8AED19q5ajuc9WzL0RJAIJJ96dJ3PXtimjnbjgdKe3XiuVnPbUhc/Xn1qNuRxz2pzgg/MOM00lcEHIHtSNLETJ2I79R2pEHyHcOR05pxGe/WmAbSQe/egCJxv4HAzTMkEZBIp5wrn1pjg8ZNMoHYAfLTUceWcgcfnQPlbKjcTTSQWYMOOnvTsBFIhzkAle2etNaTbx/kVNgY278DsKryIQ4Ixg8etOw1YHkQP0ziio5Ay8EKQaKloWhMG2jO35T096kzg7gOajVhsyrZzwD2pwbEZHI56mnYsApztdmCk5Oe1SeYASo5fqM9qjKBig35bGakiyfkxj6daQMkTO35iAc1YUkrwQFPfNV0BU5xgHgZpRlQDnI7UmTbUtxkN8oHepd4VGH3sdPrUEXC5zg08HCjkewpWJH7iFB6Y44pYyTuAPHTHrUO7KkZx3609T842nafrUpDJkJz1AqSNQHx1PWoUGTjdjnrjrU8JGcGnoS0TqQBleMjpTiBtwQCxGBzTRy6nnjjBpy4JwOR60yWtBVDAZx1o+8/bHrSsxXGTlvpShchjx6g00iQJO8cc+tJjdkgYpwYlM4HsajjI75wCSfeiwJXEOGVtvXpn0qs65Yg4GetWM7AVwfpUTDL5JxkVLNFoRBsNgEHHpUMjcjeuc8cVNKFXoSpJ6mowGzjg/4VNrFogChE+QAk96jeNoycgcmrLJl/l5Apk6hgDyzL700rgUp1ZkYE9euaoIDHLyevGTV25Ygnc3PTnsKqT5JXqe3FaRLtoNnA5C9BVZzuQIo56Zqc8fe4PP0qvMVCkpgZ7E09wSsYuoBWXb6HgmuR1iIYlGOcZ9q7PUgDk4AA9K5PWlJRypHI5reBVtDiLeMfbCwHOetddpiFVUZHPWsO0twZycdzXRadFgEDO33rWtK9iKMbXOk03DDOfoa1DGZMLwCOtZ1iBjGcjHate2iJXe4PPWubUuRQkQq25vvY4PYVQlJ3ZxyR1rauACmB+eKzrq3DsF7/pW0JEIhUx7MMoDdAT3qUwP5JZMZUZwDUiRMFyUGB1OKJ2ZlXGc4Iz04qk9R3RkXHK5+UZ45qosAkkADYDcfNVuaNTKVkJX37Gk+x4c7GBIOM9q2TsVoiq8KwkhlBbHGKqW6oC4lVsfw8VtvC5XaceYDjNV5YpCpZYySePr71akSUApRcg7Vbv61LNtZljUh2IAAFWxauYlXaAc9qY2nvGVfO/+lHMXYLW1SOQHG1+nPrV61kBuCuBkZx6Gqgid5ECAqfU1qWECxSFnbc3bPSlJjWhbjR9mVGD3PrWnZwNtOeR0zSWwEueMgDrWnHGoRSvT0rnkzGU+hVSNkbqenStS3lCqASAagZC6gjHNSLbYA6k+9ZOxCd9zRtpS+RjIPH0p5weMn8qqWgCAtgj6Grak5ODx71i0JrUaw7Ebsc5FRjOznqKeT5bZOTnpTcMXYjHTvSAiY5HIPrTSSp54FSP1yCOlRM/BycmkNETghuvNNeQcjinu2E3HHtVbcCxyPzp2KSHqeME9TwRTJG25J696YjMvQdKGw2evv600DQpIEe8f/qqtKxJIB461LsIXCsWAHemkBmPFVcaRE7HbnvRTZSIxwOvGfSinp1E0Yn9q3gUqJQF442L/AIUNq175A/ff+OL/AIUUV0cq7HO5PuCareeWD5wz67F/wqdNUvArESjP+4v+FFFJxXYnmfcJNXveB5wwOfuL/hQmrXpcgzDH+4v+FFFS4x7FKT7kr6tejOJu4/gX/CiPV77g+cM/7i/4UUUcsexSkx41e+wP3w/74X/Cn/2xfHP74df+ea/4UUUnCPYicmSJrF9s/wBcOv8AcX/CprfWL4hgZh/37X/Ciihxj2Ik2OTWr8k5nH/ftf8ACn/21fqflnA/7Zr/AIUUUKK7Gd2Kdb1D5v34/wC/a/4UDXNRKjNxnH/TNf8ACiiq5V2C7Hya1f8Akj9+OT/zzX/CmDWb/wCb9+P+/a/4UUVSiuxSbGvrV/u/1/f+4v8AhQus3xdszDr/AM81/wAKKKTiuwk2Mn1a9Mi5lH/ftf8ACo21i+JIMw4OB+7X/Ciis+VdjSMmMXWb7Lfvx3/gX/Cmy6vehciYZ/3F/wAKKKFFX2E5MqPql40TFpQTz1Rf8Krtqt4FVhMM+uxf8KKKtRj2Kcn3IZtVvCyZmHOSfkX/AAqpJqV0VJMgzn+4v+FFFNRV9ioyfcp3t9cZx5nGf7o/wrA1G7mIUF+D22iiitoxXY35nbcyYLiUMxDDOfQVsWF3ME4cf98iiinUirbExk+5t2N9cBcBxj/dH+FaKaldiQ4l/wDHR/hRRWLiuwpyd9yOXU7swgGXI/3R/hVVNRuvMH7wdP7g/wAKKKuEVfYjmfckbULoKQJeDzjaP8KqT6ndsm0y5AIH3R/hRRW6iuxSk+5RuLyfyvvj/vkf4VZ0+8nYKGcEf7o9KKK0sgcn3HNe3CuoVwBn+6P8Km+33IXiQc/7I/wooosjPmd9yjNf3KuNsuOfQVKNRujOuZepH8I/woop2RspPuWob64FxkOMkHPyD/CpZL64yfnHQ/wj/CiihpWFzPuaGm6ndi0A80dP7i/4VcXVbwKMTf8Aji/4UUVm4q5lUbuWItWvct++H/fC/wCFLHq17kHzuf8AcX/Ciis5RXYxuxw1e9WQgTAD/cX/AAqwmsXw484dP+ea/wCFFFYcq7FNsYmsXxZszA4OB8i/4U7+173aB5wxj+4v+FFFTyrsEWyI6vet1mBx/wBM1/wqP+1r3bnzhn12L/hRRRyx7D5mRnVbwquZgf8AgC/4Uw6re7x++HT+4v8AhRRTcV2K5n3Ijqt5/wA9v/HF/wAKadUvDg+d/wCOL/hRRWiiuwcz7iR6te/L++7/ANxf8KJNTuxIMSgf8AX/AAoopqK7BzMhk1O7Ocyj/vhf8KKKKUorsNSfc//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note ecchymosis of inner thigh. Note bleeding out of proportion to size of laceration. Interrupted sutures were placed for hemostasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc R. Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32449=[""].join("\n");
var outline_f31_44_32449=null;
var title_f31_44_32450="Indocyanine green: Drug information";
var content_f31_44_32450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indocyanine green: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      IC-Green&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic angiography:",
"     </b>",
"     Use doses of up to 40 mg of dye in 2 mL of aqueous solvent, in some patients, half the volume (1 mL) has been found to produce angiograms of comparable resolution; immediately following the bolus dose of dye, a bolus of sodium chloride 0.9% 5 mL is given; this regimen will deliver a spatially limited dye bolus of optimal concentration to the choroidal vasculature following I.V. injection into the antecubital vein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cardiac output determination:",
"     </b>",
"     Dye is injected as rapidly as possible through a cardiac catheter; the usual dose is 1.25 mg for infants, 2.5 mg for children, and 5 mg for adults; total dose should not exceed 2 mg/kg; the dye should be flushed from the catheter with sodium chloride 0.9% to prevent hemolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatic function studies:",
"     </b>",
"     0.5 mg/kg injected as rapidly as possible into the lumen of an arm vein; patient should be in a fasting basal state",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IC-Green&trade;: 25 mg [contains sodium iodide &le;5%; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Determining hepatic function, cardiac output, and liver blood flow; ophthalmic angiography",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Feces discoloration (green)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3413114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indocyanine green, iodides, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3413115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Immediate treatment for anaphylactic reactions should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3413111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been done.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3413113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (IC Green Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $105.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Indocyanine Green Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $105.99",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3413141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal percentage disappearance rate is 18% to 24% per minute",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3413142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 95% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 2.5-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Bile",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8982 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32450=[""].join("\n");
var outline_f31_44_32450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182600\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182605\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182601\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182602\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897879\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897880\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182594\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182584\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182595\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182603\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3413114\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3413115\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299516\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221002\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182591\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3413111\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3413113\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323196\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3413141\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3413142\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_44_32451="Complications of mannitol therapy";
var content_f31_44_32451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of mannitol therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32451/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32451/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32451/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32451/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32451/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32451/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/44/32451/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Mar 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    , given as a hypertonic solution, is primarily used in the treatment of cerebral edema and glaucoma. Although generally well tolerated, a variety of fluid, electrolyte, and renal complications can occur if the patient is not carefully monitored. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H30#H30\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Mannitol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9063?source=see_link&amp;anchor=H18#H18\">",
"     \"Angle-closure glaucoma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Volume depletion and hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    is freely filtered by the glomerulus and does not undergo tubular reabsorption. Thus, it acts as an osmotic diuretic, increasing urinary losses of both sodium and electrolyte-free water. Lack of replacement of the fluid losses can lead to both volume depletion and hypernatremia that can be severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Volume expansion, hyponatremia, hyperkalemia, and metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If very high doses of hypertonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    are infused, or if the drug is given to patients with preexisting renal failure, mannitol is retained in the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The ensuing rise in plasma osmolality, similar to that produced by hypernatremia, results in the osmotic movement of water and potassium out of cells leading to extracellular fluid volume expansion (and possibly pulmonary edema), hyponatremia, metabolic acidosis (by dilution), and hyperkalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/5\">",
"     5",
"    </a>",
"    ]. Water losses from brain cells cause neurological symptoms. Volume expansion and dilutional hyponatremia, without neurological symptoms, can also be induced when isotonic mannitol is used as a flushing solution during transurethral resection of the prostate or bladder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The rise in the plasma potassium concentration following hypertonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    is due to the movement of potassium out of the cells into the extracellular fluid via two mechanisms: (1) the rise in cell potassium concentration induced by water loss favors passive potassium exit through potassium channels in the cell membrane; and (2) the frictional forces between solvent (water) and solute can result in potassium being carried out through the water pores in the cell membrane (a process that is called solvent drag). A similar process can occur with acute hypernatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/6\">",
"     6",
"    </a>",
"    ] and also largely accounts for the hyperkalemia that is commonly seen with marked hyperglycemia in uncontrolled diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Plasma osmolal gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    in the plasma can be estimated from an increase in the plasma osmolal gap, which is the difference between the measured plasma osmolality (which includes the contribution of mannitol) and the calculated plasma osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The latter assumes that sodium salts (chloride and bicarbonate), glucose, and urea nitrogen are the primary solutes in the plasma and can be estimated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Calculated Posm &nbsp; = &nbsp; 2 x plasma Na",
"    <span class=\"nowrap\">",
"     (meq/L)",
"    </span>",
"    &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [Glucose]/18",
"    </span>",
"    &nbsp;+ &nbsp;blood urea",
"    <span class=\"nowrap\">",
"     nitrogen/2.8",
"    </span>",
"   </p>",
"   <p>",
"    The plasma sodium is multiplied by two to account for accompanying anions (chloride and bicarbonate) and dividing by 18 and 2.8 for the glucose and blood urea nitrogen convert units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    into",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/9\">",
"     9",
"    </a>",
"    ]. The corrections for glucose and blood urea nitrogen are not necessary in countries that report the concentrations in",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"   </p>",
"   <p>",
"    A number of other formulas have been used to estimate the plasma osmolal gap. There appears to be no significant difference between the accuracy of the different formulas and their correlation with plasma",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/11\">",
"     11",
"    </a>",
"    ]. The plasma osmolal gap, which is also elevated in other disorders, should not be allowed to exceed 55",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    when mannitol is used in the treatment of cerebral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with marked",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    accumulation (plasma osmolal gap greater than 60 to 75",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    which reflects a plasma mannitol concentration above 1080",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    may develop reversible acute kidney injury (acute renal failure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/3,12-14\">",
"     3,12-14",
"    </a>",
"    ]. This complication is essentially limited to patients treated with more than 200 to 300 g of mannitol per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The required dose varies with baseline renal function. Acute kidney injury in patients with normal baseline kidney function is usually seen when the total mannitol dose exceeds 1100 g. In contrast, much smaller doses (&gt;300 g) can precipitate acute kidney injury in patients with preexisting kidney disease.",
"   </p>",
"   <p>",
"    Although tubular vacuolization also may contribute, renal vasoconstriction appears to be of primary importance in this setting, an effect which may be potentiated by the concomitant administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/13\">",
"     13",
"    </a>",
"    ]. Coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    may also increase the risk of kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute kidney injury can be minimized by keeping the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    dose below 250",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients who develop renal failure appear to recover renal function rapidly if treated with hemodialysis to remove the excess mannitol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32451/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2252878\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      acts as an osmotic diuretic, resulting in fluid losses that can lead to both volume depletion and hypernatremia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Volume depletion and hypernatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retention of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      due to underlying kidney failure or mannitol-induced acute kidney injury results in hyperosmolality and osmotic movement of water and potassium out of the cells, which can cause volume expansion, hyponatremia and metabolic acidosis (by dilution), and hyperkalemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Volume expansion, hyponatremia, hyperkalemia, and metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The concentration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      in the plasma can be estimated from the plasma osmolal gap, the difference between the measured plasma osmolality (which includes the contribution of mannitol) and the calculated plasma osmolality (which does not). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Plasma osmolal gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The plasma osmolal gap should not be allowed to exceed 55",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      and the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      dose should not exceed 250",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 4 hours when mannitol is used in the treatment of cerebral edema or glaucoma; higher doses can cause reversible acute renal failure. Patients who develop renal failure appear to recover renal function rapidly if treated with hemodialysis to remove the excess mannitol. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/1\">",
"      GIPSTEIN RM, BOYLE JD. HYPERNATREMIA COMPLICATING PROLONGED MANNITOL DIURESIS. N Engl J Med 1965; 272:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/2\">",
"      Aviram A, Pfau A, Czaczkes JW, Ullmann TD. Hyperosmolality with hyponatremia, caused by inappropriate administration of mannitol. Am J Med 1967; 42:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/3\">",
"      Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine (Baltimore) 1990; 69:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/4\">",
"      Oster JR, Singer I. Hyponatremia, hyposmolality, and hypotonicity: tables and fables. Arch Intern Med 1999; 159:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/5\">",
"      Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987; 34:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/6\">",
"      Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/7\">",
"      Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/8\">",
"      Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.607.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/10\">",
"      DiNubile, MJ. Serum osmolality (letter). N Engl J Med 1984; 310:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/11\">",
"      Garc&iacute;a-Morales EJ, Cariappa R, Parvin CA, et al. Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. Crit Care Med 2004; 32:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/12\">",
"      Gadallah MF, Lynn M, Work J. Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms. Am J Med Sci 1995; 309:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/13\">",
"      Visweswaran P, Massin EK, Dubose TD Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol 1997; 8:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/14\">",
"      P&eacute;rez-P&eacute;rez AJ, Pazos B, Sobrado J, et al. Acute renal failure following massive mannitol infusion. Am J Nephrol 2002; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/15\">",
"      Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997; 52:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32451/abstract/16\">",
"      Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51:491.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2333 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32451=[""].join("\n");
var outline_f31_44_32451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2252878\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Volume depletion and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Volume expansion, hyponatremia, hyperkalemia, and metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Plasma osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2252878\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_44_32452="Pegfilgrastim: Patient drug information";
var content_f31_44_32452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pegfilgrastim: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"     see \"Pegfilgrastim: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/29/43476?source=see_link\">",
"     see \"Pegfilgrastim: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neulasta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neulasta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the chance of getting an infection in cancer patients who have had very bad bone marrow problems caused by chemo.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pegfilgrastim, filgrastim, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705177",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not get this drug on the same day that you are getting chemo or radiation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you weigh less than 99 pounds (45 kilograms), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699048",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad shoulder pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Before giving the shot, bring it to room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store at room temperature for 2 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11244 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32452=[""].join("\n");
var outline_f31_44_32452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855049\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012866\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012865\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012870\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012871\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012873\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012868\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012869\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012874\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012875\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=related_link\">",
"      Pegfilgrastim: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/29/43476?source=related_link\">",
"      Pegfilgrastim: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_44_32453="Ixodes scapularis life cycle";
var content_f31_44_32453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Ixodes scapularis",
"    </em>",
"    life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 472px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHYAc4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6a1rV7DRLL7Xqtyltb7gm9s/ePQcVif8ACw/Cv/QXi/79v/8AE1Q+L5K+H9OI6jUoP5muWt5hIvONw61jXnOlHnSujOdTldjuP+Fh+Ff+gxF/37f/AOJo/wCFh+Ff+gxF/wB+3/8Aia42iuP6+/5Re18jsv8AhYfhX/oMRf8Aft//AImj/hYfhX/oMRf9+3/+JrjaKPr7/lD2vkdl/wALD8K/9BiL/v2//wATR/wsPwr/ANBiL/v2/wD8TXG0UfX3/KHtfI7H/hYfhX/oMRf9+3/+Jo/4WH4V/wCgxF/37f8A+JrjjSUfX3/KHtfI7L/hYfhX/oMRf9+3/wDiaP8AhYfhX/oMRf8Aft//AImuNoo+vv8AlD2vkdl/wsPwr/0GIv8Av2//AMTR/wALD8K/9BiL/v2//wATXG0UfX3/ACh7XyOy/wCFh+Ff+gxF/wB+3/8AiaP+Fh+Ff+gxF/37f/4muNoo+vv+UPa+R2X/AAsPwr/0GIv+/b//ABNH/Cw/Cv8A0GIv+/b/APxNcbRR9ff8oe18jsv+Fh+Ff+gxF/37f/4mj/hYfhX/AKDEX/ft/wD4muNpaPr7/lD2vkdl/wALD8K/9BiL/v2//wATR/wsPwr/ANBiL/v2/wD8TXG0UfX3/KHtfI7L/hYfhX/oMRf9+3/+Jo/4WH4V/wCgxF/37f8A+JrjaKPr7/lD2vkdl/wsPwr/ANBiL/v2/wD8TR/wsPwr/wBBiL/v2/8A8TXG0UfX3/KHtfI7L/hYfhX/AKDEX/ft/wD4mj/hYfhX/oMRf9+3/wDia46ij6+/5Q9r5HY/8LD8K/8AQYi/79v/APE0f8LD8K/9BiL/AL9v/wDE1x9FH19/yh7XyOw/4WH4V/6DEX/ft/8A4mj/AIWH4V/6DEX/AH7f/wCJrj6QkDqQD7mj6+/5Q9r5HY/8LC8K/wDQXi/79v8A/E0f8LC8Lf8AQXi/79v/APE1xZmiXh5EH481G15bKM+Yp+nNH19/yh7XyO4/4WF4V/6C8X/ft/8A4mj/AIWF4V/6C8X/AH7f/wCJrhf7Qtwfvtnr92j+0LY8b29ORT+vP+UPaeR3X/CwvCv/AEF4v+/b/wDxNH/CwvCv/QXi/wC/b/8AxNcOt7bt/HyeR8vpTlubdvuyp+dL6+/5Q9r5Hbf8LC8K/wDQXi/79v8A/E0f8LD8K/8AQYi/79v/APE1x6sGGVII9jS4o+vv+UPa+R1//Cw/Cv8A0GIv+/b/APxNH/Cw/Cv/AEGIv+/b/wDxNcfRR9ff8oe18jsP+Fh+Ff8AoMRf9+3/APiaP+Fh+Ff+gxF/37f/AOJrj6KPr7/lD2vkdh/wsPwr/wBBiL/v2/8A8TR/wsPwr/0GIv8Av2//AMTXHUlH19/yh7XyOy/4WH4V/wCgxF/37f8A+JpP+Fh+Ff8AoMRf9+3/APia46g0fX3/ACh7XyOx/wCFh+Ff+gxF/wB+3/8AiaP+Fh+Ff+gxF/37f/4muNoo+vv+UPa+R2X/AAsPwr/0GIv+/b//ABNH/Cw/Cv8A0GIv+/b/APxNcZRR9ff8oe18js/+Fh+Ff+gxF/37f/4mj/hYfhX/AKDEX/ft/wD4muLNJR9ff8oe18jtf+Fh+Ff+gxF/37f/AOJo/wCFh+Ff+gxF/wB+3/8Aia4o0YLEKgJYnAA70v7Qf8oe18jtD8RPCgBJ1iEAck+W/wD8TXUwTR3EEc0LB4pFDow6EEZBrzK9sBbaDqMknMzW0mfb5T0rvvDH/It6T/16Rf8AoArowmK+sXaWxs4tJXOX+MH/ACLun/8AYSg/ma4hWZGypxXb/GH/AJF3T/8AsJQfzNcRXq0EnFpnBiviRft5RKBjqO1TVlIzI2VNaEEolUHIB7ivFx2BdF88Ph/IUJ30ZLRRRXmmoUUUUAHtSUtJQAUUUUAFFFFABRRRQAUUUUAFKKSlFABRRRQAUUUUAFLRkAEkjHfJqnNqEKZVP3je1AF2o5Jo4wS7qMds5P5VjSX9xK+AdoH8I/xqtySfmLe+c/nTUQNaXUkXPlIX9zVZ9RuHyF2p7gdKq9cFeg5x9P8AP1oC4+916mqsBI1xOTlpWP41GCWJYlmI9Wx/nrSr8pLUu07McZpjGYXHXGO3p9f849aX8Dz/AJ/z+lGCCcnpwDinA/MBjDdfrQA3oMn07f5/z9aFXnvnHc0u3aBz1P5U4d/XOfxpgVr+6Szs5bl1JRAMBe5JwKxNL8RrdXKw3EKxFzhGU5GT61p6/aPd6TLHG23bhzk9hXG6HbSXep2yREBg3mZPoOf6VhOUlJJHo4WjSqUZSnuvwPQCdqsd2wDkjoBjvmlttRWTP2e8R8fe2uGP/wBasTxlOy6ZHGrYaWQZA9Ov9K5LT5RbX1vKDtCyDPYY96J1OWViaGD9tSdS56omozJjzArDoPWrMWowuQHymfXp+dZZOCePmxn6+4poB9sYxWtjgOiUhvukN9DmlrnY3ZPucE8HHH+fp0q3aX7R/JLlk/vY5FTyisa1JSRSpKuUbJHandaQCUGiigBKKKKAEoopDQAGkooA3EADJJwAKQBgsQFBJPAA71vaZYC3QSSjdMR37Uml2AgHmTDMrc47CtGuSrVvojtoUeX3pblDX/8AkBaj/wBe0n/oJrr/AAx/yLek/wDXpF/6AK5DX/8AkBaj/wBe0n/oJrr/AAx/yLek/wDXpF/6AK9bKPhl8i6vQ5f4w/8AIu6f/wBhKD+ZriK7f4w/8i7p/wD2EoP5muIr6TD/AAs8vFfEhKVGKMGU4xRSVs0pKzOZGjBMJVB43elS1lIzIwKcVoQTCVRjAI6185jsC6D54fD+R0QnfRktFFFecahSUppKACiiigAooooAKKKKACiiigApaBRQAUUUUAFQXV0kC8kF/QGmX10sCbV+aQjj2rGLM7MZDkseSehppXAmuLia5YFztUdAOlQZGCDgnrn19KOvOc9vr/8AWoPTGOv8qtIYgB5zkgcc9fwpQPXJPrilAPfOaXjBwfrTAOo4/CnHGMEY7k/5/nTF5PHT0p3160gFA2ge57/5604AE4yeORSZKsuOB/If5/zmqF3qscX2uPgT2+SY8/MYwPvADrTtcaTexfBUrk9cZH8qMckDHJ/Ef59etZ9hqa3l3aRxypiS3Mxjx8x5xkfTvVyxuPtVskoBGWbg9iDim1YHFrcmPByeg5+n+TTJpFigeRh8qKWPbNSEYGRjPSqesuI9KvDg48sg59TUt2Q4LmkkcZf6ze3u4PK0cTdI16Y9KoRu0ThomZGHRhQoO0cGlxXA227s+mjCMFyxWhcvdUub6zSG6xIysCr4wcYqgh2SIxXdtIOD35p+KQ0N33HGMYq0Ud9peowalbs9vlXGN8bdQfUf41bHHfp71x/hGbytUaMnAkjOMnHIrsyDwAMEdsV205c0bnz+KoqjU5VsN4HGP8/5/wDr03n9e/8An/PandjgCkHPXpVWOYASjb0YKw6bT/n/AD71pW+ooyhZxtf1HQ/4VlnlgT+eaD8xHA9PTJpNCOiBB5ByKWsK3u5bc8HencGtiCZJkDRkEfqKloCSg0UhpAFIaWm9TgZJ9BSAMEnAGSewrc0uxEC+bMuZW6AjoKTS7DyQJZxmQ9FPYVpc5rlq1b+6jtoUbe9IO9LRRXOdRQ1//kBaj/17Sf8AoJrr/DH/ACLek/8AXpF/6AK5DX/+QFqP/XtJ/wCgmuv8Mf8AIt6T/wBekX/oAr3co+GXyMK26OX+MP8AyLun/wDYSg/ma4iu3+MP/Iu6f/2EoP5muIr6TD/Czy8V8SCiiitzlE70qO0ZDLRSdKUoqSs9gRpQSiQDb19KkrLjdo2DLWhDKJB8vXuK+bx2BdB88Ph/I6ac76MkpKWivPNRKKDSr94fWkBSm1XTYJXin1KxilQ4ZHuEVlPoQTxUf9taR/0FtN/8Ck/xrrvhjplhceGZZrixtJZjfXeXeFWY4ncDJI9AK86+HfjS61a417UvEemWSaFpS3ssvkaA4QpAT0uCxQvgfcxnivQjgeZJ3NVTRr/21pH/AEFtN/8AApP8aP7a0j/oLab/AOBSf40P8TdFs7G6uNb8FJZFNIh1mCNfJmaaKaYQxLwBtZmYZz0FS6n8RdN0i11san4GSHUNJubW1uIY/KkjjNxGZA7yKvyoABlsHkgYqvqH94PZojGs6STxq2nf+BSf41eVlZFZGV0cBlZTkMD0INdZ4Tm0fxT4Pt9Yi0jS4xcxyEJEYp0G1ivDqMHOM9iOhAIIrz/wn/yKujkDGbWP+Vc+Iw/sUtb3JlDlNaiiiuYgWobmYQRljjcegJ6mpaxdSnM1xtU/KhOMUJAVixeRpHyGY56/5xTc9j3/AMaUcKcjOf1/z+dJ0HNaIYKOv1IFPyB6cjjPamL94ZI9KU85x1PUnr60AL0GeueOaXjHB/H0pASW56dOR/n/AA9aVvcHJIoAXkn9OlAHzDPU0gycZHJ/Wnj7xBye31/z0pgKrZJI7e1VL/TotQMbOStxGcxTqBuT69iKsTSx29vLcTsqRRruZz0RR1z/AI1wHiDxVJrMBtdCytm337rnMg9sdB796Ffoa0acqkrRGWd+sF3ctZShbiLMKKFBOSpy+QMBQev1rufD0cSaPai2kaSIjJcjAZjyT9M55ryW+jNppQYoXZ5E3jJAYKQdv0yBXq/hrVrPWtKjuLD5Fj+SSIjmJhxgj+Rq5PQ6MVTcVfoaYGenp0rH8VzeVpDqOWmcJn07/wBK2sdufyrnfGR329nB0d5cg9vT+tY1H7rMsKr1o37nMzKRa2mRgMjMD681WfhSfQVr+Io1trqC0QYW3hVee5PJrKIyK45Kzse/SlzQUu5Y1CEQzRICDmJW496qOPlIHBPGakd2kbc5z2H4U1uh5xSZUU0rM29SVdK1yynt1AjeNG6cHjB/nXYfKQMZ6ZAPv/PvXJ3Ef27wbFMf9ba56dhnH+cV0unyLNY2zjnMa49ScV1U9GzxMXrFN7ptE7Y46Z6D/P8ASoyDg5pzdee/f1pHJ29P/rmtThI8c/p/9agc59qUgAtzketGSeoHHpRcBpPUk5HU1NbXDW0m5BlDwV71ERjJJHuR3pm7J4xkD7tIDoLedLhd0Zz6g9R+FSZrnUkMLK6Ocj/OD/nFblvOtxGHHHZh3B9KhoRMfT14rZ0vT/KAlnGWP3V9KNLsAmJZx838K+latclWrfRHZQo296QnOfpRQaK5zrCiiigChr//ACAtR/69pP8A0E11/hj/AJFvSf8Ar0i/9AFcfr//ACAtR/695P8A0E12Hhj/AJFvSf8Ar0i/9AFe7lHwz+RhW3Ry/wAYf+Rd0/8A7CUH8zXEGu3+MH/Ivaf/ANhKD+ZrietfR4f4WeXiviQlFFFdByhRRRQAhFOjdkYFfypKSlKKkrS2BO2ppQyLIuQR9KkrMjdkYFavwyLIu4Hn0r5rG4J0Hzx+H8jqpz5tGSUq/eH1pKVfvD6155odT8Kf+RSk/wCv68/9HvUOnfDPwro81/caXYPbz3ccyS+ZdzzQnzQd5aJ5Chznnj8qm+FPHhJ/+v8Au/8A0e9eW/GDxTq6eMbjSbe7ubSxECxskbLiUE8suTgkLknOMYr2aldUKUZNdjrirlzRvhdoOmaVrbX3iTTrsX9kmjxh4JPs9ugfeFKPOzk7gMYdcYG3HWuh8H/CvQ9Pj1S01fU5dWv724ivJGhuJrZojGhjTawlaTozAkyHO7mvnxGjWHyXeMRMwDIH80K7KuZFAYjHGd3Jzxtq9ZajqWl6pHqFrczR3bMZQ8rOxkXcXyeNxVgqjcFXrg1yLMZX1iXyH1ppGi6d4e0EaZo1pHaWMKPsiQk9ckkk5JJJJJJOc15N4S/5FXR/+vSP/wBBr1+z+1f2JH/aLRNeGDMxiGFL7ece1eQeEv8AkVdH/wCvSP8A9BrTHu8YnPUNWiiivOMRshCozHoATxXOMS28dyev61vX7bLOQ+ox+dYA5IJ46n6U4ghx4Izk+n1/yaRjhfXNL9cEY6fX/P0pDkH5cnv+XT/D/wCtVjHYGefpgdaauST343EjtVrwd4aj8WeINftrvVdYtILCO2WNLKcRqfMVixIKnJyOtZNzc+BbebxLDL4k8Z/afD08cN3F9oTcxaVYQ0fy/MoZ1B6YyPWumGFnOPMmWoNl/wBMnr0oGBwflGOT610Y8DeFA2weONW3fa/7P2/2vFn7T18j7v8ArO+z73tWVJpPw7i84t8S7vEK+ZJjXISFG7bzgf3uPrV/U590Hs2U+c/MCOtKMBSx5A5rW1Dw14I0+eK3v/iHqFvPKI9kcutQqzBxlCBtzhuoPQ1l6Vp3g288RajoM/i/xBY6laXxsI7e61WJHuX2qcxrjJHzAD34pfUp90Hs2DorxPG8aOkgKMrcgjoQR+NZtn4e0q2QR2tmkManIVCVA5/zx0ra8X+HI/Ceu6DHaapq13Ff/aFljvbhZF+RAwI+UYP0qBRz/wCPEHvWNSDpvlYtY6JnI+MdE87TBcJLIyxHypUIzjurV5ppmp32g6m0+nzlX6EMMqw9x3r3k7NsivH5qOux0Pdev5ivGvGminT71pI/ngclo3HII9PqKmWup6mEqRqx5JGxB8SNQ3ZmtLN19MlT/P8A+tVXWvGramYC1tDH5XYMTzXEkFlyAcCmBCT1NZtX3OqOHpwlzRVmdnqfi86jcLPJbIsgQIdrHnHeorbXIZHUTxvED/GOR+Jrm7aPPI7VtMqf8I7GNo+e5K78dgnT9aSoqV7l8yppJHSzwtCYgxzvjEgPsaiZcD2NaN7GV0PQZX/1httjZ7gHioNSh8hLUDq1urkehOa5Jxs2iqVXnSb63/A347Vx4KaONWZ3G/aoyTlhxWrosMlvpVtHPkShOmKnskCWVuidowamJDDnr2xXXGNrM8GrVck4+dxGIPHrzTHyMc54yKOh6cUjnIPIwTjj+dUYCdsfh+dIP/rUh5OcYJPNIzZzyD25OOKGwEb7p700fMcKOT0px+v1NREkH5fTjHv/AI0AOfBADYrb0SCS1nS5dcOTgIfQ9cioNMsuRNcDp91CK1M4I6AEcH+v+f06VzVKl/dR10KP2pHUwyJNGJI2DKehFPNc/p1ybaYbs+U33h6H/Pf/APXW+CrDKkEHoQetcbVjrFoooqQCkNLSGgChr/8AyA9R/wCveT/0E12Hhj/kW9J/69Iv/QBXH69/yA9R/wCveT/0E12Hhj/kW9J/69Iv/QBXu5R8MvkYVt0cv8Yf+Rd0/wD7CUH8zXEV2/xg/wCRe0//ALCUH8zXE19Hh/hZ5eK+JBSEUuKT6VucoUUfWg0wCiiigAp0bsjArTaO9KUVJWlsCdtjShkEqgr+NSL99fcisuNmjbKnj0rRglEgDLnjrjrXzWNwTw75o/D+R1U582h1fwpIPhJ+n/H/AHf/AKPerXiLwNoGv3ZutQsFadhiVozs88Dor4+8AQCM9wK47w5ret6BZS2UGm6fdQm5mmSV71o2YPIz8jyzjG7HWtX/AITXxB20TTP/AAYv/wDGq6I1qMoKMmjrU0upz998FIZtQH2TVJINPWIsAw3P5+7IIAwFTODhcHtmtHwp8GtE0pWOqzy6oxIIUgxRghcZKg5J69Tj2q9/wmviDHOiaXj/ALCD/wDxql/4TbX/APoCab/4MX/+NVmvqqd1Yv2vmd7MAtrKqgKoQ4HpxXi3hL/kVNGP/TpH/wCg11UnjPX3jZP7F0wbgRn+0XOP/IVc7oto9ho1hZyspkt4EjcqSRkDBwT1rLGVYTS5XcynJNaF2iiiuEyKWrki1AHZ81kL8xA3cdif8+ta2snFsg9XrHAyPrz/APXqo7AOGOo5yelAzkn6U0HHH4fQ07PAI6dfrVDOn+Df/Iz+LgOf3dln/vh6xfFfwMfXrXVpE1KC31O51+XVYpxG2Ps8nlboH9fmiVh2BA9TW18GSP8AhKPFo77LLP8A3w9esnpXsUP4aOiOx5DaeBLmX9oK+10wzx6BBAl6quAIpdQaPyi6DviMcn+8ao6b8FZrXTNJtpbywkls9P1SzkfyD+8e7dmR/wDgAbH8q9KtNSkTxzf6XO37t7OK6gDHr8zK+PXHy5+o9a149RspNRlsI7u3e+iQSSW6yAyIp6MVzkA+prW47Hgp+FfiK7v9U8PCa0t9Im0HStLudQlt2cyiBcP5A3ABsqPvZ6j0rqb/AOE01w+qOt3aeZdeIbbWY5HiJdI4gg8st1ydp56fNXb2eozXfj7ULOOQmzsbKISAHI86RmOD7hVHHuK6XtQncDyz4xsB4g8IjGWLXmP+/S1zQwenXrXS/GM48Q+Dx/EWu8H0/dCubUMcgbi3XGOa8vF/xDGpuIp6YIBxkGud8c2hk0S4cQ+ZCrbyUGDC3r7g9/SrOq+K9C0i8Npf6jHHcAfOqgnYPfHStNlj1TSpRbSrNBcwsEkjbIbIIrBXRVOUqclJHlPgXSbPWr37LdXUFqGPyvM4QE+mTxXez/B+3jube1k1iCKe73C2G4bZCoyQDnk45ryjSI3j1G18yMkRyFiGHGV9fxrrvivYXN1aaJDZ7PKiy8nzAFWbGCR2HUVrFwS95Hq1Jy9oop7nLa1o1zoGo3VlPJHKYXKb423A471s+HdPfWvCmpwwLuvLXbcxRgZLBeHwPof0rmo5RptwLKWcXEWAX2ncF9QprU8Pa8+gmaWydkuC2+KZWwY+zfUEEgipjKK1NJRm7Haa8rx22lIy4UWagAevf+lN8RHMOnKy4ItAT+Nclqnje41ERCW3t90IIDITnHoavTeLrHWEs45I/sbxARtk7lI9c/nXHODd2OlFwUE1tc9O092k0+1aT7xjB9O3SpmHrx6VHaTwXMCSWc6SwAABkOenGD7084AIOOPxzW62PCn8TE3YOOOBnJphBJyOAeRzioru6jtwxkYk45TOOPUnt9aisNN1HWnj8pTHbyj5MozGQdcqgwXH+0cL71rToSqbAotiS3sEW453leu3Bx9T0H+e9V4r6e8b/QLWa4I7xRs4/Tj9a9G0P4bRKFlv1XeOQZws0g+i/wCrT8A31rsbfw1pkaqJIDcleM3Dlx/3z90fgBXbDBxXxGigjwswazyfswjAB/1ksMf6M39KfDBqkLh2WFiMABbyDH6mvoO3s7W3UCC2hjA6bEAqYoh4KLz7Ctfq1PaxSijwZdQ1hBmSwnkUHrHEsmPxjY/yp1v4kt3lMMyES52lVOG9/lbDD8jXtVzpGm3ORcWFrIT3MS5/PrWLq3gvTdQiKcgY4SVROn5Pkj8CKwnl9KWxqqjRwkNzDcqfs7hyBzGTtYf8B6963tHu2ci3cglVynrj0rnde8BX2njzrQsI4+VwXliUf+jI/wACwH0zWXaavcWlxFBqKyLMRuR8hmcf3kYcSL9Pm9e9ebiMvnBXjqjSNRM9K9qWqOlX0V/aJNE4YYGSDkHPcGrhNeW1bRmouaSiikBR17/kB6j/ANe8n/oJrsPDH/It6T/16Rf+gCuP17/kB6j/ANe8n/oJrsPDH/It6T/16Rf+gCvdyj4ZfIwrbo5f4wf8i9p//YSg/ma4mu2+MH/Ivaf/ANhKD+Zria+jw/ws8vFfEgooorc5gNJS0YpiEooxzS4oASjFLijHFACU+J2jYFTx3FMIo6damUVNOMtgTtqjTicSAFDn6Gud8TeNNG8PFo7ic3F4P+XeDDNn0Y/w/jWlFMYSW3BVTJYt0AHXNeA+MLrSr3xFO+gWXkWpbbwxYzOTywz0yegFcGDySFSu1O7hvp+T6/cOtiHCHu7na6F4x13xZ4y0+2gdbGwWQyvBDzlFBPzseT6fU164cZOMYJ9K8o+B2llZ9U1KZcNHi1QMMEHq38hXq5riztUoYn2NGKSirad9/maYXmcOaW7EoooryDpCiiigCpqqFrTcvJQg49axeOmfr9f8/wD1q6ORBJGyHuMVzrKA4HoSDVRBAeASMcdKRQeSB9R/hS/geaOvPp3qhnUfBgg+KPFwx0Sz59fkevVpWVI2ZyAoGSScCvKPgx/yNHiz/rnZf+gPXq0qK8bLIoZD1DDIr2MP/DR0R2PNvGmt6JrNmZ7U62ZrDM0Gq6ZasVhIHOHICspGQRyCM180aT8U9XHxOufEiGOGfVUGnyvDFlkj+UB1QnG/5QcE4zXtPj1b7xnb3q29st3LNbzvpVm5PlW9tHkNdSKPvSSN8sY6DOfWvnCDSbNVFyGYyHAWPriQ8cDuc9qxq1OVnbQpc6PsrwlrOi6FZRWRtdZslmfe97qcDZuZW6s8oypY8c59hXeghgCuCOx61454Ie88L3cVpNGkFvHJHaaxp6g+VDLIv7q7h9Ec/Ky8ANnjg17EAOmBXTB3RzTVmeX/ABjJHiHwhtAJ3Xn/AKKWvMPGGi6zq00Z0/V0tbRBu+zsxjyw9WH869K+NdxDb674Qa4mjhQvdje7hR/qh61xrajpcilHv7FgRgAzKQf1rhxEJupeKOeVRQle55LplnewXF5hYlKsfOkbbIZH9FJB3H6VpaHc6gtnHp017Jp+krMbiaSFgspUkDaO4Gf51t+JdKhY+ZpzwMoYj9zKPlzz0z/9asefwzqkVtazKomeVgRgZxn19q5pSkt0bPEc6toNuDax23mWTmSS3nTYX5Mi8kkn34rS1zxZHqaRfuYl3OvmZHUA52j14yPbNVY/CeoyXj2sySCNThZNu1WA6En0q/q3gS8GnIdPuFmukbOzhQV9Af8AOahu5NSo27mH49i0yWCzvtLjjhSVcNGpBKH0Jrg7l2UbQx/Cuh1eCZLi6tPIylvIqnuA5HIGOOpqvottPJeGCCB33fK4VM4JBC89utOKtuehHFJRs+iMh42trFGdT5sx4yO3aremWfnauNNk3QzMuFeQFfnPTiuy17wrFp3h4TXt3GupKyC2t8bpJW3AAbepyTzjpivRNV0q11nSVGtQQxXaw585BhoG2jJUjqB6VXNoZvG6JtHkiXWu+DNQK3FtcWzpwflLwyj+RrrPDfizW9YkeS5s0hs1G77QyMqr/ujqzHpXT+EtSuJ/C9rNeLKZoi0R8xNpmwcBgGGfmBrpfBGiTa5qUd27EgZaF8cKoJBmx065VB06nnFa4elzy8jGpW9ppKKv3J/CPhC51S6829QgowZklUMsJ6gt/ek9F+6ucnJwD67pmmW2moy28Z3ucvK5y7n1J/p0HaprC1isrWO3t02RIMKP61Yr1ElFWRkI3IrzHxF4o1W08cXFja3lyiLeWFvBC1vH9lIl5k82UruVtobbhhltoAYnB9PPIrAWLQtYutdsnghmmMqWt/HIuPMZYo5FHPXCSocjoT6imBzEvju9tJW8yxH2Fb66gkvrln8qPy5/LVC0UTBMjJDPgcAZY5In8D+LrrVvEmraIY/tD2N3dm4uJZBGYoxO6QoibcycKcngDAySTiuil8J6FOytNpkLkO0p3ZIZmfed3PzZbnByM1LBo+jJqEF1Da263cUk8kUqHDb5DmXBBycnkjpkD04AMfV/F1xZavdxRWEUmn2Fza2t1K05WXfcMgUom0hgvmITlhn5gORyfDS81fU9LvdR1uRWee8nSJEmDoiRzSIFA8tduAoHJYnGSQSRWzPo2jahqyahNZ209/blf3hAJDKSV3DuVJJGfuk5GKuaXbWlpaCLT40jt97uFQ5G5mLN+O4tn3oAtN04rk/Ffg+z1a2lMMCLK7b2jPypI397j7j+jjn1z0rraRs4OOtAHgttc3/hLVSl2ZntHk8t/NUA7j/DJjgSY6OOHA9a9CtrmK6t457dw8UgyD/T6itPxl4di1qxkIhV5hGUKHgSp1KZ7eoPY4Neb+GNQl0rUZNOvZGeNuRI/BZc7Vkx2IbKOP7wBrxswwSt7WCN6c+jO6ooP3jxg55orwzYo69/yA9R/wCveT/0E12Hhj/kW9J/69Iv/QBXH69/yA9R/wCveT/0E12Hhj/kW9J/69Iv/QBXu5R8MvkYVt0cv8YP+Re0/wD7CUH8zXE123xg/wCRe0//ALCUH8zXE19Hh/hZ5eK+JBRRRW5yhRRRQMKKKKACiiigAozjn0oPSsHxn4gXw7pDzKQ15LmO3T/a/vfQVUIubUVuTKSSuzlPil4m8lTodhIQ5/4+nB6DqE/xqD4VeGQ80euahEGhjObWJh98/wB/6Dt71zXg7QZvE+tsLhnNuhMt1Kckn2z6mvc40jijWKBBHEgCoqjgAdq78RKNGl7CPXc5qcXUlzs0rcQhWMCRpvbe4RcZY9SfepazYZGiYY6VoRusi5U5/pXxGNwcsPLmWsX1PUhNSVh1FLRXCaCUYpaKAErG1K3MczSYxG3TA4H9K2cUyeJZo2jcHB7ihAc6euDgEf5/z2oPY1YuLaS3bBBZTwrqM59uaxdX1vTdJQ/b7tI3Az5SHc7fReo/H+VbU6cqr5YK7BtRV2dz8GCT4p8XZ4+Wzx/3w9erSossTo43I42keoPWvmPwf4h1G9vNT1Dw3qF1pMcpiik3wRSrKUB+YAjgjP610w13xhjP/CWS4/7B8H+Fel7RYf8AdVVaS3NYVYyimj1rRtPMPiDV70w+UjrDbQ8Y/dopPA/3maqcPgDwrDrh1iLQrFdRLmXztnR+u7HTOa8y/tzxj28WS/8Agvh/wo/t/wAXk/8AI1yf+AEP+FL6zSNFVtsz1O80tj4yhvzB5ttcWL2k/f5lcOmfzfn3FdGMAccAV4V/bni/OP8AhLpPr/Z8P+FB17xeeniyXOcjOnwgfyp/WqaE6iY79pzS7rV5PCNrYorzGa5OGbbwIwT/ACrxc+AtdAyLWE+wmXNetXb6vqWoWV3rWtS6g1osnkx/Zo4tpcYJyoz0FTA4IGcjHb3/AM/4100s8rYaPJRtbzX/AAThxGGp1pczPHH8E+IEz/xLix6/LIpz+tV30PxBaDix1BAD/wAs9xx+Ve2hj7kDrTgTn7w6c+n1rdcTYh/HCL+//M5/7Ph0bPEofEHiDTjt+3XsXqs2SP1Falp8QNVEZivo7a+gZSjqw2FlPGMrXrDhZF2yRrIB1DKG4/Kse+8M6JfIz3GmwBySQ0XyH9D+lUs4wVb/AHjDr1Vv+B+YvqtaH8OZyuieMfDkFjHZTaN9it928pEBIgY9z3P410fhUeHonum0G5jkmuG3yl5suxHQYbBA7cVi6h8OLOQE6ffzQN2WYb1/MYP865TVPBmt6cd62xuYwMiS3bJH4dRTWDyvF6UKjg+z/wCD+jH7fFUvjV0etzabZNqMd7NZwyXsYwszLl1A7A+lTEjaNrAjHUdfrXjOmeLtZ0siAzmaNODBcjdj29RXc6R4/wBNviqXoawnPGXO6PPru/xrhxWR4rDq6XMu6/yNaeMp1NHo/M3b1Xvb+DT1faJM7nHGxcZdvwUE/lXuHhDTV07SoyIhE8wDFMfcXGET8Fx+Oa8h8E2y6n4kZgdyMUjBU5BDsWY/98RkfQ170vQYGB6UsPDlgj0Y7C0UUVsUFefT+DrhvFF9q6WtqLmXX7e+juePNFslnDC43YyPmWQbe4J9a6fxfqcmk6TBcw7tz6hY2x2kA4muooj1B4w57Z9CDgjhte+IerQ+HNXvLbTrS3b+zdUubGT7SZGV7NthLqYwMH7wAJ6YPXIAKVv4J8QP4WbSbiztka38Mpocb/aAwnkTA34x8qkDIzz61szeBPJ1i8u9N06wtx/bFjd2zRIqGOCNYllC4Hy52uMDrn3pdL8Xanaav/YUmm3V/LZXUNnezqZp2DyhH3iRYFi2IkqE7ihwG44G4uvGHiC68M6PremadpqWuqXVn9mWW7beYZpFAEgEZCsVYZxnaSRzjkA52PwD4gnjvvtdraJLdad9muRG0SQzTC4ifKoiLiPaJNu/LckHkkn0bwlojaJe+I1jggt7G71Bbi0ihAVUj+y26NhRwuZEkOPfPesWDxdqc2u3mj2VlbzagtxcbRc3PlxLHDFbFgGWPJJa4UDI6bjngLUFt8Q571bW8tNKi/sqRtMDvJclZh9uaNUwmzHymVc5bkA0Aeh0UUUAB6HjNeUfFLSRZ3K6pDGSgLTFVH3hgCZP+BJ8494ya9XrA8bW0c+gTSSJuEBExGM/KDhx+KlhScVJWYXsczoF39t0yJ2cPKn7uRv7xH8X4ghvxrRrjfh47QC7sJH3NBmMn1aJ2jJ/FRHXZV8jiKfs6jidcXdFHXv+QHqP/XvJ/wCgmuw8Mf8AIt6T/wBekX/oArj9e/5Aeo/9e8n/AKCa7Dwx/wAi3pP/AF6Rf+gCvXyj4ZfIyrbo5f4wf8i9p/8A2EoP5muJ7123xg/5F7T/APsJQfzNcTX0eH+Fnl4r4kFFFFbnMFFFFABRRRQAUUUfWgBryRxRvJK4SJFLuxOAAOSa8J8U6vceKfEO+BGKMwhtYh2Xt+J6mu4+LOum1s00e2cia4Aknx1VOy+2cVS+EmgAl9buk4XMVqCP++n/AKA16OHiqFN1pbvY5ajdSfIjtvCuhxeH9Gjs48GdsPO4/if/AAHStejJ9aK4JSc5OT3Z0xioqyCpIJDE2eoqOis5wjOLjJaMadjURw4yvI/lTqzYZTE3qK0EYONynP8ASvmcZg5YeV18LOqE+YdRRRXGWFHX3pKqavqVrpGnTX1/Jst4hye7Hso9zTjFzajFXbE2krs534n3P2XwtI41WTT3JIRYly1wemweg9TXgBLu4J3PI3TJySa6HXtW1Pxr4iQpG7ySHZbWynIjX/PJP1r1DSPhrplnaaabomS/tphcTSKcrKf7n+6K+1w1SlkmHjCu7zlrZdP+B59zy6kZYqbcNkW/DXh6fR9AsrQxAyBQ8pHXeRk/zFaJtpwrfu5CMYxt61vscsT60lfG1K0qs3Ulu9T1IrlSSOeaGQAloZOCOdmMU0I5Yfu249q6PP0oyfXio5h3OdEcgYnYx7E4ow3GUYD3FdIeOnB/Ckznr/KjmC5zu1iOhBPfHShTg8jjP+f89a6MD/OKQqp/hQ59qfMFzngemCMAcn3zSgjk5GOmP61vNFGVIKL+VRNZW7dYwD6jijmC5jNgqR3pOTyT1OCexFaj6bGeY3K/hn/IqCTTpg2VYOPc801JDKeQe+PrSEnvnPXIPSiWN4hiRWUZwSVwM0mSRk8Ht7H/ADincDP1TR9O1RSuo2ccxPVwNrf99Vwus/DueMmTRrgTRjnyZyFYewPQ16RwucdBx9f8mmjJO0dTxXdhMyxGEf7uWnZ7f16GNTD06nxItfAOB4mjEqFJftUrMG64EZwPyevd68Q+FM4t9cKP089D+DROn80Ar2+vQ53U999TtirRSCiimTKzxOqOUYqQGAztPrQUQXdtaalD5Nykc8cc0cu0nO2SN1kQ/UMqt+ArPuPDuhy24sp7G2aKSK4hETfxJMczKBnox5NeQ6J4dn1myvNOsdNtkki0W30+5uo2IW5nWcM7M5UEsQrNz83zfNgkZ6e/8ASw+KzPYWqrpPmWslrFZm3t1s/KYMy8xM6qWy/7thuLsCBkkgHY6vYeHUuZtb1KK1WazCvNcFsbdhypcDrtPIyDjtQ3hTw6qy25061Rblt/lgkcq4fKDPy4YBvlxzg9a82uvh9r2onVftdrYrJd6TfWkuGiSCa4eaF4SqJGCE+R8M+5gSc+ratz4JvpvEqXy2JgsWa0kt7e3kt4vsPlMCUyYmYLkbv3TDO5gQOpAOv1XRvC4tnOo2tn5bXSKzMefOl2QqCRzl/kQjoeAau3Ok6PEVSWxiH2iaDASIkF4SHiJxwoUoCDwOBXmo+H2onTdQtP7LsXs/tFlcx290YZJJWhuxNInmrGpdGQMoMuWJc5IBJPf63pM97/AMIubS3igjsL5LiWEEARRiCVNq44OC6jAoA6EOjOyqylkPzAHlfrTq8++G/g648Mf2LutbW28rQLaxvPs+B5lymCScD5ur/Mf7x9a9BoAKpa2gl0a/Q9GgkH/jpq7WZ4nl8rw9qLD7xgdVx/eIwP1IoA8i8HP/xV+pp2YySf99LCx/Umu8rz3wiwPi/UJgcR+bNGD2wCqD/0Wa9C/pxXzGYfx2dNP4Sjr3/ID1H/AK95P/QTXYeGP+Rb0n/r0i/9AFcfr3/ID1H/AK95P/QTXYeGP+Rb0n/r0i/9AFd+UfDP5EVt0cv8YP8AkXtP/wCwlB/M1xNdt8YP+Re0/wD7CUH8zXE19Hh/hZ5eK+JBRRRW5zBRRRQAUUUUAFQX13Dp9lPeXLbYYELsfXHb8Tx+NT15z8X9Y8uC20eFvmfE1xg/w/wj+tbUKXtZqJnUnyxbOHhW78W+KMNnz72Xcx7Inf8AACvebS1hsrWG1tVCwQoEQew7/WuE+EmjCDT59WnX97cHy4SR0QdSPqcV6BW+Nq80uRbIzoQsuZ7sKKKK4joCiiigAqWGVo2HpUVFTOEZxcZK6BO2xqIwdQy8ilrOhmaJvY9q0FYMoYdO9fM4zByw8r/ZZ0wmpCsQqszkKqgszE4Cgdz9K8D+I3iuTxNqq29mX/s23fZAg6yv03Ed8npXXfGLxT9lh/sCwcrNKoa7dW5VOyfU9TWf8IfCYuJBr2oxAwxkraRsPvt3c+w6D3+le3lmHp4Cg8wxC1+yv67/AII5K83Vn7GHzOo+GfhBdAsft1+itqtwuSCP9Qn90e/r+VdsevvSkk8nrSV8/icTUxVR1aju3/VjshBU1yxEo5HSiiucsqafYatr/ie907TtVg06C1tYpiXsxOzmRnHdhj7tULuSK08VHw5cfEKzXWhLFCbYaExIeQKUBIbaMhh1NdP8Ov8AkoGu/wDYOtf/AEOWsV/Bfia1+OOs+JLe0nm0fUbiwYPb621oFSKJUcywhSJgDuwpI6H+9XrUKFOVNNo3jFNG4PAniFndF8XWZKcEDSUyM88jfxQngTxA4OzxdZsASpxpKHBHUffrx/wxoF9J8QNM0+0sgNUsJtZa/wDEcUU3mymaKVYnkLRqQVLAABmzgkepg8CeFbnX59QsNL8PR20cfhT+y7q6tpJbUXtybiJmdpXhBEjKrHBV+wPHFbfVqX8o+VHs0PgbX5UEkXi+ykQ/xJpKEfpJWFpL3i3Or2epXMNzPY3rWwmii8oOoVWGVyfWuk+CnhXV/Cmiajb61Bptu0935sMVnFEjLGECjzDEiIzcdQo9ye3D3XibRtM8ZeKrLUr+K2uDqTOFkBAwY071jXwt4fuoXfkRV5Yq7OloqpYajY6gM2F5a3PtFKGP5datkEdRivLlFxdpKzMU09gopM0UhgQCMEDHpVS4sIJegKHodvpVqkJoAxZ7GaA/KPNT2GSKSxtGumL8hAeeOcj/AD/kV0un2bXTbmyIh1Pr7VrXGnwSxgRjyXUYVl/rWVSso6I6aNHm957HAxltM8Txm3G1ZfkT+6GyJIjn/fBX/gVe52N1He2kFzASY5UDrn0IzXjfizSZjZNNtdWi5LoCdnIIYf7pAP4V1fwy8Qi5gNlckJIZGG3PCTYy6D2P+sX1DMB9017OAre0p26o0qRsz0GijI9RTHljjKCR0UucKGONx9BXcQeWp8Q7zS9BFxNCmpzQPcz3Sr5nmpALuWND8sZRRtjIBZhuKEdiRdbxzqtiL/7bYQTGTXJNKsDC0sjEKjyZkSOItwkbH5d2ScHA+aumvPB/hu6KxXOl2jko42HI3qzlzkZ+Yb3ZhnOCxIxmo5NN8NX+s6nprWkEt7Ksd5coAcZ3FVfI4V8oeRhuB7UAOi8QahL4Kl1ldEuf7QRJCNPYOjuyOyjAZQ+1sbhlN20j5c8VjWnja/vzY22m2WnT31yLosZLmaBITB5fyurwh1Y+aMggY685rqo9K0tdMbR0ghNptO63JzwTuJPOckknPXPPWsa98CaFNc2EsluqWtmtxuhydspl2bmds5Y4TByTkHB4oA5+f4h319oOpalpmlLFY22lwag1xJdhZh50PmIqxmJlJHQkkDvg9KvXvj+awvZZLzTIl0qO9urDzY7gvMXgtpbgtsKAYKwsMbickV1J0bR54by3FpbNFeRIk8a4w8YXaoIHbHApr6TpEjriC2837TJcIeCRO0bRu2D1bY7gj0JoAz/C3iG/1PV7zT9UsLa1lhsbW/Vre5MwKTtMoQ5RcFfIPIyDu7V09cr4K8J2fhu6v5YbhJ7ueOGCQRxiNUjj3mNQoJx/rH79CAMAAV1WRnGRmgAPSuO+JWrJp2kBc5b/AF7LnkhCCq/i5jFdZczx29vLNM4SKNSzMTwAOteHeMtWk13XxbxAlA4Z0PQHGY4z9ATIwPQkA9Kic1CLkxpXZF4StntrDfISZSwG4/xbfvH/AL63V6LEwkjRh0Zc1yVtCttBHAgwEUcHndgdfx/rW/oTqbQxgj5Dx6nPOfpXyleXPJyOtKyHa/8A8gLUf+veT/0E12Hhj/kW9J/69Iv/AEAVx+v/APIC1H/r3k/9BNdh4Y/5FvSf+vSL/wBAFetlHwz+RjW3Ry/xg/5F7T/+wlB/M1xNdt8YP+Re0/8A7CUH8zXE19Hh/hZ5eK+JBRRRW5zBRRRQAUUUUAI8iQxPLKQscal2JOAABmvArqSfxV4qZk3F72chR12J/gBmvUPilqh0/wAMG3jbEt6/lDB5CDlv8Pxrmvg9pXm3t5qkq5WBfJiyON56/kP516OF/dUpVnv0/r1OWt781A9PtbeO0tYbW3ULDAojUDjGBUlJ9evelrz276s6UFFFFIYUUUUAFFFFABVLXNcTw9pNxfvhvLGI0J+856D8+fpV39a8f+K+tm+1gadC+bay4bHRpT1/LpWtLDRxMuSavHqZ1Kjpq63Mjw1pN14w8UCOd3bzXNxdzddqZ5/PoPrX0TbwRW0EVvboscEShEVewFcR8MtGOg6IJp0AvL3EkmRyqfwr/Wu5VgwBXoa8fiGrOdVRXwR0Rrg4KMbvdi0GlpDXzx2CUUUUgLnw64+IGu/9g61/9DlrpPiB4xt/B+n29zPC07TSiMIpxjPcnsPc1zfw6/5H/Xcf9A61/wDQ5au/FzwTdeLrC0ewkiW5tGLhGAVn9lc5C/Ug/wBa9eHP9XXJudNPZXPNLn4veI5NTup7ZIILWVQkEDxlipJUq3+2SpyFU5OQahi+LfieIWUJNvK0TAysyYeUbmJyOiHYpwrYPfmsXXvAOv6AEW9tQY2ZLZWs1QGVnChgigEuMAD5yvf1qDTPA3ijU7s6eNGuQwJR5J0KIgCgY8xxt2hieFBb0JFeZ/tN+t/mb+6fR/gPxVa+LdES+tFKOm1JkHKo5UMVDdDjOPrxXzx458C6h4j8e+Kb+xubRFW/8ry5SwORGvtX0T4A0K48N+GbbTbuZJpo2dmdM4O5iep5PUcnFedW/wDyMfiz/sLN/wCi0r2ljK2DgqkH72zOLE0o1Y2keD6j4G8SaUfMbTpZFXnzLVt+PfjkVNonj7xDo0mx7prqFTgwXgLEe2TyK9/DEVj6/wCG9I16IjUrON5CMCdBskX6Edfxrphn8K65MbSUl3X+T/Ro854Nw1pSsZXhXx9pWvlYHY2N8f8AlhK3ysf9luh+ldc2VJBBBHWvBPGXgG/8Phrq1Zr3Thz5qDDxf74/qOK2/h98RHt2h03xDMZLU4WG8Y/NH6Bz3HvWWKyenVp/WMA+aPVdV/XZ6+o6eIlGXJVVmevGrOn2bXT+kQPJ9aSwtHupBj/VDkuDwR2x65roo40iQIihVUcCvl6tXl0W56tGjze89gRFjUJGu1QMAU6iiuQ7thGAIIIBB4wRkGuB1nSbjQNUW+0tJGt5MAwqcEgHIUHoHU8oT1+6etd8ajnhjuIXiuI1kjcYZG5B/wAK3w+IlQnzIUo8ysXfB/ii31m3iRpVa4YHY4G0T464B6MP4kPIIPGMGue+LXhfWvEsV1DpcFvIj6dNDbvuijkiuTnazO6MwX7uNhU7gcnoRzmtaPd6PcSX2nsZImIeTJIVyOm/byrjtKv410vhP4gJcBLe+8x5AudhA89R64HEi8feT8VHWvpqGIhWjeLOaUWgvfBN7LrNzqNrFbW9/Lrb3a3q481Lc2RhHzdeHP3c1Z+Hvhi80XWGubjS7LT4xpVtYt9nkDedLG8hZzgAkHcCCeT3wa7Wxv7a+h820mimj9Y2Bx7H0PtVjd1wDW5J5TrfgbVrvUPEn9n21tDDqNvdgyXLRSM0sm3Z5cixiVVO35lcsF4C5AGL8nhXUtX1l73VtNtUtptagvntpZVmHlJZmL5uME78cc/WvSMn0NJu9jjGaAPIr74dX48N3Npp1nZQXk+lazYu0ZVN/wBoYfZ1JA5UKFHouAO1a+oeAwuqahc6Xpun2+dR0u5tWjREMaQzRGfbgfLmNGGB94cV6PnnpxSbj6UAeNp8OtYGkavazK89/NY3VqLszwpHcGVwwYhIlkZjgE+Yx2nOC2c16vYWVhoumrbWFtbWFhCGYRxoI40BJZjgcDkkk9ySag1TX7HTgyyyeZOBkwx4Zh/vdlHuxAryvxL40udakEGnMHjLYUou+FSD1A6zOOox8g684zUykoq8hpXNLx74u89xZaewG754wRnIyMTOP7gONqn7zY7CsHw/p32SIyyBjPJ/fOWGeSSe7E9fTgdKXSdIFu7XN4zSXDkyHe24k4xvZu7fovQVrckgY79cYPPTP+fpXh4zF+192OxvCFtWIwyuOR3B9Kv6NJsvdm7IcdT/ABHrVLnIzyOSOe1SWrbLqFwQq7856V571RqbGv8A/IC1H/r2k/8AQTXYeGP+Rb0n/r0i/wDQBXH+IP8AkB6j/wBe8h/8dNdh4Y/5FvSf+vSL/wBAFetlHwzMK26OX+MH/Ivaf/2EoP5muJrtvjB/yL2n/wDYSg/ma4mvo8P8LPLxXxIKKKK3OYKKKKACj6de1FNklW3ikmk+5EpdvoBmgGeO/FjUftfic2yNmKyjEQA7seW/w/CvSfBWmf2R4XsrdlxM6+dL2O5uefwwPwrx3R4X8Q+L4FkJY3dyZJD6Lncf0Fe/Njd8owo4Ar0cY/Z040UctBc0nMSiiivOOoKKKKACiiigAooooAoa9qS6Po13fv1hQlR6seFH54rxjwXpcniHxPEtyS6Bjc3DHuAc4/E4Fdj8YtQMdnYabG2DKxmkGew4XP4n9Ks/CHTBb6Jcag6/PdPtQnrsX/E/yr0aX7jDup1exyT/AHlVR6I7w9flGB2HoPSpYJjE3qtRUV5dSnGpFxktGdadndGopDKCOc0d6oQTGNsE/KfWr4YMoIxivmcXhJYeVt09mdUJqSClpKD0rjLI/COuaVo3j7WDrGp2NgJdOtRGbq4SLeQ0mcbiM4yPzrvP+E58Jf8AQ0aF/wCB8X/xVcJJDHJzLFDJjj54wxx9TUf2W2/59LX/AL8r/hXdSxns4qPLsaKpZWO9PjnwicbvE+hHHI/0+L/4qnDx14S/6GjQv/A+L/4qvP8A7Lbf8+lr/wB+U/wpfstt/wA+lr/35T/Cr+vv+UftTv8A/hOvCX/Q0aF/4MIv/iq8z0m8tr/WfFF1Y3ENzbS6ozJLC4dHHlpyCODV0Wtt/wA+lr/35X/CnoqooVEVFH8KqFH6VjXxXtY8trEyndWH0UmaSuQgU4IIIBBGCCMgj6d68e+JngJrBJtb0WBjp2f9JhXkQk9x/snP4V7RZWr3UmFyIx95sV0C20H2Zrd4kkgdCjowyHUjBBroweaTy+qpw1XVd1/n2KeDWIjZnjnwK8cmVU8MatJlwC1jMx5b1jJ9ccj6Yr2n1HevlT4i+GrjwP4tKWbuluzfabCcZHGen1U8GvovwJ4kj8V+GLPU0ws5Hl3KD+CUfeH0PBrsz/BU/dx+G+Cpv6/8H8GPL68tcPU+KP5HQUUUV8yeoJRRRQAVy/iHwtaXkbTWkSxTg7ymCVY+oAwVb/aXH49K6ikq6dSVN3ixNJnmcE+u6TIZVeScLwryMxcD081PnP8AwMGt3TfiPfw7VuUuH9d8KzgfjGVb81rX1ayKsZ4VIX+IL296x5be2uD++hjkI/vIDXq0syml7yuZukuhtw/FCywBOtsCfWSSI/k6D+dTP8UdJC532Y+t4v8AQGuWbTLTAxE6rgkBZWXH5GvMPi34a/s5U1nTI/8AR3IjugU3bG7Pk8gN39/rXqYDFU8XWVGT5W9vXsc2I5qMHNK9j22f4nxOubSONgehjimnz9DtUfrXP3/jbVtTYxQLMNwIAZ9g/wC+Isv+bCvP/hBq9vqlvNpOoRLJewr5kTPzvi/u46fL/WvUI0VExGFQdcKMZI5/z+lZY/EVMJWlQlHVfj5lYdxrQU11ObGl31+mNRlAhHIh2BIwfURKcE+7kmtu0sobQ4jX5yOZGOWPtnoB7dKscZwevQUpzkknp+X+f89K8arXnV+JnUopACVVjzzyef8AP59qXjnAyo/z/nsaRhgKuDk84/r7/wCenSgevTHOP6/5/H1rEobt54Hf1/z/AJ6UdPmUdOxp4AYHGM+g9+3/ANb8qawBGVyRyen+f8aQG3rrbtB1A+ttIf8Axw12Phj/AJFvSf8Ar0i/9AFcTqLF/C12zDBNpJ/6Ca7bwx/yLek/9ekX/oAr1so+GZhW6HL/ABg/5F7T/wDsJQfzNcTXbfGD/kXtP/7CUH8zXE19Hh/hZ5eK+JBRRRW5zBRRRQAVzvxCvjY+ENQdTh5gIFP+8Rn9M10XWvPfjLdbdO020B5llaRh7KMD+db4aHPVjEzqvlg2Y/weshNrl3eMuRbQbVPYMxx/IGvWu9cP8IbTyvDlzdEYa4uMA+qqMfzJruKvGS5qz8iaCtBBRRRXKbBRRRQAUUUUAFFFOjIDgnoDmgDw74m3hvfF96qHcsGIE+oHP6mvYdCshp2iWFmAB5MKqf8AeIyf514faKdV8ZRg/N9pvsn6b/8ACvoBzlzxivRxvuRhTOWhrKUmNooorzjqE71LbzeUeeVNRnpSVFWlGrFwnswTs7o1FYMu4EYpaz4JjEeeVPar6sCuRyPavmMXhJYeVunRnVCakg/nikxXmGv3UkHi6dvtA1LfcRpHbRzzQ3Nv0+4g+Ur3z371L4dg1a+8TXtzbSXAhtdZuFmle6Yo0Q6QiPOO+c44z7V1vK7U/aSnZWvr+W9/w9Lmftru1j0rFGPevIvC99cr4jsHvbm5gtZbi6jM73LulwRwIipOEI6g9+KbFdRzeG/EK2WpXBm/tVYYnW6d2W3MihCMt05bnv3zWksmcZcvN21tpq2u/l/wzJWITV7Hr2KO9eUNf+IPK8TW7Pcf2hZ29vCxiJJKhiGlQdiyc5rovBF9Yz61f22lxSG3iiUif7Y8yy5PBKsPlf1rGtlkqVOU+a9u3on36303vqXGspNI7Wp7O1ku5NqcIPvNSWls91LsT7o+83oK6O3hS3iEcYwB37mvGq1OXTqdlGi5u72FghSCJUiGAOvvUlFFcbdz0ErbHBfGjw4Ne8FTTxR5v9NzcRMBksg++v5ZP4V5x+zz4gNp4judFlcm31FN8QJ6SqM8fVc/pX0JtVwUkUNGwKsp7g8EV8kanHN4L+IMqx5DaZfB0IP3k3ZA/FTX1uRv67g62Xz7Xj/Xk7feeRjl7CtDEL0f9eh9bd6U0yOVJ4o54SDFKokU57EAinV8la2jPYvfUKKKKQBRRQKAEIrn9Rs/s0pYDMTHIx6966I1FcwLcQtGw7ZB9DVRdmBy+SCS3Occn9P8/lUd9aW97ZXFrdrvtpkKSDGRgjqPpU7I6yFXG1geRj/PtTenTrnABreLaaktxNJqzPm66hvvBfi1kDMt1YzZDDjen9QQa+i9OvINU0+2v7XBhnjEinPPPOPqDxj2rz7416H9q0u31uBD5tr+6nAGcxnoT6YPHpzVX4I615kF3ok7ZaP/AEi33HjbwGUD684+tfV5l/wp5fDHL44aS/X/AD9Dx8N/suJdB7PVf1+B6gD0Lc8denfn/P8AOlwcDjqfT8v/ANX6indAc/e7f5/z7Um3DdQQP8/5/Wvkz2RGAAwOwzj09/8AP/16QsVOD91B1707OScdSaDgjAxgcf8A66AEIxkZGf8AGgtuLYz6cdf8/wCelJg8ADqc4/n/APqoUhuVGB29qLAat+S3ha8JIJ+yydP9012/hj/kW9J/69Iv/QBXAyk/8InfgjBWCUHj/ZJrvvDH/It6T/16Rf8AoAr1sp2n8jCt0OX+MH/Ivaf/ANhKD+Zria7b4wf8i9p//YSg/ma4mvosP8LPLxXxIKKKK3OYKKKKACvI/jDcb/ENpADxBbAn6k5r1yvEfijL5vjO/HZESP8AJa7svX72/kc+IfunqPgK2+y+DdLToXiMpB9WNbtVNHiEGj2EWMeXbxrj/gIq3XJUd5t+ZtBWikFFFFQUFFFFABRRRQAUy4fy7WeT+7GzfkDT6hvQWsLoKMkwuAP+AmmtxPY8R+HaCXxrpeecSM/6GvdT1rwz4akDxrpuepLgf98mvcz2rvzH+IvT9Wc+G+F+olFFFeedIGkpTSUxCGpbaYxnB+7URpKzq0oVYuE1oNNp3RqggqGB4NBqhbz7DtP3avAg4IPWvmMXhZYednt0OqElJCmkpaK5CxKmtLd7mURpnA6t6UltA9zKI0BwerY6V0dtbx20YjjH1Pc1lUqcit1NqNFzd3sFrbx20IjiHA5J7k1NRRXG3fc9BK2iCiikJpDFxuOPWvlz4z6lp+r+OLm409LiN1jEF0s8XlkSp8pIBPIwBX1Dn0Iz+deZfGTwCviKybWdHi/4nFsn7yNR/wAfMY7YH8Y5x6jivd4dxdHC4xOrpdWT7ev9aHBmNGdWj7nTUZ8EPFmoeIbSbTrmCCO00m0hhSRQd7tkjkntgV6jXk37OVmIvC2q3jKVknvPK59EXp+ZNesVz51GnHHVI0lZJ/pr+JpguZ0Iue4tJRSPuCnaoLY4BOMmvKOsdSivn340/ELxt4M8YW0Vrd2kOnsglht1gVlkXuHYjJ544NeufD7xjp3jfQLfUtOYJOV/0m1Y/PC4HOB3X0NdE8NOEFU3TJur2OmooorAoxtYttreeg4fhj6e9ZvHXGcfh/n/AD9K6a6iE1u8Z7jj2Nc2ow5Bxxx+Fawd0BDeWcV/aXFpcj91PG0Tn6j+lfOemzXHhDxnG0ykS2FzskXJG5c4PPoQc19JqCwx3b+Xf8a8U+N2ki11+21GNcJfRYcjoXXjP4jH5V9Pw3XXtZ4SfwzX4/8ABVzys0pvkjWjvFntAKlEMZDo4DKwPUEZyOxByPanAY3Envj8f8/lXJ/C7VTqfgyzMhJmtc2zse+3p+hH5V1mML6c4/8Arf5/A14GIoSw9WVGW8XY9GlUVSCmuo0Lg9Oev+f8/rRk7sdcfp/n/wDWD1pePmIAyTnOf8/56+tHr144Hr9P/rViaCEA993HHbn/AD2/UUxhlQf4jwCP5fp/nrTjjkHGCcfX1oyWZc8n2/SgC9P/AMirqAwRiCX/ANBNd74Y/wCRb0n/AK9Iv/QBXBz/APIp3wB5EEufrtNd54Y/5FvSf+vSL/0AV62U7T+RhW6HL/GD/kXtP/7CUH8zXE123xg/5F7T/wDsJQfzNcTX0WH+Fnl4r4kFFFFbnMFFFFACjqK8G8dsZvGuq+9wF/lXvI614N4w/wCR31L/AK+/6ivQy/436HNifhR7wBtVR0AUD9KKVuo+g/lSVwHQgooopDCiiigAooooAKVV3kqf4gR+dJTkOHU+hBoBngXhNzYeM9O3cGK78s59yVr3xhhj+leC+LIW0nxne7eDHcidPxIavdoJhc28M6YKyoJAR6MAa9DH+9yzXVHLh9LxH0UV5nrN/q9tq+p6dbXN0xtZ21MMZGP7gID5ec/dycY6cVy0aTqtpM6JS5T0w0leY31/PJ4ZXVJdTu4HvdRZoFF00eIN+0gAHoAM+2afr9/qVpqOu3GnXdxNY29rFFsErNtEkR2yqc9QwU5HXJNbLCNu1/60X6ke0PSjSVwV9BNLe+F/+JlqSDUIwJ1ju3UHbEpyADwc8n1qLS7qU+OLu2n1CUxxXOyOKS/dSRt6CPo1T9Xurp9L/jYOc9BNTW05jbaeVP6V5X4O1G+k1zTReXd2sUwuPmnuGkS5IOAoB4Ur19/xr0w1z4vCRt7OpqmXTnfVGsDkA9vWpreF55QkQ56k+g9azbJ28wITlCcZPauu8mOz06UxS+WwjZ/P27tpx97HfHpXxmNpvDVPZ3u+h6dCm6q5nsTWttHbRBI+vcnvU9eEadqd+tvqNpBeT6lqTadcTLqOm6pLMrEAkF4j/q29MYOe3NbcHiC41G8jfTdVnuIYPCzyXBhnZljuMcF8HiTg9fmrarklSLb5v6/S/S9n5GsMZG1kj1s0mK8R0zUPFSv4J/tG8ulsWubdRN5zZvRMvmfPz8wQYXmqeral4sTw94iltr68Gni+llF4J2DwBJSnkqc5AOYyMYGA1Wsgk5qPtY6v8219+l7fLcPr6tflf9I97x7Un6V49d6nct8T2tbjVpYbVRZlYX1OS3UllXdtQZDk9wcZ/Gqel6xqY8eH7TqF/DZN4hurXz5bt3gKr9238o/KpORg8deOlZrJJuPNzfZ5vwvYr66r2t1seh6pcPJ4k1X7f4lvdD0bTtNhupGthEAGd3UsxdG4+UV0Vt4Nu7iCK4g8b+InikUPG4NthlIyD/qa4vxhot74il8c6RpMSy313oFtFCjMFDN5spxk8Cm+KtA8YeKvCnh/S7/wna29vYTLHcxPeW88siCHaJIy6tGvzddyscEYrpweHpToRcopsucnzM7iPwHdRgrF4w8QRqTuIRbVRnuceTTv+EGvv+h08R/+S3/xmuB+Hnw11qLVPCsnjK3kktdL0FraQfbSQt0t35kYIRvnAj9crwB2FQ6T8N/Fdi/iiE/ZbiysrC70/wAOQ3M5ZJEuJHdjJg5BClYxn+VdX1ai/sr7iOZnUeMdC1Pw3og1O38Wa3cOl3axmG4W3aN1knjjYHEQPRj0I5ropVCzOAAAGPA7V49ovg3XPCXhrxU+rWRsbC+vdGe2g8yAhZFuVEpCQqqJyU7ZIxkkgmvYp/8AXv8A7xrxc0pwpzjyK2h0Um2jzH47aFJqnh+3vLa3SWe1yu51ztUkHn8RjPvXzempaxoF5Hc2TzWV5F8waJ9hB/qK+23VXRlkQOjDDKwyCK4Hx94Z8PpYBhb2tvqEp2wxuAUbuSU6kYB6VOCxbh+6aujScYSj2Zl/CH4sWfi23XTtckis9fj4XcNi3QPdc/xe3ftXqhBBIIwR614z4j+CeieI9NW80O6TT9RMQZWjQrAZAPTqg/lXPeE/it4k8H67D4T8eabLfPCy26yxLm59FPpKvoeuKmrh6dVuWHe26M02viPofvzXN3a+XcyqAcg8D6/z/nXSYxgduDgjn/PNc/qalL6Xucg1xw3NCttJCqOp6kfzrjPi9p/27wVcSqv7y0kW4AUZ4+636Emu1YckYzwfxHequp2aX+l3tnJ8yzwtGR6kqcV24Ov9XxEKvZr7uv4GNen7SnKHdHlHwM1EpfapppIxNGs6A9dynBwPoa9fOQVOeB/n8a+d/hpdtp3jnTBISod2t3B4+8CAD+OOK+iHA3nB+YdB1OK9fiWiqeN519pJ/p+hxZVPmocr6MTrgjnjOc00ZPB6dM9uaUnjGME9/XPSlbJUg57jB7dj/n9D1rwD0xvU+pPJ9jRyWJx0GM0DGeORn0/Q/wCf8KOvbnqKQF+fjwlej/p3lz/3ya7zwx/yLek/9ekX/oArhrxdvhS7H/TtLn67TXc+GP8AkW9J/wCvSL/0AV6uU7T+RhW6HL/GD/kXtP8A+wlB/M1xNdt8YP8AkXtP/wCwlB/M1xNfR4f4WeXiviQUUUVucwUUUUAGa8H8b/u/G2qE9rnP6iveK8M+JKeX411LIwGZH/NRXoZf8bXkc2J+FHuhOdpHQqD+gpKisn82xtZP70KN+aipa4HozoQUUUUhhRRRQAUUUUAFFFFAHlHxj08xarZ36L8lxF5Tn/aXp+n8q6/4a6iNR8JwKzZltGMDc84HK/of0qbx9pJ1fwvcpGubi3/0iPjqQMkflmvPvhTrC2OvNZzNi3vU2jJxiQcr+J5Fekv32Ft1j/X5HI/cq36M9jpu1SSdq7iMZx+lOIw2D1HBorzjrGGKNlCtEhUdAQOKPLTB+RQCMEYHNPpO9AhhRTtOxcr09vpTfKj37/LTfn72OalptAEZij+UBFwpyOOhqSONnYAD8aVELsAM/WrsaCNcAc9zXl5lmUcJHljrN7eXmz0MDgZYmV5aRX9WBECKABz3rU0vUTARDOcxE8En7tZppDXxk5yqSc5O7Z9R7KHJyJWR2CIiZMaqN3JKjr70ixRqGCooDcsAo5+tYek6iYSIbg5iJ4J/hrfGOxyOxou2cFSm4OzGmNMINikJ90Y6fSk8pChQxpsbkrt4NSUUXZmQtbws4dooy4/iKjNDQRFWUxIQTuI2jk+v1qWkou+4FLwt/wAlN1rH/QKtf/RktdlquoQ6ZbfaLkOIN6q7quQmTjcfbJ5PauM8Kkf8LN1n/sFWv/oyWug8YJq0uniPRBIZXypaN0UrnofmGMZ6+2a+owWmGj6HLP4jHg+JvhuXxdNoC30KyxwrL9paVfKYk42A5+9yOK6vStRg1OBp7Qs0AdkWQjAfHBI9R718bWXw+8RSeP47I2+oLfm8Ie4aBwoOfmk34xsxk5zzX1t4NXV47BodbEvmRHYjylCz4zlht7HtnmtaVSU73RdWnGFrMzPi9/yJEv8A1/2P/pXDUs3+vk/3jUXxe/5EiX/r+sf/AErhqWf/AF8hPADEk5xXkZv8cfQqjsxh5HqMVmx6HpiXTXH2KOS4c582XLt+Gen4VxWufE6y0/xNJaW5hn0y1ty00q8mSfOBGnoR1Jrjrj4730NyG/4R+0NoWzsMzCTH16ZrkjhK9rxW5oe8D0AAx0wKrXGnWFzfW99c2NtNfW4IhuJIw0kYPBAbqOtU/CuvWXifQbXV9MYm3nyCjj5o3HVT7itauV80XZ7gHJJJ5JrG1lcXcbdiuOefatnpmsrXMZiwOQDThuMyyOB79efz/SnRthg27oc8DnOcCmYPHcdT7UpIwOeh/WtWB83a6p0Xx5d+WNhtdQ3oPQb9wr6RJDtuBBzggjvx1FfPnxai8nx5qeB94JJ+aivd9GlE2jabK33mtYmP4qCa+pz9+0w2Grd4/on/AJnkZcuWrVh5/wCZcOCe3pk9/wDP/wCsd6aRyMg+3+H+f/rU7PJHfHX+lNGffpxivlj1xFORk4+vY0NnBI78/wD16VsY+UcE8ge3+f8AIppJwS3PH5UAal8u3wrdg9fsshP/AHya7jwx/wAi3pP/AF6Rf+gCuM1ddnhu9XuLR/8A0A12fhj/AJFvSf8Ar0i/9AFerlHwz9TCt0OX+MH/ACL2n/8AYSg/ma4mu2+MH/Ivaf8A9hKD+Zria+jw/wALPLxXxIKKKK3OYKKKKACvGvi3D5fi13xxNbow/AY/pXsteW/Ga326hpdxj78TRE4/unP9a7MC7VTDEL3Dv/C832nwzpM2c7rZAfqBj+ladcv8Mrjz/BloM5MLvEfbBz/WuornrLlqSXmaU3eKCiiisywooooAKKKKACiiigBQcHOM+x7+1eGePNFfQPEjm2yltM3n2zjjbzkj6g17lWJ4v0FPEOjPbcLdR5eB/R/7v0PSurCVvZT12ZjWhzx0F8Ia2mv6HDdZH2hAI51z0b1/HrW1Xg/hTW7jwvrjNMjiInybqE/zx6g8/hXulvNFdW8dzbOskEq70cHOR60Yqh7KV1swo1OZWe5JSUv/AOug1ymo3tSohdsAGlVS5wKuRIEUADnvXnZjmMcJCy1k9l+rO/A4KWJld6RW/wDkEaCNcDrWPqXiTT9O1A2U/wBpe5EYlKQ27yYUnGflB9K265e+8LpqHi6TU73a1p9lWJEjmeNw4bOTtxxj3/CvlcPKlWqyni5PZvTds+jqxnShGGHS7fI031zT111dHM/+nsnmCPaemM9emcDOKdb6xZXFtf3EUjGKxlkinO0jayDLD3/CuUn8IatJqDasL63/ALR+3fahGQfL2D5Qu/bu+5x0/wAat2WhazajXbUHTmstSuLmcP5j+YvmKQoxtx1C559etdc8Jg+VOFS7sr69b+9bTa2xjGviLvmhprb06dfvOosLuG/soLu2YtBMgdCRjIPtW5pOomLENw37sn5Sf4T71x3hKy1TTtNhstTWy8u3iWON7eR2LY67tyjHbpW7Xm4inGnVlGDur6Py6HVD99TXOrP9TshgkY5yMg0tYOk6kYsQXDZQn5WPY1venPXpWRw1Kbg7MQ0h7+uKdRjOAOcnFBByt/rUvhHxTqmv3Wk3t7pTabCjXFuyYjKSOSCGYH+IVX0X486LreoxWGleH/EFxdy7ikYhiGQBknmTjpXnPx88aC6mHhnTZg0MDCS+kU8PIOicdh1PuK3fgF4TbTtKl8Q30ZW5vVCWoIwVh6lv+BH9BX19Kn9Tyz6xiPifwr12v+foeW67q4n2VPbq/wAz1I+O73P/ACJ2vfnB/wDHKP8AhO74/wDMna9+cH/xyrGT70f5614f9rVuyO/2SOa8Y69qfiLRF0238K6vbSSXdq/nTtCERUnjkYnDk9FPaui1CGO8iuoJcmGYMjbW2kg8cHtT/wA/zorlxGKniJKUuhcYqJ5Vc/Cuxit7m0hhMs0+8294DzAeo3rnB9M1lXnwWtUsrSP7VfXF/JlZJ1ZBFH77cZ9uvevaqBWyzGr2QuU4HwB4bvfh7o89nNMl/ps0xnd1BDwEgA8dxxXeoyuqshBVgGB9QehpSAwIYAqeCD3FUEhvbUCK0MD2+cqJSQYx6DHUVzTn7V8z0ZVjQrJ1thviHfFavO35uoHODxWJrD5vcD+BR+NRDcZRI69v85P+f/10dGPXP+NCjnn5erGlJGO3JHf9a1A8H+NCj/hNHKjG61jz9cEV7D4PJbwpo7u2WNqnI+gryH41uW8aFWAwlpGox9Cefzr13wYqx+ENFTJJFomD65GT+tfUZt/yLMN/XQ8jB/73V/rqbBPHP8gKa2c4zweg69Pr/n8KdnHXjv8A5/z/AI01R0xjnpXy564ucnjt+n+f/wBXpSbS7qp6scY60nBJIH15zkd/8/8A66lss/bYA/XOTSewGvr4xoWoD0tpB/44a6/wx/yLek/9ekX/AKAK5DxB/wAgTUv+veX/ANBNdf4Y/wCRb0n/AK9Iv/QBXrZR8MzCt0OX+MH/ACL2n/8AYSg/ma4mu2+MH/Ivaf8A9hKD+Zria+jw/wALPLxXxIKKKK3OYKKKKACuH+MFt5/hy3uVHNvcc8dAwx/PFdwelY3jKyF/4V1SD+LyjIv1X5v6VtQly1IvzM6ivFo5b4N3W/TdStCRmOVZVHfBBB/kK9Crxz4SXnkeJzAThbqBkwf7w+YfyNex9Ota42PLVb7kYd3gFFFFchuFFFFABRRRQAUUUUAFFFFAHA/Ejwm2oK2raZGDdxr+/iUY81R/EPcVy/gHxe2hy/Y74mTTJW79YW9R7V7NnBz6V51488DG4aTUtDjHmnLT2o4z6svv7V6GHrxnH2NXboc1Sm4vngeiRyRyxJLDIskMg3I6nIYeuacgLkBec14d4Q8XXnh2UwSK09gW+e3Y8xnuVz0PtXt+galp+r2QudLuEnUgbuzp7MO1eVm9SWXU+e177dvn/Wp35dSWMqcl7W3/AOAXo4xGuB17mnUppK/P6tSdWbnN3bPsqdONOKhBWSCkNLRUFietJ2P8qU0UANoNKaTFACVr6RqIjxDctlP4XPb61kcUY4YnG0cknjFLYmcFNWZ2h/8A1V5t8WviJH4YtpNL0h1k12VMMwORaqe5/wBvHQds5rnfF/xaOmWkumeHXWe7+6b7qsPsn94+9cF4A8D6n441WSeZ5o9PD7rq+kJJY9Sqk9WP6V9VleTxpx+u5h7sFqk+vr5dlu/z+XxuLbk8Ph9Zd0WPhV4Im8Ya0bq+DnR7Z99zKxOZ36+WD3J7nsK+nVVEVUiRURBtVFGFUegFVdI0yy0fTYNP0yBLezgG2NF6/wC8T3J71crzM2zSeY1ufaK2X9dWdGEwqw8LdXuFFFFeUdYUUUUAFAooFAC0UUUAA6jPSuauZPMnmc8ktkD1rdvZhDbM3UkcCueDZwc4Oc8VpBdQE25BGefX3x/n2o6EDGM/1/8ArZoGNoyRg55/z/L86eo+YgD/AGf/AK1aXA+f/jJMJfHd+q/8soo0/HYDXtvh+EweHNLhI5FrECP+Agn/APVXgnxAf7X481YLls3PljHtgV9FIgjSOMc7FAHuAOlfUZ4vZ4LC0vL9I/5nkZf71erLz/UVjtU5/D/P9fypvRsjHpz0NOJI74A9B703GFI9RytfMI9cAe3Q96t6Upa+j3Dpk9O2KqZB5z07/T/PT/8AVWloUZ86R2z8q4/P+tRLYCzr/wDyA9RP/TvJ/wCgmuw8Mf8AIt6T/wBekX/oArkNf/5AWo/9e0n/AKCa6/wx/wAi3pP/AF6Rf+gCvXyj4ZfIwrdDl/jB/wAi9p//AGEoP5muJrtvjB/yL2n/APYSg/ma4mvo8P8ACzy8V8SCiiitzmCiiigApQqtlX5RgVYeoPWkooBngSF/DvjAZyDZXfPuu7/CvfiQfmXlW5B9jyK8e+Lemm28QxXiriO8i5OON68H+hr0DwDqX9qeE7KVmzLCPIk5ycr0z+GK9HF/vKcKqOWj7snBnQUUUV5x1BRRRQAUUUUAFFFFABRRRQAUqqxYBRzQqlmwBzV2GIRr6n1rgx+PhhId5PZf10OzB4OWJl/dW7OR8W+A7HXozPAwtNTA/wBao+WT2YD+Yrya7s9d8GaqHfzrKccJNHkxyfQ9CPY19FdKiura3u4WgvIIp4WGCkihh+teTgeI8RRvDEfvIPdP9P8AJnrYnJqVS0qPuSXVfr/mea+HfinFIqw+ILYxP/z824yD9V7fhXoWmanY6rF5mm3lvdLj/lm3I+q9RXDa/wDCyxuWaXRLlrN+ohly0f4Hqv61wOpeD/EWhy+abKchek9oS4+uV5H412vAZTmXvYWp7OT+y9vx/R/I5Vi8wwXu14c8e6/zX6o+giCDyMUV4Bp/jvxJpx8v+0HlVeNlygfH4nmt21+LGpqALnTrGY+qFkJ/XFclXhTHQ/h2kvJ/5/5nRTz7Cy+O8X6f5HsJ5pK8sHxbfHzaKmfa4OP5VDN8Wrkg+Ro9ujdi8rH/AArn/wBWsy/59/jH/M2/trBfz/g/8j1qmuNqF2IVByWJwB+JrxC/+KHiC4ysLWloPWOIEj/vrNYbTeIvE8uC2o6ifQAso/DoK7KXCmI+LETjBff/AJL8Tnnn9LajByf3f5nr+veP9C0gMiTm/uQP9XbkMoPu/T8q8t8TeNNX8SOLfcYLZzhbW3z83pk9WrY0P4W6ndbJNVmisIuuxT5kh/AcD869K8PeFdI8PjNhbA3B4a4l+dz/AEH4Vuq2U5TrS/e1O/Rfovld+Zi6WYZhpU/dw7df8zzvwh8NLi7Md14hVra26i2BxI/+9/dH617j4dubewtotPSGOC2iG2FUAVV9jWb15JOe9Br5/MM0xGYT5qz0Wy6I9XDZdRw8OSC179Ts6DWJpGpbcQXJ9kc/yNbftXAYzpuDswooooICiiigAoooFAC0dqKbI4jQu3ReaYGRrMweRY1IIQ5OD3Pas4k9h24HXI9KWRxI7sRncxOD3HWk6k4zyePwraOiABjdhjz1PvTkfZ8xICgcknoOv+TTSBzu/OszxXenTvC2q3RbDJbOFYepGAPzI/zzWlOm6k1BdXb7yZS5YuT6HgGns2teOrdwpP2vUQ+Op2l8/wAq+lJCPNYjBGcD2xXgHwfszdeN7SQ9LWJ5z9du0fq1e/Agk5HJ7+3+TX0fFE19Yp0ltGP5v/gHl5TH93Kb6safTpjg/j1H5Up52rnrzjpj0/8A1fqKTBJ7jHAHof8APajp1x349vSvmT1hHOQDnB6Zx1/z/n1rc0ZNllkjBZif6VhsRjnt/PFdLZrttYl9FqJ7AVtf/wCQFqP/AF7Sf+gmuv8ADH/It6T/ANekX/oArkNf/wCQFqP/AF7Sf+gmuv8ADH/It6T/ANekX/oAr2Mo+GXyMKvQ5f4wf8i9p/8A2EoP5muJrtvjB/yL2n/9hKD+Zria+jw/ws8vFfEgooorc5gooooAKKKKAOT+J+m/2h4XkmjXM1m3nD/d6N+nP4Vy3wf1Tyb+70yRvkuEEsY/216/mP5V6qyJKjxyqGjdSjKe4Iwa8CuEn8K+K2CkmSxn3Kf76dfyIr0cL+9pSov5HLW9yamj32imW9xHd2sNzAcwzoJFPXgjP+NPrz7W0Z0oKKKKQwooooAKKKKAClUEkAdTQoJOB1q5DGEHPLVxY7HQwkLvVvZf10OvB4OWKlZbLdhBEEAHf1qUEFdykEeoNcx8QryS08PbIZTG88qqMHkjvXHeB7+a08Q20XnMtvOxR0ySDwcHn3xXxdWrOvJ1Kju2fV0qcaUVCCsj1ikrJ8Ua0mhaf53liSeRtkaE8E9T+lYvhjxe+p6illeW0cTyZ8t0bgkAnBB+lY2ZodhQCR0OKWkpDKl7p1jfjF9Y2tx7yQqT+dYdz4F8MzsS2lImf+eTso/Q101JXRSxdej/AA5uPo2jGeHpVPjgn6o49vhv4ZY5FpcL7CdqfF8O/DEZBOnyPj+/O1dbRW7zTGvT20v/AAJ/5mSwOGX/AC7j9yMWy8L6FZkG20izUjoWTef1rYX5VCoAqjoFAA/SlorkqValV3qSb9Xc3hThT0hFL0VhDSGlpKzNBKKKKQxO9bWkal0guG56I5P6GsWj6HBoInBTVmdnjn3paxtI1INtguCNw4Vyevsa2ao82pBwdmFFFFBAUopKWgArP1uTFssQ6u3T2FaFYOryeZebeyCqitQKjEd+Rjv+tNGQRwcjpx/n/PpSvwG9jgdsUHJB45J44rZAGRgbhkE9v8/57+tcN8aL/wCyeEPsysA95OsZx3VfmP6ge1dyMZ6ZHXFeM/HHUhPrtjp6tlbSIyPj+85/wAr18iw/t8dTXbX7v+DY4swqezw8vPT7y98CbE79Z1Fhwqx26nHqcn+Qr1k468ZznP07f56VyPwr0w6d4Isy42y3TNcuCOTk4X9BXWZHsCT6/wCf8+lZZxX+sY2pNbXt92hWBp+zoRQoB4DA4xjB/mP880HvkjOecf55pBggnHHpn/P5/wD66avyBcZ9x/SvNOsfbRmW4jjUdTg98jrmuowBwOg4rG0WImZpSOmQP8f/AK9bVZTd2BQ1/wD5AWo/9e0n/oJrr/DH/It6T/16Rf8AoArkNf8A+QFqP/XtJ/6Ca6/wx/yLek/9ekX/AKAK9rKPhl8jCr0OX+MH/Ivaf/2EoP5muJrtvjB/yL2n/wDYSg/ma4mvo8P8LPLxXxIKKKK3OYKKKKACiiigArzf4v6OXS21mFMlf3Nxgdv4W/pXpFV9Qs4dRsLiyuVzDOhQ57Z7/h1rahV9lNSM6kOeNjivhLrP2rTJtKmfM1qS8WTyYz1/I13vevArG4u/CPindID5tpKUkX++h6/mOle8288VzbxXFuwaGZA6HOeDW+Npcs+eOzM6E7x5XuiSiiiuI6AooooAKUAkgAEk0AEnABJ9BVyGLYMnrXFjsbDCQ5pb9EdWEwk8TPlW3VhDFsAz1qX8sDqT0FFZXiqZ4PDWoyxNtcR4BzjqQK+KrVp4io51Hds+so0oUYKEFojF8X69o0ulXFmJY7q5IxGEG4K2eu7tXK+Cr6x07WPO1NTt2bUfbkRt61hKuMfTv3p3060JWRodn8RL6G+ttMks7iKeDc+SjZ+bA61zXh9mXX9OaP73nKOPc1Rwcd8Z9f6UAsrBkYqwOQw6g+tFrKwj3VgQxzxTTXMeANYm1OwngvH8y4tmA392Q9M11FZNWGNoNKaKQxtFJvXc67l3IMsM8qPf0pe3tQIDSUGigBDSGlpDQMSiikNIYUUUUAJ3rd0jUt+2G5Yb+iue49DWEaSi5nUpqasztaWsfR9S80CC5bDjhWP8VbFUebODg7MBS0UUEgSACScADJNcvIS87ucls7sjt6V0lwdsEh/2TXMR8rnGd3Ofr2rSABwNo9M4+lKckfLnLc0hxg45H+f8/wD1qOTkjn/P+f8APFaCDzI4kkmmO2KNC7MTjCgZJ/zxXzdcvP4t8asU3M9/dYXj7qZ6n0AXJ/CvYviprI0jwhNFE2Lm/P2dP93HzH8u/vXD/BHRzca5caq6/urOMxxn1kYf0Gf0r6vJV9TwdbHy3taP9ebt9x5GPft68MOvV/16HssMMdvDFBANscCBET2HA/lT25+vrjp/n1o4OS3GOB/X/PSkJ7H1/WvlG76s9e1thpGE5HGeD3pVwMZ7AnPrSt26U6GEzTLCucucH6UXGbWjxeXYxt3fn0q9TVUIiovRRinVg9wKGv8A/IC1H/r2k/8AQTXX+GP+Rb0n/r0i/wDQBXIa/wD8gLUf+vaT/wBBNdf4Y/5FvSf+vSL/ANAFe5lHwy+RhW3Ry/xg/wCRe0//ALCUH8zXE123xg/5F7T/APsJQfzNcTX0eH+Fnl4r4kFFFFbnMFFFFABRRRQAUHpRRQB558WtB+0QR6zbJ+8iHl3AA6p2b8Kh+E3iDcr6JdPzzJbFj1/vJ/WvR5Yo54nhnQPFIpR1I4IPWvCPE2lXPhbxCUhdlUN51rL/AHlzx+I6GvSw8lXpOjLdbHLUTpy50e8/SisjwrrkXiHSI72PCzr8k8Y/gfvx6HqK168+UXFuL3OlSTVwpRycYyaTvjFW4Idgy3WuHG42GEp88t+i7nVhMLPEz5Y7dWLbxbBuPLVNSClr4rEYieIm6lR6n1lGhChBQgtArm/iFII/DEi7wrPKigZ+93NdJXD/ABSZ/J01AeCz8Dueg/nWUdzU4ieFoBFuPMqCQfQ1HWr4jtzaX8FsfvRW0QYHqDtyR+tZZHynHWtSQ2kEhgQfcUqoWlRB1ZgB9SasXzI95I0X3Dj+VQB/KkjkxnY6tj1wQaAOu8Dq+k+K7zTrk7JHQqQf4mGCP0NehHrjvXn/AIvBt9e0vXbdv9Huijg+h75/A/pXoLYySOhORWc9ykJWT4oujY6R9oDukaTReaydVTcNx+mK1jVLWYppdJvEto45ZTGR5cnRx3X6kZx70Q+JXFLZ2OM13WZF1TW4LAxPFcwqY5Q3AYYzk+gHA9c1s+HmvLpoAEli023GRNJw905Xkgf3ATx9K8yTVniOlStCGs43Z2XGHb5sFG9xjH0Ney6VqVnq9hFe6fKHgcYA7pj+EjsRXViYqmuVIxotz1uWzSGlJpDXEdAlJSmkpAFJQaKBhSUtIaACkoopAGSOR1Fb+kal5oWG4bEn8LH+L61gUo4wRnPXimjOpTVRWZ21FZOkaj5wENwQJR0Y/wAVa1UebODg7Mr6gcWU2Ou2ucwERQCMdeM8V010gktpFPda5oAgAjg8HjPWtYEiZGfl6A49KOXzsbDHpQCF5AAA9fzNc34+1/8A4R7wzNOjBb24BigU9dx6t+AOfyrooUZV6kaUN5OxFSapxc5bI8o+K+uDWfFD29qS9pY/6PEAc7nz8zficD8K9c8A6L/YXhWyspFC3LDzbj1Dtzz9BgV5F8K9A/tvxGLmdfMtLHE0hbo0hPyg/U8/hXvjEk98fToO+a+iz+tGhTp5fS2irv16f5nl5dB1JSxM93t/X4CjJALdT+tMBB44Oe/t7UueDu64456nsf8AP/1qADkgZ2/SvmD1w7g5HTpmtjRoAsbSsDuY/Ln0rNs4WuZwg+6eScdMetdGqhFVF+6oxWc30AdRRRWYFDX/APkBaj/17Sf+gmuv8Mf8i3pP/XpF/wCgCuQ1/wD5AWo/9e0n/oJrr/DH/It6T/16Rf8AoAr3co+GfyMK26OX+MH/ACL2n/8AYSg/ma4mu2+MH/Ivaf8A9hKD+Zria+jw/wALPLxXxIKKKK3OYKKKTNAC0Ug60ZpiFooozzSHcDWF4w8PxeItIa3wFu4/mt3x0b0J9DW4TQDVRk4NSjuiZJSVmeEeFtbuvCuuM0yOI8+TdQEdvXHqOte5208V1bxXFs4khmAdHH8QPT8a4X4leFTfwnV9NjBu4l/fxqP9Yo/iA9R/IVg/DHxauj3g0/UmJ02ZvkkJ/wBQ/wCPb+VduL/e0HXpq8orVdTHDrlqqlN2T6ns8EOwZbk1Nzml7DBBU8gg9fekr8wxOIqYmbqVHqfeUMPChDkgtBRS0gpa5zYBXDeN5l/4SvRophugi2uy+xbk13PbvWfeaVDc6naXzMyzW2V+XkSKQeCPxpp2A848aKy+LNR3HOXDL/u4GKxq6T4jRhPE285/eQK38x/SucmjaPaDwzAMPoelbLYkARjgg0MDg4HIrR8aWqaNfSgL+7MMcirjuR/jXIXaXz2cd5JIVikZo12nABHUfrWsKbnqiXJI9S1tMfDLTjMp8xChjJHI5/wrttNc3OnWk3eSJD+lfNE1/dtEsUlxLJEuMI7kqPwzUS6nOi7FmlC+gdqHhm+o+c+npJooyVkngQgchpAP515p8SPHcaRyaPoM26WQbZ7qNshQeqoR1Pqa8qknaUFmJYnuST/WpdKtnuLtFjQEs2BgdTVU8Oou71E5XR03hzSW1DTXtFwxALFdpYkH6dzWzaaN4q8PTm68PWkru7BXgkG2NxkD5gT29a7/AMK6Qul2KRsi+cf3srY5DEYC/gO1bpPUn05NViK6g+S1+5nSi5LmuMjMhjQyhVlKjeFORnuATzwaU08RuRkI2PXFBjk/uN+Vefc6SI0U/wAqT+435UGKT+435UhkdFP8qT+435Uhjk/uN+VADDSU/wAt/wC435UeXJj7jflSAZRT/Kk/55t+VHlSf3G/KgBlOFL5Un9xvypRFJ/cb8qAGg4Oec+1dBpOo+cBDcMBKOjf3qwvKk/uN+VAjkBBCOCPQU7mdSmpqzOyNc7qVv5F05QYWTkYPH41e0jUftAEM5AlHAP97/69Xbu3S5TbIWDDow4IrSLszzZwcHZnN7lVS2/y0UEsW6ADkn8Mc188/EDxDL4p8S5tlZraL/R7WMc7+fvfVjXoHxq8RnS428OWUi/aZVBu2Q/cjPRfZj1PtWJ8G/C4uZzr1/H/AKPCdtoG6Ow6tz1A/nX2OUUYZfhpZlX3ekV/Xf8AI8TGVJYmqsNT+Z6D4G0BPDXh63syq/a5P3lzIP4nPb6Dp+ddARkjGePXt/k9v/1Uqkk5J3EfzP8An/CkC54/h7j/AD/n1r5itWnXqSq1HdvVnrU4KnFQjsgIBA79QB6+v+e1NXLcAFgTxgdSacqmVtqKXlPQD+ftituwsBB88nzOecY4B/xrFysWS6fai0gCnmQ8satUnfPrS1kAUUUhpAUNf/5Aeo/9e8n/AKCa7Dwx/wAi3pP/AF6Rf+gCuP1//kB6j/17yf8AoJrsPDH/ACLek/8AXpF/6AK93KPhn8jCtujl/jB/yL2n/wDYSg/ma4mu2+MH/Ivaf/2EoP5muIzX0eH+Fnl4r4kLSZ5ooroOUM0UUUAFFFFABRRRQAUdelJ1FWreHHzOPpXLi8XTwlPnqfJdzfDYaeJnyQ+/sLBER87DnsMV5R8T/BX2R5NY0iLNq5LXMKj/AFTd2Uf3a9dpCAwKuFZGGGVhkEdwa+Xw+d4mhivrKfk10t2/4J9HVyuhUoext8+t+55P8M/HIt1i0jW5v3BG22uWP+r/ANhj/dr1s8ZB7c8HivGPiL4FbS2k1LRoy2nMSZYV5NufUeq/yqz8PPH32RItL12Qtaj5YLk8mIf3W9V9+1exmWWUswp/X8u1v8Uevnp37rrujz8FjqmDn9Uxnyf9f13PXu9FNUhlVlZWRhuVlOQw7EH0pwr5A+iFFL3pKWgR598T0Vb7T5Bje0LA/geP51g3cXmapYRkjEiQDg1u/E5SNRsWOdhhYD865hre4S8tYyrCV/LZPXBPFbR2JZvfFzZJqcUQGCkC7v8AvriuQuIvI8D28shwbm/keJT/AHFUKSPx/lXYfEu33a9HlhtuIUXdnIBzg/41kfFYwW8WiaPpy/6DYxeRDJjBnJO6STHoWOPwNd2EV4M5q8tUefXJUBfemi0d8YUkHpxW5pE+maLqdlea5ZvfWySAtboRllHXH06++K9e8F+KPD/iW01e9j8LwpDaSrFBAWVWCHu59T+QrojCLV5SsKVSS2VzwiezkhVd4Iz616N8OfD2fs97Io3yNmMMOgHVv8965fxtq8eqanNLBYx2KI5jWBX3Bcd84Fe0+E9MXTNDtEIJneJWkZhzkjOPYCuevNUlpv0NIpzsayosa7UztHc9TSr94fWg0J99frXltt6s6FpoXPAvgvQdd0Rr/VbJ7i6kuZw0huZV4EhAGAwHaui/4Vn4S/6BTf8AgXN/8XS/Cj/kUR/193H/AKNauwLKMZYcnA5619dRpQdOOi2R4NScud69Tjf+FZeEf+gS3/gXN/8AF0f8Kx8I/wDQJb/wLm/+LrswQaK09lT/AJV9xHPLucX/AMKx8I/9Apv/AALn/wDi68/8JN8OvEfjHXPD8OiXFs2mI8iXUt7MI7mOOQxyOh3/AHVYYzXtuoRSz2NxFbT/AGed42WObbu8tiOGx3wecV5LpnwM0jS20R7PWNTEllbTWl35sryJdxTIVlUKzYi3MzP8vc55IzR7Kn/KvuDnl3MG01X4X3fiO4tINOkOjW2kyapLqz3F5GoCzLEVVGALr8+d6kjtWn41tvh/4es7g22kf2jfW0lostqL64iKR3MgRH3Ekdyce2OKuW/wXD201rqviS4vLc6A3h6BVtEiaGDzEdGyCdzDYByOfapH+D092uoyat4puL67vRYK0zWUce0Wsm9QFUgc9OeR156Ueyp/yr7g55dzH0q7+FN7Hr0s9lc2cekXrWUpmkuj5rZUAoFYltzNgL97jp0rrtA8FeAtesPtumaZO8G8xnzZLqBww6gpIVYfiKgv/hYbm18T2Sayh07W9Q/tNra50+OdY5jt3Z3H5gdgxjBHY10/w68Jp4L8Mx6RHf3N+FleXzJycKWOdqAk7UHYZPfnmj2NP+VfcHPLuUv+FYeEf+gS3/gXN/8AF0f8Kw8I/wDQJb/wLm/+Lrs6KPZU/wCVfcHPLucZ/wAKx8I/9Alv/Aub/wCLrP8AEHw58K2mgalcQaa8csVrK6OLqbKkISD9+vQ6yvFn/Irax/15zf8AoBo9lT/lX3Bzy7nlGms72Fi4LFzBEc87idg6/nR4u8exeGPDzzSgS6s+UtY+zn++fYfriuG+IuuS6T4O0i3s5mhu7uKEh0bDKiopP5nA+ma8zll1Xxn4hjDkXN9cYjUdFRQP0GASa48oyL6yli8Q0qSbbXkv03+40zPMY039Xpq89LfM0fBPhzUPH3it0nlkaNmM9/dnJ2qTyPqegHv7V9NpoVlb2kNrYx/Z7eFBGiJ0AHQ/U9axvh1pVh4d0RNKtgv2hTvnmIwZ3xy3+A9K62uTOc2ePq2p6U47L9TLCYJ4Ve/8T3Mr+x+R++z1xx0pU0hMnzJWYemK1KK8fmZ2EFtbQ24/dIFz3qajNFIAooopAFIaWm0AUde/5Aeo/wDXvJ/6Ca7Dwx/yLek/9ekX/oArj9e/5Aeo/wDXvJ/6Ca7Dwx/yLek/9ekX/oAr3co+GfyMK26OX+MP/Iu6f/2EoP5muJrtvjB/yL2n/wDYSg/ma4g19Hh/hZ5eK+JBRRRXQcoUUUhNABRRSUALmkoHNWLeH+Jx9BXNisVDC03Un/w5vh8PPET5IDoIv4n/AAFTjigUtfEYrFVMVUc5v0XY+tw2Ghh4ckP+HCiiiuY3Dg5DAFTwQRkEV5R4/wDh6U8zU/D8W6PlprNeq+pT29uter0oJBBBINd2X5jWy+r7Sk/VdH/Xc5cZg6eLhyVF6PqjwzwN46uvD5Szvt9zpecbCfnh91/wr2vTb+11OyS60+ZZ7d+jKensR2PtXH+NvAFtrjSXml+XaakeWHSOb6+h968vsb7W/Bmrui+Za3A/1kEoykg+nQj3FfT1cJhM9i62EfJW6xfX+u6+Z4lPEYjKpKniFzU+j7f12PorvjvUf2iEMqmaJWYZAZwM464rlvCXjnTNfRIZCLHUcf6mRvlb/dY9fpWX41+Gket38l9pl+2n3bnMkUoLws394Acqa+Vq4SeGqOliU4v+vw8z36VeFeCnRd0Uvih4o0uSOOxtSJ7iBtzSofkXPGM968x1zxBqV/JFJcsYwkapGF+X5R0NbN14MlsLy7i1G8aaGzXdLIkZSMDjueTnpWungTWfEV9PrF+YNH0zyAFSb75jRPlO3twBya3pKlFbhJy6HAPfTIY3aRyG6MWJ5qydWklCPI7uyDCljnH0zVa1tJZNHkLgmMNlGx1wcH+Ypktm1k4VmR2I5Cjp9a6FGPQy9rFvlfQ3vDlhe6tfTmOz+3KV2MhyCM+noa9S+F+iR2GkaksIjK3yt84kyQQCAMe3Jz7V534a1ifTNIuYrRdk9w23zA2GVepNFlqN8tnMLOdkikcq2wkZOcjHp+FYVE2rGM8UoystUOh0htR1SAg7oJrxY8jvhgG/SvoA7ckIQUAwMe3FeD2OrTWVrp6wqiC0nZ13j7xbBw3qeM/StS18a31rvAcIG6/NkbyeW+ntWdeDqNWLjiY01qj2Lr0oT74+tcJoPjC/vmWKOwa4x1fpu98noPbpXcWxkZUM0YjfOSgbdj8a4pwcdzrp1Y1FeJ2Pwp/5FAf9fdx/6Nao/i9qLaf4Kn8got9czw2tozEjbK8ihWGO45OPapPhVj/hEBnH/H3cdf8Arq1HxR8P3viDw7CdHkVdV026i1G0R/uSSRnIRvqCR9SK+tp/wVbt+h4kv4jv3OuiDKiqzb2AALYxk+tSVzHgTxdY+LdLM9srW17CfLvLGbia1l7q69eucGoPHfxB8P8AgZ9OXxDdPAb+QxwhE3HjGWb0UZHNbJq1zOzvY61ulcJ8TNTbSLzwncz4Omy6qltcxlsDMisEckf3WGcd67hHWWNXQqyMAVYHIIPevK/Hlw/j7xBb+DtBbdaWNzFeatqKjclvsbcsCnp5hIBxngZ96U3oOK1PVh96nU0EZpT9eaokWjNct8QhqFr4eudV0iWcXtgouBCrnZKiMGdSvclAwHuRW1omp2usaTZ6nYSB7W7hWeNvZhnn37Y9QaV9bDtpcv0UZHrSHoeaYhcjHWsvxRz4Z1Yf9Ok3/oBrB8b6rcjVtC8O6TI0d7qc5eeRDhobWP5pGz2J4UH1NbHiCI2/hPVIw8jbLKUBnbcx+RuSe5qb3HY+Q9ftNV8X69ENJsppbW1t4bZJCNqLtQZJY8cmul8O/C5LaWO41q+Z5VORFakgA+79fyr0PTWLaVYZP/LvF+PyDmrFeRWz/EeyWHoe5FK2m7+f+R3Uspo+0dar70nrrsKMqVK5BUAA554rotK1EXKiKUgTAY/3hXOUqkqQVJBHQjtXgno1KSmrHaUGs3S9RW5URykCcf8Aj3vWicVR504ODswooooJCiiigAptOptAFHXv+QHqP/XvJ/6Ca7Dwx/yLek/9ekX/AKAK4/Xv+QHqP/XvJ/6Ca7Dwx/yLek/9ekX/AKAK93KPhl8jCtujl/jD/wAi7p//AGEoP5muIrt/jD/yLun/APYSg/ma4ivpMP8ACzy8V8SCiikrc5QNFFFABSdaDU9vDk7nGB2Fc+JxMMNTdSbNqFCeInyQC3iz8zDHoKtCjjtRXxGLxc8XU557dF2PrcNhoYaHLEWkzRRXKdAUZoooAWikpaAD/PSs/XdF07XrT7NqluJVH3HHDofVW/pWhRV06k6UlOm7NdUTOEakXGaumeH+Kvh5qWjlp7AHULIchkX94g/2l7/UUvhf4iano6rbX2dQsl42SNiRB6K39DXuCkqcjiuZ8SeCdH14mR4fsd4f+W9uoBY/7Q6GvqcPxBRxVNUMzhzL+Zbr+u618jwq2UVKEva4GXK+3T+vUqXOq6f460dLPSNUjtLtZo5mt7lQDJsIbYw7jjtXW6laR6jYXdldlliuYWhcpwQGXBx9K8O8QfD7W9IJkgjF/bryJLYZcD3TqPwzUeh+Ptd0fbE84u4F48m7BYr7BuoqqvDtPEw9rltVSW9nuvn/AJpE085nRlyY2m4vuv6/I9F8P6Jcy6bHoHiPR4/Ksl2wanA6hZ1U4XKjlW29fWuG8S/D7UrLV7MQh763u3IklhiZhFg/Lux7d+ldlo/xQ0e7AGpRTWEnc48xD+I5rstO1Sw1KPdp99bXCntHICfxGc14mIw2Lwcm6tNx/L79vxPSp1MLil7kk/zPJIvAGraVJZXs1rLexq0kNxa2kqrJtYEBwTwQMg4r1DS9B0qw0yKygsgLcZfbKMvkjByfWtYhgehB96Q571wzrSqbnVChGnsjlrjwRpk+pJdNkIo2+SBxjbjH/wBeqtp4DsItNmgdt0jsTGzDPl85A967Lr0oNT7SS6j9jB9DF8PeH7XR4AEBkl6lz29hW0p+dfqOlJSr94fWobvqzSMUlZHR/D0348FIdMW3af7ZcZ+0MwUDzW/u1FceMPE+jyyr4g8F3k9tH/y96NKLoN6YjO1/04rR+FH/ACKI/wCvu4/9GtXYMcAn0r7Ckr042fRHgTaU3ddT5+8Tah4V8S68mt+DPFMXhjxlGAkwvI2t/tI7RyK2ATkAZGfevE/jP4wvPGHiO3XW7RLa90y1+ySpFKJIzMGJZgRxg8cZ7V9HftBeJ/DWkeHpdO1PTbPVdauY2NtbSIGMfBHmscZUD9SK+MNOIETjq2Mn3rKppc6aKvZ/cfSug+Ntc8a+C9K07StZtvDOjafaxW+o6zeTKjzyhQDHEM5H1ruPBvjDwP4W0qPQvA1vqOuuhJk/sy1eZpJO7ySHA5x1zgD2r5h+EWreH9K8WtceKtFXVdK2gEMC32Y55k2DhsAcj0r7s8PzaXc6VbXWh/ZTp86B4mtlCow9sfy7VcLt7mdW0VtoYGh614s1Nnmm8MRaVaqwCx3d4GmcZ5OEBA/E12IJwCeKdQenXFbpWOdsa4BRgwBBGCD3ryiO4l+Et5JBdRzTeA7mVpYbhAWOkuxyY2AyTESeD2J5ru/EXizQ/DsBl1bUoIedqxA75GOeiouWJ+grnL3xrq13aztp3gjU57PYSZdSlis4yPUiQ5C455FTJr5lQv20OM/aC+JWqeHdK8PS+C9QtyNREs/2hFWVXjVRjGcjBLfpXYH4l6bp3gjQdS1OU3GrapaJJb2Nqu6a5lKjKqo6Ddxk8CvjDxFqUOp69f3NtZQ2Fs0reXaQyGSKL1Ck9ieeOPwr0/8AZs8Q3Gn69f2mn+G4NX1Fk8xJmvFinjj7pH5nBHfAwfWsFVbkzolSSgj6L8A+H9QXULrxR4pCjxBqESxi2U5SwgBysKHuc8se5rpfFX/Ir6x/15zf+gGuYj+ItnZyKnijStV8PMxAWW8h3QE+nmoSo/Eit/Xru2vfCmryWdxDOhspTvicMOYzjkV0RtbQ5mne7PLNL/5BNh/17Q/+gCrNVtL/AOQVYf8AXtF/6AKs18XLdn0MdgooopFCqxVgykqw5BHaui0vUVulEcuFnAz/AL30rnKVWZGDISrDkEUGVSmqiszs6Kz9L1BbtQj8TjqPX3FX6o86UXB2YtFFFBIU2nUlAFDXv+QHqP8A17yf+gmuw8Mf8i3pP/XpF/6AK4/Xv+QHqP8A17yf+gmuw8Mf8i3pP/XpF/6AK93KPhn8jCtujl/jD/yLun/9hKD+ZriK7f4w/wDIu6f/ANhKD+ZriK+kw/ws8vFfEhM0lKetJW5yi0gODRU1vDu+ZunvWGIxFPD03UqPQ1o0Z15qEFqLBDk5Yce9WRwMUv06UV8RjcZUxlTnnt0XY+twmFhhocsd+rCiiiuQ6QopM80ZoAWikzRmgBaKTNLQAtFJRQAtFFFACg4NZes+HtI1oH+0rGGWTp5ija//AH0OTWnRWlKrOlLnpyafdaEzhGouWauvM801X4UQuS2jakYu/l3S7h/30On5Vx+o+BfEmmOWXT2mA5Elq2/+XP6V73SgnPH8697DcUY6jpUamvNfqrfjc8mvkWFq6xTi/L/I+e4PE3ibR22f2hfw7eNlx8wH4MK2LT4o69EMTrZXA9Wj2k/kRXtUyxzqVnjjlX0kQN/MVkXfhbQLskz6PZFj1KJsP6V1/wBvZfX/AN5wqv3Vv+A/xOdZVi6X8Cu/nf8A4JwEXxan/wCW+jwN/uTMP5g1YT4tw7vn0WTH+zcD/Cujn+HnhmUkrYSRH/Ynb+tVX+GXh1hwL5T7TD/Cl9a4flvRkvv/APkh+wzeP/LxP7v8jIf4tW5HyaNN/wACuBj+VRn4toBlNEyfe4/+tWynww8OqcsdQb2Mw/wqRPhp4b3jMV4w9DNx/Kj2/D6/5dy/H/5IPZZu/tx/D/I9V+B99/aXw7sL7yxGbiaeQqDnH71u9dN4x8RWXhbw3e6zqBYwWyZCIMtIxOFRR3JJArnvg3axaf4CgtbYN5MFxcIo6nAlao7Dwvd694qXxH4paTybVmGmaS2PLgHTzX/vSN7/AHfr03vFr91t09CEmvj36nhnxUju9O8MW1z4kCS+KvFFx9rmBX/j0tY1+SBc9Mblz6n6V4xPoUjOXtHCq/VT2r6a8XeH5vin488WwwuqR+H7NLGxfoDdMd75/AFfbINeD6hFc6NdyWWrW0tndxEq0ciFT+vUV5mIc6cuaGx9Dl9OlXpuFT4k7lHQZpvCF5bapZ7JLq1cSkSDcsi9GQj0IJH419ReBtTg8HeKLbSEkx4T8Sr9v0SQghbeV1DNb56AHOVH4V5l8Fvh5N4v1K4v9XtpYtCjhkiBdSvnu6lQVz2XOc+oFeo/Cqyt/FvwsuPC3iW3jkm0e4l0mXaMOhjOEkU9VbGOR6VthVNrmluzlzN0lU5KeyVmeujGfenHpXJ+BLfWdKhm0TXZ5tQNng2upOmPtER6B/8ApovQ+owfWusPSu9O55DVjOuoNOsxNqNxDbQmFGlkuCgBRQCSxbGegNeD/FPX5PEnhG51rVprzT/DsqmPRtNjfy5dRk/5+JR1EY6hfoT1GfXfHOm32vQWuiWjSQWVzIr31x0/cIQWiHu/T6E15/d6C3jf/hNtZlg3R2sM2i6PAF4RYuXdR2LOMAjsuKyq32RrStuz47tn4bJGevH+elb3gGSyXxjZNq011BZb8SXFpIUlgzwJFbsVJDfhWDeW0llcSRSBgVYjkY/A+/avR/2ePDTa98SLBZ7cTWcQaWdXXKmMKev1OBXPpuup1PRan1P4M169TUR4U8WNHdXphM1jqIAMWqW4/jx0DgEbl98jium8QWtvaeFtZW1ghgU2c2RGgUH92fSvMNF8P36Qap4Tsrkpqfha9jv9FuZAebeQEiJj6YMkZ/D0r07W52ufBupTSQyQPJYys0Un3kPlng11Qbe5xzSvoeW6X/yCbD/r2h/9AFWTVbS/+QVp/wD17Rf+gCrJFfGy3Z78dgopelIKRQUUUds0CFVmjdXQlSOQRXR6XqC3abXwJR19/cVzdEUjRuGjbawNBnVpqojs6WqOmX4vEIbAmHUevuKvVR5souLswooooEZ+v/8AIC1H/r3k/wDQTXYeGP8AkW9J/wCvSL/0AVx+v/8AIC1H/r3k/wDQTXYeGP8AkW9J/wCvSL/0AV7uUfDL5GFbdHL/ABh/5F3T/wDsJQfzNcOa7j4w/wDIu6f/ANhKD+Zrhq+jw/ws8vFfEhaQ9KKmhi3kFs4qq9eFCDqVHZIyo0Z1pqEFqwgh3YZvu1axgD07UvQD0or4jG42eMnzS2Wy7H1mEwkMNDljv1YUUUhrjOoKSiigAooozQMKKM0ZoAKKKKAFpabS0CFozRRQAuaKSigBaKSjNAC0UmaKAFzSUUUAFKv3h9abmlT74+tDGdh8J/8AkUB/193H/o1q3fFOrw6D4c1PVblwsdpbvMc9yBwPqTgfjWF8J/8AkUBj/n6uP/RrVa8caFceJtOTRisaaVcOjXkhYh9iuH2KAO5UZPoTX2FK/so27L8j5+VvaO/cy/gzoUmjeBrOW93NqeqM2pXruPmMsvzc+mBgY+tdnNawTndNbxSN6ugJ/lU0aiNVRFCooAAHYU+tFFJWJcm3ciCBECqoVR0AHArzeyA8N/HC6tkby7DxNY/agpGFN3DhW2+5Q5PrXpp6Vyvjjw7NrDaTqGneWuraRdC6tjIcK4PDxkgHAZTj64okuwRfc6rNFQ2rSPDG88flSFQWTdnae4yOtTVRJBfTG3s5pgjyFFLBEUszHsABXN/DXRrjQvBthaX2ftz77i5P/TSRy7Z9/mx+FdWeRzRStrcd9LHA+K/hP4R8TXr3l/ppivJDmSa2cxl/qOn6Vt+EPB+h+EbRoNAsEthIcyPks8h92PP4V0dFLkinew3OTVm9DlDpctn8SDq6JI1tfaetpJsUkLJG5ZS3oCrEZPetbxV/yLGsf9ec3/oBrVrL8U8+GNYA6/Y5v/QDTSsK9zyTSv8AkFaf/wBe0X/oAq1VXSv+QVp//XtF/wCgCrVfFS3Z9FHZCGg0ppDSKCiiigApD7UtFABGzRSCSM7WBzkf59zXTaZfC8jw2BMo+YVzFLG7xyLJGdrqcg5oTMqtJVF5naUVR0y/W8QBsCYfeXP6irtUebKLi7Mo6/8A8gLUf+vaT/0E11/hj/kW9J/69Iv/AEAVyGv/APIC1H/r2k/9BNdf4Y/5FvSf+vSL/wBAFe7lHwy+Rz1t0cv8Yf8AkXdP/wCwlB/M1w/U13Hxg/5F3T/+wlB/M1xkEJdtxBAr3o1oUKTqVHZI8+rSlVqqEFdsSGLeQeQKudAMcUAY4A4oNfI47HTxk7vSK2X9dT6LB4OGFhZat7sKKKK4TrCkoNJQAUUUlAwooopDCiiigApc0lFAhaKSlzTAKXNJRQA6im0UCHUUmaM0ALRTaXNABQaSigAoBxyOaKSgZUgtby0DpY65rNrCztIIYZ0CKWOTgFDUv/E2/wChn1//AL/x/wDxFTUVssTWSspv7zN0Kb15UQf8Tb/oZ9f/AO/8f/xFH/E2/wChn1//AL/x/wDxFT0UfWq387+8XsKf8q+4g/4m3/Qz6/8A9/4//iKP+Jt/0M+v/wDf+P8A+IqegUfWq387+8PYU/5V9xB/xNv+hn1//v8Ax/8AxFH/ABNv+hn1/wD7/wAf/wARU+KSj61W/nf3h7Cn/KvuIf8Aibf9DPr/AP3/AI//AIij/ibf9DPr/wD3/j/+Iqaij61W/nf3h7Cn/KvuIf8Aibf9DPr/AP3/AI//AIij/ibf9DPr/wD3/j/+Iqeij61W/nf3h7Cn/KvuIP8Aibf9DPr/AP3/AI//AIio7iHUrm3lgn8Sa88UqGN1M8eCpGCPuelW6KPrVb+d/eHsKf8AKhkMawwxRRg+XEixrk5OFGB/Kn0UVgahRRRQMDSUtFACUUUUAJSU6kNACxu0UgeNirg10+m3yXkYHAlH3lrljTopHikDxsVYc/WhGNWkqi8zpdf/AOQFqP8A17Sf+gmuv8Mf8i3pP/XpF/6AK4S+vo7zw7qByBMLaTcuf9k9K7vwx/yLek/9ekX/AKAK9/KPhl8jx68XF2ZT8Z+Hh4l0mOz+1vaNHOk6Sogcgr2wfrXMj4d3ygAeJpcf9eUf+NFFerUpxqK01dGUZODvF2F/4V5f/wDQzS/+AUf+NH/CvL//AKGaX/wCj/xoorL6pQ/kX3Gn1ir/ADMP+FeX/wD0M0v/AIBR/wCNH/CvL/8A6GaX/wAAo/8AGiij6pQ/kX3B9Yq/zMT/AIV3f/8AQzS/+AUf+NH/AAru/wD+hml/8Ao/8aKKPqlD+RfcH1ir/Mw/4V3ff9DNL/4BR/40f8K7vv8AoZpf/AKP/Giil9UofyL7g+sVf5mH/Cur7/oZpf8AwCj/AMaP+FdX3/QzS/8AgFH/AI0UUfU6H8i+4PrFX+Zh/wAK6vv+hml/8Ao/8aP+FdX3/QzS/wDgFH/jRRR9TofyL7g+sVf5mH/Cur7/AKGaX/wCj/xo/wCFdX3/AEM0v/gFH/jRRR9TofyL7g+sVf5mH/Cur7/oZpf/AACj/wAaP+FdX3/QzS/+AUf+NFFH1Oh/IvuD6xV/mYf8K6vv+hml/wDAKP8Axo/4V3ff9DNL/wCAUf8AjRRR9TofyL7g+sVf5mH/AAru/wD+hml/8Ao/8aP+Fd3/AP0M0v8A4BR/40UU/qlD+RfcH1ir/Mw/4V3f/wDQzS/+AUf+NH/Cu7//AKGaX/wCj/xooo+qUP5F9wfWKv8AMw/4V3f/APQzS/8AgFH/AI0f8K7v/wDoZpf/AACj/wAaKKPqlD+RfcH1ir/Mw/4V3f8A/QzS/wDgFH/jR/wru+/6GaX/AMAo/wDGiij6pQ/kX3B9Yq/zMP8AhXV9/wBDNL/4BR/40f8ACur7/oZpf/AKP/Giil9TofyL7g+sVf5mH/Cur7/oZpf/AACj/wAaP+FdX3/QzS/+AUf+NFFH1Oh/IvuD6xV/mYf8K6vv+hml/wDAKP8Axo/4V1ff9DNL/wCAUf8AjRRR9TofyL7g+sVf5mH/AArq+/6GaX/wCj/xo/4V1ff9DNL/AOAUf+NFFH1Oh/IvuD6xV/mYf8K6vv8AoZpf/AKP/Gk/4V1ff9DNN/4BR/40UUfU6H8i+4PrFX+Zh/wrq+/6Gab/AMAo/wDGl/4V1ff9DNL/AOAUf+NFFH1Oh/IvuD6xV/mYf8K6vv8AoZpf/AKP/Gj/AIV1ff8AQzS/+AUf+NFFH1Oh/IvuD6xV/mYf8K6vv+hml/8AAKP/ABo/4V1ff9DNL/4BR/40UUfU6H8i+4PrFX+Zh/wrq+/6GaX/AMAo/wDGj/hXV9/0M0v/AIBR/wCNFFH1Oh/IvuD6xV/mYf8ACur7/oZpf/AKP/Gj/hXV9/0M0v8A4BR/40UUfU6H8i+4PrFX+Zh/wrq+/wChml/8Ao/8aT/hXV9/0M03/gFH/jRRR9TofyL7g+sVf5mH/Cur7/oZpv8AwCj/AMaP+FdX3/QzTf8AgFH/AI0UUfU6H8i+4PrFX+Zh/wAK6vv+hmm/8Ao/8aP+FdX3/QzTf+AUf+NFFH1Oh/IvuD6xV/mYf8K5vv8AoZpv/AKP/Gj/AIVzff8AQzTf+Acf+NFFH1Oh/IvuD6xV/mY1/hvfPHIn/CTzgOpRsWcY4Iwe9d/p1qtlp9raKxZYIliDHqQoAz+lFFa06UKXwKxnOcp6ydz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://www.cdc.gov/ncidod/dvbid/lyme/images/TickLifeCycle_707.myextj.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32453=[""].join("\n");
var outline_f31_44_32453=null;
var title_f31_44_32454="Dextroamphetamine: Drug information";
var content_f31_44_32454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextroamphetamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/15/28917?source=see_link\">",
"    see \"Dextroamphetamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/7/6263?source=see_link\">",
"    see \"Dextroamphetamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexedrine&reg; Spansule&reg;;",
"     </li>",
"     <li>",
"      ProCentra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexedrine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral: Initial: 10 mg/day, may increase at 10 mg/day increments in weekly intervals until side effects appear (maximum dose: 60 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F158805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/7/6263?source=see_link\">",
"      see \"Dextroamphetamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral: Children 6-12 years: Initial: 5 mg/day, may increase at 5 mg/day increments in weekly intervals until side effects appear (maximum dose: 60 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder (ADHD):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 3-5 years:",
"     </i>",
"     Immediate release tablets or oral solution: Initial: 2.5 mg/day; may increase at 2.5 mg/day increments in weekly intervals until optimal response is obtained, usual range: 0.1-0.5 mg/kg/dose (maximum dose: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;6 years:",
"     </i>",
"     Initial: 5 mg once or twice daily; may increase at 5 mg/day increments in weekly intervals until optimal response is reached, usual range: 0.1-0.5 mg/kg/dose (5-20 mg/day) (maximum dose: 40 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; start at lowest dose. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sulfate: 5 mg, 10 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexedrine&reg; Spansule&reg;: 5 mg, 10 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProCentra&reg;: 5 mg/5 mL (480 mL) [contains benzoic acid; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule (sustained release), oral solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F158813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dexedrine&reg; Spansule&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088583.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088583.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ProCentra&reg;:  file://fsclabs.com/pdf/2010_Updates/2639_ProCentraMedGuide.pdf",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer initial dose upon awakening; do not administer doses late in the evening due to potential for insomnia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets and oral solution: If needed, 1-2 additional doses may be administered at intervals of 4-6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release or sustained release capsules: Do not crush sustained release drug products. Formulations may be used for once-daily administration, if appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Narcolepsy; attention-deficit/hyperactivity disorder (ADHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexedrine&reg; may be confused with dextran, Excedrin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dextroamphetamine may be confused with dexamethasone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggression, dizziness, dyskinesia, dysphoria, euphoria, exacerbation of motor and phonic tics, headache, insomnia, mania, overstimulation, psychosis, restlessness, Tourette's syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, unpleasant taste, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation abnormalities, blurred vision",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to dextroamphetamine, other sympathomimetic amines, or any component of the formulation; advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension; hyperthyroidism; glaucoma; agitated states; patients with a history of drug abuse; during or within 14 days following MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: Use has been associated with serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke and MI in adults).",
"     </b>",
"     These products should be avoided in the patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities (driving, operating machinery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential:",
"     <b>",
"      [U.S. Boxed Warning]: Potential for drug dependency exists; prolonged use may lead to drug dependency.",
"     </b>",
"     Use is contraindicated in patients with history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Use is contraindicated in patients with moderate-to-severe hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur with stimulant use; observe for symptoms of aggression and/or hostility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in this age group due to CNS stimulant adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Appetite suppression may occur; monitor weight during therapy, particularly in children. Use of stimulants has been associated with suppression of growth; monitor growth rate during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F158791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Potential for drug dependency may increase with prolonged use. Ethanol may increase CNS depression. Management: Avoid ethanol. Use is contraindicated in patients with history of ethanol or drug abuse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Dextroamphetamine serum levels may be altered if taken with acidic food, juices, or vitamin C. Management: Avoid caffeine. Take 30 minutes before meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Ephedra may cause hypertension or arrhythmias. Management: Avoid ephedra.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6470944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15041842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Amphetamines are excreted into breast milk and use may decrease milk production. Increased irritability, agitation, and crying have been reported in nursing infants (ACOG, 2011). The manufacturer recommends that mothers taking dextroamphetamine refrain from nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Dexedrine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $1056.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $1056.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (90): $1056.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Dextroamphetamine Sulfate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $405.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $505.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $645.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ProCentra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (473 mL): $570.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dextroamphetamine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $290.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $315.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac evaluation should be completed on any patient who develops chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants; growth in children and CNS activity in all",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk.   Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dexamphetamine (AU);",
"     </li>",
"     <li>",
"      Dexamphetamini Sulfas (CH);",
"     </li>",
"     <li>",
"      Dexedrine (GB, NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amphetamines are noncatecholamine, sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 3.5-4.6 L/kg; distributes into CNS; mean CSF concentrations are 80% of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP monooxygenase and glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 10-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: ~3 hours; sustained release: ~8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):751-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/21343793/pubmed\" id=\"21343793\" target=\"_blank\">",
"        21343793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golub M, Costa L, Crofton K, et al, \"NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,\"",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2005, 74(6):471-584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/16167346/pubmed\" id=\"16167346\" target=\"_blank\">",
"        16167346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta S, Ghaly N, and Dewan M, \"Augmenting Fluoxetine With Dextroamphetamine to Treat Refractory Depression,\"",
"      <i>",
"       Hosp Community Psychiatry",
"      </i>",
"      , 1992, 43(3):281-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/1555827/pubmed\" id=\"1555827\" target=\"_blank\">",
"        1555827",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011,",
"      <i>",
"       JAMA",
"      </i>",
"      , 306(24):2673-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/22161946/pubmed\" id=\"22161946\" target=\"_blank\">",
"        22161946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaGasse LL, Derauf C, Smith LM, et al, \"Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(4):681-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/22430455/pubmed\" id=\"22430455\" target=\"_blank\">",
"        22430455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mattson RH and Calverley JR, &ldquo;Dextroamphetamine-Sulfate-Induced Dyskinesias,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1968, 204(5):400-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/5694457/pubmed\" id=\"5694457\" target=\"_blank\">",
"        5694457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parker G and Brotchie H, \"Do the Old Psychostimulant Drugs Have a Role in Managing Treatment-Resistant Depression?\"",
"      <i>",
"       Acta Psychiatr Scand",
"      </i>",
"      , 2010,  121(4):308-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/19594481/pubmed\" id=\"19594481\" target=\"_blank\">",
"        19594481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/44/32454/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9341 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32454=[""].join("\n");
var outline_f31_44_32454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708681\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158794\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158795\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158811\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158798\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158805\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158799\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796031\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796032\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158775\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158759\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158813\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874427\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158777\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158776\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158809\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158780\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158763\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299162\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158768\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158791\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158770\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6470944\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158802\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15041842\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989310\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158772\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038597\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158762\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158779\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/15/28917?source=related_link\">",
"      Dextroamphetamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/7/6263?source=related_link\">",
"      Dextroamphetamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_44_32455="Pathophysiology of heart failure: Neurohumoral adaptations";
var content_f31_44_32455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of heart failure: Neurohumoral adaptations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32455/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32455/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32455/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/44/32455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Mar 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of heart failure (HF) are due in part to compensatory mechanisms utilized by the body in an attempt to adjust for a primary deficit in cardiac output. Neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems by the low-output state, can contribute to maintenance of perfusion of vital organs in two ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of systemic pressure by vasoconstriction, resulting in redistribution of blood flow to vital organs",
"     </li>",
"     <li>",
"      Restoration of cardiac output by increasing myocardial contractility and heart rate and by expansion of the extracellular fluid volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In HF, these adaptations tend to overwhelm the vasodilatory and natriuretic effects of natriuretic peptides, nitric oxide, prostaglandins, and bradykinin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Volume expansion is often effective because the heart can respond to an increase in venous return with an elevation in end&ndash;diastolic volume that results in a rise in stroke volume (via the Frank-Starling mechanism). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23076?source=see_link\">",
"     \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, a number of",
"    <strong>",
"     maladaptive",
"    </strong>",
"    consequences of neurohumoral activation (",
"    <a class=\"graphic graphic_algorithm graphicRef61754 \" href=\"mobipreview.htm?36/4/36941\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elevation in diastolic pressures is transmitted to the atria and to the pulmonary and systemic venous circulations; the ensuing elevation in capillary pressures promotes the development of pulmonary congestion and peripheral edema",
"     </li>",
"     <li>",
"      The increase in left ventricular afterload induced by the rise in peripheral resistance can both directly depress cardiac function and enhance the rate of deterioration of myocardial function (",
"      <a class=\"graphic graphic_figure graphicRef71440 \" href=\"mobipreview.htm?17/0/17421\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Catecholamine-stimulated contractility and increased heart rate can worsen coronary ischemia",
"     </li>",
"     <li>",
"      Catecholamines and angiotensin II may promote the loss of myocytes by apoptosis, the induction of maladaptive fetal isoforms of proteins involved in contraction, and hypertrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative importance of these beneficial and detrimental effects is not fully defined. However, the slowing of disease progression and improvement in survival observed with angiotensin converting enzyme (ACE) inhibitors and beta blockers in patients with heart failure due to systolic dysfunction suggests that there is, over time, a",
"    <strong>",
"     net negative",
"    </strong>",
"    effect of the neurohumoral adaptations on ventricular function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major neurohumoral adaptations that occur in HF, including activation of the sympathetic and renin-angiotensin systems, and increased secretion of antidiuretic hormone, natriuretic peptides, and endothelin will be reviewed here. The effects of HF on other signaling systems (eg, nitric oxide and adrenomedullin) and on cytokines and chemokines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROHUMORAL ADAPTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal neurohumoral systems involved in the response to HF are the sympathetic nervous system, the renin&ndash;angiotensin&ndash;aldosterone system, and antidiuretic hormone&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef58128 \" href=\"mobipreview.htm?8/48/8973\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. Other vasoactive substances are also affected, including the vasoconstrictor endothelin and the vasodilators atrial natriuretic peptide and nitric oxide. These hormonal changes are seen with both systolic and diastolic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first responses to a decrease in cardiac output (sensed as a fall in blood pressure) is activation of the sympathetic nervous system, resulting in both increased release and decreased uptake of norepinephrine (NE) at adrenergic nerve endings. Downregulation of peripheral alpha-2 receptor function, which normally inhibits NE release, may contribute to sympathetic activation in heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early in heart failure, catecholamine-induced augmentation of ventricular contractility and heart rate help maintain cardiac output, particularly during exercise. However, with progressive worsening of ventricular function, these mechanisms are no longer sufficient. As an example, an increase in heart rate also enhances ventricular contractility due to the normal force-frequency relationship; this relationship is blunted in heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased sympathetic activity also leads to systemic and pulmonary vasoconstriction and enhanced venous tone, both of which initially contribute to the maintenance of blood pressure by increasing ventricular preload. Renal vasoconstriction (mediated by both NE and angiotensin II) occurs primarily at the efferent arteriole, producing an increase in filtration fraction that allows glomerular filtration to be relatively well maintained despite a fall in renal blood flow. Both NE and angiotensin II also stimulate proximal tubular sodium reabsorption, which contributes to the sodium retention characteristic of HF.",
"   </p>",
"   <p>",
"    Sympathetic activation results in an increase in the plasma NE concentration, which correlates directly with the severity of the cardiac dysfunction and inversely with survival (",
"    <a class=\"graphic graphic_figure graphicRef62001 \" href=\"mobipreview.htm?42/52/43853\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/9\">",
"     9",
"    </a>",
"    ]. An analysis of more than 4000 patients from the Val-HeFT trial found that those with an initial plasma NE concentration in the highest quartile (&ge;572",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [3.38",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    had a significantly higher mortality rate at two years than those with an initial plasma NE concentration in the lowest quartile (&lt;274",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [1.62",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    (24.2 versus 13.8 percent) (",
"    <a class=\"graphic graphic_figure graphicRef59265 \" href=\"mobipreview.htm?42/38/43630\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of sympathetic activation can be reduced by effective treatment of HF, as with administration of an ACE inhibitor. In a study of 223 patients with mild or moderate heart failure, for example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    therapy for 12 weeks significantly lowered the plasma NE concentration (compared with placebo) in patients with the most pronounced degree of neurohumoral activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/11\">",
"     11",
"    </a>",
"    ]. In the SOLVD trial, patients who had more marked neurohormonal activation, as reflected by plasma NE or angiotensin II, had a larger survival benefit with ACE inhibition than patients with less activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to systemic sympathetic activation, there is an increase in cardiac efferent sympathetic activity in patients with heart failure. This effect has been demonstrated by increased cardiac NE spillover (ie, elevated NE levels in cardiac veins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A reduction in ventricular filling pressures reduces cardiac NE spillover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/15\">",
"     15",
"    </a>",
"    ]. A similar effect is seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chronic increase in sympathetic activity also leads to downregulation and reduction in density of the cardiac beta-adrenergic receptors and desensitization of the signaling cascade through which the receptors couple to physiologic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/17\">",
"     17",
"    </a>",
"    ]; this results in impaired inotropic and chronotropic responses. In addition, chronically increased stimulation of beta-adrenergic receptors may cause molecular and cellular abnormalities, which contribute to progression of myocardial dysfunction by the reexpression of fetal protein isoforms and the loss of cardiomyocytes due to apoptosis or necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocyte apoptosis in HF has been attributed to beta-adrenergic receptor coupling to stimulatory G protein (Gs)-dependent cAMP-mediated signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/19\">",
"     19",
"    </a>",
"    ]. Less evidence is available for a potential myocyte necrosis pathway mediated through a beta-1 adrenergic receptor modulated pathway involving calcium overload and mitochondria permeability transition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/20\">",
"     20",
"    </a>",
"    ]. On the other hand, beta-1 adrenergic receptors may also deliver an antiapoptotic signal through transactivation of epidermal growth factor receptors (EGFR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Role of beta adrenergic receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that ventricular myocardium contains beta-2 as well as beta-1 adrenergic receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/22\">",
"     22",
"    </a>",
"    ] and that, in HF, there is a selective reduction in the density of beta-1 but not beta-2 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As a result, the failing heart is more dependent upon beta-2 adrenergic receptors for inotropic support. There is evidence that myocardial beta-2 adrenergic receptors may mediate both beneficial and deleterious effects in heart failure.",
"   </p>",
"   <p>",
"    Genetic heterogeneity in the structure of the beta-2 receptor has been found and the most important polymorphic receptor results from a threonine (Thr) to isoleucine (Ile) switch at amino acid 164 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/25\">",
"     25",
"    </a>",
"    ]. This receptor displays a small decrease in binding affinity for catecholamines and certain beta receptor antagonists and a substantial decrease in basal and epinephrine-stimulated adenylyl cyclase activities. Transgenic mice expressing the Ile164 receptor display depressed resting and agonist-stimulated contractile function compared to mice with the Thr164 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/25\">",
"     25",
"    </a>",
"    ]. In one series in humans, there was no difference in the frequency of these receptor genotypes in 259 patients with HF compared to 212 healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/26\">",
"     26",
"    </a>",
"    ]. However, patients with the Ile164 receptor had a reduced one-year survival (42 versus 76 percent for those with the Thr164 receptor) and a relative risk of death or cardiac transplantation of 4.8 (p&lt;0.001). A possible mechanism is blunted cardiac beta-2 receptor responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition to helping to support the myocardial contractile response to sympathetic stimulation, beta-2 adrenergic receptors located on the cardiac myocyte exert an anti-apoptotic effect that opposes the pro-apoptotic action of beta-1 receptor stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, stimulation of beta-2 receptors may also mediate adverse effects. In contrast to presynaptic alpha-2 adrenergic receptors, which inhibit sympathetic norepinephrine release, presynaptic beta-2 adrenergic receptors stimulate norepinephrine release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/29\">",
"     29",
"    </a>",
"    ]. Possibly related to this action, beta-2 receptor stimulation appears to increase the propensity for ventricular fibrillation. As an example, one study of animals with experimentally induced HF found that an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion activated beta-2 receptors to a greater extent and resulted in a greater intracellular influx of calcium during ischemia compared to non-HF rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/30\">",
"     30",
"    </a>",
"    ]. These actions were prevented by selective blockade of the beta-2 receptor, but not by blockade of the beta-1 receptor, and beta-2 receptor blockade prevented ischemia mediated ventricular fibrillation. These data suggest that activation of the beta-2 receptor on the cardiac myocyte, leading to increased cytosolic calcium, may produce afterpotentials that can ultimately trigger ventricular fibrillation.",
"   </p>",
"   <p>",
"    These changes may explain the beneficial effects of beta blockers on both cardiac performance and survival in some patients with chronic HF. Acute studies suggest that cardiac sympathetic activity is reduced to a greater degree by nonselective than selective beta blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renin&ndash;angiotensin system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the factors that stimulate renal renin release is activated in HF: decreased stretch of the glomerular afferent arteriole, reduced delivery of chloride to the macula densa, and increased beta-1 adrenergic activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also evidence that angiotensin II can be synthesized locally at a variety of tissue sites including the kidney, blood vessels, adrenal gland, and brain. For this reason, measurement of the plasma renin activity or angiotensin II concentration may underestimate tissue angiotensin II activity. As an example, the plasma renin activity is often normal in patients with stable, chronic HF, despite persistence of the low output state and renal sodium retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/31\">",
"     31",
"    </a>",
"    ]. Studies in experimental models of heart failure suggest that there may be increased activity of the intrarenal renin-angiotensin system in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/29\">",
"     29",
"    </a>",
"    ]. In comparison, plasma renin levels are usually markedly elevated in patients with recent onset or very symptomatic HF (",
"    <a class=\"graphic graphic_figure graphicRef58128 \" href=\"mobipreview.htm?8/48/8973\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/1,6,31\">",
"     1,6,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to activation of the systemic renin-angiotensin system in heart failure, there is evidence of local cardiac angiotensin II and angiotensin converting enzyme production is in proportion to the severity of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. This phenomenon could explain in part why angiotensin converting enzyme inhibitors are more beneficial in patients with HF than other vasodilators. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin II has similar actions to NE in HF, increasing sodium reabsorption (an effect mediated in part by enhanced release of aldosterone) and inducing systemic and renal vasoconstriction. Similar to NE, angiotensin II can act directly on myocytes and other cell types in the myocardium to promote pathologic remodeling via myocyte hypertrophy, reexpression of fetal protein isoforms, myocyte apoptosis, and alterations in the interstitial matrix. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary hyperaldosteronism in heart failure has been thought to reflect angiotensin II-mediated stimulation of the adrenal glands. However, there is also local production of aldosterone in the failing heart in proportion to the severity of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/36\">",
"     36",
"    </a>",
"    ], an effect that is mediated by the induction of aldosterone synthase (CYP11B2) by angiotensin II in the failing ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blockade of the adverse effects of aldosterone-induced stimulation of cardiac mineralocorticoid receptors is thought to contribute to the survival benefit associated with the administration of mineralocorticoid receptor antagonists in selected patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     ACE gene polymorphism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma and tissue concentrations of ACE, and therefore of angiotensin II, are in part determined by the ACE gene. This gene may manifest insertion (I) or deletion (D) polymorphism and three genotypes (DD, ID, and II). Plasma and cardiac levels of ACE are 1.5 to 3-fold higher in patients with the DD compared to the II genotype; the values are intermediate in patients with ID genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/38\">",
"     38",
"    </a>",
"    ]. The DD genotype of the angiotensin converting enzyme gene has been associated with a number of adverse cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link&amp;anchor=H4#H4\">",
"     \"Actions of angiotensin II on the heart\", section on 'ACE gene polymorphism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There may be an association between the DD genotype and increased mortality and reduced transplant-free survival in patients with HF due to idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. This difference may be abolished with beta blocker therapy as, in one study, transplant-free survival was equivalent in patients with the DD, ID, and II genotypes who were treated with a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/41\">",
"     41",
"    </a>",
"    ]. The adverse effect of the DD genotype on survival in patients with HF may be related to progression of HF rather than to arrhythmic sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32455/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antidiuretic hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the carotid sinus and aortic arch baroreceptors by the low cardiac output in heart failure leads to enhanced release of ADH and stimulation of thirst. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .) Elevated levels of ADH may contribute to the increase in systemic vascular resistance in HF via stimulation of the V1A receptor, which is found on vascular smooth muscle cells, and also promote water retention via the V2 receptor by enhancing water reabsorption in the collecting tubules. The combination of decreased water excretion and increased water intake via thirst often leads to a fall in the plasma sodium concentration. The severity of these defects tends to parallel the severity of the heart failure. As a result, the degree of hyponatremia is an important predictor of survival in these patients (",
"    <a class=\"graphic graphic_figure graphicRef55554 \" href=\"mobipreview.htm?29/6/29805\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Atrial and brain natriuretic peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial natriuretic peptide (ANP) is primarily released from the atria in response to volume expansion, which is sensed as an increase in atrial stretch. ANP release is increased in heart failure. Plasma ANP levels rise early in the course of the disease and have been used as a marker for the diagnosis of asymptomatic left ventricular dysfunction. With chronic and more advanced heart failure, ventricular cells can also be recruited to secrete both ANP and brain natriuretic peptide (BNP), an analogous peptide, in response to the high ventricular filling pressures. These relationships have allowed the plasma concentration of these peptides, particularly BNP, to be used to detect heart failure and to predict the outcome and perhaps guide therapy in patients with established disease. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Endothelin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin, another substance produced by the vascular endothelium, may contribute to the regulation of myocardial function, vascular tone, and peripheral resistance in HF. Plasma endothelin concentrations are increased in patients with HF; experimental studies suggest that endothelin is released in part from cardiac myocytes and coronary vascular endothelium, and that angiotensin II may contribute to the high circulating levels in HF. Over the long-term, high levels of endothelin (as with angiotensin II) may be deleterious to the heart due, for example, to pathologic remodeling. This has led to the evaluation of endothelin inhibition as a therapy for heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/20/11592?source=see_link\">",
"     \"Role of endothelin in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the short term, neurohumoral activation is beneficial in patients with HF since the elevations in cardiac contractility and vascular resistance and renal sodium retention tend to restore the cardiac output and tissue perfusion toward normal. However, the deleterious effects may predominate over the long term, leading to pulmonary and peripheral edema, increased afterload, pathologic myocardial remodeling, and more rapid progression of myocardial dysfunction. The ability of ACE inhibitors and beta blockers to improve survival and slow the progression of the heart failure is compatible with this hypothesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/842?source=see_link\">",
"     \"Cardiac remodeling: Clinical assessment and therapy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/1\">",
"      Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/2\">",
"      Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/3\">",
"      Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/4\">",
"      Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008; 127:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/5\">",
"      Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/6\">",
"      Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/7\">",
"      Aggarwal A, Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001; 37:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/8\">",
"      Bhargava V, Shabetai R, Mathi&auml;sen RA, et al. Loss of adrenergic control of the force-frequency relation in heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol 1998; 81:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/9\">",
"      Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/10\">",
"      Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/11\">",
"      Sigurdsson A, Amtorp O, Gundersen T, et al. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J 1994; 72:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/12\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/13\">",
"      Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/14\">",
"      Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/15\">",
"      Azevedo ER, Newton GE, Floras JS, Parker JD. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 2000; 101:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/16\">",
"      Kaye DM, Dart AM, Jennings GL, Esler MD. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J Am Coll Cardiol 1999; 33:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/17\">",
"      Nozawa T, Igawa A, Yoshida N, et al. Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. Circulation 1998; 97:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/18\">",
"      Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998; 98:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/19\">",
"      Vatner DE, Asai K, Iwase M, et al. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol 1999; 83:80H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/20\">",
"      Nakayama H, Chen X, Baines CP, et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007; 117:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/21\">",
"      Noma T, Lemaire A, Naga Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007; 117:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/22\">",
"      Newton GE, Azevedo ER, Parker JD. Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study. Circulation 1999; 99:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/23\">",
"      Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/24\">",
"      Altschuld RA, Starling RC, Hamlin RL, et al. Response of failing canine and human heart cells to beta 2-adrenergic stimulation. Circulation 1995; 92:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/25\">",
"      Turki J, Lorenz JN, Green SA, et al. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 1996; 93:10483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/26\">",
"      Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/27\">",
"      Brodde OE, B&uuml;scher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001; 103:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/28\">",
"      Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Circulation 1999; 100:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/29\">",
"      Newton GE, Parker JD. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996; 94:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/30\">",
"      Billman GE, Castillo LC, Hensley J, et al. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997; 96:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/31\">",
"      Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/32\">",
"      Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/33\">",
"      Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76:18D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/34\">",
"      Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/35\">",
"      Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/36\">",
"      Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/37\">",
"      Silvestre JS, Heymes C, Oub&eacute;na&iuml;ssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/38\">",
"      Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/39\">",
"      Raynolds MV, Bristow MR, Bush EW, et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/40\">",
"      Andersson B, Sylv&eacute;n C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/41\">",
"      McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32455/abstract/42\">",
"      Bedi MS, Postava LA, Murali S, et al. Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism. J Cardiovasc Electrophysiol 2004; 15:1162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3481 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32455=[""].join("\n");
var outline_f31_44_32455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROHUMORAL ADAPTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Role of beta adrenergic receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renin&ndash;angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - ACE gene polymorphism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antidiuretic hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Atrial and brain natriuretic peptides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Endothelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3481|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?36/4/36941\" title=\"algorithm 1\">",
"      Neurohormonal stimulat HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3481|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/0/17421\" title=\"figure 1\">",
"      Neurohumoral activation HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/48/8973\" title=\"figure 2\">",
"      Hormone levels in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/52/43853\" title=\"figure 3\">",
"      Norepinephrine in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/38/43630\" title=\"figure 4\">",
"      NE and survival ValHeFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/6/29805\" title=\"figure 5\">",
"      Hyponatremia in HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/20/11592?source=related_link\">",
"      Role of endothelin in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_44_32456="Overview of echogenic masses and calcification in the fetal abdomen";
var content_f31_44_32456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of echogenic masses and calcification in the fetal abdomen",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32456/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32456/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32456/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/44/32456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Mar 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echogenic masses and calcifications in the fetal abdomen are observed relatively commonly during fetal sonography. These findings may arise from the liver, gallbladder, kidneys, adrenal glands, gastrointestinal tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritoneal cavity. Although some of these findings carry few consequences, others are important for diagnosis of disorders affecting management of pregnancy, delivery, and the neonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHOGENICITY IN THE GASTROINTESTINAL TRACT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastric pseudo-mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second and third trimesters, debris is commonly visualized in the fetal stomach as a pseudo-mass consisting of discrete echogenic areas 4 to 12 mm in diameter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74924 \" href=\"mobipreview.htm?24/16/24833\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/1\">",
"     1",
"    </a>",
"    ]. The pseudo-mass is thought to represent swallowed cells (red blood cells, meconium, fetal skin cells) that have aggregated due to relatively poor gastric peristaltic activity early in the second trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Gastric pseudo-masses resolve over time and are not associated with adverse neonatal outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Echogenic bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echogenic bowel is the most common echogenic mass visualized in the fetal abdomen, with an incidence of 0.5 to 1 percent in the second trimester in a general obstetrical population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By definition, the bowel is termed echogenic if on ultrasound examination it is as bright as adjacent bone; the iliac wing is the usual standard for comparison (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53753 \" href=\"mobipreview.htm?32/12/32960\">",
"     image 2",
"    </a>",
"    ). Hyperechogenicity can be diffuse or focal, is uniform over a well-defined area that does not shadow, and is located primarily in the lower fetal abdomen and pelvis.",
"   </p>",
"   <p>",
"    Echogenic bowel in the third trimester is common and a normal finding since meconium is present in the colon and can be echogenic. In the second trimester, however, echogenic bowel can be a marker for underlying pathology, including cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/4,7\">",
"     4,7",
"    </a>",
"    ], chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/4,7-12\">",
"     4,7-12",
"    </a>",
"    ], intraamniotic bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], congenital infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/4,14,16,17\">",
"     4,14,16,17",
"    </a>",
"    ], gastrointestinal atresias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/6\">",
"     6",
"    </a>",
"    ], intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and fetal demise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/10,18,20\">",
"     10,18,20",
"    </a>",
"    ]. In the absence of underlying pathology, many cases diagnosed in the second trimester resolve over time. Echogenic bowel is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36166?source=see_link\">",
"     \"Fetal echogenic bowel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bowel calcifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A loop of bowel containing calcifications and located in the",
"    <span class=\"nowrap\">",
"     midabdomen/pelvis",
"    </span>",
"    is a marker for cloacal malformation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62048 \" href=\"mobipreview.htm?18/11/18610\">",
"     image 3",
"    </a>",
"    ). This anomaly occurs exclusively in phenotypic females, with an incidence of 1 in 50,000 births.",
"   </p>",
"   <p>",
"    Failure of the urorectal septum to reach the perineum results in formation of a single perineal opening that serves as the outlet for urine, genital secretions, and meconium. The mixture of meconium and urine results in enteroliths, which appear as shadowing foci within a dilated loop of bowel. Urinary tract abnormalities (reflux, ureteral ectopia, duplication of bladder, urinary tract obstruction), gastrointestinal obstruction, and genital abnormalities (duplication or atresia of uterus and vagina, ambiguous genitalia) are frequently present, as well as abnormalities of the bony pelvis and vertebrae. Oligohydramnios is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PERITONEAL CALCIFICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial consideration when calcifications are visualized within the fetal peritoneum is whether they are scattered in the peritoneal cavity (meconium peritonitis), associated with a mass (meconium pseudocyst), or outlining the liver (indicating peritoneal origin and thus likely due to meconium peritonitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Meconium peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meconium peritonitis is a sequelae of in utero small bowel perforation with extrusion of meconium intraperitoneally, resulting in a sterile chemical peritonitis. The diagnosis of meconium peritonitis is made when scattered calcifications are seen throughout the peritoneum, often outlining bowel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80975 \" href=\"mobipreview.htm?42/56/43904\">",
"     image 4",
"    </a>",
"    ). At times, only a focal calcification with shadowing is seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60172 \" href=\"mobipreview.htm?43/6/44129\">",
"     image 5",
"    </a>",
"    ). Calcifications can be visualized after 18 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meconium peritonitis and meconium pseudocyst (see below) can be related to cystic fibrosis. The incidence of cystic fibrosis among fetuses with meconium peritonitis or pseudocyst varies widely among case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The association is weak when peritoneal calcifications are an isolated finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22503?source=see_link\">",
"     \"Cystic fibrosis: Prenatal genetic screening\"",
"    </a>",
"    .) Other causes of meconium peritonitis include ileal or jejunal atresia, volvulus, microcolon, intussusception, Meckel's diverticulum, imperforate anus, and peritoneal bands.",
"   </p>",
"   <p>",
"    Evaluation of the fetus with meconium peritonitis should be thorough, including documentation of the site, size and location of calcifications, and assessment for additional abnormalities, such as dilated or echogenic bowel loops, meconium pseudocyst, ascites, and signs of hydrops. Serial fetal sonography is recommended and delivery at a center with a newborn intensive care unit and pediatric surgery is suggested due to the potential for postnatally diagnosed fetal anomalies. In a study of nine fetuses with abdominal calcifications on prenatal ultrasound, five fetuses without other sonographic findings had normal abdominal examinations and fed normally after birth, suggesting a bowel perforation that healed in utero. Of four fetuses with associated dilated loops of bowel, two required surgery for ileal atresia and ileal perforation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meconium pseudocyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extruded meconium can become walled off by adhesions between bowel, omentum, and peritoneum, and develop a heterogeneous cystic appearance known as a meconium pseudocyst. The meconium pseudocyst is seen as a well-defined hypoechoic mass surrounded by an echogenic calcified wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74069 \" href=\"mobipreview.htm?22/25/22929\">",
"     image 6",
"    </a>",
"    ). Associated findings include ascites, polyhydramnios, and dilated bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Evaluation and management are the same as with meconium peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LIVER CALCIFICATIONS AND CALCIFIED LIVER LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcifications in the fetal liver are a relatively common finding, identified in 1 in 1750 second trimester ultrasound examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/26\">",
"     26",
"    </a>",
"    ]. The site, size and distribution of the lesions are major factors in determining outcome and management. The presence of an associated liver, abdominal, or retroperitoneal mass, as well as the association with ascites, are important considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surface calcifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Punctate echogenic lesions on the surface of the liver usually represent peritoneal calcifications; meconium peritonitis is the most common source (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Meconium peritonitis'",
"    </a>",
"    above). Isolated subcapsular calcifications also can be due to emboli from the portal or hepatic veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intrahepatic calcifications without a mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcifications in the liver parenchyma can be single or multiple (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64120 \" href=\"mobipreview.htm?41/2/42016\">",
"     image 7",
"    </a>",
"    ). When intrahepatic calcifications are visualized, it is important to assess for: (1) any associated hepatic mass; (2) normal hepatic blood flow by Doppler to exclude thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/28\">",
"     28",
"    </a>",
"    ]; (3) signs of infection (eg, ventriculomegaly, intracranial calcifications, ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/29\">",
"     29",
"    </a>",
"    ]); and (4) structural or growth abnormalities. In the majority of cases in which isolated hepatic calcific deposits are detected, no underlying abnormality is found, and the finding is of no clinical consequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. Follow-up sonography typically shows stability or regression of the liver calcification, and no further work-up is required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 14 fetuses with hepatic calcifications, 12 fetuses had one or two calcified foci, one fetus had four scattered foci, and one had diffuse calcification of the liver, as well as peritoneal and intestinal calcifications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/26\">",
"       26",
"      </a>",
"      ]. Three fetuses (21 percent) had associated severe malformations: two with trisomy 18 and one with dwarfism and hydronephrosis. One fetus with polyhydramnios and calcifications within the bowel died in utero. No case had serologic evidence of recent infection. Ten fetuses were normal at birth.",
"     </li>",
"     <li>",
"      In another series of fetuses with liver calcifications, 40 of 61 fetuses had additional abnormalities. Ten of 11 fetuses with abnormal karyotypes had other abnormalities that were detected prenatally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/31\">",
"       31",
"      </a>",
"      ]. Twenty-one fetuses had no other sonographically detectable abnormalities. Of these, one fetus with a single liver calcification was diagnosed with trisomy 21 postnatally. The work-up of one fetus with multiple liver calcifications revealed maternal parvovirus B19 infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intrahepatic calcifications with an associated mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcified liver masses are rare and potentially malignant. The most common tumors are hepatoblastoma, which appears as a heterogeneous mass with coarse or punctate calcifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/32\">",
"     32",
"    </a>",
"    ], and metastatic neuroblastoma, which most commonly originates in the adrenal gland. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=see_link&amp;anchor=H14#H14\">",
"     \"Gardner syndrome\", section on 'Hepatoblastoma'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Neuroblastoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NON-CALCIFIED ECHOGENIC LIVER LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most solid liver masses are hypoechoic, but echogenic masses also occur. The differential diagnosis of intrahepatic echogenic liver masses includes benign entities such as hemangioma, mesenchymal hamartoma, adenoma, and focal nodular hyperplasia. Other pathologic lesions include hepatoblastoma and metastatic neuroblastoma. Vascular hepatic lesions such as hemangiomas, hemangioendotheliomas, and hepatoblastomas, can act as vascular reservoirs, leading to anemia, high output cardiac failure, and hydrops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. Doppler assessment of the fetal middle cerebral artery (MCA) peak systolic velocity is the best tool for predicting fetal anemia in at-risk pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hemangioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hemangioma is a benign tumor characterized by increased turnover of endothelium, mast cells, macrophages and fibroblasts. Hemangiomas are classically well-defined echogenic liver lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62653 \" href=\"mobipreview.htm?27/63/28656\">",
"     image 8",
"    </a>",
"    ). When seen in utero, they typically appear avascular on color Doppler sonography and rarely have calcifications; however, rarely large vascular spaces are present, with arteriovenous shunting and punctuate calcifications. Isolated small masses have a good outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemangiomas up to 12 cm have been described antenatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/39\">",
"     39",
"    </a>",
"    ]. With lesions this large, substantial morbidity can occur from congestive cardiac failure, thrombocytopenia, anemia, or intraabdominal hemorrhage from rupture of the tumor. Treatment of the mother with steroids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    4 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/37\">",
"     37",
"    </a>",
"    ]) to reduce the size of these lesions in utero has been described in case reports, with varying success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/37,40,41\">",
"     37,40,41",
"    </a>",
"    ]. Steroids and interferon alpha have been used to treat these lesions in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. When medical treatment fails, surgery may be required postnatally, but spontaneous regression of hemangiomas has been documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mesenchymal hamartoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This tumor is composed of connective tissue, hepatocytes, and biliary elements arranged in a disorderly fashion. Although typically cystic, solid and mixed echogenic tumors have been described. Hamartomas do not communicate with the biliary tree and do not contain bile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FETAL GALLSTONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstones or gallbladder sludge can be identified sonographically in the expected location of the fluid-filled gallbladder in the fetal right upper quadrant (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73816 \" href=\"mobipreview.htm?11/10/11425\">",
"     image 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 26 fetuses with echogenic material in the gallbladder, gestational age at the time of diagnosis ranged from 28 to 42 weeks, with a mean of 32 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/46\">",
"     46",
"    </a>",
"    ]. The echogenic foci were associated with distal shadowing in eight fetuses (30 percent), comet-tail artifact in nine (35 percent), and no distal artifact in nine (35 percent).",
"   </p>",
"   <p>",
"    Postnatal follow-up was available in 17 cases. No hemolytic anemias, other predisposing risk factors, or clinical sequelae associated with biliary tract disease were identified in any of the infants. In nine infants, the echogenic foci resolved. Echogenic foci that cast an acoustic shadow were more likely to represent stones than sludge, and were slightly less likely to resolve in the postnatal period. In three cases, the foci persisted, but none of the children became symptomatic at up to 4.5 years follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ENTERIC DUPLICATION CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric duplication cysts are structures in immediate contact with the alimentary tract. They are made up of a two-layer smooth muscle wall and an internal epithelium of a respiratory or intestinal type. In one third of cases, they are associated with additional abnormalities, particularly of the spine and gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enteric duplication cysts may or may not communicate with the lumen of the gastrointestinal tract. Most gastric duplications are cystic and of the non-communicating type (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63158 \" href=\"mobipreview.htm?20/20/20802\">",
"     image 10",
"    </a>",
"    ). They are found on the greater curve of the stomach near the pylorus. The differential diagnosis of gastric duplication includes retroperitoneal tumor (neuroblastoma) and teratoma of the stomach.",
"   </p>",
"   <p>",
"    Duplications can be single or multiple. Intraabdominal duplications account for 78 percent of all duplications, and within this group, 65 percent are jejunoileal, 20.5 percent are colonic, 8 percent are gastric, and 6.5 percent are duodenal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/50\">",
"     50",
"    </a>",
"    ]. The most common complication is bowel obstruction; ulceration, perforation, and hemorrhage have also been described so surgical rather than expectant management is recommended. Surgery does not need to be performed in the first few days of life, but probably should be performed within the first few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These cysts are typically anechoic, but can present as an echogenic abdominal mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59236 \" href=\"mobipreview.htm?20/12/20673\">",
"     image 11",
"    </a>",
"    ). Two sonographic signs suggestive of enteric duplication are the &ldquo;double-wall&rdquo; sign and the presence of peristalsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The double-wall sign consists of an inner hyperechoic rim and an outer hypoechoic layer reflecting the mucosa-submucosa and muscularis propria, respectively.",
"   </p>",
"   <p>",
"    If an abdominal enteric duplication is suspected, examination should be directed towards identifying the communication with the remainder of the gastrointestinal tract, dilated bowel loops,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of perforation. Due to the known association with spinal malformations, a thorough evaluation of the spine should be performed. Monthly follow-up examinations should be directed at documenting change in size, development of calcifications, and assessment for bowel obstruction. Most fetuses can go to term and be delivered in a nontertiary hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis of fetal intraabdominal cysts includes the above described enteric cysts, as well as meconium pseudocysts. There can also be cysts originating from the kidney, liver, ovary, common bile duct, mesentery, or urachus. Uncommon and rare etiologies include true or pseudo pancreatic cysts, a closed intestinal loop obstruction, sacrococcygeal teratoma, anterior sacral meningocele, hydrometrocolpos, and abdominal cystic pulmonary sequestration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ECHOGENICITY IN THE AREA OF THE FETAL ADRENAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for an echogenic suprarenal mass includes: adrenal hemorrhage, exophytic renal tumor, neuroblastoma, and extralobar sequestration. Less common lesions are adrenal adenoma, adrenal carcinoma, duplication of the renal system, Wilms tumor, congenital mesoblastic nephroma, and mesenteric and enteric duplication cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adrenal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia and increased intravascular pressure have been postulated as causes of adrenal hemorrhage in utero; however, the etiology is not well-understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/57\">",
"     57",
"    </a>",
"    ]. The right adrenal gland is involved in 75 percent of cases, possibly due to the relatively shorter adrenal vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key to the diagnosis of adrenal hemorrhage is the change in appearance over time. The initial appearance is that of an echogenic and solid-appearing lesion. Subsequently, a hypoechoic central region develops, and then a more cystic appearance and a decrease in size are observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Dystrophic calcifications may be present.",
"   </p>",
"   <p>",
"    In the latter stages, differentiation from neuroblastoma may be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/57\">",
"     57",
"    </a>",
"    ]. Since neuroblastomas may also regress in utero, it is important to obtain postnatal follow-up in fetuses with presumed adrenal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastoma is the most common neoplasm of the fetal adrenal gland. It is usually identified in the third trimester at a mean gestational age of 36 weeks, and is typically right-sided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/60\">",
"     60",
"    </a>",
"    ]. The retroperitoneal mass can be cystic, solid, or of mixed echogenicity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51604 \" href=\"mobipreview.htm?32/47/33520\">",
"     image 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The mass will typically displace the adjacent kidney inferiorly and laterally. Metastases (liver, placenta) and hydrops have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous regression occurs in up to 40 percent of cases, but peripheral calcification may persist. Fetal magnetic resonance imaging is useful for detailed anatomic characterization of the tumor and extent of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be maternal symptoms of hypertension, tachycardia or preeclampsia, which result from elevated catecholamines, and correlate with a more advanced stage of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/65\">",
"     65",
"    </a>",
"    ]. Prenatally detected neuroblastomas generally have a favorable outcome and surgical resection is usually curative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Prenatal diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18586?source=see_link\">",
"     \"Treatment and prognosis of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subdiaphragmatic extralobar pulmonary sequestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 15 percent of extra-lobar pulmonary sequestrations occur below the diaphragm; there is a 4:1 left sided predominance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52061 \" href=\"mobipreview.htm?16/19/16689\">",
"     image 13",
"    </a>",
"    ). Features that help distinguish sequestration from neuroblastoma are that sequestration is left-sided, found earlier in the pregnancy (in the second trimester) and is more echogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/44/32456/abstract/60\">",
"     60",
"    </a>",
"    ]. Visualization of a feeding vessel arising from the thoracic aorta and extending below the diaphragm to the mass strongly favors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ECHOGENIC MASSES IN THE RENAL FOSSA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Congenital mesoblastic nephroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital mesoblastic nephroma is the most common primary renal neoplasm in utero. Sonographically, it appears as a large solid vascular mass in the renal fossa. Heart failure and polyhydramnios are common due to arteriovenous shunting. Prenatal diagnosis, differential diagnosis, and management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12500?source=see_link\">",
"     \"Prenatal diagnosis of congenital mesoblastic nephroma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dysplastic kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased echogenicity in one or both renal fossae suggests the possibility of a dysplastic kidney. Increased echogenicity is relative to the surrounding structures and presumably due to abundant fibrous tissue or numerous tissue interfaces from tiny cysts. Amniotic fluid volume may be normal, decreased or absent, depending on the extent of renal involvement. A detailed description of the prenatal diagnosis, differential diagnosis, and management of cystic kidney disease can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15737?source=see_link\">",
"     \"Prenatal sonographic diagnosis of cystic renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The identification of echogenic lesions in the fetal abdomen should prompt a detailed survey for additional findings and review of the maternal history. In some cases, fetal karyotyping may be indicated. In utero diagnosis can often be made with careful evaluation of the lesion location, echotexture, associated calcifications, additional findings and evolution over time.",
"     </li>",
"     <li>",
"      Due to the association of echogenic bowel with fetal abnormalities and growth restriction, the following are recommended when echogenic bowel is identified in the second trimester: genetic counseling, consideration of karyotype analysis, evaluation for fetal viral infection, and cystic fibrosis testing of the parents (with subsequent fetal testing if parents are carriers for the mutation). In addition, serial fetal growth ultrasounds and antenatal testing in later pregnancy are recommended.",
"     </li>",
"     <li>",
"      Once meconium peritonitis or meconium ileus have been diagnosed, serial fetal sonography is recommended. Due to the association with postnatally diagnosed fetal anomalies, delivery at a center with a newborn ICU and pediatric surgery is suggested.",
"     </li>",
"     <li>",
"      When peritoneal calcifications are seen in conjunction with other bowel findings, a bowel obstruction and perforation are likely. Postnatal surgery will often be needed.",
"     </li>",
"     <li>",
"      Fetal gallstones are usually an incidental finding at third trimester ultrasound carried out for another indication. If no other abnormalities are seen, a single postnatal ultrasound may be indicated to confirm expected resolution.",
"     </li>",
"     <li>",
"      Once the antenatal diagnosis of an intrahepatic solid lesion has been made, it is important to document lesion vascularity, portal vein patency, and any signs of hydrops. In cases of discrete, small, uniform, non-calcified lesions with no associated abnormalities, sonographic follow-up to document change, if any, in the above factors is recommended. Any substantial increase in size",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      change in vascularity should prompt close follow-up. Signs of hydrops, depending on gestational age, should prompt consideration of in utero treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delivery at a tertiary care center.",
"     </li>",
"     <li>",
"      When an echogenic mass is seen in the adrenal region, it is important to determine if it is renal or adrenal or represents a sequestration. When a mass identified at routine fetal survey (18 to 22 weeks of gestation) is uniform and left sided, consider subdiaphragmatic extra pulmonary sequestration the most likely cause. If the mass is uniform with a central cystic portion, right sided or bilateral, then adrenal hemorrhage is most likely, particularly if follow-up shows rapid resolution. In both cases, management is expectant.",
"     </li>",
"     <li>",
"      If an adrenal mass identified after 34 weeks is right sided with cystic spaces, consider neuroblastoma and assess carefully for liver metastases.",
"     </li>",
"     <li>",
"      If a highly vascular mass is identified later in pregnancy and is not clearly separate from the kidney, this is likely a mesoblastic nephroma. Close expectant management should be advised with resection in the neonatal period. Fetal renal tumors have an excellent oncological outcome, but a high risk of perinatal complications. Delivery at a pediatric tertiary care center is highly recommended in cases of prenatal diagnosis to avoid a potentially life-threatening condition in neonates in the first hours of life.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/1\">",
"      Fakhry J, Shapiro LR, Schechter A, et al. Fetal gastric pseudomasses. J Ultrasound Med 1987; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/2\">",
"      McNamara A, Levine D. Intraabdominal fetal echogenic masses: a practical guide to diagnosis and management. Radiographics 2005; 25:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/3\">",
"      Corteville JE, Gray DL, Langer JC. Bowel abnormalities in the fetus--correlation of prenatal ultrasonographic findings with outcome. Am J Obstet Gynecol 1996; 175:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/4\">",
"      Al-Kouatly HB, Chasen ST, Streltzoff J, Chervenak FA. The clinical significance of fetal echogenic bowel. Am J Obstet Gynecol 2001; 185:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/5\">",
"      Sepulveda W, Sebire NJ. Fetal echogenic bowel: a complex scenario. Ultrasound Obstet Gynecol 2000; 16:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/6\">",
"      Tan HH, Tan VC, Yeo GS. A case series of gastrointestinal abnormalities in fetuses with echogenic bowel detected during the antenatal period. Ann Acad Med Singapore 2003; 32:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/7\">",
"      Berlin BM, Norton ME, Sugarman EA, et al. Cystic fibrosis and chromosome abnormalities associated with echogenic fetal bowel. Obstet Gynecol 1999; 94:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/8\">",
"      Scioscia AL, Pretorius DH, Budorick NE, et al. Second-trimester echogenic bowel and chromosomal abnormalities. Am J Obstet Gynecol 1992; 167:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/9\">",
"      Nyberg DA, Resta RG, Mahony BS, et al. Fetal hyperechogenic bowel and Down's syndrome. Ultrasound Obstet Gynecol 1993; 3:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/10\">",
"      Strocker AM, Snijders RJ, Carlson DE, et al. Fetal echogenic bowel: parameters to be considered in differential diagnosis. Ultrasound Obstet Gynecol 2000; 16:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/11\">",
"      Goetzinger KR, Stamilio DM, Dicke JM, et al. Evaluating the incidence and likelihood ratios for chromosomal abnormalities in fetuses with common central nervous system malformations. Am J Obstet Gynecol 2008; 199:285.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/12\">",
"      Leung WC, Waters JJ, Chitty L. Prenatal diagnosis by rapid aneuploidy detection and karyotyping: a prospective study of the role of ultrasound in 1589 second-trimester amniocenteses. Prenat Diagn 2004; 24:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/13\">",
"      Sepulveda W, Hollingsworth J, Bower S, et al. Fetal hyperechogenic bowel following intra-amniotic bleeding. Obstet Gynecol 1994; 83:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/14\">",
"      Yaron Y, Hassan S, Geva E, et al. Evaluation of fetal echogenic bowel in the second trimester. Fetal Diagn Ther 1999; 14:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/15\">",
"      Sepulveda W, Reid R, Nicolaidis P, et al. Second-trimester echogenic bowel and intraamniotic bleeding: association between fetal bowel echogenicity and amniotic fluid spectrophotometry at 410 nm. Am J Obstet Gynecol 1996; 174:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/16\">",
"      Simon-Bouy B, Satre V, Ferec C, et al. Hyperechogenic fetal bowel: a large French collaborative study of 682 cases. Am J Med Genet A 2003; 121A:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/17\">",
"      Muller F, Dommergues M, Aubry MC, et al. Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome. Am J Obstet Gynecol 1995; 173:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/18\">",
"      Ghose I, Mason GC, Martinez D, et al. Hyperechogenic fetal bowel: a prospective analysis of sixty consecutive cases. BJOG 2000; 107:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/19\">",
"      Sepulveda W, Nicolaidis P, Mai AM, et al. Is isolated second-trimester hyperechogenic bowel a predictor of suboptimal fetal growth? Ultrasound Obstet Gynecol 1996; 7:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/20\">",
"      Al-Kouatly HB, Chasen ST, Karam AK, et al. Factors associated with fetal demise in fetal echogenic bowel. Am J Obstet Gynecol 2001; 185:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/21\">",
"      Gonz&aacute;lez R, De Filippo R, Jednak R, Barthold JS. Urethral atresia: long-term outcome in 6 children who survived the neonatal period. J Urol 2001; 165:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/22\">",
"      Jaramillo D, Lebowitz RL, Hendren WH. The cloacal malformation: radiologic findings and imaging recommendations. Radiology 1990; 177:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/23\">",
"      Dirkes K, Crombleholme TM, Craigo SD, et al. The natural history of meconium peritonitis diagnosed in utero. J Pediatr Surg 1995; 30:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/24\">",
"      Konje JC, de Chazal R, MacFadyen U, Taylor DJ. Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Ultrasound Obstet Gynecol 1995; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/25\">",
"      Foster MA, Nyberg DA, Mahony BS, et al. Meconium peritonitis: prenatal sonographic findings and their clinical significance. Radiology 1987; 165:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/26\">",
"      Bronshtein M, Blazer S. Prenatal diagnosis of liver calcifications. Obstet Gynecol 1995; 86:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/27\">",
"      Achiron R, Seidman DS, Afek A, et al. Prenatal ultrasonographic diagnosis of fetal hepatic hyperechogenicities: clinical significance and implications for management. Ultrasound Obstet Gynecol 1996; 7:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/28\">",
"      Blanc WA, Berdon WE, Baker DH, Wigger HJ. Calcified portal vein thromboemboli in newborn and stillborn infants. Radiology 1967; 88:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/29\">",
"      Yamashita Y, Iwanaga R, Goto A, et al. Congenital cytomegalovirus infection associated with fetal ascites and intrahepatic calcifications. Acta Paediatr Scand 1989; 78:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/30\">",
"      Stein B, Bromley B, Michlewitz H, et al. Fetal liver calcifications: sonographic appearance and postnatal outcome. Radiology 1995; 197:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/31\">",
"      Simchen MJ, Toi A, Bona M, et al. Fetal hepatic calcifications: prenatal diagnosis and outcome. Am J Obstet Gynecol 2002; 187:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/32\">",
"      Shih JC, Tsao PN, Huang SF, et al. Antenatal diagnosis of congenital hepatoblastoma in utero. Ultrasound Obstet Gynecol 2000; 16:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/33\">",
"      Foucar E, Williamson RA, Yiu-Chiu V, et al. Mesenchymal hamartoma of the liver identified by fetal sonography. AJR Am J Roentgenol 1983; 140:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/34\">",
"      Horgan JG, King DL, Taylor KJ. Sonographic detection of prenatal liver mass. J Clin Gastroenterol 1984; 6:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/35\">",
"      Platt LD, Devore GR, Benner P, et al. Antenatal diagnosis of a fetal liver mass. J Ultrasound Med 1983; 2:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/36\">",
"      Pott B&auml;rtsch EM, Paek BW, Yoshizawa J, et al. Giant fetal hepatic hemangioma. Case report and literature review. Fetal Diagn Ther 2003; 18:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/37\">",
"      Morris J, Abbott J, Burrows P, Levine D. Antenatal diagnosis of fetal hepatic hemangioma treated with maternal corticosteroids. Obstet Gynecol 1999; 94:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/38\">",
"      Gembruch U, Baschat AA, Gloeckner-Hoffmann K, et al. Prenatal diagnosis and management of fetuses with liver hemangiomata. Ultrasound Obstet Gynecol 2002; 19:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/39\">",
"      Chuileannain FN, Rowlands S, Sampson A. Ultrasonographic appearances of fetal hepatic hemangioma. J Ultrasound Med 1999; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/40\">",
"      Schmitz R, Heinig J, Klockenbusch W, et al. Antenatal diagnosis of a giant fetal hepatic hemangioma and treatment with maternal corticosteroid. Ultraschall Med 2009; 30:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/41\">",
"      Chou SY, Chiang HK, Chow PK, et al. Fetal hepatic hemangioma diagnosed prenatally with ultrasonography. Acta Obstet Gynecol Scand 2005; 84:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/42\">",
"      Cabrita SV, Gon&ccedil;alves S, Rodrigues H, et al. Antenatal diagnosis of congenital hepatic hemangioma: a case report. Cases J 2009; 2:6829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/43\">",
"      Yoon HS, Lee JH, Moon HN, et al. Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine. J Pediatr Hematol Oncol 2009; 31:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/44\">",
"      Petrikovsky B, Klein V, Holsten N. Sludge in fetal gallbladder: natural history and neonatal outcome. Br J Radiol 1996; 69:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/45\">",
"      Petrikovsky B, Klein VR. Cholecystomegaly and fetal gallstones. Prenat Diagn 1995; 15:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/46\">",
"      Brown DL, Teele RL, Doubilet PM, et al. Echogenic material in the fetal gallbladder: sonographic and clinical observations. Radiology 1992; 182:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/47\">",
"      Kiserud T, Gjelland K, Bogn&oslash; H, et al. Echogenic material in the fetal gallbladder and fetal disease. Ultrasound Obstet Gynecol 1997; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/48\">",
"      Suma V, Marini A, Bucci N, et al. Fetal gallstones: sonographic and clinical observations. Ultrasound Obstet Gynecol 1998; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/49\">",
"      Richards DS, Langham MR, Anderson CD. The prenatal sonographic appearance of enteric duplication cysts. Ultrasound Obstet Gynecol 1996; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     Wrenn, EL, Hollabaugh, RS. Duplications of the digestive tract. In: Pediatric Surgery, Ashcraft, KW, Murphy, JP, Sharp, RJ, et al (Eds), WB Saunders, Philadelphia 2000. p.556.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/51\">",
"      Laje P, Flake AW, Adzick NS. Prenatal diagnosis and postnatal resection of intraabdominal enteric duplications. J Pediatr Surg 2010; 45:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/52\">",
"      Segal SR, Sherman NH, Rosenberg HK, et al. Ultrasonographic features of gastrointestinal duplications. J Ultrasound Med 1994; 13:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/53\">",
"      Kangarloo H, Sample WF, Hansen G, et al. Ultrasonic evaluation of abdominal gastrointestinal tract duplication in children. Radiology 1979; 131:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/54\">",
"      Gerscovich EO, Jacoby B, Field NT, et al. Fetal true pancreatic cysts. J Ultrasound Med 2012; 31:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/55\">",
"      Gupta P, Sharma R, Kumar S, et al. Role of MRI in fetal abdominal cystic masses detected on prenatal sonography. Arch Gynecol Obstet 2010; 281:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/56\">",
"      Sherer DM, Dalloul M, Wagreich A, et al. Prenatal sonographic findings of congenital adrenal cortical adenoma. J Ultrasound Med 2008; 27:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/57\">",
"      Schw&auml;rzler P, Bernard JP, Senat MV, Ville Y. Prenatal diagnosis of fetal adrenal masses: differentiation between hemorrhage and solid tumor by color Doppler sonography. Ultrasound Obstet Gynecol 1999; 13:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/58\">",
"      Rahman S, Ohlsson A, Fong KW, Glanc P. Fetal adrenal hemorrhage in a diamniotic, dichorionic twin: case report and review of controversies in diagnosis and management. J Ultrasound Med 1997; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/59\">",
"      Schrauder MG, Hammersen G, Siemer J, et al. Fetal adrenal haemorrhage--two-dimensional and three-dimensional imaging. Fetal Diagn Ther 2008; 23:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/60\">",
"      Curtis MR, Mooney DP, Vaccaro TJ, et al. Prenatal ultrasound characterization of the suprarenal mass: distinction between neuroblastoma and subdiaphragmatic extralobar pulmonary sequestration. J Ultrasound Med 1997; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/61\">",
"      Heling KS, Chaoui R, Hartung J, et al. Prenatal diagnosis of congenital neuroblastoma. Analysis of 4 cases and review of the literature. Fetal Diagn Ther 1999; 14:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/62\">",
"      Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 2002; 94:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/63\">",
"      Tom&agrave; P, Lucigrai G, Marzoli A, Lituania M. Prenatal diagnosis of metastatic adrenal neuroblastoma with sonography and MR imaging. AJR Am J Roentgenol 1994; 162:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/64\">",
"      Blackman SC, Evenson AR, Voss SD, et al. Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther 2008; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/65\">",
"      Jennings RW, LaQuaglia MP, Leong K, et al. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg 1993; 28:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32456/abstract/66\">",
"      Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993; 92:358.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6810 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32456=[""].join("\n");
var outline_f31_44_32456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHOGENICITY IN THE GASTROINTESTINAL TRACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastric pseudo-mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Echogenic bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bowel calcifications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PERITONEAL CALCIFICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Meconium peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meconium pseudocyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LIVER CALCIFICATIONS AND CALCIFIED LIVER LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surface calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intrahepatic calcifications without a mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intrahepatic calcifications with an associated mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NON-CALCIFIED ECHOGENIC LIVER LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mesenchymal hamartoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FETAL GALLSTONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ENTERIC DUPLICATION CYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ECHOGENICITY IN THE AREA OF THE FETAL ADRENAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adrenal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subdiaphragmatic extralobar pulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ECHOGENIC MASSES IN THE RENAL FOSSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Congenital mesoblastic nephroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dysplastic kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6810|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/16/24833\" title=\"diagnostic image 1\">",
"      Gastric pseudomass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/12/32960\" title=\"diagnostic image 2\">",
"      Echogenic bowel1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/11/18610\" title=\"diagnostic image 3\">",
"      Cloacal malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/56/43904\" title=\"diagnostic image 4\">",
"      Meconium peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/6/44129\" title=\"diagnostic image 5\">",
"      Peritoneal calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/25/22929\" title=\"diagnostic image 6\">",
"      Meconium pseudocyst 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/2/42016\" title=\"diagnostic image 7\">",
"      Liver calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/63/28656\" title=\"diagnostic image 8\">",
"      Echogenic liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/10/11425\" title=\"diagnostic image 9\">",
"      Fetal gallstones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/20/20802\" title=\"diagnostic image 10\">",
"      Gastric duplication cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/12/20673\" title=\"diagnostic image 11\">",
"      Duplication cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/47/33520\" title=\"diagnostic image 12\">",
"      Neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/19/16689\" title=\"diagnostic image 13\">",
"      Sequestration ultrasound",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36166?source=related_link\">",
"      Fetal echogenic bowel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12500?source=related_link\">",
"      Prenatal diagnosis of congenital mesoblastic nephroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15737?source=related_link\">",
"      Prenatal sonographic diagnosis of cystic renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18586?source=related_link\">",
"      Treatment and prognosis of neuroblastoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_44_32457="Left phrenic nerve course";
var content_f31_44_32457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52752%7ESURG%2F52959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52752%7ESURG%2F52959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Course of the left phrenic nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 604px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Course of the right phrenic nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 603px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJbAgsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKr3NytvNAr8LKSgP8AtYyB+PNWKo6zaG806WOPiZcSRH0deV/UUpXtoONr6loSqe9ODisGyvBdQJKuV3DlT1U9wfocirayn1rFVrmrpWNTcKXIrPEh9ad5retX7RE+zZezRVHzmpRcGn7RC5GXaKrrNmpBJVKSZNmSUU0OKdTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFIWA6mgBaKRGDqGHQ9KWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOZvYTYa0+0YgvAZF/2ZB94fiMH8DVhHqXxZGTpDXCfftXWcfQcN/46TVBJMgEHg1xVVyTO2m+eFzQV6fv4qkj1KH4pKQOJMWpA9Ql6TfRzBylpXFTo9ZwcinrNjvVKpYlwNEN71IkmKz1uBT1nHrWimZuBpBwaN4qisvvT9+a05yOQteYKUMKqg04GmpicCzuFGRUG40u40+YXKTbhRuqLdRmi4WJd1JmmZpC1FxWJM0ZqPdS7qLhYcWwKyNZuGSOJckJJNHG5H90sAa0JJMCsvUoxc28sTEgOMZHUHsfwrOpLQ2pR11N4AAADoKKzdAvmv9OV5sC4jYxTAdnHX8+D+NaVappq6MZJxdmFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARXkIuLSeFukiMh/EYrjNHkMmmWrN97y1B+oGK7iuF0X/kHx+zMP/HjXJilsdeF2ZpKalB4qFe1SrXOjdiPmmhjUu3NQ3IKxtt5bGSB1C5GT+GaJOycuwaDDcLzjJwccdz6UNJxzxWRHdve3kbWqbNPgJJlYY8xsEYX2561ENbhvpZItN/fCM4Z/wCHP17/AIVzYepOceappfZC0uar3BB4NNF0w71Thk3xgnrSseK6LtFWTNCO+PrVuK+HHNc4r4ZsE4B61Ksh9c1SqNCdNM6hLtT3qZbhT3rlVnYd6lS7Yd60VUzdI6kTKe9OEo9a5pb1vWpBfH1q1VRDos6ISj1pfMB71zpvj60ovznrT9qheyZ0W/PekLgd6w0vie9ON4T3pe1QeyZrmUDvUclyoHWshrk+tQSXBPepdYpUjQnvfQ1VN0W6mqDSZPWmh8msnNs2ULGp4clMevXkI+7PCs2P9pTtP6FfyrqK5Hwypl8Qzyj7sFsEJ92bP8lrrq7KHwHJiPjCiiitjAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA8DnpXCaGc6Xbt/eBb8yT/Wux1SX7Ppt3NnHlxO/5AmuT0uPy9Ptk6FYlB/KuPFPVI7MMtGy0siGTyw6+YBnbnnH0qWCWOXd5bq+04O05wa8O8A6dpdjYJB4p8J6rdeL47i5e7vhp0jtNkv8AOtwBhkKEKFDcnjHernwu0v7N8VtWvNJ0me10WbTfLjkGkvpsULCbIiaNgPNk2kZk46e9Z8lrmnPse2gU22ligjvNQuSFjGY1J/ur1/M5/IVxurweKtOsJJ28TWDNkIi/2TjcxOAP9b6n8qzoNdbSYbaLxBrltqcsnlxWtnBa+VtkJ6t87ZJJHXpg4qKuJjho8zV29kS4SqaJF3xBc3N7p093qbf2dpI4WBTmSUehxwAfQdasaFD9n09ZfJETP83ljoq4GB9cAVi6hHcXl3Lq2szAaTC7NbRscL1wGx+H61Y0rxI1/drALaVbcglHIAL46nHXFcdCMub2tZ+9LZdvQpaaI3ynGUwV9GFV5AR1SP8APNaKKHiDKcqeQRVG6QhT9a65NmsbMbGw3Ek9hmnE4YH8Kpq22Rh9DU0ZzyOai5pylgGimjNLkii4rDqXcaj3e9Lup3FYfuNG6mZoBouFiVXIqUS8VVzTgaLisTmQmoyxoAzSSMkSFpXVF9WOBSuNIUZNLK628JkfJPRVHVmPQD3NJbNNdY/s+1mus8B1G2MfVjx+Wa6LRtBME63epOs10PuIv+rh+nqfetadKUyKlSNPcs+G9OfT9P8A9IwbuZvNmI7Mf4R7AYFa1FFejGKirI8yUnJ3YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeW/Hj4gX3grTNNg0KfTYtXvGmlX+0GCxeTDEzuOSPmY7FUdy1epVi33hbRL/xBHrd9p8VzqUdsbRJJiXVYi24gITsBz/FjPbOKAOHv/i9Attpsuk6Lc6n9s0R9d/d3EcYjiTG9SW/iHI4zyKzdJ+MF3c6xrV3caSF8MWWiW+srIrj7QiSRNJhhnDEkBQBjB5JxXaab8NfCemxLFZaUYo1s59PVftMxC28zl5Ixl+AWJPqO2KSH4a+FIbmCaLTGQxWA0zYLqby5LYIUEcibtsgCsQCwJ75yAaAORX43Wo0y8upPD2ol4GtQiRsNs3nvtAV2CjcpIyOnPBI5qxrfxOm8O6pqUuu6ffW4t9Ntp10oeS7iWa5eFR5qsQSdoJ5wB78V0dt8MPCsFmbQ2d5NbbomWO41G5lEflNujCbpDtAPOBgHvmnTaJ4P8bz67LJbxalIf+JNqBLyDBhfeI8ZADKz53LzkjnigDAvPi4lks9tceHr06zb6xb6NJYxTxtmSdC8bLISFIIHfbg9cV0Pjbxt/wAIh4PtNc1PSrkPK8Mc1srhvsrOOfMdcjap4LDPbGc06y+HPheztoIY9OeTydQj1USzXUskrXScJI8jMWfHoxI9q2/EGiWev2S2t+bpY0kEqva3UtvIrAEZDxsrdCeM4oA4fS/ik2t3NnaeHtDbVbyWxbUZFt7+HykiErRDbIThmLIflwMd8Gkm+LFpH44i8NmwZnnuZbJLmCcSqkqKWw4Awp46BiR3ArSk+FHg421nBHpctutrE8CPbXs8LtG7F3R3VwzgsSTuJ5NWYPhr4Vh1watHp8ovRdyXyf6ZP5aTuCHdY9+wFsnPHP4CgDzjw98cWtfCPh86vY3Gqa7d6Y2p3H2dQgMYmeMBQAcudhwMAcdRmulvfjBBbX7qPD9+2nRXtnZTXZljUxtcxo6fuyd3G8AjtW8/wu8JfY9NtoNOntU06Fra2e1vp4ZViZizRmRHDspJJwxNXJvh/wCGZop45dN3JPc293IPtEvzSwKqxN97+EIox0OOc0Ac3pHxcsdV8XpottpV68D301gLtQWCvGSCzLjAQlSAdxPTIFem1y1r4C8P2mvvrNrbXMN3JcNdukd7MsDTN1kMIfyyxz12+/Wrmja8bnUJNL1W2+wavGC4iLbkuIwceZE+BuXkZGAyk8jkEgG7RRRQBjeL5Nvh+5Qfem2wj33MF/kTWUgwABV3xY4d9Otu7SmY/RF/xZaprXBiHedjvw6tAeKsRiq61M0iQxPLKwSNFLMx6AAZJrOJozj/ABzfFtRgtFPyW8ZmfB6u+VX8lD/99CvNtKt21j4i2MXWO133kp/3R8p/762/nWrqV/Jdme+lJR7tjcEHgomPkX8FVQffNR/CVPOt/FWvdVRVtIWP1DP+gQ1M9YyfZM9arFYbC26v9ToPFN9bPY6Hp9xzbWdql1Oo/jcjCL75O44+lXvCGmnUBNf36bXk+WNB/wAs1HTHvXG6eJNV1555RmBm3Ip7IoCpn32gfrXpWmh4xH5WQo4FZqleq6st9l5I8VaRsXbOLarxmQq69R2+tQXcRwd1woHsOa2oUWWPLqp+oqnNbwqxIjXPriumTTV2hwuYcMQLybQxGAcnv1qwkXtz61ZjCySTZA+UhR+Wf604DkjGQO9Yvc6Y7EaL8o4pjpVpE4PpmlMdFguZroe1M5FaLwZqJ7fPapsO5T3Gng5p7wEdKjCkGgGh4pJZEhjaSQ4VeTSgVe0CzF9raCUZgtUExHq5JC5+mGP4CrjHmdkZSkoptk9hoF9expLdTfYoWGREi5lx7k8KfwNbdl4d0y1cSC3E0w/5aTkyN+vT8K16K9CFGEdkefOtOXUAMDA6UUUVqZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V8WPB+r+Jte32cFxLYx6FfRR+XeeSPtrbDBkB1ycg4J+Ud69VooA+d9V+HvjRfCur2ulx3q3l74d04SeZqW5pNRjmDTjc0hwxUY3cKc4BqfXPDPjbW7LxNdT6XrWntqGr2l3bWtveW0zLEkBDK6GVUdN+NyblySDzjn6BooA+foPCnjJP+EeuPEfhyXVrOPSZbaTSNO1MQLa3hnZllJaUdYyoyrNtOdowBUGr+A/GqRahJZ2s/2OXxXfalNYwzws91bSxoIpMM4RsFWOxyD7V9EUUAcv8ADHTb3SPA2l2Op/bftUIkBF7IjzBTIxQMULLwpUYBOAAM8V1FFFABRRRQAUUUUAFZ+t6RaazZ/Z7xXBVt8U0TlJYX7OjjlWGTyPUg5BIrQooA5jT9Xu9Huo9M8USqzOwS01MJsiucnAR8cJN2xwG6r3VenqC+s7bULOa0voI7i1mUpJFKoZXU9QQetcldX954Hs5W1Ay3/h6IfuroktPZr2WbPLoDgCT7wBG4HBegNyTUJftfiG6kBzHbItuvpu+8381H4U8VnwrcR6PJJBslvJEaYHPyvI2W6+mTXi3wy1XTlsre9lv9Y1L4ihblrnS5buVWlkAf928bfu0QDGDgYOPpXm2525HpXULRPfFrnviDeeToS2isA17IImGefLHzP+YG3/gVebfB/UPEdx428dWeqLfx6ibe0nzflXhtZmRyUCLIcKS2VCn7qckHGbOvDxZrXiV7cX2iyNaH7MhSylVCzYZzzKf9kHntSqWppuTOjBpVKik1otX8jH1231HXLn+zdLUCWQfvJCcLFGOSxPYCug8KQx2fgK10iy3Kb2UR7j95nlYgn8Ezn8Kj1AXvhjw1e6dPeafe6jqFxHZNLawtGYldXZ9xLtnCKxGMYP1rf8H2gu/F2n2igiHSo2kkH/TUgZz9MqP+AGuKhVliJcsfhb/Bat/kjoxdb2yc1stv6+4n8fLY6DdQ2enAJdunmyHaMRR9M+5PYVY0Q6lb2duZbhmM3C7gCN2M4PH8vSub1NJdd8Z393JxaNOEQk/eWP5R+GQTXdQol3aiGJtjRHdG/uP8/rXbG/tZSltsl+vzPJs+W3U2dLuRLbgONkq8Oh6qf896jvWAB5qKAzsALuzV2AwJFIP5d6qXsQycWsh/3pMj8s1rOKtoxwk76oihlBuJNnzLgZx61YjYZxVOD91Od5GSoGFHAq0uCa5nvodsNi0vSpBUMZyoqUdapEMdtHpSMgqQdKQ07E3KzIKrzoAM4q43Wqt2eKlotFMda3fBf/H5qZ9oh/6FWH3rf8Ejc2pSDp5qp+Sg/wDs1a4f40Y4j+Gzp6KKK9E80KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlJq2nR6vFpUl9arqcsRmjtGlUSvGDgsEzkjg847VdrxT4o/D3X/ABX8V7PU9Fu5dJW10QxW+qLgiOcz4ZNuc8xPJ7c0AenQeLvD1w1strrVhcG4uWs4jBOsgadRkx5XPzAEHFX5tWsIdXttLluol1G4jaaK3J+Z0XG5gPQZFeE+C/Afifww1rYaTaXVnp8PjC9uRicbWsTCEidwG+ZSQODzx0rJ0nwb43aeG5i0nWLTXoNC1G0uNRvL9ZRPevjY0R8xioPY4UDj0zQB7/qnizQdKuLqDUdUtrea1SKSdJGwY1kfYhP+83Arbr5eu/AfiTULHX5LHwzq9oLux0uJI7+7SaWWWK5V5juMjEDALckfQZxXU2PhzxrH8V5rzUpdba2/ttrq3ntmRrZrIjAictONqhcgoIicjIJzQB7xRXi3xp0bxXfeLtPu/DNvqt5HHaLELUPssncykszOs8bxuFx821hjGOQarHSPFNrrvi2S80LWdX1ee5vJ9JvV1Mx2K2zQMIoSolUqc/LgKDuIbcMbgAeya1q1homnvfatdRWlojKjSyHCgswVR+JIH41er5mTwf42vvCHiq0uNN1Mi9/sqa2tbmRQBJHPun2KZpNoAA5LAnA4rcn8N+NT8Tbq5uX17yDra3VrcWjI9u1nwPKdmnXYoXcCgjJzyM5oA99or548N+CvHVjo2lPazarb63c+H7+C9lutReVUuyw8jIZ2CnGcFRgV1XwO0bxFpl3ePrya1AGs4YpIb7Z5XnqTuaMieQsTnlsKDxxmgD12iio7iaK3heWeRY4kGWZjgCgCSuS1e8/ti6+zxc6dA+XbtM4PQeqg/mfpRqN/NrDGOAyQacOrcq8/07hf1NCIsaKiKFRRgADAArjrVub3YnZRo8vvS3OYksrnwxmbRYZLnSNxMumoMtAD/FB7DvH05+XBG1t3TL201K1jvbCWOaCUZWRO+OMHuCDkEHkHg1YY1gahpV1a3j6n4eMcd2xzcWjnbDd+5x9yT0cfRgRjHOtdzotY37u4W0sp7mQEpDG0jAegGf6V43qmoXOlWYnSTZeSbpZHH99uSfzNdt4g8Q2+oaD9nti8N3LMsM9tLgSwY+ZldfcDGeQQwIJBBryfx7fhQ+GGE6e+KiolL3We3llJeylOXUu+DpftVv8AbrpvMgsr24upNxyXMcMYA/Fpcf8AAq7TwvPe6Zo15fIc3t0C55wXY5wP++2NcV4NiW3+HdlbyHM99qDSOO+zYjn9RH+Vek6bb+dqGl2bDcsbiaQf7MYzn/vvZWWEi/aSa72MpxXs5zktNf6/rsQeJFs/D8tjYl3eWOFC6qPmY4IH5lTWt4S1Fb+OTIjiZcfu85bGOv8AkVxetXg1fxnfSkbzJMLdSP4I0wGx9SG/Wu7W0hWGF2AVRhCw42+hHoQeB9a6ISdSpK2i2X6nhPSOp1Kfc/CqN+flxTreWVYlVsTAD76nk/UVVvZZCcLC31YgCrnFrQqDV7mc4/fN67QanjXbgDp71Eilp2LsGOB93oOvFTAY9awejOuGqLUfAqZetQRnIqZKtEyJhQaQU40zIjYZqjd/exWg1Z10fnpMuJVkYIjO3RQSa67wjbG20C2LjEkw89/q3P8AIgfhXGXkZmjS3X708iwj/gRAP6Zr0tFCKFUAKBgD0FdGFjduRz4uWiiLRRRXacIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnvxA+J9t4O1i4099G1DUZLbTP7Wne2aJVjgEnlknewJIOOBnr9a9CrmfEPgfQvEF/eXmqW0ktxd6a2lTMsrLm3L7yuAeDu79aAOXPxesYYtQN9omp2ktpPYxGKRomZlu8+U+VcjHByM5FJrvxj0jR7W+mm0+9K2utSaI7sUSMSogcuzlsKhBwM8+1burfDbw1qtvqcN3aSkahHaxzMs7qw+zZ8kqQflK5PI6981Xi+Fvh2DSrjT7Z9XgiuLmS7nkj1OcSTSOio+992WBCjIOeeaAILP4lJqWrQ6bouhX2pXX2KK/ufs9xblII5DhRv8za5wCfkJGOhPSuR0r42x2GniPXoDdanNeX6xrAUhRYYJSi5LH7x6ADqc9K7j/hV3haOWwksbW709rO3SzX7FezQebCp3COTaw3jPPzZJzSSfC7wyUtzbQ3tlc2889xFdWl7LDOjTNukAdWB2sf4Tx6UAdN4a1iHxB4f07V7aKaGG9gSdI5l2ugYZww9RWlVbTLKLTdPt7K3aVooEEatNI0jkDuzMSWPuTmrNABRRRQAVm61Y3t7FF/Z2q3GmzRktujijkWT2dXU5H+6VPvWlWPrWsfZJBa2aCe+YZCk/LGP7znsPbqamUlFXZUYuTsjHvda8QaBCDqtrp2qbjtj+wSNBPKfaF8r9T5mK5ybxfZ3t2h8TNNpBVv3VrfxmKJW7fvT+7kb6MfYV0MVufPe5uHM12/3pG7D0Udh7VO6LIhSRQyMMFSMgiuKpWc9Oh2woqGvUSNlljV42VkYZDKcgj1zTivFYDeD9KSRpdLWfSJicltOlMCk+rRj92x92U06e18SWbbrK/sdShA/wBTexGGRv8AtrH8o/791nyou7NiRaROKwT4na0GNd0jUdOA6zCP7RD9d8W4qPdwtaumalYapb+fpl7bXkGceZBKsi59Mg0mrFqSZ5v8SYRe+I/tFpILa806AIk4H3i3zFHH8SY28dskjB5rxjVbyTWNSj02VDFdTzLCUByNufmZT3HX39QK9Q8S6isgvLpW+Wd3mBPdc/L+mPyrgfDWinV9csZJpJosJJPC0TbWUg435/3iRg8HByDUcyvqfRxp+ypRhHd9PzPRbK2RY9OixxHdXBwPTZD/AExXZ6dfpp1tfatKu5lhZI0x6cn8zj8q5UKY7i1UtuxNdfNjGcLAuf0rb09f7Uu9M08/6lyLi49Ag+Y5+uQPxqcHvp3f5nPilGVCV9rv8ypoejf2RHBNeAmeVQ/I555/M9TXbaTdi4Q4AZWOCK861HW5/E/ioojlbSSbEaJwfKXufrgn8fau9sof7NulBX92OGIH8J6N+B4NbRam3ybL8T5xt6XOgFrGBkJj/d4/lWfdW6bsncfYsTWyhDR5BBB6EHrWfeDLcVUm7FxMlXbzZNuAN2wDHp/k1OCT16iookOWYcgyMc/iamIyc1gzqhsTx9BVhKrJVmOqRMiQU49KbTqozGNWdc/fNaL9DWbcN8xqWXEXSohNr2nIeiyNIf8AgKnH6kV31ecLLPb3UF1aYM8JJCt0cHgqfr6122j6tbarCWgJWVOJIX4dD7j+tdeFkrOPU5MXCV1LoaNFFFdZxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRQTgc1zGpatLqJe20xjHbA7ZLodW9RH/8AFflUTmoK7LhTc3ZE+saw7yNZaU4M4OJZ8ZWH2929u3es+1t0t4yqbmZjl3Y5Zz6k9zTreGO3hWKFAka9AKlArgnUc3dnfCCgrIOtOAoApwFSkO4oFI1O7V434i1abUvihr2ka14suvDOm6bZQzWKwTpB9pLqS8rMwO8Kfl29OPrVqNyXKx68a5jxlpOltpOoX01jB9s8llW4Rdku4jC4dcMOSO9eb6trV/pvxFhnvPENze6TdalaWlraadqcYdGKLu823KElWYEnDAgH3Fdd8SNb1K3szaLoV08LzgLMLiECQL82QC+Ryo6ilKLia4e1SootdTzZ9Me+vbPQbKSZ/Ofyg0jl2EY6ksecAZ61ueFreOTxNrE8KgQW2y0gA6BU/wDrirfgO4GlifX9bsJbQSyRWdoZHRt5d9rbQCe+P1q34c04aTBfxEnK3U2Sepw5Gf8Ax3P415santK8l0X59f0PfjUVXEWjtFaFeYHMLjkDzyP+BzKn/sn6VYa9ay0vVZIf+Pi6xZQ+ynIb9M/lVaVvKtNM7k26yMPTc0sn9RWfezNJ5ccUkaJZ5EjsM/OcZwO56fnW9GrGlDnl3f4s58XL/Zn5v9bnR+BNANvILiQb5SQoI6KO9ejXNs05jkhZVkT16MPQ1x/g7Upktw1zGpjHy7l4IHqRXb27BuVOVNdcHa1jwHqM3NGmHtwD32YqnIQ7HEB/4FWjcDAzVPG4H3FOU2XGKIYkxGM/WkK1Mg+QdaY3WsZHRF2EQVYjqFOtTqKEKRIKXtSUjNirMxszYWsmZssauXUnas92yaiRrBDo/vVM0CSssgZ4p1+7LG211/Gktk3c1aEZBGOlJIqTWxcsPENzaERarG08Q4FzCvP/AANR/MflXR2V/aX0ZezuIplHXYwOPr6Vywj9ary6fDJIJVDRTjpLExRx+IrqhXlHR6nJPDwlrHQ7qiuPtr3V7TAS5ivIv7twu1h/wJf6itBPEgjIF7p91F6vGBKv6c/pXRGvB+Ryyw81tqdBRWZba9pVwcR38Ab+67bG/I4NaSMrqGRgynoQcitVJPYycWt0LRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHcTRW0DzTyLHEgyzMcACoNS1C306DzLl8E8Ig5Zz6KO5rmJWudTmWfUQFjU5itQcqnu395v0HasqlVQ9TWnSc9eg++vZta3KPMg009F+68/ufRfbqf0p6KqIqooVVGAAMACnUtcEpOTuzuilFWQgpwpKeo5oSAVRTwKBS1dhXGt0rN1PRdL1V4n1TTbK9eI5ja4gSQp9NwOK0WNIKQGemhaQmp/wBpLpdguo9PtQt083pj7+M9OOtcx42tZtW8QWGnxHZHHCZZZOyKzck/98EfjXaXEywxlmyT0Cjqx9BXM69qcWmoyPELvUrv5Vt0Gd3op/2Rz+vrXn4/FeyjyR+J/wBXN8NN0580dzy34o2s97bWBjcwadbSxx6dADzK27/Wt7cZFdrq5QQX91Hwk0X2lPo0Y5/PNcJrBvdS8cWMGoSeZcRO0jop+SPGAAB6cmuu1YhfCkwH/LGKezPsF+eMf98GufDpwVNvrdff/wAN+J6eHi4qNTvdf180Y2v3K213Kg4WGKCNc9gsUZ/q1HhjSzdeVLIhd5P3rK3OCef61Q15GvvE0tsvHntETnuphQ/yzXVWMn9mXRk08l7eNRuLnIds/wAPoP0rpoVIqNODV3a/ocuNn+6hBdrnQ6ZZPp08KMg8iY42+hroNNRoMws20L90EcH3FUbB5tR8i5njWOFRuRA24knufatxcBeQD7GvRi7Hl2uQXLt0+X86rgnbjIyfSo9Xu4LC0lurkARxjJwOT6Ae5PFcRF8SLQ3QRLKRlJwMPz+WMZ/H8aylOKZ20cNVqq8Fc9CAGKicdadazJc20U8edkiB1yMHBGRTnUUMyWjsQoOanXpUajmpBUobFJqNj1pzGopDgUySncNkmqbnmrUxyaqty4FSzaJq2Mf7sE1bKgCorUYjWp26VoloYyeomM0hWpUGQKeFppE81iACnAVZCD0o8sVXKLmKskMcoxLGkg9HUGoF0y1Rt1sJLV/71u5j/QcVoeXRsxSSaFzEaTapbgfZ7yO4Ufw3MfJ/4EuP5GrMXiARcanaS2v/AE0X95H+Y5H4io9po5rSNSS6mbhGW6Ny2uIbmISW8qSxnoyMCKlrlXso/M8y3Z7Wf/npCdufqOh/GrdtrE9owj1ZA0XQXUY+X/ga/wAP16fSt4Vk9GYyotfCb9FIrBlDKQVIyCOc0tbmAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFISFBJIAHJJoAWsnV9ZjspBbQIbi9YZEanAUerHsP1NUL7XJLx2g0c4iBw92RkfRB3Pv0+tVLW2jtlYJuLMdzuxyzn1J7muarXtpE6adDrMbFA73DXd5J5143Bb+FB/dQdh/OrFFLXHvudSDFApCaAaZVhwqVajWpBVIljqDSZppam2SkNY80ZppNNJxU3KsY+o6mLdppCrPJG4hgjH8TEdfr/T61nW1sNJim1HU2E2oy56DlQeiKP8ACryCFrv+03jy7DFugyS2RjfjpuIH4Dr7Vr652XKW6AT6ncERALysIYgcn05ye5/l8rXcq9eUYe9d/wBL0NE+VHlvhjzNQ8Z6nqEwwwYIo/AMf/Qq6nU7d59M1e2jPzvB9oT0yg2v+JVsfhWb4Vslsr7VFDmUR3c6+YRjdtkK5/IVq6hqaaRNDeS8wRNmcYzmM5VuP+BZ/CvcnSapcsd1b70e8qb9hGMd7J/qc1e2rHVNOuZ+BLp9ueuNzbAp/wDQf1rt9F003cKoRtVU4OMAnHFQXOmpbppqySI0EUbLHISMGMOSpz/usta48S6BYIFOp2zMBysTeaw/BcmrwcoypKS/qzPCqKVWbsrkGoeJ9P8ADAjs7xZ5HVA5WJAfLUkgZJI4yDXLeI/FutX2uXdtotyIdPiVNjRhQ77kVsksDj72OMdKwvGes2msazqsls7NBJDGkTsjJuKjPQgHqTVPwlO9yLl5BhgVTrnO1QoP44zXtZXyVK0uZJ2X6ozzfCPDYSnUjdNuz+64s3iTW3tL/TNQuzcxYRw0mC6FZEPDADP40zWDs0+OWPKsxUuRxkVna7Othq1wZFJSZNvHY5Bz+lXJbuC50xYmJU7MAkcGsM7hGGIXKrJpHq8LOU8I+Z3tJ/kj3HwtKJfDmmP620YP1CgGtUjIry/4aeLLW209NM1W4EDqx8iSThCD/CW6A5yecdcCvTw2RxXHCSkrnJi6EqNVxkhmKTNONMJpmAGq8zVKzYWqcrZoBLUikOTUcS7phTmNT2MeW3GpWrNG7I0rcYXFTGmRjFSYBrU52EfBqYVEBipFpolkq08CkXpS5rUgdikIpN1JmgVhcUmKWlFFguMK0wjghhlTwQanK0xlqWrAmVLWd9FYkbn0wnLIOTB7r/s+o7dq6WN1kRXjYMjDIIOQRWGB2PSotLn/ALLvEtGz9iuG/dE/8s3/ALv0Pb3ralUt7rM6sObVbnR0UUV0nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVW1C/ttPgMt3KsadBnqx9AOpPtXO3mq32oLttlawtz1dsGZh7Dov6n6VnOrGG5pClKextanrFpp52SuZLgjKwRDc5/DsPc4Fc9dS3eqvuv28q2/htY24P++f4vp0+tNtrWK2VvKU7mOWZjlmPqSeTU2a4qlaU9NkdtOjGGvUcoVVCqAFHAA7UFqYc0AGsjWw7dTs8VHtNOUGhBYWilpDTGPU1Juqqz4polH94fnTTE4lvNNJqHzfegPk8GncmxKcVBdyLHazOxOFQk4+lKZKhmkUoytypGDUsdjPs45rlbWGNisoWOOWQf8s14yF/2iMn6D6U7SbCO216SdsGK1iJT1LMSBk9z94fhWlqdxpfhbQjdXVx5NpGS25zueRyMADuTjIx7e1fPfxG8e6hrNtcrpvm2Gny/LtDYeU8/eI+p4HHPescLh6eCp2es3/X3FYbC1cZJ8qtBbs7vwuVk02W6IGbh2l/77JP9RXK/FC/8jR50VsNKwQevTP8AOut8O2L6b4ctrWQENEiLk+yD/CvJPijfmXU7azXJK/OQOxPP9R+VUfTQta/odRoEt74u8CDSb+XfrVrIbvTy7ZMygHMeT3wWx+HYVR0640/yv9KLrMp2ukpO5WHUEVi+HtG8Saqbe40eC4AtyGimQhVUjphmIB+gNWNUez1m5fVJpfst3KM3cAQn98OGKgcDPXBI+ua5qVCo6nLTi2n26P8AyZm69HBt80kov8H/AME25tR0uNBtUDePlOw4P0OMUzwW+83YH97PH4VlG+tJdMa2ki3vgAOBg8DAPequlXVzp0jPA27cfm3d6+wwmVfVqnPB6NWd++h8ZmGe/XaHsqi1Urq21rNdeps+ObfKwzAZI4P+fzqvoGo2/wBmEFyFZR0JqDVNTnvwolCKo7CqNv4f1a7w2l2FxOCc/KpA/BulRm+XutCNSL95fka8PZxHCTlRqfBLW/Z/8E6iV7LaTERz2NWdH8XX+gyqLWVpbQcG2lO6PH+yeqfhx7GoNM+HviC8iVpIktvVZJAf/Qc1sRfC3U8fPfWw9gGP9K+XVKcXoj7WpjcJUjy1JJo9B8M+LtN8QxYtnMN0oy9vLw49x2Ye4/Q8VsvJzXmFn8OtSspknt9RjjnjO5JFBBU/4eo716HF9pS2i+3Rqsm0B5IzmPd+PI/H862XNbVHz+JhRhL91K6J5JKrSNSS7lJzULMTSbMlEdnJxWjassaDccCsyEbm61qaWomBmyCinamP1NOK1JqNJF5Msm4/KD2PWpUxUZBzSorZ54rQx6EoGakQVGrheO9SBvWqRBJmgmmFqbuqrkpD80Zpm6lzTuOxIpp6moM09Tg0JisWF6UjDimq1SDkVe5D0ICMGobqBLq2eJ+jDqOoPYj3FWXFR1m0UmXtDu2u9PQykGeMmKX/AH14J/Hr+NX65/S3+za7LF0ju494/wB9OD+YI/Kugrspy5onNUjyyCiiirMwooooAKKKKACiiigAooooAKKKKACiimu6xozuwVFGSScAD1oAdXPahr5eRrfR1SeVTh52/wBVGfT/AGj7D86pahqEutOY7cvFpg6uCVa4+non86dDCkUaxxIqIOAqjAFclWv0gddOglrMgS1BuDc3LtcXR/5ayc49lHRR9KsBSalCipUWue1zfmsQiL1pTGBU2MUhUmq5SeYrEYpuD6VZ2Y7U3bjtS5R87INpPcUoRiev5CpsgUoYHgUcqJc5EQjPfJpDAp6qD9eakaVE+86j6mmmePHDZHsCaqyJu2NECDoiD6CneWvemG6i9W/75P8AhTTeQ/3m/wC+G/wpXQcr7DzDH/dH5UeRH/cX8qj+1w/3m/74b/Cn/aIcZMgA9+KLoOV9hDbRf3E/75pktnCIWeTIXHZjUqXEBb/XR7RyfmHSqF/fxSh5DNGtrGCxcsAuB1JPpTshxUm7HK+K/DEPiWSFtRub7yoRiKNJQFX3xjr71yl18LLK6ubdU1G6VEcNsdFYEA9OMV6BYaxa6oJP7Pd5YVCkTiNhHJnP3GIw446jI5rYsLM71kkGOelTyJu7OxYupRp8kJWQupaZFc2yRhUQjjcCeeK4qHwJpFrq0+rXlvBe30jEp5xLKg7YUjH416BqF0kPyqAZCOnpWVHbh23PXR7JT1kcKxdWEeSMtDidf8PeIddBjOsw2tn0EEETKpHoTnJ/l7Vgp8Kn4Euqrgdlh/8Ar17CkSBcYqKZEUcHmu2liqlJctPReiOCrRjUfNPV+rPL4PhfbKR52pSsPRIgv9TWrbfDvRY8eY13L7NIAP0Ars8DNLVvF1nvJmaw9NbRMnTfDWkWDBrXT7dWHR2Xc35nJrYIC9KQUtYSk5at3NUktESohADx8N+hqxAyyg4GGHUVU8zjANMW48qZZAeR19xWM4cxvCbiX3HFPtRuyjDKnjmnALKoeNgVNWIYtg4HXqa57anS5rlMW8tJoJGVLdpYP4WQjIHoQSP0rDura+nlKiDyou25wM+5wSfwArt52BG0c1W8tfQVpCmk7mcq8rcpzlnpjtGEuJWK/wB1MoMemep/Stz7GYoU+ykJsAAUD5cDtj0qwEA7VbtlBQg0Sh1JVVvcz4LgSEq6FJB1U/zFFxcCP5E5kPb09zVi+tFkXJGCOhHBFUY7ONF+bLMOuT1rLlZqpLqSW7ZPXJ7mrWeKrRYBwBgDsKsjpUI2YUtJSirRLFpaSlpiAU7NNFFMRKhqZTxVdanSmiZCvURqZuRUTUMUSneN5V3p846pcKpPs3yn+Yrp65jVOLNm/uMj/kwP9K6etqHVGVZbBRRRW5gFFFFABRRRQAUUUUAFFFFABRRRQAVyut3bapdvYwEiygbFww/5asP4B7Dv+VaPiPUZLWGO1syPttySqHr5a/xOfp298VmWlultbpFHnaoxk9SfU+9ctep9hHVQp/bZIBgAAYApwFGKUDNcp0XHqKkANCLxUoXFapGbYwJTtlPFITxV2II2AFRMD2qbHc0x6llIrsp9aYYwfvZP41ORTSKlo0RCFVBhFAHsKY3NSvURqGaIiYVGycVOaawAFQ0WmQFeKQKMFnIVFGSScACsO48R/a5Ht/DtqdSlUlXuN2y1iI67pf4iO4QMR3x1qO80CefSJ73XZDq9xDC0sdgE8u1LgEgeXyX5x98t6gA0cvcXPfSJwPxH8YnV430LwuRdpMNt1dI2IgP+eYf+LPBO3I4xnk15rdeGlsYgs2oTSS8MVQlI0I5GFzzg9zk11FlqcEv2mZpDJdsxZ8jGT9Ow9vSjw3o03ibXvKk3fY4iHuXBxxnhAfU/oMmubnlOXLDQ+sp4Wjg6DnX1S382dB8LY/EzrJqOo6xdTWAysEMuHMmOrZIzgc49TXZeLfG8/h3TYXjMd5eS8xw4wMf3mI6D+f51ZvzBotpKGURW9soCovZcfKB+gry0XNz4g1KWSwjjuJN2Hmc/6PB/s8csR/dX8Sua9vAYdTd6nwr8fI+KzaunaVLRv8EarfGCW1Xz9T0RgCcZSbqT2AI5PtWvB8XtPKZm0y/iP+6p/rVWz8LWMGbu8/0u+Ix5soGEHoi9FH05Pcmud1fShqWtwWOmRqHYfN6KO7H2H+eteuqOHldtWXqeI6laNtbs73R/iZZa5fiy07T9QeXGWbYoVB6sc8V1tvqMK8y287N/wHH86q+BPCFhY2DRIj+rS5wzt6n/AA6Vs3fhuZSWtZkdeyyfKfzHX8hXi15py/dLQ9bDxp8v756/gQyatbvGU8iUDt04/WsHUvGEOn3C2s9lMxIyrsQFYex5q5d2lxZuq3MZQsMqcgg1QvrOC+gMVwgZeoPcH1FYRn0n/wAMd/1eEkpQ1/Uj1vV9UXSmu9Itbdmxu8uQlsr6rjr9K89ufFfiO5ID3iRq3I8iMAY+vNdppd0+i3n2C/O+wmOI5T/Af8PWsbxhpKafqWVTEUwMi46Bs/MPocgj8fSunLsR+8+r4hJy3T7o4MfhVGPtaTsuqObbU9YbltSuif8AroadaeMNa0u4U3MhvLbPzJJ97Hs3r9c1oWNiLhvQVNf6HE8LbeTivelSpyVnFHjxqSi73PQfh54qsfEkNwLNJo5LcjzElAGM+mCa7V3wvy9K8c+CtrDY6vrlq/y3EgjlQ55KjIOPxI/MV62jlG2P+deHiKKp1HbY9GnPnih1FKwwanghzhmH4Vm2DRGkRb2FW4k2LipAoHalxUN3KWhHIAyEVmSDDEfhWsRWRqBZT8nDFsZ9BUPTU0jq7EaD5qnFQQjAFTisUdbFpRRinYq0QIKWikzTELRTc0oNAD1qxH0qstWYulVEmQ+onFTGmMKpkpmfqo3aZdgdfKY/pXSxNvjRh0YA1z1+N1ncD1jYfpW1pbb9MtG/vQof/HRV0N2RW2RZoooroOcKKKKACiiigAooooAKKKKACo55Y4IZJpmCRopZmPQAdTUlc14muBd3MWloTtOJrjHTYDwp+p/QGoqT5I3Lpw55WKVm8l7PNqNwpV5ziNT1SIfdH49T9au0gGKWvPvfVnf6HiOv+LfEWm/EC4/tfUdQstAOoRWtlPp1vb3NqQSA0c+cyK5OQcEEdhXRad8TpLy/srP+zoke51q80gkT5KCBCwkxjqfTt612KeCvDba7/bTaFpx1Xf5n2o2679/97OPve/WrMHgrw1FrD6vHoWnJqbymZroQKJC5BBbdjOTk5+prdcr6GL5l1PKvBnxW1bTfDumHxRYR3gl0GbVorqC5LzS+V94SrsATd2IJA9+cb974s8SNN4Pl1OPT9Ngv9TgLCxvDOJLeS3ncrJuRcYKKcjIPY8Gu40bwX4Z0R7ltJ0HTLRrmLyZjFbqvmR90PHIPcd6bpXgjwxpO3+zdB0622zC4Xy4FGJArKG+oDMB6bj61pddjOzPPdL+LWqahc6lbWmi2d5JHpMurWT200wjuFjkCsgMkSliecMoIJGKhu/ijJ4g0+C/0iC4g0gavptlHdwXARp3mUNKjAoRtTcqkdSc8ivTND8HeHNBvGu9F0TT7G5ZGjMsEKo21iCVyO2QDipIfC2g2+mQafb6RYxWME4uooEhUIkoOQ4H97POaV49gs+551Z/Fe6n1yW2/s+zuNOltr2e0u7WSba5thkqWeJVbPQlCwB9a0fh94+1HxLq9rZapo9tYre6RHrFq8F0ZsxlwhVwVXByc8Z4rp7TwT4Ys7uW6tNB02G4lEgeRIFDMJBhxnHQjqKv2Wh6XYTQTWVhbQSwWws4njjAKQg5EY9FyAcVLaLSZ554h+JtxpPjOLTIbG0vdNOpW+mSzQyTeZDJKB94mLysgk/KHJwO3bn/EnxK8V3PhG+1XR9LstPt7bUxYrdyXQkaQi4EZHllDgEdz0ycdBn1G68G+G7jWG1W40PT5NSMiSm5aBTJvXG1s+owOfapZvDeiy6RcaVJpdm2m3DtLLbGIGN3LbixHru5z61PNFdCrSfU4HVfiNrNn4hutLi8PLeS6b9mGoi2aZ8GVQxMbeXt2qpzlypOCAOKST4ia0um6xqx8P2/9i6XfSWs04uyZGSOfy3cIF4wuW69j9a7C58C+F7mSzkn0HTpHtEWKBmgUlEXlV+g7A1Nqnh6zufD2q6RaKljDqKTLK0MYzulB3vg8FjknJ71DcexaUu5meEfEl14m0TUNUsrGEQC5mh08vMQt1Gh2iQttO0MwPQHgZ5qZPD82oOJvE139tPaziBjtU9imcyfVyR3CrWtoWl22iaNZaZYrttrSFYIx3woxk+/HNXSKhvsaJdysIkiiiggRY4xhFVBgKo7AemK1LiLy7XcvTFZ0pw8f+9WzeSwQaZJNdzRwW8aFnlkYKqADkkngCqgrmVWXK0eO+I/Blhqd6bu3Y2l0zHcyLlWPPUcYz04re8L22neF7G2tJg012VMqWsEe6e6fPLBOuAcDcSFHGSBWXPf3+siRdEX7LaeYf9PuIzlhnOYoz17YZsDuAwruPAlhY6dav9nUtdT4aa4lO6aZh/fbvjsOg6AAcU4QinfqdGLxNadKMG7xOH+IfhzWtb0ma61MLbxjaU0y3bfkA5Blk/jbttXCgnq2Aa8s03ULnSJ1jX5Il42AYUfhX1nLEkyMkihkIwQa8u8Z+BbS4nLuGjL/AHZkHX2Ydz79fevUweMjQThUWjPHq4aWItyP3l+Jx8+vRTaT5kbASEYx6Gtnwdp39mwme5XN5cjL7hyi9l/qff6CqWj+B/sN4klxdpLAj7wiqcsR0z6D867B0VxhgCPepxuLg1yUXddTpweAm7zq6PodloM1uLRUSVS/cVqnk4/E15oEkjOYZCPZuf1rWh1i5TTntz/rGOPM3ZwvoK8/nRtLC1L2J/E92lzeJHEQywggkep6/wAhWPQPaism7u56VOCpxUUQXtrHeW7QzLlSOD6H1FY729zqely6LOQb+1Pn2bt/y1UZyn1wTj/61b9ZuuLJHbLe2xxcWh81WHXA6imk5NcvxJ3Xk/8AJ7MmtBSg77df68jmtGfCYIIOcEHqD6VqnkUmsCGae31WyXbbagpdlH8Eo4cfj1/OpI4yyg+tfTYauq9JVFpf8H1R8pWpunNxZzl5ey+HtbtNWgUsImxKo/jjP3h/nuBXs9peQalp8N5ZyLNDIu9HXowryfxFaeZancMg8GuK0/xHrfhGV4tJuR9mlcfuZV3oCT1A7H6VGJw/tFzRNKFSz5WfTtuVdUPUGr4FcH8OfEw13SEabC3cGI5lHTPZh7H/ABru1bIBrwutj0JxcdGPopKWmSBrI1Q4mT0Oa1jWdqcRcLtxkHPNRLYum7SVynFVlRxUESMOoH51aQcVEU1udUpJ7ABRTsc0lUQIaaafikIoAjNIGxTyKicYpMpEqNzVyGs1G5q9A3SqiyJos9qawp1Ia0MiCVNysvqMVc0A7tEsj/0xUfpUO3mrWkqE0y1Udo1H6VdJWZNV+6W6KKK3MAooooAKKKKACiiigAooooAhvLhLS0muJThI0Ln6AVyOlJI6SXlyP9Jum8x/9kfwr+Aq/wCKpzcT2umxniQ+bNj+4vY/U4H50BeK4q8uaVux2UY8sb9wpyLk0AZqeNazirmjY+NcVJRjAorZKxkwooopiCiiigBjCmYqakK0rDuV2HFR45qw4qPHNZtFpjCtQyLVrGajkWpaKTKlIxAGararqNppcAmv50hRmCJnlnY9FVRyzHsACTXOyjVvELKr/aNH0pzjYPlu7he+SD+5UjsPn90PFRY0uS654iit7pbHTom1DVPlb7PGcCIHoZX6Rjnv8x7A1vaf4ee+NreeJbldQnjw8VsqbbWFs5DKhyWYdmckjqoXOKof2fbafF9n0+3jhjCE7VHVj1YnqScck8mum0S4WexQg9BWsH0RhXTsmzmPEMHkatKAMCQCQfyP8hVSyu3spw4P7snJ9jXR+LbQy2iXUakvAfmx12nr/j+Fcrww7EGk/ddzro2rUuV9D0Cwu0vLcSIRnuPQ1LPDHPE0cqhkYYINcBp1/LpdwHUkwHqCentXdWF5DewiSFgfUdxVp3OCpTlTlZnLavo8tmWlhBkt/Xuv1/xrJr0isjUNBtbrLQ/6PL6oPlP1X/DFS4djqpYy2kzjqKv3mj3tq2DF5ydmi5/Tr+WaoEEHBBBHUGs2rHdCpGesWFFFFBQVX1P/AJBt3/1yf+RqxUN+C1jcqOpjYfoacdxS2Zyvgk/a9H1TSX5khAvYPXIGGA+owPxNbFt80a7e9cr4SvPsPjDR5M4jnAib33Db/Miuyhj+z6i8J6RyFfyNe3h/3eIqUujtJfkz5jEe/CM/kVtQgLW7I45xXmXiC2BvbdCP+Wo/ka9g1Vcop/CvM/FUXlXkcmOFYGvRWsWcsNJp+ZJ8OtTfSvFcEecQ3R+zyD/0E/n/ADr6FtJSFVTXz58OYLe78b2aXSBhl3QHpuCkj/H8K97jBjYoTnHIPtXztWDT5ke9iGuflNVWzS1FF90GpATWZytC1BLHvbk1MQe9JwKBrQz5E2ORTk6Ut26qwJOMnApI+lJm8XoONJmlNNNIoXNGabmjNAAelRSCpSaYw4pMaK2cGrds3SqkgwamtT8wqY7lSV0ai9KXFNQ8U+t0cwCrOnf8eqj0JH61XUVYsuEYejn+ea0huRPYs0UUVsYhRRRQAUUUUAFFFFABQTgEnoKKx/Fdy9vo8iQnE9wwgj9i3GfwGT+FTJ8qbKjHmaRiWbG8vLu/bnz32x+0a8D8zk/jWhUNpCsEMcUYwkahV+gqcV5++rO9j0HNWEGKijHFTDpWsUZSZ4x8U/Gnivw54ouj5k+l+GIIo/K1G30xb6PzGxu+0HeGjAJAGBk5B5yK6EfFK3a68lNNdlPiRPDocTDBLIXE3Tpx939a3NZ+H3hbWtYk1TVNIiubyUoZWeR9kpQALvQNtbAAHIPSll+H3haXX/7bfR4f7T+0pd+cHcfvlGA+0Hbn14575rW6M7M4TQPirfadaWreJ7F7m2u7rU44r6GRA3+jPIwQxBRxsQKGzyRz61b1/wAd+IpPDXh3VrbTk0i21TUtPWKQXCXDS28z8qylBsYqQeM4z1zXYWHw98K2GqNqFvo0P2phKN0jvIo83PmYViVG7Jzgcg46VFY/DbwlYoqW2kKqJNFOimeVgjxsWTaCxCgEk4GB7UXQWZgW3xVW68Yf2BZ6Ul2832tLSe3uGaOWSBSxRmaMKCcfwM+0kZrKvvi4NW8M6jd6JbXNr9js7K5uLlHRmgmnmVfI2shBIXdkkfgDyO70zwD4Y0vWo9W0/So4b+OSWaORZHIRpRiQqpbaM+gGKli8D+G4dN1Owi0mBLTUrn7XdxqWAll3BtxOcjlQcDA9qLoLM53/AIWdB/wncHh4WKTQzXr6f9rt5ncRzKhba+YwgPynKiQsO461X8EfFQ+JtV0S1l0KWxg1m3uZrWf7SsmTA5RwygAjpwf07100HgLwzBrh1iHS0TUDdNe+YJZMCdgQ0gTdtDEE5IHPeptL8HaBpMmmSadpscD6YksdoQ7HyllbdIBk85Jzzmk2hpM5zxZ8SYvDviK80W5013vvLtX09RMB9u86UREDj5SrHnrxzVDTPimmq+I5dMstGvWtFvZrA3aJIxR4wcuw8vYEJGAd+7kZUV2+reGtH1bWdN1XUbCKfUNNYtaTNnMROM45weg65x2qingfw7Hr0msRaasd/JKZ3ZJZFRpCMFzGG2FuTzjNS3Epcx53ovxZvl8L2M40qfVrkaHNrdxNNcxwHyo5mRgQqbcgDIwBn9a9Jj1W81Xw7puoaFbRb9QgjnRrp8LAroGBYLyxGfujGT3HWobXwL4atbU29vpUSQ/YJNL2h3/49nYs8fXoSSc9fetmztINPsLeys4xFa20awxRgkhUUYUc+gAqZNdBxT6mJpugxWd2b+9nk1DVSpU3c+MoD1WNRxGvsOTgZLHmtCIeZeqPRGP8qmmPWodOOdUUesbfzWsd5HR8MGyHU0Mcy+6n9P8A9dJ4cuhDeyW7nCv8y/j/APX/AJir+vQ/6Msg/gPP06f4VzBkaOVZE+8pql7rGo+2pW6noRAZSCMg1xOuaadOuNyD/RZD8hH8B/un+ldPo98t5bg5G4frVu4gjuYHhmQPG4wQa0aujkpVHRlc87IBGD0pbS4n06XzLZjs/u+n+IrR1jSZdOJkUmW0/vnqn+9/j/k51ZaxZ6fuV4nV6X4hgugqy4jc8exrbDqwyCMV5q0Sltwyreo71Ytb28tiAJWaP0B/oatTOKphJR21O7MmZBjnPT2FcVqcizahcOhBUucEdxWjqOrrLZxRWpYFkxISMEe1YlKT6G+FpON5MKKKKg7AoIypB7iigUwPIXlaC30y6H34GRvxH/6q9U1YiPXZ2X7pYOPfIBry7WkENvdwH/ljcSIP++yR+lekX8m+aykJ5ls4ZPzWvbb/ANqpyXWLX5M+YmrUXHsy/dyLLCu3k9a4fxlabrfeBzXZW8TPGTngVka7AJbdkxnivQWhxre555o982l6rZaggO63lVyB1I7j8RkV9IxXEV1b29zAweOUAqw6EEZH9K+dJtLuBKVSMlT7V0vhXxhf+HFhsNQiMumI4OcHfEM549Rnt/8AqrycQlFux7jpyrRU1ue7WjZBU9qs9Kz9NninjSaFw8cqhlcHIYHkVodRXnoyluITTHGadRTJuU7mPKZ7g5FNSrTAEEVXK7TUtG0JXVgPNNxTqKDQYRTcVIaYaACkNLSGkMrSii3OJKfKKii4kFTsyuhrxnipagiNTCt0c8h61PbffkHvn9BUK9qkg4nb3ANaRM5bFuiiitjEKKKKACiiigAopD1pRQAVzGuMbnXoIs5jtIjIR/tvwPyAP5109cZp8hunur0nP2mZnX/cHyr+i5/GufEStG3c6MPH3m+xfT7tSIKYKlQVzJG7ZKgp9Io4pa2RmwooopiAUtJRQAtGaSigAzSGlpDSYxh60hpTSGpZSA9KgkPWpmqvLUMuJTuDxxyT0FRWxEGpwZPUlM/UZ/oKmHzzn0Ufz/8A1VRvwweTZ99GDL9RgioWmprbmTidLNEs8LxN0YEVw11E8E7xSDDKcGu1sLhbm1jlQ8MAao+IdO+1Q/aIRmZByB/EK0auZYer7OVnsznNOu3s7gOp+Q9R6e9drY3sV3ErIw3Y6VwNT2lzJbSBkJwDnAP8qUZWN8Rhuf3o7noBAIIIyD2rnNX8PbmM2m7UP8UB4Vv930Pt0+laOmarFdoMkBq0600ZwRlKm7rQ84kV4pDHKjRyDqrjBFJXoF5Z297HsuYlkA6E9R9D1Fc3qPh54A8lpPvRQWKSdQPYj+o/Gs3Dsd9LGKWk9DDoooqDsCiiq9w7BZNrFAgA4GWZj0AzTjFydkKUlFXZDd6nFb+YEjluHj+8sQB2nHQkkDPtU9ldwXlv50Dgp3zwVPoR2Nc3oU89lPPp2qcTiRtxI6sTk/nnNSanpc8TST6c2N4xJH2cehHcfr+tek8CnFWep56xslJ8y0OX8Xp++v5ghWOdkuI891I25/EoTXXao7KmgEfxabBn8q8+1bVZLzVLi1liES+QFjQEnG1j/wDFV6XrEe2TSUYcxWEKfjitZ3jWop9L/kefO0o1Ld0TRTEIFXqavW9g04BYcGoNLtTI4JHFdVaQYUACtK+JtohUcOlqzJm0dFtiY4xuHPSuR13TVmifdGM/SvVRDhMVz+r6arlivBPWvnpOSm5HsU6iikjG+EWoOdNutOmcs1lL+7B6iNuQPwOa9NU5FeZeA7CO08S60h/1jQwspHYZfP8AIV6NayF1w33l4NdltL9zhrNObsTUUHrRQYjW61BKMnIJqwelRMMg0DTIKTNB4OKDV8qL5mGaRqUCkbpWbNVtqJRRRUlEcg4quvEgqy44qv8AxipZSNKHoKsDpVWFu3oM1aXpW0TCRInapI/+Phfof6Uxe1LnbJGe27H6GtUZSLtFFFbGIUUUUAFFFFACHqaWk70tAGd4huTZ6JezJ99YiF/3jwP1IrFs4Rb28MC9IkCfkMVf8WndZ2kIPEt1GCPULlz/AOg1VTrmuOu7ysdlBWhckHWp0FQoKsIKiKKkPooqjNq+mwXgtJtQs47skAQvMofJ6fKTnmtTMvUUVXsb601CFpbC6guoldo2eGQOAynDKSO4PBHagCxRRRQAUUUUAFIaWm0hjTSGmzSxwoXmdY0BALMcDk4HP1px6VDKQ16qymrMh4qlOeDWcjSCCwXe057gj+VVNUQpPn+8M/5/SrGkvi9kQ9HT9Qf/AK/6VPq1uZLclRlk+Yf1oteI1LlqamXo199muvIkP7uQ/KfQ+ldQpwa4Cfknn8RW9pGtxLD5eoTRxFB/rJGCgj6mri7hiKPL7y2G6/pO0tdWi5U8ug7e4rn66CXxz4Whn+zt4h0ppz/yyS6R3/75Uk1ha3qumygz6Xa6vcSE/cg0u4KP7hygX9cUSg3qiqGJ5fdmJFI0T74zhv51u6drxTCTjj17VwEmt6qzlLfwvqYI/iupYYR+W8t/47TfO8VT/dstGsh2L3Mk5/EBEH61KujepThVVz2KC6inXMbAnGcd6oa1dfZrWVnI3yKURfXPU/hXmMFp4nDbn8SRW/tZWCrj6eY0n8qW50CW/k8zVte129bGObv7OPyhCY/CrckcscJLm12Nysy/1/R9OJF/qthbEdRNcIh/U1WTwpoiqFlsEugOn2t2uP8A0YWq9ZaRpti2bLT7O2PrDAqfyFZ6Hoe8Zf8AwmWjPxaS3V6e32OzmnB/FFI/WsDxH46nsJYjZ6HqJkBWX/SkSFeNwBwz7u54x27V22q3f2GwlnwCVwBnpkkAZ9skV5vFHqWs6lO95Ht8v5UZyCxAPXjp9BgVpSlGL5mtC1hp11ZSt8h2mX3iHxPqf2+9t7eGNk4KzbieeBtC8d/4jj8677TROLYC5IZgcZ74rk9FvhpF+6XQKQy4Uk/wsOAT9f510t7q1rb2jyrNGzY+UA8k17lCSqU04Hi4qhKhUcJnmXiaHb4xtxH/ABtIn8q9i1y336wI1HCIifgFFeL3E5u/Gmmr1K5kb6FgP616zf8Ahrw//bzx/wBh6V1yR9kj/wAK4sbPlxMF2T/QmjDmi/U6nTbcIg4rbtkCiuZtvB/hzaM+H9IP1so//iatp4Q8NZ/5F3R//AKL/wCJrlqO5qtDpSMiqN9DuQmqK+D/AAzj/kXNG/8AAGL/AOJps3g3wzsOPDujD/txi/8Aia5nFFXZz/nDS/GmnzOdsV2jWrk9Mn5kP5jH/Aq7uE7bn/eH+f6V5L4/8JaFHYnyNF02Jv70dqikfkK0vAdj4Z1uyjWfw9o/2y2Xy7gGxiG48YYfL0I5/MVtTa9nZmVSDupo9VNFYI8G+FyMjw5ov/gDF/8AE0f8Ib4Y/wChc0X/AMAYv/iaehibp6Uxqxf+EN8Mf9C5ov8A4Axf/E1p2NjaadarbWFrBa2yZ2xQRhEXJycAcdTmkxo8A8D/ABO8WeILqwYfZ7uCWO9a/WLTpIlsREG8pvOLFH3EDjHtWp4d+L17F4eWTxDokhvI9AGtJOk6bbtAwVvlUfuySeBzx6V6zpfh7S9F0T+ydLtEt9O+f9yrMR85Jbkknkk1jN4F8NSQJA+lRmJLA6Wq734tiQfL69Mgc9feqckaQi7aHKeIPizPojWttd+GbmPVJ7eS9FnJdKT5CnCkNGHBdjnC9Bjkim658XDpyXdzD4cup9NsobG4up2uFjeFLr7mYyMlgTgj9RXd634V0bWpbaXULQtPbIY4poZpIZFQ9V3owbbwOM4qC68FeHrqzvrW402OSC9jt4rhS7/vFg5iBOc/L+vfNTePYu0u5yC/Eaa2lvrVLKfUtSl8Qz6PZWxkSJfkRWJL44UAnkgtz3rofFPi248M+Bm1/UtHcXKNEklgtwpIZ5VjwHxg/ez/AIVeu/BPh68t7iGfTIys94dRdld1cXBABkVwQytgD7pFWrrwzpF34fXRLqzE2mKVYQvI5yVcOCWzuJ3AHJPNHujtI4C/+LI06zvF1PQ5bXVYNUXS1tPtIdSzRiQOZFU4XaecBj9aSH4nz3b6DBYeGbu4v9UN0ot/PWPyzAV3Hc4UMpDZB4OO2eK7bUfBugagt59r02ORru4S7lfcwbzlUKsisDlGAAGVIqK18K6NY3dhcwWjfaLHzRbyyTSSOnmY35ZmJOcDrnpSbj2BKXc5az+L9kFf7Vpk0Vxax30mpQLKGa0FqcHsNxcsgHT73tXQfDb4g/8ACZXF1A+lS2LRQR3CPvMkbo+eNxRcOMcgZHIwTWja+EtAi1bUtRXSrY3eqxGG9dl3CdMAFWB4wQOeOe+av+GvC2keHS/9kW8sIZBHte4llCqOiqHYhR7DAq010IknfU6Fe1JOcRM3935/y5/pSrT8BsqehGDWiIZbHSimW+fIj3fe2jP5U+tjAKKKKACiiigBB1paQUtAHPeI3DarpsX91ZZfyAUf+hGo06UzV23+J8dorMfmzn/4kVIvSuCq7zZ3U1aCJI6sJ0qGPrU69KcRSFrwPxX8ONX8X/E7xmptrK00u8isVXUbuzMkgCoNxtnyArjGCee1e+Vz1/4z8O6friaPe6rbwai7pEsL5HzuAVXdjGTkYGe9aptbGbSe55ot34yt/FFxpTWviGSEeKYJ47sKzW404qAU35+7nqvbvWNo/h3xYG0/T4m1/SrGW61qe5azLREksGgJOP4jnHrzivYLPx34XvNd/sa11uyk1TzJIvswf598ed6/UYPHsazdF+JGia942Tw9oc0d+ps5Lp7uGTKKUcIU6c9c5BxTu+wrLueaWlt8SbOxna0udeuLu78KJO/2w7hDfiVVZI8gBZPK34HUnBOTUgj8azw30WjS+LYtFk1bTktZL/cL1IzkXR+YbvLHyn5hj04zXsd14q0O1fUkudSgjfTniju1YnMLS48sEf7WRjHWqdz458Ppd3tjbanaT6laxysbcSbdzRrudN2NuQOo5I5yOKLvsFl3PKL2PxrZabd6UyeKLuBfEFxFbX/nzGWO1EamNm8vDyIWLYOQARycYrS8K6d401m/8Iwa9qHiLT7ZdGd794m8ovcLONqSEqcMU64wxHfk13B+JXhmz0rTbrXNVstNmvrSO8SF5t/yPwCCB8wyDyPStP8A4TTw5/baaQur2r6i5VRCjbuWGVBI4BI5AJyaLvsFl3PPPhFe+J9S8WahYa1qE89l4XWbTZJjIT9vuGlLLI3qViCjB5BaqfxFn8Zn4ho3h+212G1trqzw8LSyW9xESPNO0fu1AyQQcscZ4Fey2VjaWImFlawWwmlaaUQxhN8jfedsdWPcnmrJqebW4+XSx4L4o8K+JNY8C+J7q+vfEt1eDVnNtpiyYQ2yXqsrIm3cx8sEryegwOBVfxE3jseK4zpkviOLSFitG0xzDLKSAB5q3Cggbycg+b0GMYr6ApDS5x8h4bqmneLU0Tx3r765rdneadqVzNp1rPNstnto2jkB24yQyq6D5tuD06muv+Gtxf6j4W/trVJpmk1ed7+GCRywtoHP7qNfYIAfqxrtNQt4Ly2ltruGKe3lG2SKVAyuPQg8EVXkjSKBYoUWONFCqijAUDgADsKynK6sb042dzzjUfEHjmw1IONCsoLNDkXVuWv8DpzGGic8egNa+n6u2szrbXPxDFndt0tItOjsJj9I7kO/6V0bVdtIrHVbE6fqlrb3caceVcRrIrL24II9R+FEJLawV6bXvXOJ1jwPDDPm91PW7yN+he/kiBPoViKD8MYqlD4O8OxOJP7HspJR0kmiErj/AIE+TXY3Hw/0hUxpEuoaQOojsbpliH0hbdGPwWuV1PS/E+lXG221Cxvov4UvYDEzj18yM4B/7Z03fozWhUjJcslqdp4d1G2to0s2hht+y+WgVT+ArpeoyK8abXr62G3WPD99EveWyIu4/wAAuJP/AByt/wANeP8ATJZltBqUE+OPKdtk8f8AvRthv0ppvqZ1aKjrA7y/sIL5MSjDjo46iuY1DSriz+YjzIv76jp9R2rroJo54lkiYMhGQQaeeRQ43M6daVPbY8+orqdT0eCVXeAeVLjdgdD+FctWbVj0KVVVVoFFFFI1IL62S8s57aXOyVChx1GR1HvXC6cJNO1KW2ucearYJHQn1HsRz+Nd7cTR28Ek0zBIo1Lux6AAZJrgdZvDrGoR3NtF5McY27m+9IO2R0GOfXr+FFrqx24GUlPRXRf1yxW7tiwXdxgj1FcTFaXcMrI08IgHSWYkAf7xAO36niu8sLn92ElIzjrWB4t8mGCZozjch3bT7VWFxdTDytF7nbi8BTxcbT3XUwNHtfL8SXsk0sErQSQwK8Em9Dlgxw3f+Gvab5T/AMJVIe2B/OvCfAkeLEuej3Qf8mA/pX0PdQBvEbHHQV04ybliISfZ/ofJ0o8l4m7AMIv0qdOoqJOFFPX71ZkNlkU5hmOo+tSDpiptoTc5HxfbedaMMVyHw4P2bxZPAOktuSR/uMP/AIuvQ9fjDWz/AErhfBdpI3ja5njXMdtbkP8AV2GP/QDRHVNGl1yO561F9wfSnU2Fg0YI9Kcao5WFNPWnU1qBEbjIqsRhqtN0qs3BppJlxk0KOlLTRTqlqxsndCCig0npSGB6VWkHNWTUEtJjW5LEfufX+lX4xxWdF9wexB/WtSPpWkDOY8dKcOtNFOrVGLLSdKWmx/dp1bIxCiiigAooooAQUtAooA5O4O/xHqh/uiGP/wAdJ/8AZqsjtVOP59W1d/W5C/lGoq+BXny1kz0FpFDkqdelRJUo6VcTOQteX+Jvhfe674rm1SbxG32Jr21vYrWa3aVoDCVJSNvNCqrYyfkzk9+/qFFWnYh6nmkfwrj2xpLqxZBrl3rDbbfaSJ0dDEDu4xv+93x0FN+H/wAM7zwtrmm315r0V/BpunSaZbQpY+SfKaQOGZt5ywxjoM/z9NxS0+Zi5Tz/AMT/AA2t9d8faZ4jOoPbw25ia8sViyt40LM0JZsjG1m9DkADisSy+D5stQu/J1a2fTpZbqaJJrJnngaZHUgSeaFwC5OdmSOM969boo5mHKjy5vhQDo7WB1gc+Gl8Pb/svTaxbzsb/f7v61FpnwpubDxTp+qxa6kEVs8TyrZ20kEl2I0CBJSJTGynGSfL3ds969WNIaOZj5UNpDQaSoZQUxzgU6opmqGy4ogc81WlOamY5qq7YfBrI3iirKMNVWSV4JUnh/1idv7w7itB4/MXjrWZc5BwetC0ZvFKaszrrC6jvLZJojkEcjuDTb+zS7hKuM+ntXI6dfyabcmRQWgc/vEH8x712tvNHcQpLCweNhkEVsnc4alOVKRxd9ZyWkhDglezVl3+nWWoxiPULO2ukHRZ4lcD8CK9FubdJ0KuoIIxzXMajpEtuWeEF4xzjuP8ahxtqjqpYhSXLM49PD62Mol0O/1PSnHGy0uiI8e0T7o//Ha6DTb/AMUxri31DSdVK9Yb+JrOb/v5HuU/hGKjFIVBIPIYdCDgimptbjq4aM9Y6MsX3jS5sUeHWPD2q2U7qQskKrdxHPcGIl8f7yCsOw8Q6Pf3JtrXUrV7odYPMAlH1Q/MPyrYlkklbdK5d8AZPpVDU9LsNUh8nU7K2u4v7k8SuB+YpOSZVGi6S8y5RXOf8IpDbc6PqOp6WeyQz+ZH/wB+5QygfQCnxp4ns2wZtL1OEd3V7WT8SN6k/gtK3Y25mt0blxClxbywyjMcilGHqCMGvPpND1iK4+zRwPIidJUKhWHY8kc+1dI/iSS0YjVdE1W1Qf8ALaOIXMZ9/wB0WYD6qKsQeJ9GubWaa01G2uPJUl443BkX2KdQfY0WaNqOIdN2h1OQu9F1i1jM5ik2DqVIbH5EmuP8T6hKNPcP0YfeBzkfWu91PxFqk8bm2ItYeyqAXI9yf6Yry/XIpbzVI45JpG86QFwTnPc/yrahBVJpHpVMRWpUZTqLodH4PtzDo0AYYOFJ+pIr6AvR/pyzxHdkBX/2TgV4xpkWyBVA+UAH8iK9ekd49XO08fdIPQjjioxs268XHz/Q+ZinY2Y2OBU6HNQDbgH7v1/xqRCuOGQ/8CFP2sersZNF2MZFSgVHA67OoqYEE8U1KMnoyHdGVqib0cHuK5TwNiLxFrkLcOVhce4y4/z9a7PUl6+9ed/bP7I8a21y3EMp+zS/7rkbT+DBfwJopaTsNrmgz0qyYh3TsD/9f+tWzVG3P+ltjpgVePSqluzDoFIelLSGkA0jiqjnnpVyqs4w1F7FwSb1Gg5paavWn0m7myVhDRig0UhiGoJKnNQSd6TGhYD8rD2rXTpWND9/HrW3EuYlPqK0pamdXQUUo5IpQpqSNK2SMGyVOlLQOKK1MgooooAKKKKAAUUUUAchYfNdak3reyfpgf0rRFZ+jjd9ub1vZj/4+a0wtcCWp3ydhUFSU0cUE1ojN6jqMgUzdSZouFh+6k3VHmjNK47Em6jdUeaMmi4WJd1ITTM0uaLhYDSGikzSY0hTwKqzNzU0jYFVHOTWcmaRQhNUbg81JqUjRWM7xnDqhI+oFVBMJ03joWIH4HH9KybN4ItwvkA1U1W3IAmTlT19qdC5VsVqQQiWIqeQR3q46ik/ZvmOTNWtLv5dNkOzLwMctH6e4pdSs3s5yrD5G5U1Up6pnQ1GrE7u0uoruFZIWDKalZQetcNZ3UtnL5kLY9V7N/n1rrNN1GG9QbTtlA5Q9RWidzzqtGVN+RW1TQo7gGW1xHN3H8Lf4VzM8MlvKY50KOOxr0BOlRXlnBeRbJ0DDse4+hpONx0sTKno9UcBRWhqulTWDswBkt+zjt9f8az6zaselCpGavEKKKKCgrlviBpdjqGmwfbLK2nPnxrvkjBZRnseo/CuprO8QWj3ukXEUIzMAHjHqykMB+OMULcuFuZc2x55JYwaVaSrbNP5b87JZnkC/wC7uJwPYVylmhufEAPURqT+J/8A1Gug8QaipjMf3CnLq3DA9wR2xVDwpb5kadx88p3c+nauzCxavUfQ3zWrFU40YdfyOutUCwNgf3V/NhXp93/yFXP+0f515xbp+5+siD/x4V6Pe/8AIQkP+23868+tL9/D5/oeWlqbMXKCpkFQWZ3RirSLxXTF3RzTjZli1PBFWQBmuUuPCGj3d7LcXCX3mysWbZqFwgyfRVkAH4Cnr4E0IkfJqP8A4NLr/wCOVorMwlc39TX5Qa8v8ZwK8zFh8rAqa66+8CaEseRHqP8A4NLo/wDtSuD8S+DdJjViiXvHrf3B/m9RopmlFs6b4Z6xc3n2q0vpmmngcYkb7zKQMZ/l+Feh9q8J+Hvg/TrjV9QmlS9+zRJGhK31wp3HceocdsV6ZH4F0Flzs1H/AMGl1/8AHKpqzM6qs9DqqK5f/hBNC/uaj/4NLr/45V7RvDOmaPdG5sVuxKUKHzb2eYYJB+67kdhzjNGhkcdpXxe0TUtP8P3EEMvm6xqJ01LbzEMsLbmXe6g8L8v6it5vG3hubUrmyi1i1a5t1keRAx4Ef+swejbe+M4xXJaN8GbLStN8MQx3tu19o+q/2lJerYKsl0u52ERO7IHzAZyfu9Kr2Pwhl0uZ0tdbhW2jS7Wzm+xt9rtvPR14l83b8pfOQgJwMmqaiyotp3Oog+IXhSa0ubpdcs1gtnRJmclPLLnCbgwBAPY9Ki0r4k+G9V8VRaDp98Li4mthcRTR8xSZZhsU/wB4BSemMEc1xkXwYndbpr7xBFLNcCzDlLFsH7PJvyd0rFi3QknrzjtXdv4YuE+IEHiOwv4YLf7AthcWbW27eiyPICjhhtOX54PAqXFI1UmzqjTSacelMNQaATUL1IxqFqTGhYiA4J9a6K1X9xHn+6K5nG4qo7so/UV1ijCgVtQ6mGIewbRS4oorpOYKKKKACiiigAooooAKKKRjwaAOU8P821wT3uZj/wCRGrUNZugDFpN/18S/+hmtAmuKOx2y3FJppNITRTBIM0UUUhhRRRQAUUUUAFFFFACUhNKajkOBSY0RyvVfNK7ZNMzWLZtFaENyodWQ9CCDWVpIxpsIJyQCCfcE1sOM1lWA2W0ajpub/wBCNR1NYkrcdKvaXeDf5bVSlGM1RZikm5Tgirg7FSgpqx1t7bJeW7Rv35B9DXIXVu9tMY5BgjoexrptKvRcRAMfnHFTahZJeR7W4bsfStWrnLTqOjLlexx1KjMjq6MVdTkMOoqa8tZLSYxyj6HsagrPY79JrujpNL19XKxXuI3PAk/hb/A1v+YMZHP0rzwgEEEZBq1Yalc2GFQ+bB3jY8j6H+laKfc4auEtrA7UuOTjoK47W4o4dTmSEAJwcDsSM10lhfW97bSSxvhVwXB4K/WuSuZTPcSSnq7E0T2DBxfM2RUUUVmegFFFFAHNeO7jy9IEC8G5kCE/7Iyx/PGPxrjdDjHmMR0HArp/iBndYn+HEn58f/XrndB6sK7qelA4amtY37YYijB7zIP1r0C+ONQkH+2x/U1wCHbDGfSdCfzx/Wu+1MYvGPq7/wAzXl1f40Pmap7mnp8meK1ErB018MM1uIRxXTExqLUlUZar8I4561RU81ei6VrFnNJEd6MxmuE8SJuSQV3l1/qzXF+IFzvPtWc/iuVS3KHwxACawh+99oU49vLH+BrvLA4jZP7pwPp2rzHwVd/YfFUsDHEV7HtH/XRMkfmC35V6XZtieRfYGt5axTMqiaqMuUUUVBAhqvcsFXLEAepqdutRzDKGlcaRVUhhlSCPanLUDQoTkDa3qvBqWIFVwWLe5ocrm8Y2HnpUZNPbpURNQUIxqJqeTTWpMpBF/rY/99f/AEIV1QrlYv8AXwj/AKaJ/wChCuqrow+zObEboKKKK6DnCiiigAooooAKKKKACo3PBqQ9KhkPBpMa3Oe0gbYJh/03k/8AQjVsnNQWQwJx6TP/ADqeuPodr3CiiigAooooAKKKKACiiigAooooAQ1BMeKnbpVWc81Mtio7kB60UlLWBuRzMEidz0UE1l6cCbG3J6mMMfx5qzrchj0q5I6lCo+p4/rSQx+XAqjooCj8BigqITKWhyvJHb2rLmPWtdW4B/Os/ULfZ86fcNUaU5WdmVra5e3mDoenUetdfp92l1CGU81xNT6fqD2M4b7yHqKcZW3CvR51dbnZ3dtHdRFJRn0PcVyuoWMtnId65j7OOhrqrO5juoFliYMp/SpXRZEKOoZSMEGtGrnBTqypM4Wity/0Mrl7M5H/ADzPX8DWI6sjFXBVh1BGDUNNHo06sai0EUlS20kbhg4OMj3ooopGlgorPvda02xJF1fW8bD+EuN35daxbnx3o0JIjNzOf+mcJH/oWKCkmzqqK4eT4iWgPyaben03bR/Imo2+I0KkeZpV0B7MDRZj5Jdjb8b2/m6QJcZMEiv+B+U/+hZ/CuK0OQLdPGeta9x8QNHv7K4tbiG7tvNjZN7xhlGRjPBz+lc5ua3niuMEK6hvwI6120PepuBwYmLhUUmdbJzYXABwRtYfgwNegahIJY4bhejsD/30u7+teeWEi3ivEpH72Nl/HFdtoj/bfDFsc/OkSnnrlfkP/oIrzMSuWcG+/wCa/wCAUnqXIHKSD0Nb1rJuQHvXORguAc8itexlwBXTFkSV0bCNVuF+1ZyN3BqeOXBFClYxlEtzn5DXKa2MowrpJpcpXM6w3DGp5uZijFpnnOqealwXt38u4iYPG/8AdYcg16j4L1P+19JgvmGJZB+9H91hwR+GK88ubJp53YsFUn0611fwwhkt9MvdxBi+2SBPwxk/99ZrZu+iKrJWTO9paapyop1BxjWqOT7jfSpW6VDKcKaBoqAgjipF6UzaOo604VLVmbxd0DHioGPNTN0qE9aTLQlI1LTWqSrDrYZuoB/00X+ddTXL2f8Ax9wf74rqK6qGzOXEboKKKK3OcKKKKACiiigAooooAD0qGQcGpjVe7bZbyt/dUn9KUthx3MayG6Bn/vuzfrUpqa1i2WcS452jNMkXBrk5bI6+a7YyiiikUFFFFABRRRQAUUUUAFFFIaAEaqs55qwxqtKeaiexcdyGloorE2MvXmzBbxf89J0B+gOf6VZYYGD1xVS+/fa1YxDkRh5W/IAfzq7OMnPcUDRUZ9rY7Gnrh1KMMjtVe5PWks7jEmG59qqLNJR0uijdQmGUgj5T0NVZRzXWvaR3cRUjg9D6VzeoWktpLslB9m7GnKJVGspPle4/Sb2aym3RHKn7yHoa7Kyu4ruLfEee6nqK4i1WotU16y0BBPd3awuBlUU5d/YL3/lVQdkTXw6qO8dz0Wql7YQXi/vVww6MOorjfBnxJ03X3aC6RrG53YTzSNsg7YPY+3867wcjjpWmjPOnCdGVpKzPMPG9j4n0992jR281ltJaRVLSp7lemPzrzaVNT1B/9PvbqZT1y5Cj/gI4/SvpfzBGPm+7yWPoBXA2/hoz3k1wybFkcsEA6AnNS49j08HieZNT6dTyyDw46gEIGiP8SjNa0HhN5kDxAyfTgivYrDQoIR8sKkHrkda1ItOijxtiVfoKpUmzWWNjHY8Vj8HFgeJAfcVMvgi4IwybkI4IPSvbEtV7oD9RTzaL/CgFV7ExeYeR86eIfBUiwurxENjIZR1pnhRYbu2XRdbiaOeHiCbpuX0z619ETaWkyFZEUj0IrA1nwtZXieXPAMj7rgYYfQ0nTktUTPFU6y5ZHm1r4WuLDU4ZLFmltgfmJPKiul0pxZ3V5aE8RuJkHqknDD8GFSxWepaGzxzLLfWRPyyxjMiD0Ydx7iq0n+l6xazWQLp5Ukcr4xgHBAPvntXDjHJwbqdP0/qxnCLTstjWtbaZ2bYM7SRVyOGWM8qal0aVJbdWTGWUGtKs/ayT0JuRW5OzmpQfmpjxhueQfUVF5c4cbZUK+68/zqlW5viKVi1I3y471kXtq05I7D+daYT+8zGnY4rP2rT0E7HD3lq0TnPSt7wFgaNOndLubP4tu/kwqTWIFKFwOvWqHgy5SLVNRsScPKFulHrxsb8tqfnXfhZ3kc+I1hc7WBuADU9VYjg4qzW0lyuxzXurg3SqsrZU1aPSqVywjQluBkD8zgUiojBTqiDZOOh9DThSk9TeKshWPFRGnsaZUMpCGmGnE0ykUPgO25hPpIv866quUQZYCuogffCjeoBrpw70aObELVMfRRRXQcwUUUUAFFFFABRRRQAVT1Q/6FIvd8J+Zx/WrlU9Q+Z7WP8AvSgn6AE/0FTPYqHxIcV44qtMtXCKhlHFRJaGkWUDwaKVxhqSuc3CiiigYUUUUAFFFJQAtNY0E1E7UN2BIR2qBzmnM1Rt0rKTuaxQlFFRysEidicAAnNZmhn2f77V7ubtGixD8csf5irk44NUvD6k2LTt964kaX8DwP0FXphkGhD6mVcHmqRYq+4HBFXLkEMQapyDFNHVHVG/pF2HUDv3FaV5axXsBjkH0PcGuPgnNvIJAcAda39L1aLUEBtXDp/eBzmtYu5xV6Ti+ZHC/EC71Pw3aA2VsXRzg3RGVj9OPX68V4/OJ764ae5keWVzlnY5Jr6vlhiurd4bmNZInG1kYZBHvXlHjL4cG1El3om57blmt+rJ9PUUpR7HXg8ZD4amj7nD6Dp8EjxrvPJ6Z/wr2HwtcahaxCIO01uOgkzx9DivNvCsBtbpcoC2emMkf4V7DpDK0K79oc9s06a7m2NkuWzVzTM32m3ESo6SsQGBHAXOTz7jj8av2toFHNPtLdSoJq+oCDAFdcYWPClU5dIkaRY4AFPVOuadmnjpWljBybItqjpTiv1p+B6UUWFcj20jxK4wwqWinYLmZc2PGQeK47UtLktb1fsW4eVG7JGznYZG4Xj0HzfnXoMzrFEzv91Rk1mWNt57vczDlido9P8APSuDGU41eWjbV/guv+XzOmjWcE5PY8ygvrnTJsy20qxSSnKqRm3kPJQ5/hJyVPTBxXTWWsQXCHaT5i8MhGCD7jtXR32kW9wd5AEgGN69ceh9R7GuU13w1DKu8Eh0GFkhby5FHoOxHtkCuaeFlTVrXX4/Nf5fcdUKsKnkzWjuYnHXafQ1KpVuhBrzSQ61aNIunagL7Zx5MiASj/gJI3f8BJqlaeMtVtrsx3tnExHVQGikH1Vs1zKHNpFnR9Xn0PWsUveuZ0zxVZXcKs7+TJ3jkOGH+Na8OqWsw+SZc+5ocWuhi4SW6DVone22xfezXNvYyxzQ3dkypfQNuTePlYdCrd8EH+R7V0N7rOn2UJku7qFFHqwridS8bRX135GgWsl7OflUqpxmtqXOvhHGDlpbQ6tfGFpCyLqFreWkm4K26Pcg5xneOMe/FdfEweNWU5BGQa8ktPCfiPVLhZtWnW3R/vIHyAvcbR1/Gu28JzvYSXGiXcheS0wYXbq8J+6fw5X/AIDXdzN/EctWjCC9x3OnAqjf/ejX1f8AkCf6VeDDGQazpzvvAOyJk/ieP5GhmUFqNzzS5prcGipOgDTTxTqQigBhptPIppqSh0X3hXQ6a261XPYkfrXPwj5xW7p3COPcN+mP6VvQ3OevsXKKKK6jlCiiigAooooAKKKKACqc3z6nCv8AcjZvzIH+NXKpxjdqVw391EQfqf8ACpl0RUerJmqJxUzCo2FJjTKMw5qKrU61VPWueSszpi7oKKKKkoKKKKACkJoJqN2oAR2qBm5pzmo6zkzRISkbpS0jVDKQlZuvuw08xR/6ydhEv4nn9M1pVlXDefrttD/DAhlb6ngf1qWWjQijWGFI0GFQBR9BRJTzTJDgj0NNAVLuDemQORWVKvY10KjIrkviC9zY6RLNYKS5HzleqL3Iq2uppRneXKzhvHfiMqz2FlJhR8sjKep9PpWd4C8RXfh69SU7pLGXIdCenPJFcxGpurolywU9wM4rpbax/wBDZGG6KMmVZE5VhgBh9eFODzgGolJQsenKnBx5JbH0HpOo22qWUd1ZuJIm7g9Parorwrwxr154YuPMUF7OXrB/eHr7GvZdF1iz1ezS4s5Qwbqh+8h9CK3TueJisLKhLyKOseG7e7drizVLe6PVlGA31/xqjp6yWMwt5o2Rm6s3f6V1tR3FvFcRlJkDL79R9KdjKGIklyy1QmnagEYRSnBHAbsa2uqgg1yctlLbqdmZox0/vqP61NpmuCIiGbLAcA+v51Ua3s9J7d/8/wDMUqHtFzU9Tpxx2p2W9Ky49atHOCxVumDT31e1X+MV0Kce5h9XqbcppCjcN2MjPpWPJr1ohbDE4HHvVK81O3vF3BPmC/K2SCKmVVJe7uXHCVXurHSM4XJJGB3qGW7hjXO8H2B5rkVmvJ4ywd4Y+hZ8Afy5qFL0wIEjmed2PMrgAHHYAYxXC8dOT5YRV/X/AIB0RwDbte5v3d/HNOqTP5cQP3e5qZtXghIQlNnRcdx7VyG/fuJHU8g+tIyZ5FOk3C8nrJ7v+uh2fUINJNnQalrwRv8ARAzgjgjjB981y9/rcqzRW9xdRRPcErFG7AM5AyQueScc8VODnP61R1jS7TV7J7W/hWaFsHGSCpHRlI5VgeQRyKuU3Lc6aWHp0laK18yvJZK+WIGTznFV7pZQvzMJVHOyZRIv5NnH4YrOTUrvw2yW+vO1zpxbZDqmOUH8K3A7Ht5g+U99vd/iLWYrTFvAPNuX6KOcD3rGVOMviVzoTU9zL1qW0WNWkhjiJyHjAyjehUHJ/DtXPR6dLq90kWk2U4lJ6xOw49wDgV3vh3wFcaky33iCRo0blYF4Yj3/ALo9utej6dYWunW4gsoEhjHZR1+vrVwpuKsclXFU6ekdX+B5xpXwpt2EU2rXcjyEZeJBkA+m4k/yrvtG0PTtHiCafapFxgtjLH8a0qO9aHmzqynuxMVheJrGf9xqemx77+0P3BwZoj95Pr0I9xW8TxQKCCpo2o22pWKz2sm5ejA8Mjd1YdiPSn2ykiWUnJlcsP8Ad6D9Bn8arvpFi9814ISk7cOY5GQSf76ggN+INXzTJtZkDLTcVMaTFKxZCRRUpWmEc0gIzTTUpFRsKRSY+3H7ytiwb/SZV7eWh/VqybUfPWpZcXz/AO1Ev6E/41tS3Ma2xo0UUV1HIFFFFABRRRQAUUUUAFVLP5prt/WXb+SirdV7IYWb3lc/rUvdFLZkxFNIp5FJTEVpkyDVCUbTWswyKp3EORwKynE2pyKWaM/SgoRTTmsDcdSE0wtimM9K40h7NUTtTS1MJqGykgJpKKKkoKaacelNqWUhOlZGi/v7i8uzz5shVf8AdXgfyNaF9J5NlPIDgrGzfpUOjwfZ7CKMjkKAfrjn9aRXQuGorjmM1K1QSn5CKGC3C0nDqQxAK9arOBdOSwyp4wfSuV8Ya02lRQx25DXErZKDqUHXH6frW74V1CHVLJJoXDA9fatacrodSk4LmOD8YeDDpUjX2noTYucuoH+qP+Fc/Yyv9o3xO0aR91OMn0Pr9K+hfIjkgaORQ8bDBUjIIry/xd4OfTHNxpqFrJm3MgHKH/ClOFzrwmNU/wB1VMSG2W6TzEjDMRjyNwBB9Vz1Ht1HvVSKa90G+E8DSxS56FSM+xBrT09YUtzNc5KA7UQHBc/XsPU1fl1C+EAVJmgj6JHCAoA+vX8zXLzzTtDVLv8A56/l8zvcW/d3XmdT4W8bW+obLe92w3PTP8LfT0rs0cOMg14tP/aYTd/aV4WPJUynAFaHh7xFe6YRG7y3CM2AjnJz6D/CuinUn9tL+vkeXiMtesqf3HrlUr3T4LvJYbZP769/r61S0jX7PUAFSVVk/uk/5zWyCD05Fb6NHl+/Sl2ZyeoWF3a4ZkM8a9HXOQPT2/HIqK0aCQ/vruONv7jEMf0P9K7Ks+70q1uWL7PLkPV04J+vrXNPDu/7uVjtp457T/AyVSzTPmTPIcZIRcfzp0d3EmRbW6rju53GibQ7pGzDLHIvocqaqvp1/GTmBjwOVIPNT7C/x3Z2Rq0ZrWf36DriV5m3yOWYcgHpUeF5xjk7h9aa1tdg820vX+6abFaXzZAtZOvGcD+dbRptK0Voa+1oxVudfeiXeoOc9acpBHHSlj0m+kPzCOMf7TZ/lV+20VY1/fXDv6hRtH9TWkaUmc9THUILR39DOfCkHvnGB3pLgNDEHlUop6E10cFtDAP3Uag/3up/PrTp4I5oHilQNG4wRWvsVbc5P7TfMvd0PKPE2tbydOsohPcXH7spt3DB4wR3z6VL4a8FXfgJbfVZbd9VswCZ7JF8yazHZ4uf3gXunX+7nAU934U8IadoTvcRl7m7cn99NglRnoP8a6VjURjy7l4nFqrpT27lLTdQtNWsIb3TriO5tJl3RyxtlWH+e3apq5nVtCvLC+k1fwoYortzvutPkO23vfUnA+SX0kHXowIwRpaBrtprUMnk74LyAhbmznAWa3Y/wuv8iMgjkEjmm0cVzUpKWkqR3CiiikMKKKD0piQ3vR1paKChtNPWnGkYUhjGqNhUppjUhoktB89aUAxfRn1jYfqtUbQfNWnEvzo3pkVtSRhVZbooorpOYKKKKACiiigAooooAKRVCggepNLRQAUmKWigBMU1lzT6QilYCpJCD0qu8NaLCo2QGolBGkZsy3hqB4jWq8dRNHWLpm0ahktGRTCCK1GhB7VC8FZOmzVVEUKKneEjtUTKRWbVi07jD0pKcelNqWaIz9bb/QhH/wA9pEj/ADYZ/TNXIR+7HvzVDUiJL6zhz93dMR9Bgfqa0VGFA9BSGIailGVI/Kpjz9RUN03l20kg/hUt+lUiep4H491KS78WXGNyiBvKQegHf8Tk1teEtZl0y6EsA3F+ZbcceZ6svv7U/wAY6Cbjy9UhUkgfvQO49a5e2YmQygkFPukdjQ1bY9mMY1qdj6P0LUoNUsY7m1kDxuPxHsa0WVWUq4BUjBB6V4Z4Z167srprjTWH2n709o33Lgd2T0b2r1vwz4jsPENqJbOTEoHzwtwyH6VpCalp1PDxGGlSfkYHiHwgfON3p2XRR/x7+nf5f1/OuetoHBMtypBB2qp9a9a71m6lo1tfEvjy5sH5wOv1FJ010OnC5i6fuVNUcBHamRsg5HXH9aq3ECqspEeHceWrei55x7np9M+tdXdabPp0DkxmQdS68jH9Ky0Ecis0gyIwFx2LHk/596wnF3SZ6sa0Ky9x3RzYimtWaQZBH8S10WkeJruzWNbnMy45J6imi2UiIA8yEtj2FJd6WCjMnytj8KtSaKrUqdVWmjtNO121vEXDbWPY1qq6uMqc15Q9rcWo+ZWHuKvWWtXlupAkLADoea1U+55VXLHvSZ6XRXEW3iqb/loqn6VbTxWvRo+frVcyOOWCrx+ydQ/WkrlpPFkA5KPn2xiqV34yVEJjt2Y+710KcEtzH6liJPSDO0LKOpFRPOqgnsO54rza58XanP8AJbLDEx6YXcf1rpfDuk3kgW71i4kmmPzLGx+VPw9aqM4y2JrYSdCN6ll5dTqInDoCKfSKoUYFQzzEMsUS7pW6D+vsKo5SxbyqZGjB5xmp26VFaWwgUkndI33m9f8A61THpWEtXodMFZWGd6wPEfh2PU5or+ymaw1u2Ui3vYxk46+XIv8AHGT1U/UEHBG+aKks5vRfELzaj/ZGt232DWghdUDbobpR1eF/4gO6nDL3GME9BTLqztrpoGuYIpjBIJYi6BvLcAgMuehwTz714d4z8UapYa18RrpPFk2mvoRtm06ybyTFMWgVzGUZSzbm44II3UJX2E3Y90pDXiUXxC1Syv8AxPNdMtvfbdHjt7S5WWZFnuICzRpGpBDZB7jJHJqxpHxP8Qatp+hxw2mj2mpXt/fWMz3ZcQxm3jL7uGyM4wRk/WjkYcyPZaQ18+QfEvxTqkkGv6XHZRCPwtc6lcWNy8htyYblkZ0C8liE+XJ6N1PfqLX4j67qN9qD2lpo9tpVhpFrq11NdySl40lgaQgBAd2CPbgdyeBwY1NHrXelrwcfGXXLew1kXmm2BuYFs2tJ2R4Ittw20PKpZiFHXORn0FaQ+JfiFgtpBFoN1fN4gj0VZojJ9nYNB5m8YYng8f5zRyMfOj2U9DSGvJPCPxF8Raj4i8M2esWGkpaaxJf2pa1aQuktru3N83G1tuAOT3z2r1s1LVik77EbcU3rT2pq/eqRly0XmtKLjFUrZeBV5O1dNNaHNUZNRRRWxiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABppFOooAiZajZKsU0ipaGmVWWmlKtFaaUqXE0Uio0QNQSW+e1aOykKCocEylOxgzxFKgrXvovlJrIYYNclSPKzrpy5kY7tu8Rso6rbqPzck/yFbFYUQP8AwlDMejxHH4ED+hrdrNGzG1U1NhHYzFiAGG3n1JxVwHmuS+Kt01l4UMsZIf7RHtI7YOf6VSCMeaSiXbWzD27RyL8r9q898VeGX02ZpLaM+QxLEAdK7/wTrdtr+mrIpC3CACRPQ+o9q3ry1juEKuoI6c1pZSRVPESoVLM8Dt42Uh1JVwcgjgg+orZhnMtytxbz/YNWTpMp2xzf73o3v0NdJ4i8Jtab7qzXdF1KAcrXPx2Ae3UuMO5zj2rnnF3v1PZi6eJjeJ3fhvxyQy2XiOM210OPMIwre5/xru4Zo54xJDIroejKcg14iRttlhuo/tFsPugnDp/ut2+nSrWk3GpaZmbRbpp4U5e3P31Huvce4zVRr20meZiMuSd46fl/wD2eqF7pFpdA7o9jf3k4rmdD8e2l2VjvkMEvQsOldjbzxXEYeCRZEPdTXRdM8udOpQl72jOWutAuoZRJCwlRV2gDggfSqz+ZHIVmjdef4hiu3pjxpIu11Vh6EZqXBdDqp5jUjpPU4y6mUSc47VVmht5IZGMa5HccV11zotlcZ3RlSe6nFUZfDieW6wzsA3ZxmpcGdtPMKNle6OSOnQEqUcqGOPWq0+nskuBICM10zeHLtQqpNC20qckkdPwpJfD15I5O+Bef7x/wo9lU7HQsww3Wf5nMz6W6ruLriok0hpl2RkySHoqjk128Ph7cgF1OSO6xjH6mtezsrezTbbRKmep7n6mtI4dv4jkrZvCKtSV336HO+GvC6WBWe7VWuOoB52f/AF66pQAMDpS1FNII1J6n0rrilFWR4VWrOtLmm7sJ5fLACgs7cKo6k1PZW/kqWkIaZ+Wb+g9qbaW5jYyzczMMf7o9Ks5rOcuiLhG2otFJmjNQWIwptPNMNJlIKyrjw/o1xqH2+40jT5b3cG+0PbI0mRgA7iM5GBj6VqZpKVx2M2+0TSb37R9t0yxuPtJQzebbo/mlRhS2R82O2elY+p+BfD2o3OlST6bbCDTpJZY7RIYxBI0ibGLptweOR05ArqSKTFK4WKA0fTAmwadZhfs5tMCBceSesfT7n+z0oj0rTollWOwtEWWJYJAsKjfGowEPHKgHAHTFX6bQM5vUPBeh3Oi3mmWljb6ZFdKqyPYQRxOQrBgPukEZHQgjk1D4Q8CaJ4WsWtrOBrktdfbTLdhXcTbQoZcABcAYG0DFdVRTux2RRj0rT4pIJIrC0SSBneFlhUGNn++VOOC2TnHXvVtqcaYakY006FctTetW7dO9EVdibsi3AuBVlajiXAqZa64o5JO4+iiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigApKWigBMUmKdRSAjxRipMUYosO5TuY9yGsO4iKOa6crkVn31sGXIFYVqd1dG9GpZ2Zx97bNb63psrEYnhcY9Oc1p0viyLyrnRHH8DPGT9VH+FNrkqR5ZWOynPnjcToa5L4rWpvPCYiT7/AJ6lfc4biuvxx7GsDxoA+jxKTz569foaI7mlN2mmeKeGdUudBvVvLcn5TiRD/EPSvetA1e31qwjuIGBVhkgdRXjni7S/Ija9gXEchCyAdm9fx/z1qv4Q1u40O8yrObZz86qeR7j39u9Jtx1R34jDrERU4bnv7oCu0jINc7rPhlZMXFmDkfej9var+ha3BqEUeXQO/wBxx92T6eh9V6it1RWicaiujyYVamHleOjPILqF0KpIpUghcH61Peaeim2aItHMzHa6nBGPQ16Xqej2mogGaMCQch165/rXM6roF7FcQvEglhjUjK9fyrKVNrY9qhmVOr7tTR/gcxd2ksiLJqMC3Knjzo8Rzfn0b8R+NJYjUbKTdol/5n/TCX92/wBMHg/ga3b0bbSNDwwdcg01ERrSQsqnJ7iseRx+B2/L+vQ6HShOOm33r+vQLbx9d2cgh1exZZB1+UqfyrorDxnpF2AGmMLHtIOPzrntPkbZcK5EsaHiOUb1/I1R1OwgZ/NjsYXiIzmLKMv1AOPxAp/WJxaUkcU8upydrW9P+Cek299a3KgwXEUgP91hVmvF3so0f92LqFvTIb/Cjzb2AkW2oXY9txUfzrdVk90YSymX2Zfgeynk0V47/amsrjbqFwf+2hprarrJJBvp/wDvuun6xA5/7Gr91+P+R7GTjrSI6uuUYMPUHNeUafYarqtwizXEzg9QXJwPU+1enaXZR6fZR20WSEHJPc9zWkJ8+qRxYrC/VmouV32LROBmoreMz3HmN/qkPHu3/wBb+f0pzK0riNOp6n0FXFVY0CqMAcVUnZGEI31FJpPrQTTawOgXNGaSigApDSmikUkJSUtFIYlJS0UgGkUlKaPxpiGUtLTTgEAkDPSgdxDTTTjSomTSAIkzV+BMVFEmKtxLxW0ImU5EqinikApwrdHOxaKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZIu7aO2eafRQBz/AIzi3WNpKOsVyh/A5X+oqgOQK3/EEfmaPdcZKL5o+qnd/SsJUwxX0JFcWIj71zuw0vdsSxx71wK5P4npJBotlPF1W6VyueSArZ+vGa7uzg+RWPQ8VxPxrgmXwxb3NuSGtLlZcjtkEfzIqfZvlutzSjO9ZROejWC/04qwDxS4BB9K4m/0ltNumif5omyUb1H+NdP4UvIr6z3RAI6sBLEOik9x/sn9PyrpbrRI9UtGhfh8ZR/Q1lfnWh6lOt7CdpbHnOjajPpN020mS3fBeInhvcejehr1PQPE6SQK0khnthwXIxJF/vj09xx9K8tmtZLTULq3u0KvH8pBq2PMtJEmtJWilXkEGsneL5o6P8zqxGDhiVzLc91gmjnjEkLq6HoQal7V5HoniJ4LoRzubOR/+WsYzET/ALSdvqMV2Vp4oMbsl7EHVOGmt/mA/wB5eo+vStY4iLfLLR/11PCrYGrSdrXOjubO3ulxPCj+5HP51lXXh6FoytvI0QPOCMir9lqtleqDbXMUmewbmrbsAOvWt1FS0OeNSpRfuto48aBd25n2bZQ4GNpxj86rLa3lqfmhlGOMhSRjNdtkUtaSw1OWjRss1xC3afyPKLjV5IfFH2DUo44Y7g77KUDAkAX5o2J/jHJ916dDVuOOPzfnCY55yK7vX9Htdc0ySyvg4QkOkkbbZInU5WRG7MDgg1l+GdUlkurjRNaCDWbNdxfYFW7hzhZ0Hv0Zf4W46FSZ+qwWxrHOKsVblX4nJNYNNMwt42fnjYN38q19M8LXE0gkuR5K/wC11/L/ABruhS1UcPBeZFXN8RNWVl6Fays4bKERwJgdz3b61O7YwAMsegpNxZgkY3MfSr1raiL53O6Q/pW2x5usndjLeHykO7755NOapZKiaspM3ihhpKU0lQWFFFFIANFBooKQhopaSkMSilpKAEqG4k2KxA5Az/n3qaqd9ueWCFR98lifpj/HP4ClJ2QRVyrfXYFg58754/lk2ZB3Y7e3U++KuWZaZPPcAF/uj0X/AOv1rPi0yR/MSRghPLADPOCQR9Cx/KtuCEKiqowqgAD2qIKTd2VNxirIRUyasRxVJHHU4XFdMYHPKYxUqZRQBThWqRi3cUU4UgFLVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJoxLC8b/ddSp+hrmbaNsxh/vbFJ+uMH9Qa6msy6twlzGw6Nu/nn+prGtG6ubUZWbRZto825WsrxFp6atod5YyAHzomUZ7Njg/nituEYWoJ02OT/C1Nx90mMmpXR8u6VdTaFqiSOpBhl8q4jPdc8j/AA9wK9s0OWKcfu3DgdD6j/GuR+LXhgQXR1m1X9zNhLgKOjdmpPDmom2cupyoWPeQc4Kx9R79AfpXm1FKnUTjr3PoKiWKpKpDc7HxX4ag1q23xgJeIPlfH3vY15bqltcWMrw3UbRyKOhFey6Jq9rqtssltKrEqGwD1HqP88U/V9Is9Wg8u8hD+jdCPxrVxVRcyOXCY+eFfJNXX5Hh4fMkZIyNtaml3Ed0ZonaSOaEboZ4yQyAdVOOq+n6da6bU/AssbhrNlkQA4GcGsBPDupWU0jrbzKSwOdvoQf5iuepRlJWPZ+uYetH4kvXQqSz3aw75hHcx5wJlHP/AH2uDn2NLa63dQYKXN1GRwAW3j+lRXXhqa8gkt5bWdonPKqGHfI5HPBqpB4C8QRkf2Td3iL2ivk8+P8A76JD/wDj1aU6U47XRnVq4a1pOLXqvyZ0cHji9gwHeKf3Kkf0FaUPxBGAJbRif9lq5n/hFfEdmiPqekC5j/jbTZlkdR67JCn5KWNdR4Vfwgl2luLkJqhHFtqMTW0x/wB2OQAn6jIrth7b7TPHxE8vSvTTb8rr8zpNC1i51Zd6WM0MX9+UgA/T1p/ibRP7Ws4pIJRb6raN51ldgcxSehx1RujL3HvgjYLqgwuOOMDtU9vYTXBDTExR+n8R/wAK6EjyZNN6Kxz3hvxANYgkilt2ttWtj5d5ZH5mhf1GPvIeqsOCPQ5A6CCxuZuZj5CenBY/0H61R8Q6BNDcW+t+G4YV1mzUo0bnaL2AnLQu3rnlWOdrD0LZ1vD2tWniDSYr+xLhGJSSKRdskMinDxuv8LKQQRTEWIYI4FCxrj3PJP41IelOYU2oZaInFQMKtMKhdazkjSLIDSU9hTKzNEFFFFABRRRSGFIaWlxRYdxuKKeFp4jJp8ouYgxShSasCE1KkPrVKDIcyskRParMceO1SqgFPxWihYzlO40ClpcUoFXYi4gFPAoApaZIUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACobpdwQ+hqamyDKmk1dDTswT7tJNH5kZXoeoPvTl6UtAjFu4Ir62mtrlNyMCjoe1eO6hpreGbzUbGYnyZIme3k/vAgjH1r3S5tvNIdCElHGcZBHoaxdf8PDWrTyJxEv/TQckfTisJ0mzvweL9jLXZnkHgjRPELxC50xGjUMHUseG/yK9Zs5r2O3H9q2pikA+aRPmT/61b+n2UNhaR29su2NAABVnFEcOl1DFY327+FfqYisrqGUhlPQg5odgq5JrUezt3yTEoJ6lflP5iq8mlW7kZaYY7CQ1Spa6nI56Gb5iDvSeavbJrQGjWw/inP/AG1NSpplon/LNm/3nZv5mtbIyMdp1UgHgnoD1NNu9Ej1u1a21Oyt57NvvR3UIdT/AMBauiit4YT+6ijQ+qqBUtOwzjbT4f2OmSLJoGparpLL/wAs4JxJD+EUodF/4CFqV5PGmmOSYdJ162Bz+6ZrK4A+jF0c/wDAkFdbRQBySePdJt2WPX4r7w/KTj/iaweVFn0E4JhJ9g9V9aWTRrt/FXh1Re2NwFbVLS3w/wBojAwLiLHWVRjI/jVcdVWu0dVdSrqGVhggjIIrmrvwPoMpL2do+lTk7vO0uZ7Ni3q3lkBv+BA0Abdld2+oWMF5YzJPa3EayxSxnKupGQQfQivDPA3xKaw+FXiG8uNVg1XxLYz30sVjcXQecojnblM79ijnjsDXqPgnwnd+Fp9QiGu3Oo6XcP50VvdQoHgkJ+ba6bRtPXbtHOTnk5h0XW/A19rJttDvdAm1Uq7GO2aLzcAkPnHPrmk0NM8wf4o+IrOwv7n7Zo2sWumpp1/d3djAwRIJ3KzQ43t86jDBs9M5FM0b4ueItU1X7HHp1tvjgu9YeMRNl9PFuklrg5++zSBCfY8V6ZY+JPAcelal9g1Lw+unQYe8ELxCNQzbAzgcEFuM9zVqy8S+EX+03Vlqmjn7JamSWaGRP3durFclh/AGUj0yKkpHiSfF7xd/wiGq6u0ejSKmlw31u6vCWSVp4o3QxR3EjlNsn3mCEEYIB4r0nx7PrWl/CLxDd6vPaSarDayyb7HzIYwM5UAht4wMDIYGt2O/8ErrDaVHNoK6lebd1qBEJJsjeoZepJA3AHnvV7T/ABB4c8RXV3pmn6ppupTxKfPtopUlIUHacqM8Z4+tS0UmeOy/EDxTbXuofZZNM/svSrvSrR4ZYJHmlW5SPcfM38EFjyQf8cs/EDxL4dtvGM0+r2eoz2/iE6fFbTQgNaxsyDz/AJpQBEMlQrFV3HJfHFfRB0mzO/Nnb/OVZv3S/MV+6TxzjAx6UjaNYPNPK9jatLcLsmcwqWkX0Y45HsaVvId/M8M074geNtS1bQ9Htv7BivNQvL6AXDlJ0McUCSozLBM4V/mOV3HPy1dk+Iutx/8ACUXj6joKvo9xe20WiNE32q48iJmEgbzM4JXdgIRsB5zXs1noenWYi+yWFpAIizR+VCq7CwwSMDjI61L/AGPYG++2mxtjeY2+eYl8zGMY3YzjHFPl8hc3meBv8T/E8NvqltY3Xh7WLqOys7uG8hxDFG0zYeEhpdrOACyjepOPwqHT/Hmua74o8Cyw+Jbewsru41G1uRcaf5CM8Kxna6+eysTuwpV8A8852j3+PQNIjs5bSPS7BbWVt0kIt0COfUrjBNSnRtNa2gt20+zMFu26GMwLtjPqoxgH6VSiiXNnz+Pilq+ralqmnwXNvNpV5peqS206QLbzwtArbSAszsBkEZdUJxkCvZ/ho8lz8OvC1xcSPLPLpVq8kkjFmdjCpJJPJJPetpNH02OV5E06zWSQsXYQKCxb72TjnPf1q5FGkMSRwoscaAKqqMBQOgA7Cq5UTzMAlG2n0UWENxRTsUYosA3FOAoopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAA6UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXj2lfB+a2stAtrjUIMWLar58kMZV5FvFdRtPYruHX0r2GigD5/j+BepHwvqOkTX2mtPJp0emwX3mXcjmNZ4pQGSSVkRcR/dQAZPGBkHr/AIifCtPEutaNdaVc2+mWsKfY9Rt0hwt1Z+ck3lADgfMh/wC+jXqNFAHjv/CpLmLx9cawlzaXWm3Grx6x5dzNdLJBKpBIVElETn5flZlyAcHIGKv/AAq+HOreDdbubi41K3TSmt2ii0uzeZoFkaQO0qiVmMfTG1SQc9eBXqdFACYpcCiigAxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32457=[""].join("\n");
var outline_f31_44_32457=null;
var title_f31_44_32458="Epidemiology and clinical features of multiple sclerosis in adults";
var content_f31_44_32458=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(true",
"	);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <!-- TC:SLA_MESSAGE -->",
" <div id=\"slaMessageContainer\">",
"  <div id=\"closeMessage\">",
"   <a href=\"\" id=\"close\">",
"    Close",
"   </a>",
"  </div>",
"  <div id=\"slaMessage\">",
"   The use of UpToDate is subject to the",
"   <a href=\"#\" id=\"sla_message\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
" </div>",
" <div id=\"slaDialog\">",
"  <div id=\"slaDialogTitle\">",
"   Subscription and License Agreement&nbsp;",
"   <a class=\"icontxt\" href=\"./license?view=print\" onclick=\"\" target=\"_blank\">",
"    <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\">",
"     Print",
"    </img>",
"   </a>",
"  </div>",
"  <div id=\"boxDialog\">",
"   <strong class=\"largeGreenHeader\">",
"    Subscription and License Agreement",
"   </strong>",
"   <p>",
"    By clicking the \"accept\" button (or opening and using",
"the software/content package if applicable), you agree to become bound",
"by the terms of this Subscription and License Agreement (the",
"\"Agreement\"). If you do not agree to these terms, if using the",
"online version of UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    software/content, click \"decline\"",
"or do not open the package (and promptly return it). READ THE FOLLOWING",
"TERMS IN THIS AGREEMENT CAREFULLY BEFORE INDICATING YOUR ACCEPTANCE. In",
"this Agreement, the term \"you\" refers to: (i) an entity",
"entering into this Agreement for use of its employees, (ii) an",
"individual purchasing an UpToDate subscription under this Agreement,",
"either on his or her own behalf (or as agent for a corporation or other",
"entity or organization); or (iii) an individual entering into this",
"Agreement as a condition of using UpToDate through a subscription",
"purchased by a hospital, medical school, or other institution",
"(\"Institution\"), where the individual is employed by or",
"affiliated with the Institution.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"LICENSE: UpToDate, Inc. (\"UpToDate\"), in consideration of the",
"subscription fee and acceptance of this Agreement, grants you a",
"non-exclusive, non-transferable license and right to use and access the",
"UpToDate database and software (the \"Licensed Materials\") in",
"accordance with the applicable subscription terms (as may be provided in",
"UpToDate&amp;apos;s separate invoice terms):",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"INDIVIDUAL: An individual subscription permits one individual to access",
"and use the Licensed Materials for his or her own use only by loading",
"the software on a single computer (i.e., within a single CPU) at a fixed",
"location, by loading the PDA software on a single Personal Digital",
"Assistant (PDA), or by using his or her unique user name and password to",
"access the Licensed Materials from any location via the Internet.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"STANDALONE WORKSTATION: A standalone subscription permits multiple users",
"employed by or affiliated with you to access and use the Licensed",
"Materials only for a purpose related to your business by loading the",
"software on a single computer (i.e., within a single CPU) owned or",
"controlled by you, with a hard drive owned or controlled by you",
"connected directly to such computer. You may not install the software on",
"more than one computer. A Standalone Workstation license does not",
"include Internet access to the Licensed Materials.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"INSTITUTIONAL SUBSCRIPTION: An Institutional Subscription permits only",
"individuals who are employed by or affiliated with the relevant",
"institution to access and use the Licensed Materials at any",
"Internet-connected computer validated for such use by UpToDate, but only",
"for the clinical, educational or research purposes of the Institution.",
"Further, access may be restricted to particular websites per the",
"applicable invoice terms.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"OWNERSHIP: The Licensed Materials, including without limitation all",
"copyrights and other intellectual property rights therein, are the sole",
"and exclusive property of UpToDate (or its parents, subsidiaries,",
"affiliates, or designees) or its suppliers. By indicating that you",
"accept these terms, you do not become the owner of the Licensed",
"Materials, but are entitled to use them only according to the terms of",
"this Agreement.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"PERMITTED USES: You may print out, or email to a colleague, individual",
"articles containing only insubstantial portions of the most current",
"version of the Licensed Materials, but only for a) your personal",
"clinical, educational or research use; b) teaching healthcare",
"professionals; or c) consulting with individual colleagues, provided",
"that any printed or emailed articles include a source reference to",
"UpToDate and its copyright notice. You are not permitted to print or",
"email substantial portions of the Licensed Materials, nor to email",
"individual articles to large numbers of recipients.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"PROHIBITED USES: Except as expressly permitted in this Agreement, any",
"copying, distribution or modification of the Licensed Materials is",
"strictly prohibited. No part of the Licensed Materials may be copied for",
"resale or other commercial use, or posted on public bulletin boards, web",
"sites, Internet domains, or online chatrooms. No part of the Licensed",
"Materials may be reverse engineered or included in other software.",
"UpToDate electronically monitors compliance with this Agreement, and",
"reserves the right in its sole discretion to change and or cancel an",
"individual's user name and password or to disable an IP address without",
"notice in the event of multiple concurrent logins, excessive search",
"quantities or excessive download traffic volumes. You agree to comply",
"with all applicable laws, including all US export laws and regulations,",
"in connection with the Licensed Materials.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"SUBSCRIPTION TERM: You have obtained the right to use and access the",
"Licensed Materials for a specific limited period of time, i.e., the",
"subscription period for which you or your Institution have agreed to pay",
"subscription fees. At the end of this period, your license and your",
"associated rights, such as technical support, will expire automatically,",
"unless you or your Institution have renewed your subscription on",
"UpToDate's then-current terms. UpToDate may embed technology in the",
"Licensed Materials causing them to become inaccessible after your",
"subscription term. The Agreement and your license to use the Licensed",
"Materials will also terminate if you fail to comply with any term or",
"condition in this Agreement.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"RESTRICTION AGAINST TRANSFER: You may not sublicense, assign, share,",
"sell, rent, lease, or otherwise transfer your right to use the Licensed",
"Materials (including your username and password) whether by merger,",
"operation of law, or otherwise.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"USE OF PROFESSIONAL JUDGMENT: The editors and authors of the Licensed",
"Materials have conscientiously and carefully tried to create the",
"identified diagnosis measures, treatment alternatives and drug dosages",
"in the Licensed Materials that conform to the standards of professional",
"practice that prevailed at the time of publication. However, standards",
"and practices in medicine change as new data become available and the",
"individual medical professional should consult a variety of sources. For",
"this reason, only the most current release of the Licensed Materials",
"should be consulted when information is sought. New updates of the",
"Licensed Materials are issued periodically; do not rely on older",
"versions. In addition, when prescribing medications, the user is advised",
"to check the product information sheet accompanying each drug to verify",
"conditions of use and identify any changes in dosage schedule or",
"contraindications, particularly if the agent to be administered is new,",
"infrequently used or has a narrow therapeutic range.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"The Licensed Materials describe basic principles of diagnosis and",
"therapy. The information provided in the Licensed Materials is no",
"substitute for individual patient assessment based upon the healthcare",
"provider's examination of each patient and consideration of laboratory",
"data and other factors unique to the patient. The Licensed Materials",
"should be used as a tool to help the user reach diagnostic and treatment",
"decisions, bearing in mind that individual and unique circumstances may",
"lead the user to reach decisions not presented in the Licensed",
"Materials. The opinions expressed in the Licensed Materials are those of",
"its authors and editors and may or may not represent the official",
"position of any medical societies cooperating with, endorsing or",
"recommending the Licensed Materials.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"LIMITED RIGHTS NOTICE. Any access to the Licensed Materials provided",
"under contract to the Government are provided with limited rights. The",
"Licensed Materials may be reproduced and used by the Government with the",
"express limitation that they will not, without written permission of",
"UpToDate, be used for purposes of manufacture nor disclosed outside the",
"Government. The term \"Government\" as used herein shall have",
"the meaning ascribed to it in 48 CFR 52.227-14.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"LIMITED WARRANTY: If UpToDate has supplied physical media to you",
"containing the Licensed Materials and they are defective, such media",
"will be replaced without charge if returned to the place of purchase",
"within 60 days after date of payment of the license fee. EXCEPT AS SET",
"FORTH IN THE FOREGOING SENTENCE, NEITHER UPTODATE NOR ANY OTHER PARTY OR",
"MEDICAL SOCIETY MAKES ANY WARRANTY OR REPRESENTATION, EXPRESSED OR",
"IMPLIED, WITH RESPECT TO THE LICENSED MATERIALS, WHICH ARE LICENSED",
"\"AS IS\". ALL OTHER WARRANTIES ARE EXPRESSLY EXCLUDED AND",
"DISCLAIMED, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES OF",
"MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTIES",
"ARISING BY STATUTE OR OTHERWISE IN LAW OR FROM COURSE OF DEALING, COURSE",
"OF PERFORMANCE, OR USE OF TRADE. ANY STATEMENTS OR REPRESENTATIONS MADE",
"BY ANY OTHER PERSON OR ENTITY ARE VOID. YOU ASSUME ALL RISK AS TO THE",
"QUALITY, FUNCTION, PERFORMANCE, AND ACCURACY OF THE LICENSED MATERIALS.",
"   </p>",
"   <p>",
"    LIMITATION OF LIABILITY: IN NO EVENT WILL UPTODATE OR ANY OTHER",
"PARTY WHO HAS BEEN INVOLVED IN THE CREATION, PRODUCTION, PROMOTION OR",
"MARKETING OF THE LICENSED MATERIALS BE LIABLE TO YOU OR ANY OTHER PARTY",
"FOR ANY SPECIAL, INDIRECT, INCIDENTAL, RELIANCE, EXEMPLARY, OR",
"CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF DATA OR PROFITS, OR FOR",
"INABILITY TO USE THE LICENSED MATERIALS, EVEN IF UPTODATE OR SUCH OTHER",
"PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT",
"SHALL UPTODATE OR SUCH OTHER PARTY'S LIABILITY FOR ANY DAMAGES OR LOSS",
"TO YOU OR ANY OTHER PARTY EXCEED THE LICENSE FEE PAID FOR THE LICENSED",
"MATERIALS.",
"   </p>",
"   <p>",
"    Some jurisdictions do not allow limitations on how long an",
"implied warranty lasts and some jurisdictions do not allow the exclusion",
"or limitation of special, indirect, incidental, exemplary, or",
"consequential damages, or the limitation of liability to specified",
"amounts, so the above limitation and exclusion may not apply to you if",
"prohibited by applicable law. You may also have other rights which vary",
"from jurisdiction to jurisdiction. You agree that this Agreement shall",
"not be subject to the United Nations Convention on Contracts for the",
"International Sale of Goods.",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"GENERAL: If any provision of this Agreement is determined to be invalid",
"or unenforceable under any applicable law, it shall be deemed omitted",
"and the remaining provisions shall continue in full force and effect.",
"This Agreement may be modified only in writing authorized by UpToDate.",
"UpToDate's waiver of any right shall not constitute a waiver of that or",
"any other right in the future. This Agreement shall be governed by and",
"construed in accordance with the laws and in the state and federal",
"courts of the Commonwealth of Massachusetts, USA. This Agreement",
"constitutes the entire understanding between the parties with respect to",
"the subject matter hereof, and all prior agreements, representations,",
"statements, and undertakings, oral or written, are hereby expressly",
"superseded and canceled. Sections 2 and 4-9 survive in full force and",
"effect following expiration or termination of this Agreement.",
"   </p>",
"   <p>",
"    Should you have any questions regarding this Agreement, you may",
"contact UpToDate at the email address or telephone numbers set forth",
"below.",
"   </p>",
"   <p>",
"    UpToDate, Inc.",
"    <br/>",
"    <a href=\"#\" id=\"infoEmail\">",
"     info@uptodate.com",
"    </a>",
"    <br/>",
"    Telephone: 1-800-998-6374 or +1-781-392-2000",
"   </p>",
"  </div>",
"  <div id=\"slaButtons\">",
"   <input id=\"closeSLABtn\" type=\"button\" value=\"Close\"/>",
"  </div>",
" </div>",
" <div id=\"slaMask\">",
" </div>",
" <script type=\"text/javascript\">",
"  $(function(){		",
"				$.extend($$.showSLAMessage,{",
"					checkUrl: '/services/AgreementWebService?type=sla_msg_check',",
"					acceptDrugUrl: '/services/AgreementWebService?type=drug'",
"				});",
"				$$.showSLAMessage.init();",
"			});",
" </script>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"headerLogo\">",
"    <a href=\"./search\">",
"     <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"     </img>",
"    </a>",
"   </div>",
"   <div id=\"headerLinks\">",
"    <a href=\"/home/about-us\" target=\"_blank\">",
"     About Us",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"file://learn.uptodate.com/global\" id=\"newsLink\" target=\"_blank\">",
"     News from UpToDate",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"/home/contact-us\" target=\"_blank\">",
"     Contact Us",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"/help\">",
"     Help",
"    </a>",
"   </div>",
"   <div id=\"headerFeedback\">",
"    <img alt=\"white circle\" src=\"./../images/icn_feedback_arw.myextg\">",
"     <a href=\"/login\" id=\"headerLogin\">",
"      Log in",
"     </a>",
"    </img>",
"   </div>",
"   <div id=\"headerMenu\">",
"    <ul>",
"     <li>",
"      <img alt=\"\" class=\"menuUp\" height=\"23\" src=\"./../images/menu_up.myextg\" width=\"14\"/>",
"     </li>",
"     <li>",
"      <img alt=\"\" class=\"menuDots\" height=\"24\" src=\"./../images/menu_dots.myextg\" width=\"2\"/>",
"     </li>",
"     <li id=\"searchTab\">",
"      <a href=\"./search\">",
"       New Search",
"      </a>",
"     </li>",
"     <li>",
"      <img alt=\"\" class=\"menuDots\" height=\"24\" src=\"./../images/menu_dots.myextg\" width=\"2\"/>",
"     </li>",
"     <li id=\"patientInfoTab\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Info",
"      </a>",
"     </li>",
"     <li>",
"      <img alt=\"\" class=\"menuDots\" height=\"24\" src=\"./../images/menu_dots.myextg\" width=\"2\"/>",
"     </li>",
"     <li id=\"whatsNewTab\" }>",
"      <a href=\"mobipreview.htm?3/13/3294\">",
"       What's New",
"      </a>",
"     </li>",
"     <li>",
"      <img alt=\"\" class=\"menuDots\" height=\"24\" src=\"./../images/menu_dots.myextg\" width=\"2\"/>",
"     </li>",
"     <li id=\"calcTab\">",
"      <a href=\"mobipreview.htm?0/37/606\">",
"       Calculators",
"      </a>",
"     </li>",
"     <li>",
"      <img alt=\"\" class=\"menuDots\" height=\"24\" src=\"./../images/menu_dots.myextg\" width=\"2\"/>",
"     </li>",
"     <li style=\"background-image: url(/images/spacer.myextg);\">",
"      <img alt=\"\" height=\"23\" src=\"./../images/right_shim.myextg\" width=\"16\"/>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"topSearchBar\">",
"    <form action=\"./search.do\" method=\"get\" name=\"SearchForm\">",
"     <div id=\"smallSearchBox\">",
"      <div id=\"new_search\">",
"       <div id=\"searchbox_dd\">",
"        <input autocomplete=\"off\" id=\"txtSearch\" maxlength=\"200\" name=\"search\" type=\"text\" value=\"\"/>",
"        <span id=\"searchbox_dd_submit\">",
"         Search",
"        </span>",
"        <span id=\"searchbox_dd_type\" title=\"Change Search Type\">",
"         <span id=\"searchbox_dd_type_name\">",
"         </span>",
"        </span>",
"       </div>",
"       <div id=\"searchbox_dd_dropdown\">",
"        <ul id=\"searchbox_dd_dropdown_topics\">",
"         <li class=\"active\" id=\"searchoption_topic_all\">",
"          All Topics",
"         </li>",
"         <li id=\"searchoption_topic_adult\">",
"          Adult",
"         </li>",
"         <li id=\"searchoption_topic_pediatric\">",
"          Pediatric",
"         </li>",
"         <li id=\"searchoption_topic_patient\">",
"          Patient",
"         </li>",
"        </ul>",
"        <ul id=\"searchbox_dd_dropdown_graphics\">",
"         <li id=\"searchoption_graphics\">",
"          Graphics",
"         </li>",
"        </ul>",
"       </div>",
"       <input id=\"spinput\" name=\"sp\" type=\"hidden\" value=\"0\"/>",
"       <!-- the real searchType input, value is copied from above radio buttons with jquery",
"		because the radio buttons are moved outside of the form (for display purposes) -->",
"       <input id=\"searchType\" name=\"searchType\" type=\"hidden\" value=\"0\"/>",
"       <input id=\"source\" name=\"source\" type=\"hidden\" value=\"USER_INPUT\">",
"        <input id=\"searchControl\" name=\"searchControl\" type=\"hidden\" value=\"TOP_PULLDOWN\">",
"         <input name=\"searchOffset\" type=\"hidden\" value=\"\">",
"         </input>",
"        </input>",
"       </input>",
"      </div>",
"     </div>",
"    </form>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </span>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <!-- <a href=\"#\" onclick=\"javascript:$('body').removeClass('fontSmall fontMed fontLarge').addClass('fontSmall');return false;\" id=\"fontSmall\" class=\"fontControl\" title=\"Smaller Font\"></a><a href=\"#\" onclick=\"javascript:$('body').removeClass('fontSmall fontMed fontLarge').addClass('fontMed');return false;\" id=\"fontMed\" class=\"fontControl\" title=\"Normal Font\"></a><a href=\"#\" onclick=\"javascript:$('body').removeClass('fontSmall fontMed fontLarge').addClass('fontLarge');return false;\" id=\"fontLarge\" class=\"fontControl\" title=\"Larger Font\"></a>-->",
"     <a class=\"findInPageLink\" href=\"#\">",
"      <img alt=\"Find in Topic\" src=\"./../images/icn_fop.myextg\" title=\"Find in Topic\"/>",
"     </a>",
"     <a class=\"findInPageLink icontxt textLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"patientInformationLink\" href=\"#PATIENT_INFORMATION\">",
"      <img alt=\"Patient Info\" src=\"./../images/icn_pt.myextg\" title=\"Patient Info\"/>",
"     </a>",
"     <a class=\"patientInformationLink icontxt textLink\" href=\"#PATIENT_INFORMATION\" title=\"Patient Info\">",
"      Patient",
"     </a>",
"     <a href=\"mobipreview.htm?31/44/32458?topicKey=NEURO%2F1689&amp;elapsedTimeMs=7&amp;view=print&amp;displayedView=full\">",
"      <img alt=\"Print This Topic\" src=\"./../images/icn_print.myextg\" title=\"Print This Topic\"/>",
"     </a>",
"     <a class=\"icontxt textLink\" href=\"mobipreview.htm?31/44/32458?topicKey=NEURO%2F1689&amp;elapsedTimeMs=7&amp;view=print&amp;displayedView=full\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"etacLink\" href=\"#\">",
"      <img alt=\"Email This Topic\" src=\"./../images/icn_email.myextg\" title=\"Email This Topic\"/>",
"     </a>",
"     <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"   </div>",
"   <div id=\"findInPage\" title=\"Find in Topic\">",
"    <div id=\"findInPageInput\" style=\"display: none;\">",
"     <input id=\"findInPageTerm\" maxlength=\"30\" size=\"30\" type=\"text\">",
"      <p>",
"       <input checked=\"checked\" name=\"findInPageSearchType\" type=\"radio\" value=\"syn\">",
"        <span class=\"icontxt\">",
"         Find synonyms",
"        </span>",
"        <input name=\"findInPageSearchType\" type=\"radio\" value=\"exact\">",
"         <span class=\"icontxt\">",
"          Find exact match",
"         </span>",
"        </input>",
"       </input>",
"      </p>",
"      <div id=\"findInPageButtons\">",
"       <input class=\"icontxt\" id=\"findInPageFind\" type=\"button\" value=\"Find\">",
"        <input class=\"icontxt\" id=\"findInPageClear\" type=\"button\" value=\"Clear\">",
"        </input>",
"       </input>",
"      </div>",
"     </input>",
"    </div>",
"    <div id=\"findInPageProgress\" style=\"display: none;\">",
"     <img src=\"./../images/progress.myextg\">",
"      Searching for",
"      <span class=\"emphasis\" id=\"findInPageProgressTerm\">",
"      </span>",
"     </img>",
"    </div>",
"    <div id=\"findInPageResults\" style=\"display: none;\">",
"     We found",
"     <span class=\"emphasis findInPageResultsCount\">",
"     </span>",
"     &nbsp;",
"     <span class=\"emphasis\" id=\"findInPageResultsInstance\">",
"     </span>",
"     &nbsp;of&nbsp;",
"     <span class=\"emphasis\" id=\"findInPageResultsTerm\">",
"     </span>",
"     <div id=\"findInPageResultsIterator\" style=\"display: none;\">",
"      <span class=\"emphasis\" id=\"findInPageResultsIndex\">",
"       1",
"      </span>",
"      &nbsp;of&nbsp;",
"      <span class=\"findInPageResultsCount\">",
"      </span>",
"      &nbsp;highlighted",
"      <input class=\"icontxt\" id=\"findInPageResultsNext\" type=\"button\" value=\"Next\">",
"       <input class=\"icontxt\" id=\"findInPageResultsClear\" type=\"button\" value=\"Clear\">",
"       </input>",
"      </input>",
"     </div>",
"     <div id=\"findInPageResultsNone\" style=\"display: none;\">",
"      <input class=\"icontxt\" id=\"findInPageResultsNewFind\" type=\"button\" value=\"New Find\">",
"      </input>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"     <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"      <br>",
"       <div id=\"printHeaderText\">",
"        Official reprint from  UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"        <br>",
"         <a href=\"file://www.uptodate.com\">",
"          www.uptodate.com",
"         </a>",
"         &copy;2013 UpToDate",
"         <sup>",
"          &reg;",
"         </sup>",
"        </br>",
"       </div>",
"      </br>",
"     </img>",
"    </img>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <!-- TC:TOPIC_PAGE -->",
"  <div id=\"topicContent\">",
"   <div id=\"topicTitle\">",
"    Epidemiology and clinical features of multiple sclerosis in adults",
"   </div>",
"   <div id=\"topicContributors\">",
"    <div>",
"     <a id=\"authors\">",
"     </a>",
"     <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32458/contributors\">",
"      Author",
"     </a>",
"     <br/>",
"     <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32458/contributors\">",
"      Michael J Olek, DO",
"     </a>",
"     <br/>",
"    </div>",
"    <div>",
"     <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32458/contributors\">",
"      Section Editor",
"     </a>",
"     <br/>",
"     <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32458/contributors\">",
"      Francisco Gonzalez-Scarano, MD",
"     </a>",
"     <br/>",
"    </div>",
"    <div>",
"     <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/44/32458/contributors\">",
"      Deputy Editor",
"     </a>",
"     <br/>",
"     <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/44/32458/contributors\">",
"      John F Dashe, MD, PhD",
"     </a>",
"     <br/>",
"    </div>",
"   </div>",
"   <div id=\"disclosures\">",
"    <a href=\"mobipreview.htm?31/44/32458/contributor-disclosure\" target=\"_blank\">",
"     Disclosures",
"    </a>",
"   </div>",
"   <div id=\"reviewProcess\">",
"    <span>",
"     All topics are updated as new evidence becomes available and our",
"    </span>",
"    <a href=\"/home/editorial-policy\" target=\"_blank\">",
"     peer review process",
"    </a>",
"    <span>",
"     is complete.",
"    </span>",
"   </div>",
"   <div id=\"literatureReviewDate\">",
"    <span class=\"emphasis\">",
"     Literature review current through:",
"    </span>",
"    Mar 2013.",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"emphasis\">",
"     This topic last updated:",
"    </span>",
"    Dec 6, 2012.",
"   </div>",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diseases that affect central nervous system myelin can be categorized as demyelinating (acquired, inflammatory) and dysmyelinating (abnormal formation of myelin, usually genetic basis) (",
"     <a class=\"graphic graphic_table graphicRef80553 \" href=\"mobipreview.htm?9/28/9676\">",
"      table 1",
"     </a>",
"     ). The most common autoimmune inflammatory demyelinating disease of the central nervous system (CNS) is multiple sclerosis (MS).",
"    </p>",
"    <p>",
"     The epidemiology, risk factors, clinical features, and disease course of MS will be reviewed here. Comorbid problems associated with MS, and the diagnosis and treatment of MS are discussed separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"      \"Diagnosis of multiple sclerosis in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"      \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link\">",
"      \"Treatment of progressive multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PATHOGENESIS",
"     </span>",
"     &nbsp;&mdash;&nbsp;Multiple sclerosis is a heterogeneous disorder with variable clinical and pathologic features reflecting different pathways to tissue injury [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/1\">",
"      1",
"     </a>",
"     ]. Inflammation, demyelination, and axon degeneration are the major pathologic mechanisms that cause the clinical manifestations [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/2\">",
"      2",
"     </a>",
"     ]. However, the cause of MS remains unknown. The most widely accepted theory is that MS begins as an inflammatory autoimmune disorder mediated by autoreactive lymphocytes [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/1,3\">",
"      1,3",
"     </a>",
"     ]. Later, the disease is dominated by microglial activation and chronic neurodegeneration [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/2\">",
"      2",
"     </a>",
"     ]. Supporting evidence includes the following observations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Inflammation in conjunction with blood-brain-barrier disruption, characterized by gadolinium enhancement on MRI, is seen in the early stages of most demyelinating lesions in patients with relapsing-remitting and secondary progressive MS. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H4#H4\">",
"        \"Diagnosis of multiple sclerosis in adults\", section on 'Magnetic resonance imaging'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Inflammatory T cells, B cells, and macrophages are typically seen on histopathologic examination of MS lesions at biopsy and autopsy [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/4\">",
"        4",
"       </a>",
"       ]. At least four histopathologic subtypes of MS demyelinating lesions have been described.",
"      </li>",
"      <li>",
"       Increased oligoclonal IgM and IgG levels are found in the cerebrospinal fluid (CSF) of patients with MS. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"        \"Diagnosis of multiple sclerosis in adults\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Approximately one-half of patients with MS have a specific serum IgG autoantibody directed against the inwardly rectifying potassium channel Kir4.1, which is expressed by oligodendrocyte cell bodies and perivascular astrocyte processes in the central nervous system [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/5\">",
"        5",
"       </a>",
"       ]. This finding suggests that Kir4.1 is a target of the immune response involved in MS pathogenesis, at least in a subset of patients with the disease.",
"      </li>",
"      <li>",
"       Myelin reactive T cells are found in MS plaques and in the CSF and peripheral circulation of patients with MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/6,7\">",
"        6,7",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       T helper 17-type immune activation, mediated in part by interleukin 23 expression, is associated with active MS lesions [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/8-10\">",
"        8-10",
"       </a>",
"       ]",
"      </li>",
"      <li>",
"       The risk of developing MS is associated with certain class I and class II alleles of the major histocompatibility complex (MHC), loci that are involved in T-cell activation and regulation. (See",
"       <a class=\"local\" href=\"#H8\">",
"        'Genetic factors'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Reduction in MS disease activity has been demonstrated with immunomodulatory drugs that reduce the Th1 immune response (ie, interferon beta), increase the Th2 and Th3 responses (ie,",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"        glatiramer acetate",
"       </a>",
"       ), or block T-cell movement from the blood into the central nervous system (ie,",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"        natalizumab",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"        \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       An animal model of MS (experimental allergic encephalomyelitis or EAE) can be induced by myelin antigens [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/11\">",
"        11",
"       </a>",
"       ], including myelin basic protein (MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/12\">",
"        12",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, direct proof of an autoimmune cause of MS is lacking, as no specific autoantibody or autoreactive T-cell directed against a self-antigen in the nervous system can passively transfer MS to experimental animals. EAE itself is an imperfect model of MS, as it does not exactly parallel the clinical or pathological features of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/1,3,13\">",
"      1,3,13",
"     </a>",
"     ]. In addition, EAE is responsive to many drugs directed against T-cells (eg,",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     ,",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"     , and monoclonal antibodies directed at CD4 cells). These same drugs have failed to demonstrate consistent effectiveness as therapy for MS.",
"    </p>",
"    <p>",
"     In addition to loss of myelin and oligodendrocytes, axonal injury is a prominent pathologic feature of the MS plaque [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/14-17\">",
"      14-17",
"     </a>",
"     ]. Disease progression involves a degenerative phase of cerebral atrophy and axonal loss that is not clearly related to immune mechanisms or inflammation.",
"    </p>",
"    <p>",
"     Alternate theories of MS pathogenesis include the following [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/3,13\">",
"      3,13",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A possible immune (but not autoimmune) etiology due to a chronic viral infection",
"      </li>",
"      <li>",
"       A nonimmune noninflammatory etiology due to a genetically determined neuroglial degenerative process",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Neuropathologic evidence suggests that oligodendrocyte apoptosis, perhaps triggered by viral or glutamate excitotoxicity, may be the primary event preceding inflammation in at least some newly forming lesions in patients with relapsing-remitting MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/18,19\">",
"      18,19",
"     </a>",
"     ]. However, the importance of oligodendrocyte apoptosis in the pathogenesis of MS remains to be established [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/17\">",
"      17",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </span>",
"     &nbsp;&mdash;&nbsp;Multiple sclerosis affects more women than men. A systematic review of 28 epidemiologic studies found that, from 1955 to 2000, the estimated female to male ratio of MS incidence increased from 1.4 to 2.3 [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/20\">",
"      20",
"     </a>",
"     ]. A later systematic review and meta-analysis also found evidence suggesting that the incidence of MS is increasing in females [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/21\">",
"      21",
"     </a>",
"     ]. The reason for this is unknown. A case-control study from Crete found that an increase in the incidence of MS in females since 1980 was concurrent with a population shift from rural to urban areas, and speculated that environmental factors accompanying urbanization may trigger the development of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/22\">",
"      22",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The incidence and prevalence of MS varies geographically, as discussed below. (See",
"     <a class=\"local\" href=\"#H6\">",
"      'Geographic factors'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     The median and mean ages of MS onset are 23.5 and 30 years of age, respectively. The peak age of onset is about five years earlier for women than for men. Relapsing-remitting MS tends to have an earlier onset, averaging 25 to 29 years; this may convert to progressive MS at a mean age of 40 to 44 years. Primary-progressive MS has a mean age of onset of 35 to 39 years. Onset of MS can rarely occur as late as the seventh decade.",
"    </p>",
"    <p>",
"     In support of a possible autoimmune basis for MS, some [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/23,24\">",
"      23,24",
"     </a>",
"     ] but not all [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/25\">",
"      25",
"     </a>",
"     ] studies have observed that patients with MS are more likely than controls to have other autoimmune disorders, such as autoimmune thyroid disease. In addition, patients with other autoimmune disorders are more likely to have MS. As an example, a large Danish study found that patients with type 1 diabetes mellitus had an increased risk for developing MS compared with the general population [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/26\">",
"      26",
"     </a>",
"     ]. Another large, well-designed cohort study found that patients with inflammatory bowel disease have an increased risk for demyelinating diseases, including MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/27\">",
"      27",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h2\">",
"      Role of immune system stimuli",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because the pathogenesis of MS is thought to involve the immune system, it has been hypothesized that a stimulus of the immune system (eg, a vaccine) may trigger the disease. However, substantial evidence exists that there is no association between vaccines and MS.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Two well-designed studies seemingly refuted the possible link: one finding no association between hepatitis B vaccination and the development of MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/28\">",
"        28",
"       </a>",
"       ], and the other finding no association between several different vaccines and disease relapse in patients with MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/29\">",
"        29",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       A systematic review of nine case-control studies found a negative association between tetanus vaccination and the risk of MS (odds ratio 0.67; 95% CI 0.55-0.81) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/30\">",
"        30",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       A summary of published evidence (through January 2001) supported the safety of vaccination in patients with MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/31\">",
"        31",
"       </a>",
"       ], and a subsequent case-control study found no association between several different vaccines and the development of MS",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       optic neuritis [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/32\">",
"        32",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Although a later, well-designed, case-control study found an increased risk of MS in patients who had received hepatitis B vaccination [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/33\">",
"      33",
"     </a>",
"     ], the indisputable large benefit of this vaccine far outweighs the possible and still unproven risk of developing MS that the vaccine may carry [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/33,34\">",
"      33,34",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h3\">",
"      Viral infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;A possible infectious stimulus of the immune system has received more support than vaccines in the literature [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/31,35\">",
"      31,35",
"     </a>",
"     ]. Although many viruses have been associated with MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/36\">",
"      36",
"     </a>",
"     ], no specific evidence linking viruses directly to the development of MS has been reported. It should be noted that there is no evidence linking hepatitis B infection with the risk of developing or worsening MS, despite the possible but unproven link with the",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"      hepatitis B vaccine",
"     </a>",
"     .",
"    </p>",
"    <p>",
"     Increasing attention has centered on the Epstein Barr Virus (EBV), which causes infectious mononucleosis, as a possible cause or trigger of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/37,38\">",
"      37,38",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In a meta-analysis of 14 case-control and cohort studies, the risk of MS was increased after infectious mononucleosis (relative risk 2.3, 95% CI 1.7-3.0) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/39\">",
"        39",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       A prospective nested case-control study of women found significant elevations in anti-EBV antibody titers before the onset of MS, particularly antibody to the EBV nuclear antigen 2 (EBNA-2) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/40\">",
"        40",
"       </a>",
"       ]. Another nested case-control study found that higher antibody titers to EBNA complex and EBV viral capsid antigen were associated with an increased risk of MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/41\">",
"        41",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       There is conflicting evidence concerning whether EBV infection is present in brain tissue of patients with MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/42-45\">",
"        42-45",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     One difficulty in proving a link between EBV and MS is that serological evidence of EBV can be found in 83 to 90 percent of adults in the Western hemisphere [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/40,46,47\">",
"      40,46,47",
"     </a>",
"     ]. On the other hand, EBV seropositivity among adult MS patients is near 100 percent, significantly higher than healthy controls [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/47-51\">",
"      47-51",
"     </a>",
"     ], and children with MS are significantly more likely than healthy peers to have serological evidence for prior EBV infection, at an age when EBV seropositivity is much less common than in adults [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/52\">",
"      52",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     While these findings do not confirm that EBV is an etiologic agent, they are suggestive and warrant further study.",
"    </p>",
"    <p>",
"     Varicella zoster virus (VZV) has also been linked to MS in some studies [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/53-55\">",
"      53-55",
"     </a>",
"     ]. A case-control study found viral particles identical to VZV, and DNA from VZV, in cerebrospinal fluid (CSF) samples from patients with acute relapses of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/54\">",
"      54",
"     </a>",
"     ]. Viral particles were not seen in CSF samples from cases of MS in remission or in samples from control subjects, and DNA from VZV was not seen in most patients in remission. These findings suggest that VZV participates in MS exacerbations, but require confirmation in additional studies.",
"    </p>",
"    <p>",
"     Another hypothesis proposes that early life infections may attenuate the response that leads to autoimmune disorders such as MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/56\">",
"      56",
"     </a>",
"     ]. In support of this theory, a population-based case-control study found that higher exposure to infant siblings during the first six years of life was inversely associated with the risk of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/57\">",
"      57",
"     </a>",
"     ]. The proposed explanation was that greater infant sibling exposure leads to increased early life infection exposure or reexposure; this in turn confers protection against autoimmunity later in life.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h2\">",
"      Geographic factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The incidence and prevalence of MS varies geographically [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/58,59\">",
"      58,59",
"     </a>",
"     ]. High frequency areas of the world (prevalence of 60 per 100,000 or more) include all of Europe (including Russia), southern Canada, northern United States, New Zealand, and southeast Australia. In many of these areas the prevalence is more than 100 per 100,000; the highest reported rate of 300 per 100,000 is in the Orkney Islands. In the United States, the prevalence is 100 per 100,000 (0.1 percent), for a total of 250,000 persons with MS. This geographic variance may be explained in part by racial differences; white populations, especially those from Northern Europe, appear to be most susceptible; people of Asian, African, or American Indian origin have the lowest risk, with other groups intermediate.",
"    </p>",
"    <p>",
"     There is also a widely held belief of an association between latitude and MS, with the risk of MS increasing from south to north [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/20\">",
"      20",
"     </a>",
"     ]. In an analysis from the Nurses' Health Study, for example, the adjusted rate ratios were 3.5 for the northern United States and 2.7 for the middle tiers relative to the southern tier [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/60\">",
"      60",
"     </a>",
"     ]. Persons migrating from a high to low-risk area after the age of puberty are thought to carry their former high risk with them, while those that migrate during childhood seem to have the risk associated with the new area to which they migrated.",
"    </p>",
"    <p>",
"     However, the universal association between latitude and risk of MS has been challenged by findings from a 2010 systematic review and meta-analysis of epidemiologic studies of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/21\">",
"      21",
"     </a>",
"     ]. The results showed that, while the prevalence of MS increased with geographic latitude in Western Europe, North America, and",
"     <span class=\"nowrap\">",
"      Australia/New",
"     </span>",
"     Zealand, the incidence of MS increased with latitude only in",
"     <span class=\"nowrap\">",
"      Australia/New",
"     </span>",
"     Zealand, and not in Western Europe or North America. Thus, there was no latitudinal gradient for MS incidence in the northern hemisphere. In the absence of association with incidence, the observed latitudinal gradient of MS prevalence could be explained by other factors, such as survival time, diagnostic accuracy, and ascertainment probability.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H806175124\">",
"     <span class=\"h2\">",
"      Sunlight and vitamin D",
"     </span>",
"     &nbsp;&mdash;&nbsp;One proposed explanation for the possible association of MS with latitude is that exposure to sunlight may be protective, either because of an effect of ultraviolet radiation or of vitamin D [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/61\">",
"      61",
"     </a>",
"     ]. The following observations support of this hypothesis:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A number of studies have found an inverse relationship between sun exposure, ultraviolet radiation exposure, or vitamin D serum levels, and the risk or prevalence of MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/62-66\">",
"        62-66",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       An analysis of data from the Nurses' Health Study and Nurses' Health Study II observed that the risk of developing MS was significantly reduced for women taking &ge;400 international",
"       <span class=\"nowrap\">",
"        units/day",
"       </span>",
"       of vitamin D (relative risk 0.59, 95% CI 0.38-0.91) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/67\">",
"        67",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       A longitudinal cohort study of 469 subjects with MS found that vitamin D levels were inversely associated with the risk of new T2-weighted or gadolinium-enhancing T1-weighted lesions on brain MRI [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/68\">",
"        68",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h2\">",
"      Other environmental factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Environmental triggers unrelated to geography may be involved in the development of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/69\">",
"      69",
"     </a>",
"     ]. A number of studies have suggested an association between smoking and MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/69\">",
"      69",
"     </a>",
"     ]. As examples, a cross-sectional study of 22,312 people in Norway found a higher risk of MS in ever-smokers than in never-smokers (relative risk 1.81, 95% CI 1.13-2.92) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/70\">",
"      70",
"     </a>",
"     ], and a case-control study in the United Kingdom found similar results [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/71\">",
"      71",
"     </a>",
"     ]. Smoking may also be a risk factor for disease progression [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/61,71-73\">",
"      61,71-73",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Month of birth has been implicated as a possible risk factor for MS. A large population-based study found that the risk of MS is increased for those born in May and decreased for those born in November, suggesting that the gestational or neonatal environment influences the risk of MS later in life [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/74\">",
"      74",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h2\">",
"      Genetic factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of developing MS is associated with certain class I and class II alleles of the major histocompatibility complex (MHC), particularly the HLA-DRB1 locus [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/75-80\">",
"      75-80",
"     </a>",
"     ]. Mounting evidence suggests that the risk of MS is associated with multiple non-MHC susceptibility genes of modest effect (eg, CD6, CLEC16A, IL2RA, IL7R, IRF8, and TNFRSF1A) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/76,78,79,81-85\">",
"      76,78,79,81-85",
"     </a>",
"     ]. In addition, polymorphisms in the IL-7R gene may slightly increase the risk of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/76,81,82\">",
"      76,81,82",
"     </a>",
"     ]. (See",
"     <a class=\"local\" href=\"#H2\">",
"      'Pathogenesis'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     The presence of a vitamin D response (VDRE) element located in the promotor region of many but not all HLA-DRB1 alleles suggests that environmental differences in vitamin D might interact with HLA-DRB1 to influence the risk of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/86\">",
"      86",
"     </a>",
"     ]. The VDRE enhances gene expression when stimulated by vitamin D. However, other factors related to HLA variation may have more impact on MS risk than vitamin D regulation of HLA-DR expression. In one study of Caucasian subjects from Australia that compared 466 MS cases and 498 controls, the risk of developing MS varied more than 10-fold according to HLA-DRB1 allele type and associated sequence variation in the promotor region, with odds ratios ranging from 0.28 to 3.06 [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/87\">",
"      87",
"     </a>",
"     ]. A protective effect was associated with HLA-DRB1*04, *07, and *09 (DR53 group) alleles, while an elevated risk was associated with DRB1*15 and *16 (DR51 group) and *08 (DR8 group) alleles. However, VDRE sequence variation itself was not independently associated with MS risk. Most of the Caucasian HLA-DRB1 alleles expressed a functional VDRE sequence, including alleles that had no apparent effect on MS risk.",
"    </p>",
"    <p>",
"     In twin studies, the risk of developing MS for dizygotic twin pairs is the same as that for siblings (3 to 5 percent); however, the risk for monozygotic twins is at least 20 percent and may reach close to 39 percent [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/88\">",
"      88",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The frequency of familial MS varies from 3 percent to 23 percent in different studies. One well-designed population study of 8205 Danish patients with MS found that relative lifetime risk of MS was increased sevenfold (95% CI 5.8-8.8) among first-degree relatives (n = 19,615) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/89\">",
"      89",
"     </a>",
"     ]. The excess familial lifetime risk for first-degree relatives was 2.5 percent (95% CI 2.0-3.2) added to the sporadic absolute risk of MS in Danish women and men of 0.5 and 0.3 percent. These sporadic rates from the Danish population are among the highest in the world.",
"    </p>",
"    <p>",
"     For purposes of genetic counseling, the sibling risk of MS is 3 to 5 percent. Studies of unaffected family members that have noted abnormalities on MRI scanning suggest that the risk may be even higher.",
"    </p>",
"    <p>",
"     Accumulating data suggest that transmission of MS is influenced by the sex of the affected parent [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/90-96\">",
"      90-96",
"     </a>",
"     ]. Most studies have found a maternal parent-of-origin effect, with an excess of maternal transmission observed when examining half-sibling pairs with MS and unaffected parents, patients with MS in extended pedigrees, or avuncular pairs of patients with MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/90,94,95\">",
"      90,94,95",
"     </a>",
"     ]. In contrast, studies of parent-child pairs with MS have found that paternal transmission is equal to or greater than maternal transmission [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/91-93\">",
"      91-93",
"     </a>",
"     ]. The explanation for this discrepancy is unclear, but epigenetic mechanisms (eg, DNA modifications such as histone acetylation and DNA methylation that do not modify the DNA sequence) transmitted through cell division may be involved in direct transmission from an affected parent [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/96\">",
"      96",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Results from a meta-analysis and a large population-based study suggest that apolipoprotein epsilon (APOE) variation plays no role in MS disease severity or susceptibility [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/97,98\">",
"      97,98",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H176638034\">",
"     <span class=\"h2\">",
"      Chronic cerebrospinal venous insufficiency",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronic cerebrospinal venous insufficiency (CCSVI) is a controversial condition characterized by purported anomalies of cerebrospinal veins that interfere with venous drainage from the brain [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/99\">",
"      99",
"     </a>",
"     ]. Proposed diagnostic ultrasound criteria for CCSVI require two or more of the following five parameters:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Reflux constantly present in internal jugular veins",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       vertebral veins with the head at supine (0&deg;) and sitting (90&deg;) positions",
"      </li>",
"      <li>",
"       Reflux in the deep cerebral veins",
"      </li>",
"      <li>",
"       High resolution B-mode evidence of proximal internal jugular vein stenosis",
"      </li>",
"      <li>",
"       Flow not Doppler detectable in the internal jugular veins",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       vertebral veins despite numerous deep inspirations with the head at 0&deg; and 90&deg;",
"      </li>",
"      <li>",
"       Negative change in cross-sectional area of the internal jugular vein with the head at 0&deg; and 90&deg;, denoting the loss of normal postural control",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In the original report, CCSVI was present in all 65 patients with MS and in none of 235 controls, yielding a sensitivity and specificity of 100 percent, which is unusual for any diagnostic study [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/99\">",
"      99",
"     </a>",
"     ]. However, the high sensitivity and specificity of CCSVI for MS have",
"     <strong>",
"      not",
"     </strong>",
"     been consistently replicated by all subsequent reports from other investigators. The evidence has been conflicting, with a few studies supporting a strong association of CCSVI with MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/100,101\">",
"      100,101",
"     </a>",
"     ], and most others finding either an uncertain relationship [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/102\">",
"      102",
"     </a>",
"     ] or no association [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/103-109\">",
"      103-109",
"     </a>",
"     ]. The largest of these studies evaluated 499 subjects, made up of 289 patients with MS, 163 healthy controls, 26 with other neurologic diseases, and 21 with a clinically isolated syndrome [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/102\">",
"      102",
"     </a>",
"     ]. The prevalence of CCSVI was highest in patients with MS (56 percent) and lower but not uncommon among subjects with other neurologic diseases, clinically isolated syndrome, and healthy controls (42, 38 and 22 percent, respectively). These findings strongly suggest that CCSVI is unlikely to be a primary cause of MS.",
"    </p>",
"    <p>",
"     One proposed mechanism linking CCSVI and MS is that insufficient venous drainage in the brain might lead to extravasation of blood products and perivenular iron deposition thus overloading the brain and thereby promoting oxidative stress, inflammation and lesion formation [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/110\">",
"      110",
"     </a>",
"     ]. However, this hypothesis is speculative, and is discordant with the following observations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Brain iron deposition is a nonspecific finding that is seen in neurodegenerative disorders without demyelination such as Parkinson disease and Alzheimer disease [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/111,112\">",
"        111,112",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       In MS, brain iron accumulation may be a result of inflammation rather than the cause [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/113\">",
"        113",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Other conditions characterized by increased venous pressure, such as cerebral venous thrombosis, are not associated with a risk of developing MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/111\">",
"        111",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       CCSVI may be a secondary phenomenon in some patients with MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/114\">",
"        114",
"       </a>",
"       ], perhaps caused by reduced arterial blood flow and globally decreased cerebral perfusion noted in a number of studies [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/113,115-118\">",
"        113,115-118",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CLINICAL SYMPTOMS AND SIGNS",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are no clinical findings that are unique to MS, but some are highly characteristic of the disease (",
"     <a class=\"graphic graphic_table graphicRef63940 \" href=\"mobipreview.htm?21/53/22363\">",
"      table 2",
"     </a>",
"     ). Common symptoms of MS are listed in Table 3 (",
"     <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"      table 3",
"     </a>",
"     ). The typical patient presents as a young adult with two or more clinically distinct episodes of CNS dysfunction with at least partial resolution.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h2\">",
"      Optic neuritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Optic neuritis (ON) is the most common type of involvement of the visual pathways. It usually presents as acute or subacute unilateral eye pain that is accentuated by ocular movements [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/119\">",
"      119",
"     </a>",
"     ]. This is followed by a variable degree of visual loss (scotoma) affecting mainly central vision. Bilateral simultaneous ON is rare in MS; its occurrence in isolation may suggest another diagnosis such as Leber's hereditary optic atrophy or toxic optic neuropathy. When ON does occur bilaterally in patients with MS, the impairment begins asymmetrically and is usually more severe in one eye.",
"    </p>",
"    <p>",
"     Bitemporal hemianopia is rare in MS and, if present, should raise the suspicion of a mass lesion compressing the visual pathways. Homonymous field defects are uncommon but can be seen in MS due to involvement of the optic radiations.",
"    </p>",
"    <p>",
"     Physical examination of patients with ON reveals a relative afferent pupillary defect (Marcus Gunn pupil). Disc edema may be observed on fundus examination when the acute ON lesion involves the head of the optic nerve, a finding more common in children than in adults. Most often the lesion of the optic nerve is retrobulbar, and fundus examination is normal in the acute stage. Later the optic disc becomes pale as a result of axonal loss and resultant gliosis. This pallor predominates in the temporal segment of the disc (temporal pallor).",
"    </p>",
"    <p>",
"     Ninety percent of patients regain normal vision over a period of two to six months after an acute episode of ON. Desaturation of bright colors, particularly red, is often reported by recovered patients; some also report a mild nonspecific dimming.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h3\">",
"      Progression to MS after optic neuritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The reported risk of progression to clinically diagnosed MS after an episode of ON ranges from 15 to 75 percent. MRI can help differentiate groups of patients with ON who are likely or unlikely to develop MS. This topic is discussed in greater detail separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=see_link\">",
"      \"Clinically isolated syndromes suggestive of multiple sclerosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h2\">",
"      Internuclear ophthalmoplegia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Internuclear ophthalmoplegia (INO) refers to abnormal horizontal ocular movements with lost or delayed adduction and horizontal nystagmus of the abducting eye. It is caused by a lesion of the medial longitudinal fasciculus on the side of diminished adduction. Convergence is preserved. When present bilaterally, it is usually coupled with vertical nystagmus on upward gaze. A bilateral INO is most suggestive of MS but also can be observed with other intraaxial brainstem lesions, including brainstem glioma, vascular lesions, Arnold-Chiari malformations, and Wernicke's encephalopathy. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=see_link\">",
"      \"Internuclear ophthalmoplegia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sensory symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sensory symptoms are a common initial feature of MS (",
"     <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"      table 3",
"     </a>",
"     ) and are present in almost every patient at some time during the course of disease. The sensory features can reflect spinothalamic, posterior column, or dorsal root entry zone lesions. Symptoms are commonly described as numbness, tingling, pins-and-needles, tightness, coldness, or swelling of the limbs or trunk. Radicular pains also can be present, particularly in the low thoracic and abdominal regions. An intensely itching sensation, especially in the cervical dermatomes and usually unilateral, is suggestive of MS.",
"    </p>",
"    <p>",
"     The most common sensory abnormalities on clinical examination include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Varying degrees of impairment of vibration and joint position sense",
"      </li>",
"      <li>",
"       Decreased pain and light touch perception in a distal distribution in the four extremities",
"      </li>",
"      <li>",
"       Patchy areas of reduced pain and light touch perception in the limbs and trunk",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Patients also frequently report that the feeling of pinprick is increased or feels like a mild electric shock or that the stimulus spreads in a ripple fashion from the point at which it is applied. A bilateral sensory level is more common than a hemisensory (Brown-S&eacute;quard) syndrome.",
"    </p>",
"    <p>",
"     Impairment of facial sensation, subjective or objective, is a relatively common finding in MS. Trigeminal neuralgia in a young adult may be an early sign of MS. Facial myokymia, a fine undulating wave-like facial twitching, and hemifacial spasm also can be due to MS, but other causes of a focal brainstem lesion must be excluded. Unilateral facial paresis can occur, but taste sensation is almost never affected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h3\">",
"      Lhermitte's phenomenon",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lhermitte's phenomenon is a transient sensory symptom described as an electric shock radiating down the spine or into the limbs with flexion of the neck [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/120\">",
"      120",
"     </a>",
"     ]. It may be infrequent or occur with the least movement of the head or neck. Although most frequently encountered in MS, this symptom also can be seen with other lesions of the cervical cord, including tumors, cervical disc herniation, postradiation myelopathy, and following trauma. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=see_link\">",
"      \"Complications of peripheral nerve irradiation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h2\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain is a common symptom in patients with MS. A multicenter cross-sectional study assessed pain in 1672 patients with MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/121\">",
"      121",
"     </a>",
"     ]. Overall, 43 percent of the patients reported one or more painful symptoms. Types of pain and their frequencies in this population were as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Trigeminal neuralgia in 2 percent",
"      </li>",
"      <li>",
"       Lhermitte's sign in 9 percent",
"      </li>",
"      <li>",
"       Dysesthetic pain in 18 percent",
"      </li>",
"      <li>",
"       Back pain in 16 percent",
"      </li>",
"      <li>",
"       Visceral pain in 3 percent",
"      </li>",
"      <li>",
"       Painful tonic spasms in 11 percent",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h2\">",
"      Vertigo",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vertigo is a reported symptom in 30 to 50 percent of patients with MS. It is commonly associated with symptoms reflecting dysfunction of adjacent cranial nerves such as hyper- or hypoacusis, facial numbness, and diplopia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h2\">",
"      Nystagmus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 2 to 4 percent of patients with MS develop acquired pendular nystagmus [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/122,123\">",
"      122,123",
"     </a>",
"     ]; most patients with this form of nystagmus have MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/124\">",
"      124",
"     </a>",
"     ]. It is seldom a presenting sign of MS, more typically developing later in the course of disease and persisting indefinitely, resolving in only 5 percent. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1034?source=see_link\">",
"      \"Pendular nystagmus\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Acquired pendular nystagmus is characterized by rapid, small-amplitude pendular oscillations of the eyes in the primary position resembling quivering jelly. Patients frequently complain of oscillopsia (subjective oscillation of objects in the field of vision), which impairs visual performance. Marked impairment of visual acuity may also be present, due in part to blurring from constant eye motion and perhaps also to concurrent optic neuropathy [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/123\">",
"      123",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h2\">",
"      Motor symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Paraparesis or paraplegia is more common than significant upper extremity weakness in patients with MS due to the frequent occurrence of lesions in the descending motor tracts of the spinal cord. Severe spasticity can occur, such that extensor spasms of the legs and sometimes the trunk may be provoked by active or passive attempts to rise from a bed or wheelchair.",
"    </p>",
"    <p>",
"     Physical findings include spasticity, usually more marked in the legs than in the arms. The deep tendon reflexes are exaggerated, sustained clonus may be elicited, and extensor plantar responses are observed. All of these manifestations are commonly asymmetrical.",
"    </p>",
"    <p>",
"     Occasionally, deep tendon reflexes are decreased due to lesions interrupting the reflex arc at a segmental level, and an inverted triceps reflex may be observed where the triceps contraction is lost and the efferent component is represented by a contraction of the biceps muscle. The Achilles reflex can be absent due to lesions of the sacral segments of the spinal cord, with or without concomitant sphincter and sexual problems. Occasionally, reduced reflexes reflect hypotonia resulting from cerebellar pathway lesions.",
"    </p>",
"    <p>",
"     Amyotrophy can occur and is usually of the disuse type, most frequently affecting the small muscles of the hand. Less commonly, lesions of the motor root exit zones cause muscle denervation due to axon loss. Secondary entrapment neuropathies are also a cause of muscle atrophy in MS.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h2\">",
"      Coordination",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gait imbalance, difficulty in performing coordinated actions with the arms, and slurred speech may occur as a result of impairment of cerebellar pathways. Physical examination typically reveals dysmetria, decomposition of complex movements, and hypotonia, most often observed in the upper extremities. An intention tremor may be noted in the limbs and in the head. Walking is impaired by truncal ataxia. Ocular findings of nystagmus, ocular dysmetria, and failure of fixation suppression (square wave jerks) suggest cerebellar or cerebello-vestibular connection dysfunction. Speech can be scanning or explosive in character. In severe cases there is complete astasia (inability to stand), inability to use the arms due to a violent intention tremor, and virtually incomprehensible speech. Cerebellar signs are usually mixed with pyramidal (corticospinal) tract signs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h2\">",
"      Bowel/bladder/sexual function",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bowel, bladder, and sexual dysfunction are common in MS. The extent of sphincter and sexual dysfunction often parallels the degree of motor impairment in the lower extremities. The most common urinary complaint is urgency. Urinary incontinence becomes more common as the disease progresses, and an atonic dilated bladder that empties by overflow can be the end result.",
"    </p>",
"    <p>",
"     Other causes of urinary urgency and incontinence need to be considered in patients with MS. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"      \"Clinical presentation and diagnosis of urinary incontinence\"",
"     </a>",
"     .) Urinary tract infections are common in MS, particularly in women, and may increase the extent of bladder dysfunction.",
"    </p>",
"    <p>",
"     Constipation is more common than fecal incontinence. These problems may be a result of both upper and lower motor neuron impairment in addition to decreased general mobility.",
"    </p>",
"    <p>",
"     Sexual dysfunction is common in patients with MS. About 50 percent of patients become completely sexually inactive secondary to their disease, and an additional 20 percent become sexually less active. Men experience various degrees of erectile dysfunction. Most women preserve their orgasmic capabilities, sometimes even in the presence of complete loss of bladder and bowel function.",
"    </p>",
"    <p>",
"     Sphincter and sexual dysfunction associated with MS are discussed in greater detail separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h2\">",
"      Heat sensitivity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heat sensitivity (Uhthoff phenomenon) is a well known occurrence in MS; small increases in the body temperature can temporarily worsen current or preexisting signs and symptoms [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/125\">",
"      125",
"     </a>",
"     ]. This phenomenon is presumably the result of conduction block developing in central pathways as the body temperature increases [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/126\">",
"      126",
"     </a>",
"     ]. Normally, the nerve conduction safety factor decreases with increasing temperature until a point is reached at which conduction block occurs; this point of conduction block is reached at a much lower temperature in demyelinated nerves.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h2\">",
"      Paroxysmal symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Paroxysmal attacks of motor or sensory phenomena can occur with demyelinating lesions. Within the brainstem, lesions may cause paroxysmal diplopia, facial paresthesia, trigeminal neuralgia, ataxia, and dysarthria. Motor system involvement results in painful tonic contractions of muscles of one or two (homolateral) limbs, trunk, and occasionally the face, but these only rarely occur in all four limbs or the trunk. These paroxysmal attacks typically respond to low doses of",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"      carbamazepine",
"     </a>",
"     and frequently remit after several weeks to months, usually without recurrence. These symptoms and their management are discussed in greater detail separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h2\">",
"      Fatigue",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fatigue is a characteristic finding in MS, usually described as physical exhaustion that is unrelated to the amount of activity performed. Many patients complain of feeling exhausted on waking, even if they have slept soundly. Fatigue can also occur during the day but may be partially or completely relieved by rest. In addition, there appears to be a correlation between fatigue and disrupted sleep in MS patients. Fatigue is often seen in association with an acute attack and may precede the focal neurologic features of the attack and persist long after the attack has subsided. There is a poor correlation between fatigue and the overall severity of disease or with the presence of any particular symptom or sign. Fatigue associated with MS is discussed in greater detail separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h2\">",
"      Depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Affective disturbance occurs in up to two-thirds of patients with MS, and depression is the most common manifestation. Depression may be more common in patients with MS than in others with chronic medical conditions. It is not known whether depression in MS patients reflects a comorbid association with bipolar illness or an effect of frontal or subcortical white matter disease. Early trials suggested that treatment with interferon beta may contribute to the development of depression, but subsequent studies have not found such an association.",
"    </p>",
"    <p>",
"     Euphoria is usually associated with moderate or severe mental impairment. Patients may also manifest a dysphoric state with swings from depression to elation. Mood disturbance in MS is discussed separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h2\">",
"      Cognitive dysfunction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Frank dementia is an uncommon feature of MS, occurring in less than 5 percent of patients. It is usually only encountered in severely affected individuals. However, 34 to 65 percent of patients have cognitive impairment on the basis of neuropsychological testing, and cognitive impairment may be common even at the onset of MS. The most frequent abnormalities are with abstract conceptualization, recent memory, attention, and speed of information processing.",
"    </p>",
"    <p>",
"     The degree of cognitive decline in patients with MS correlates with the severity of cerebral pathology on MRI, and cortical atrophy on MRI (",
"     <a class=\"graphic graphic_diagnosticimage graphicRef58083 \" href=\"mobipreview.htm?40/26/41379\">",
"      image 1",
"     </a>",
"     ) correlates with cognitive impairment. Acute cerebral lesions occasionally manifest as a confusional state associated with progressive focal paralysis. Cognitive dysfunction in MS is discussed separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h2\">",
"      Epilepsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Epilepsy is more common in patients with MS than in the general population, occurring in 2 to 3 percent of patients. Convulsions may be either tonic-clonic in nature or partial complex. They generally are benign and transient and respond well to antiepileptic drug therapy or require no therapy, although up to 11 percent of patients with MS and epilepsy may develop intractable seizures. This topic is discussed in greater detail separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"      \"Comorbid problems associated with multiple sclerosis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      RELAPSES",
"     </span>",
"     &nbsp;&mdash;&nbsp;Multiple sclerosis is most commonly characterized by relapse, which is defined as the acute or subacute onset of clinical dysfunction that usually reaches its peak from days to several weeks, followed by a remission during which the symptoms and signs resolve to a variable extent. The minimum duration for a relapse has been arbitrarily established at 24 hours. Clinical symptoms of shorter duration are less likely to represent new lesion formation or extension of previous lesion size.",
"    </p>",
"    <p>",
"     Analysis of prospectively collected data from a cohort of 195 patients suggests that symptomatic demyelinating events in early RRMS have a tendency to recur in the same location (eg, spinal cord, optic nerve, brainstem) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/127\">",
"      127",
"     </a>",
"     ]. However, relapses can present with any of the typical clinical symptoms of MS, and there are no specific clinical features that can reliably distinguish the initial clinical attack of MS from a relapse, other than history. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Clinical symptoms and signs'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     The frequency of relapses is highly variable and depends upon the population studied and the closeness of observation and recording by patients and physicians. Summaries of many studies provide an average figure of 0.4 to 0.6 relapses per year. Relapses tend to be more frequent during the first years of the disease and wane in later years.",
"    </p>",
"    <p>",
"     In a single center study that analyzed data from 2587 relapses occurring in 1078 patients during an average follow-up of 7.4 years, relapses causing permanent disability were rare [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/128\">",
"      128",
"     </a>",
"     ]. Relapses were not associated with starting or stopping interferon treatment.",
"    </p>",
"    <p>",
"     In the absence of a new demyelinating event, worsening of previous clinical dysfunction can occur in the setting of fever, physical activity, or metabolic upset, and may last for hours to a day or more. Such worsening is thought to reflect conduction block in previously demyelinated axons.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      DISEASE PATTERN",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pattern and course of MS is categorized as follows [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/129\">",
"      129",
"     </a>",
"     ]:",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h2\">",
"      Relapsing remitting",
"     </span>",
"     &nbsp;&mdash;&nbsp;Relapsing-remitting multiple sclerosis (RRMS) is characterized by clearly defined relapses (see",
"     <a class=\"local\" href=\"#H27\">",
"      'Relapses'",
"     </a>",
"     above) with full recovery or with sequelae and residual deficit upon recovery. There is no disease progression during the periods between disease relapses. This type of MS accounts for approximately 85 to 90 percent of MS cases at onset. However, most patients with RRMS will eventually enter a secondary progressive phase as discussed below.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H30\">",
"     <span class=\"h2\">",
"      Secondary progressive",
"     </span>",
"     &nbsp;&mdash;&nbsp;Secondary progressive multiple sclerosis (SPMS) is characterized by an initial RRMS disease course followed by progression with or without occasional relapses, minor remissions, and plateaus. Some studies suggest that SPMS ultimately develops in most patients with RRMS and causes the greatest amount of neurological disability.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h2\">",
"      Primary progressive",
"     </span>",
"     &nbsp;&mdash;&nbsp;Primary progressive multiple sclerosis (PPMS) is characterized by disease progression from onset with occasional plateaus and temporary minor improvements allowed. This type represents about 10 percent of cases at disease onset [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/130\">",
"      130",
"     </a>",
"     ]. In PPMS, patients experience a steady decline in function from the beginning and never have acute attacks. These patients have a more even sex distribution, tend to have a later age of onset, and may have a worse prognosis for ultimate disability compared to patients with RRMS.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h2\">",
"      Progressive relapsing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Progressive relapsing multiple sclerosis (PRMS) is characterized by progressive disease from onset, with clear acute relapses, with or without full recovery. Progression continues during the periods between disease relapses.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H33\">",
"     <span class=\"h2\">",
"      Clinicopathologic correlation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pathogenesis of brain injury may be different between relapsing and progressive forms of MS. In a neuropathologic study, tissue from 52 patients with MS was compared with 30 controls, and the following observations were made [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/131\">",
"      131",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Active focal inflammatory demyelinating lesions in the white matter were present mainly in patients with acute and RRMS, while inactive or slowly expanding white matter plaques were found in SPMS and PPMS.",
"      </li>",
"      <li>",
"       Global inflammation of the brain and meninges was characteristic of SPMS and PPMS.",
"      </li>",
"      <li>",
"       Cortical demyelination mainly affecting the subpial layers of the cerebral cortex was a characteristic feature of PPMS and SPMS, but it was rare or absent in acute MS and RRMS.",
"      </li>",
"      <li>",
"       Diffuse injury in normal appearing white matter (NAWM) was prominent in SPMS and PPMS, but it was rare or absent in acute MS and RRMS.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These data suggest that MS begins as a focal inflammatory disease but that longer disease duration is associated with accumulation of diffuse brain inflammation, cortical demyelination, and slowly progressive axonal injury in the NAWM [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/131\">",
"      131",
"     </a>",
"     ]. However, other studies have found that inflammatory cortical demyelination is present even in the early stages of MS, at least in some patients [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/132-135\">",
"      132-135",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H34\">",
"     <span class=\"h1\">",
"      DISEASE SEVERITY",
"     </span>",
"     &nbsp;&mdash;&nbsp;A clinic-based study of 1100 patients found that 66 percent had relapsing-remitting MS (RRMS) disease at onset, 15 percent progressive relapsing (PRMS), and 19 percent primary progressive (PPMS) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136\">",
"      136",
"     </a>",
"     ]. The clinical course can evolve from relapsing to secondary progressive (SPMS); 85 percent of patients begin with a relapsing course, but the proportion remaining as relapsing falls steadily, so that only one-half are still relapsing by nine years from onset. The course of MS with onset after the age of 40 years is progressive in over 60 percent of patients [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136\">",
"      136",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Progression of disability due to MS is highly variable (see",
"     <a class=\"local\" href=\"#H36\">",
"      'Rate of disability progression'",
"     </a>",
"     below). At the extreme ends of the severity spectrum, there are benign and malignant forms of MS (see",
"     <a class=\"local\" href=\"#H38\">",
"      'Benign MS'",
"     </a>",
"     below and",
"     <a class=\"local\" href=\"#H52978808\">",
"      'Malignant MS'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H35\">",
"     <span class=\"h2\">",
"      Measures of disease progression",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Kurtzke disability scale (",
"     <a class=\"graphic graphic_table graphicRef76465 \" href=\"mobipreview.htm?26/34/27179\">",
"      table 4",
"     </a>",
"     ), or DSS, and the expanded version (expanded disability status scale (",
"     <a class=\"graphic graphic_table graphicRef57639 \" href=\"mobipreview.htm?5/40/5775\">",
"      table 5",
"     </a>",
"     ), or EDSS) are commonly used indices of clinical disability in MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/137,138\">",
"      137,138",
"     </a>",
"     ]. These indices use numbers ranging from 0 for normal examination and function to 10 for death due to MS. The scales are nonlinear, with great emphasis on ambulation capabilities with scores above 4.",
"    </p>",
"    <p>",
"     Most MS cohort studies have found bimodal distributions of EDSS scores, with peaks at values of 1 (no disability with minimal neurologic signs) and 6 (cane needed for walking). The time spent by a patient at a given level of disability varies with the score. The median time spent with a DSS score of 4 or 5 is 1.2 years, while the median time spent at DSS 1 is four years and at DSS 6 three years [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136\">",
"      136",
"     </a>",
"     ]. These results have powerful implications for the conduct of clinical studies with respect to patient selection, stratification, and duration of follow-up: if many patients of DSS 1 or 6 are included, little movement will be seen in a group followed for a year or two.",
"    </p>",
"    <p>",
"     The EDSS is universally used in clinical trials, but it has a number of serious limitations. Inter- and intra-rater variations in scoring are common. EDSS scores of 4 and higher depend almost entirely on the ability to walk. Problems such as the development of dementia, visual loss, or hand weakness may pass undetected by the scoring. Thus, other outcome measures should be also be used, and minor changes in the EDSS alone should not be over-interpreted.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H36\">",
"     <span class=\"h2\">",
"      Rate of disability progression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Progression of disability due to MS is highly variable, but accumulating evidence suggests that progression in most patients with MS is slow [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/130,139-143\">",
"      130,139-143",
"     </a>",
"     ]. One of the largest longitudinal studies followed 2319 patients from British Columbia for 22,723 patient years [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/141\">",
"      141",
"     </a>",
"     ]. Disability scores were prospectively assigned in greater than 95 percent of the patients.",
"    </p>",
"    <p>",
"     The following observations were reported [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/141\">",
"      141",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The median time from disease onset to EDSS 6 (cane needed for walking) was 27.9 years; the median age from birth to EDSS 6 was 59 years",
"      </li>",
"      <li>",
"       A primary progressive course was associated with more rapid disease progression than a relapsing course, and was a risk factor in multivariate analysis for time to use of a cane (EDSS 6) from both MS onset (hazard ratio [HR] 2.90, 95% CI 2.39-3.52) and from birth (HR 2.68, 95% CI 2.20-3.26)",
"      </li>",
"      <li>",
"       Although men progressed more quickly than women from onset, both men and women required a cane at similar ages (58.8 and 60.1 years), and male sex was not associated with a worse outcome after controlling for other factors",
"      </li>",
"      <li>",
"       The type of onset symptoms (eg, motor, sensory, optic neuritis, cerebellar, ataxia, or brainstem) did not predict disease progression after controlling for other factors",
"      </li>",
"      <li>",
"       A younger age at onset was associated with slower progression, but patients older at onset were consistently older when they progressed to EDSS 6 than patients younger at onset (",
"       <a class=\"graphic graphic_figure graphicRef71819 \" href=\"mobipreview.htm?18/9/18591\">",
"        figure 1",
"       </a>",
"       ). Similar results were found in a large epidemiology study from France [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/144\">",
"        144",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some earlier studies suggested that MS progressed more rapidly. As an example, a 25-year follow-up study of 308 patients with MS found that 50 percent of the patients reached EDSS 6 within 16 years of onset [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/145\">",
"      145",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H37\">",
"     <span class=\"h2\">",
"      Mortality",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mortality due to MS is difficult to determine because of poor data collection and reporting.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The US Department of Health and Human Services reported 1187 deaths in women in 1992 (89 percent white and 10 percent black); 713 men also died of MS (90 percent white and 9 percent black). The mean age of death of all MS patients was 58 years, compared with a national average of 71 years for all causes of death.",
"      </li>",
"      <li>",
"       A longitudinal population-based study of 441 patients with MS from South Wales with prospective follow-up for 20 years found that the mean age at death was 65 years [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/146\">",
"        146",
"       </a>",
"       ]. Respiratory disease or infection was the most common cause of death. The median survival time from symptom onset was 38 years. The standardized mortality ratio was 2.8, suggesting that patients with MS were nearly three times more likely to die prematurely than the general population.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H38\">",
"     <span class=\"h2\">",
"      Benign MS",
"     </span>",
"     &nbsp;&mdash;&nbsp;Benign MS refers to disease in which the patient remains fully functional in all neurologic systems 15 years after the disease onset, and is usually a retrospective diagnosis. Approximately 15 percent of patients will never experience a second relapse, although the exact frequency of this benign form of disease is unknown since many of these individuals never come to medical attention. Among patients in a population-based cohort study who had MS for 10 or more years, about 17 percent had minimal or no disability [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/140\">",
"      140",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Autopsy studies have found a significant number of cases with CNS pathology consistent with MS but no documented clinical evidence of disease. MRI studies of asymptomatic relatives of MS patients have discovered lesions consistent with demyelination in up to 15 percent of these relatives [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/147\">",
"      147",
"     </a>",
"     ]. The use of MRI may expand the spectrum of MS by detecting milder cases that previously were not included in prognosis studies. Prospective MRI studies are needed to determine if there are reliable imaging features that can distinguish benign MS from RRMS and progressive types of MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/148\">",
"      148",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     In our experience and that of most others, patients who have had a known benign course for 15 years will only rarely develop a more severe course [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/140,145\">",
"      140,145",
"     </a>",
"     ]. However, evidence is conflicting, and some have found that patients with benign MS for 10 years still have a substantial risk of disease progression and increased disability [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/149\">",
"      149",
"     </a>",
"     ]. The range of evidence is illustrated by the following reports:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In one long-term cohort, only 8 percent of patients with mild disease (EDSS score 0 to 3) five years after diagnosis progressed to severe disease (EDSS score 6) by 10 years, and only 12 percent by 15 years [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/145\">",
"        145",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Similar results were noted in a second cohort, 17 percent of whom had minimal or no disability (EDSS score of 2 or lower) at study onset despite a 10-year or longer history of MS [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/140\">",
"        140",
"       </a>",
"       ]. The longer the duration of MS and the lower the disability, the more likely the patient was to remain stable and not progress.",
"      </li>",
"      <li>",
"       In contrast, a cohort study of 169 patients with EDSS scores &le;3 at 10 years from MS onset found progression to EDSS scores of &ge;6 at 20 years after onset in 21 percent [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/149\">",
"        149",
"       </a>",
"       ]. The EDSS score at 10 years was the only independent predictor of score at 20 years.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H52978808\">",
"     <span class=\"h2\">",
"      Malignant MS",
"     </span>",
"     &nbsp;&mdash;&nbsp;Malignant MS refers to disease with a rapid progressive course, leading to significant disability in multiple neurologic systems or death in a relatively short time after disease onset. In a single center study of 487 patients with MS that defined malignant MS by the need for assistance with ambulation (ie, an EDSS score &ge;6) within five years from symptom onset, the number of patients with a malignant course was 59 (12 percent) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/150\">",
"      150",
"     </a>",
"     ]. Malignant status was transient for 17 (3.5 percent) and sustained for 42 (8.6 percent). Predictors for malignant MS were older age at onset, motor symptoms at onset, and progressive disease onset.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H39\">",
"     <span class=\"h1\">",
"      PROGNOSTIC FACTORS",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of factors have been identified as possible prognostic indicators in MS that may modify the disease course or predict exacerbations.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H40\">",
"     <span class=\"h2\">",
"      Demographic and racial factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;As already noted (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Geographic factors'",
"     </a>",
"     above), white populations, especially those originally from Northern Europe, appear to have the highest risk for developing MS, while people of Asian, African, or American Indian origin have the lowest risk.",
"    </p>",
"    <p>",
"     Racial differences may also exist for the clinical features and prognosis of MS, although this is less well established than for differences in the risk of developing MS. A retrospective study found that black Americans who develop MS have a later age of disease onset than white Americans (age 33.7 versus 31.1 years, respectively) and are more likely to develop ambulatory disability than white Americans with MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/151\">",
"      151",
"     </a>",
"     ]. Since the median time to both MS diagnosis and MS onset to treatment was significantly shorter for blacks compared with the whites in this study population, it is likely that the increased risk of disability for blacks is independent of health care access.",
"    </p>",
"    <p>",
"     The same study noted that black Americans with MS were more likely to present with multifocal signs and symptoms, were more likely to have clinical involvement restricted to the optic nerves and spinal cord (opticospinal MS), and were more likely to develop transverse myelitis compared with white Americans with MS [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/151\">",
"      151",
"     </a>",
"     ]. It should be noted that while 63 black Americans in the study had opticospinal MS (defined as relapses or clinical signs restricted to the optic nerves and spinal cord), only three met the criteria for neuromyelitis optica (NMO or Devic's syndrome) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/152\">",
"      152",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H25#H25\">",
"      \"Diagnosis of multiple sclerosis in adults\", section on 'Neuromyelitis optica and optic-spinal MS'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Earlier data suggested that MS followed a more benign course in women than men and that onset at an early age has a favorable prognosis compared with onset at older ages [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136\">",
"      136",
"     </a>",
"     ]. These notions have been challenged by subsequent data showing that sex and age of onset are not independent prognostic factors [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/141\">",
"      141",
"     </a>",
"     ]. (See",
"     <a class=\"local\" href=\"#H36\">",
"      'Rate of disability progression'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H41\">",
"     <span class=\"h2\">",
"      Relapsing versus progressive phase of disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;The relapsing form of MS is generally associated with a better prognosis than progressive disease [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136,141\">",
"      136,141",
"     </a>",
"     ]. An observational natural history study found that irreversible disability occurred sooner in patients in whom the disease was progressive from the onset than in those in whom the onset was relapsing-remitting [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/139\">",
"      139",
"     </a>",
"     ]. Once irreversible disability occurred, however, the time course of progressive disability was similar in the two groups.",
"    </p>",
"    <p>",
"     Although not firmly established by the existing evidence, there are data suggesting that most patients with relapsing MS will eventually enter a progressive phase of disease [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136,153\">",
"      136,153",
"     </a>",
"     ] where neurologic disability gradually worsens regardless of the presence or absence of superimposed attacks. The development of a progressive course may be the single most adverse factor influencing prognosis [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/145,153-159\">",
"      145,153-159",
"     </a>",
"     ]. One study found that the progressive phase of MS appeared to be independent of relapses that occurred before or after the onset of relapse-free progression [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/153\">",
"      153",
"     </a>",
"     ]. In addition, disability in MS may be more dependent on patient age than on the initial course, whether relapsing or progressive from onset [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/144,160\">",
"      144,160",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H42\">",
"     <span class=\"h2\">",
"      Early disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain types of MS symptoms at disease onset were once thought to predict a favorable (sensory symptoms, optic neuritis) or unfavorable (pyramidal, brainstem, and cerebellar symptoms) prognosis [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/136\">",
"      136",
"     </a>",
"     ]. However, subsequent data suggested that none of these onset symptoms were independent prognostic factors [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/141,161\">",
"      141,161",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     In a systematic review of 27 eligible studies published by May 2005 that evaluated patients with RRMS, bowel",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     bladder symptoms at onset were the only symptoms that had strong and consistent associations with poor prognosis. Additional factors that predicted long-term disability in those with RRMS were incomplete recovery from the first attack, a short interval between the first and second attack, and early accumulation of disability [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/161\">",
"      161",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     An observational study found that early clinical variables predicted time to disability defined as an EDSS of 4 (ie, limited walking but without aid) but not the subsequent progression of disease [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/162\">",
"      162",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     A long-term observational study of patients with progressive types of MS found that polysymptomatic compared with monosymptomatic onset of MS was associated with a significantly shorter time to the development of progressive disease [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/153\">",
"      153",
"     </a>",
"     ]. (See",
"     <a class=\"local\" href=\"#H36\">",
"      'Rate of disability progression'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H43\">",
"     <span class=\"h2\">",
"      Lesion load",
"     </span>",
"     &nbsp;&mdash;&nbsp;A serial MRI study in 71 patients followed for a mean of 14 years found that lesion volume at five years and the change in volume during the first five years of illness correlated more strongly with disability scores at 14 years than measures of volume at earlier or later times, suggesting that the development of lesions in the early years may have an important influence on long-term disability [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/163\">",
"      163",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     However, there is only weak correlation between MRI lesion load and age at disease onset, disease duration, and progression, as shown in an analysis of 1312 placebo subjects with MS in pooled data from 11 randomized controlled trials [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/164\">",
"      164",
"     </a>",
"     ]. The correlation appears to plateau at higher levels of disability, suggesting that MRI lesion burden is a poor measure of disease progression in patients with advanced disease.",
"    </p>",
"    <p>",
"     Furthermore, the extent of cranial MRI abnormalities in individual patients does not necessarily correlate with the degree of clinical disability. Patients with small numbers of lesions may be quite disabled, while others can function well despite a large burden of disease detected by MRI. There are several possible explanations for this observation: lesions may occur in areas that are clinically silent; small lesions in the spinal cord can cause major disability in the absence of cerebral lesions; MRI may miss or underestimate lesions that are clinically relevant such as those in cortex, basal ganglia, and brainstem; and large plaques detected by MRI may not have functional correlates but reflect increased tissue water without impairment of neural function.",
"    </p>",
"    <p>",
"     The amount of ongoing MRI activity (new or enlarging lesions",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     gadolinium-enhancing lesions) exceeds the observed clinical activity by a factor of 2 to 10 [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/165\">",
"      165",
"     </a>",
"     ]. This may reflect not only the factors discussed above, but also may be due in part to underreporting of minor symptoms and under recognition of minor signs in MS patients. It does, however, suggest that MS is a much more dynamic and active disease than is clinically apparent.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H44\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Since MS is a disease that predominantly affects women and has a maximum incidence during child-bearing years, the course and prognosis of MS with pregnancy has been studied. Some studies have noted a reduction in relapses late in pregnancy and an increase in the three-month postpartum period [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/166\">",
"      166",
"     </a>",
"     ], but these findings are not universal. It is generally agreed that there is no difference in overall prognosis between women who have been pregnant compared with those who have not. Furthermore, women with MS do not have an increased number of stillbirths, ectopic pregnancies, or spontaneous abortions [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/167\">",
"      167",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20634?source=see_link&amp;anchor=H3#H3\">",
"      \"Neurologic disorders complicating pregnancy\", section on 'Multiple sclerosis'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     These data suggest that pregnancy has no ill effect on MS and that MS has no negative effect on the fetus or the course of pregnancy. However, pregnancy may affect the choice of therapy since some drugs used to treat MS are known teratogens (",
"     <a class=\"graphic graphic_table graphicRef73903 \" href=\"mobipreview.htm?1/12/1228\">",
"      table 6",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H45\">",
"     <span class=\"h2\">",
"      Psychosocial stress",
"     </span>",
"     &nbsp;&mdash;&nbsp;Relapses of MS may be more common after stressful life events [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/168-170\">",
"      168-170",
"     </a>",
"     ]. Perhaps the strongest evidence comes from a meta-analysis of 14 observational studies that found a significant association between stress and MS exacerbations [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/168\">",
"      168",
"     </a>",
"     ]. The authors cautioned that the study does not offer absolute evidence of a causal association.",
"    </p>",
"    <p>",
"     The potential biological mechanisms that might link stress to MS exacerbations remain unproven. Proposed mechanisms include proinflammatory responses mediated by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Increased T cell production [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/171\">",
"        171",
"       </a>",
"       ] of gamma interferon [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/169\">",
"        169",
"       </a>",
"       ]",
"      </li>",
"      <li>",
"       Increased cortisol concentrations enhancing sensitivity of T cells to proinflammatory cytokines and peptides [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/172\">",
"        172",
"       </a>",
"       ]",
"      </li>",
"      <li>",
"       Increased cortisol altering glucocorticoid receptors on immune cells [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/173\">",
"        173",
"       </a>",
"       ]",
"      </li>",
"      <li>",
"       Increased permeability of the blood brain barrier via activation of endothelial mast cells [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/174\">",
"        174",
"       </a>",
"       ]",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H46\">",
"     <span class=\"h2\">",
"      Other factors",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Physical trauma does not appear to be related to disease induction or relapse [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/44/32458/abstract/169\">",
"        169",
"       </a>",
"       ]",
"      </li>",
"      <li>",
"       Neurologic diagnostic procedures such as myelography and lumbar puncture have not been linked with aggravation of the disease course, nor has administration of local or general anesthetics",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"     <span class=\"h1\">",
"      INFORMATION FOR PATIENTS",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"     <sup>",
"      th",
"     </sup>",
"     to 6",
"     <sup>",
"      th",
"     </sup>",
"     grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"     <sup>",
"      th",
"     </sup>",
"     to 12",
"     <sup>",
"      th",
"     </sup>",
"     grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Basics topics (see",
"       <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=see_link\">",
"        \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H190608281\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Multiple sclerosis (MS) is a heterogeneous disorder with variable clinical and pathologic features reflecting different pathways to tissue injury. Inflammation, demyelination, and axon degeneration are the major pathologic mechanisms that cause the clinical manifestations. However, the cause of MS remains unknown. The most widely accepted theory is that MS begins as an inflammatory autoimmune disorder mediated by autoreactive lymphocytes. Later, the disease is dominated by microglial activation and chronic neurodegeneration. (See",
"       <a class=\"local\" href=\"#H2\">",
"        'Pathogenesis'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Multiple sclerosis affects more women than men. The median and mean ages of MS onset are 23.5 and 30 years of age, respectively. The peak age of onset is about five years earlier for women than for men. Onset of MS can rarely occur as late as the seventh decade. (See",
"       <a class=\"local\" href=\"#H3\">",
"        'Epidemiology and risk factors'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       The incidence and prevalence of MS varies geographically. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Geographic factors'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       There is no association between vaccines and MS. Although many viruses, and particularly the Epstein Barr virus, have been associated with MS, there is no specific evidence linking viruses directly to the development of MS. (See",
"       <a class=\"local\" href=\"#H4\">",
"        'Role of immune system stimuli'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Genetic factors appear to contribute to the pathogenesis of MS, particularly variation involving the HLA-DRB1 locus. (See",
"       <a class=\"local\" href=\"#H8\">",
"        'Genetic factors'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Chronic cerebrospinal venous insufficiency has been reported in some patients with MS but its relationship to MS is controversial (See",
"       <a class=\"local\" href=\"#H176638034\">",
"        'Chronic cerebrospinal venous insufficiency'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       There are no clinical findings that are unique to MS, but some are highly characteristic of the disease (",
"       <a class=\"graphic graphic_table graphicRef63940 \" href=\"mobipreview.htm?21/53/22363\">",
"        table 2",
"       </a>",
"       ). Common symptoms of MS (",
"       <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"        table 3",
"       </a>",
"       ) include sensory symptoms in limbs or face, visual loss, acute or subacute motor weakness, diplopia, gait disturbance and balance problems, Lhermitte's sign (electric shock-like sensations that run down the back",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       limbs upon flexion of the neck), vertigo, bladder problems, limb ataxia, acute transverse myelopathy, and pain. The onset is often polysymptomatic. The typical patient presents as a young adult with two or more clinically distinct episodes of CNS dysfunction with at least partial resolution. (See",
"       <a class=\"local\" href=\"#H9\">",
"        'Clinical symptoms and signs'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Multiple sclerosis is most commonly characterized by relapse, which is defined as the acute or subacute onset of clinical dysfunction that usually reaches its peak from days to several weeks, followed by a remission during which the symptoms and signs resolve to a variable extent. The common patterns of MS are categorized as follows (See",
"       <a class=\"local\" href=\"#H27\">",
"        'Relapses'",
"       </a>",
"       above and",
"       <a class=\"local\" href=\"#H28\">",
"        'Disease pattern'",
"       </a>",
"       above.):",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Relapsing-remitting multiple sclerosis (RRMS) is characterized by clearly defined relapses with full recovery or with sequelae and residual deficit upon recovery. There is no disease progression during the periods between disease relapses. This type of MS accounts for approximately 85 to 90 percent of MS cases at onset. However, most patients with RRMS will eventually enter a secondary progressive phase.",
"      </li>",
"      <li>",
"       Secondary progressive multiple sclerosis (SPMS) is characterized by an initial RRMS disease course followed by progression with or without occasional relapses, minor remissions, and plateaus. Some studies suggest that SPMS ultimately develops in most patients with RRMS and causes the greatest amount of neurological disability.",
"      </li>",
"      <li>",
"       Primary progressive multiple sclerosis (PPMS) is characterized by disease progression from onset with occasional plateaus and temporary minor improvements allowed. This type represents about 10 percent of cases at disease onset. In PPMS, patients experience a steady decline in function from the beginning and never have acute attacks.",
"      </li>",
"      <li>",
"       Progressive relapsing multiple sclerosis (PRMS) is characterized by progressive disease from onset, with clear acute relapses, with or without full recovery. Progression continues during the periods between disease relapses.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Progression of disability due to MS is highly variable, but accumulating evidence suggests that progression in most patients with MS is slow. At the extreme ends of the severity spectrum, there are benign and malignant forms of MS. Benign MS refers to disease in which the patient remains fully functional in all neurologic systems 15 years after the disease onset. Malignant MS refers to disease with a rapid progressive course, leading to significant disability in multiple neurologic systems or death in a relatively short time after disease onset. (See",
"       <a class=\"local\" href=\"#H34\">",
"        'Disease severity'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       A variety of factors have been identified as possible prognostic indicators in MS that may modify the disease course or predict exacerbations. White populations, especially those originally from Northern Europe, appear to have the highest risk for developing MS, while people of Asian, African, or American Indian origin have the lowest risk. The relapsing form of MS is generally associated with a better prognosis than progressive disease. (See",
"       <a class=\"local\" href=\"#H39\">",
"        'Prognostic factors'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"   <div id=\"topicAgreement\">",
"    Use of UpToDate is subject to the",
"    <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"     Subscription and License Agreement",
"    </a>",
"    .",
"   </div>",
"   <div class=\"headingAnchor\" id=\"references\">",
"    <h1>",
"     REFERENCES",
"    </h1>",
"    <ol id=\"reference\">",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/1\">",
"       Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004; 61:1613.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/2\">",
"       Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/3\">",
"       Roach ES. Is multiple sclerosis an autoimmune disorder? Arch Neurol 2004; 61:1615.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/4\">",
"       Lucchinetti C, Br&uuml;ck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/5\">",
"       Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367:115.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/6\">",
"       Oksenberg JR, Panzara MA, Begovich AB, et al. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993; 362:68.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/7\">",
"       Zhang J, Markovic-Plese S, Lacet B, et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179:973.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/8\">",
"       Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/9\">",
"       Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13:1173.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/10\">",
"       Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172:146.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/11\">",
"       Petry KG, Boullerne AI, Pousset F, et al. Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis. Pathol Biol (Paris) 2000; 48:47.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/12\">",
"       Steinman L. Multiple sclerosis. Presenting an odd autoantigen. Nature 1995; 375:739.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/13\">",
"       Chaudhuri A, Behan PO. Multiple sclerosis is not an autoimmune disease. Arch Neurol 2004; 61:1610.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/14\">",
"       Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/15\">",
"       Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123 ( Pt 6):1174.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/16\">",
"       Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157:267.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/17\">",
"       Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006; 354:942.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/18\">",
"       Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55:458.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/19\">",
"       Matute C, P&eacute;rez-Cerd&aacute; F. Multiple sclerosis: novel perspectives on newly forming lesions. Trends Neurosci 2005; 28:173.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/20\">",
"       Alonso A, Hern&aacute;n MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71:129.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/21\">",
"       Koch-Henriksen N, S&oslash;rensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9:520.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/22\">",
"       Kotzamani D, Panou T, Mastorodemos V, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012; 78:1728.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/23\">",
"       Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999; 53:883.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/24\">",
"       Heinzlef O, Alamowitch S, Sazdovitch V, et al. Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 2000; 101:36.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/25\">",
"       Ramagopalan SV, Dyment DA, Valdar W, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007; 6:604.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/26\">",
"       Nielsen NM, Westergaard T, Frisch M, et al. Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study. Arch Neurol 2006; 63:1001.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/27\">",
"       Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129:819.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/28\">",
"       Ascherio A, Zhang SM, Hern&aacute;n MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/29\">",
"       Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344:319.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/30\">",
"       Hern&aacute;n MA, Alonso A, Hern&aacute;ndez-D&iacute;az S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006; 67:212.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/31\">",
"       Rutschmann OT, McCrory DC, Matchar DB, Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology 2002; 59:1837.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/32\">",
"       DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60:504.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/33\">",
"       Hern&aacute;n MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004; 63:838.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/34\">",
"       Naismith RT, Cross AH. Does the hepatitis B vaccine cause multiple sclerosis? Neurology 2004; 63:772.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/35\">",
"       Brahic M. Multiple sclerosis and viruses. Ann Neurol 2010; 68:6.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/36\">",
"       Hern&aacute;n MA, Zhang SM, Lipworth L, et al. Multiple sclerosis and age at infection with common viruses. Epidemiology 2001; 12:301.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/37\">",
"       Pender MP. Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis? Brain 2009; 132:3196.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/38\">",
"       Bagert BA. Epstein-Barr virus in multiple sclerosis. Curr Neurol Neurosci Rep 2009; 9:405.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/39\">",
"       Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59:499.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/40\">",
"       Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286:3083.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/41\">",
"       Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293:2496.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/42\">",
"       Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204:2899.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/43\">",
"       Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132:3318.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/44\">",
"       Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010; 74:1127.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/45\">",
"       Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012; 78:15.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/46\">",
"       Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55:178.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/47\">",
"       Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35:435.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/48\">",
"       Bray PF, Bloomer LC, Salmon VC, et al. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983; 40:406.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/49\">",
"       Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11:220.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/50\">",
"       Sundstr&ouml;m P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62:2277.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/51\">",
"       Levin LI, Munger KL, O'Reilly EJ, et al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67:824.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/52\">",
"       Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004; 291:1875.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/53\">",
"       Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4:195.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/54\">",
"       Sotelo J, Mart&iacute;nez-Palomo A, Ordo&ntilde;ez G, Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. Ann Neurol 2008; 63:303.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/55\">",
"       Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. J Infect Dis 2011; 204:188.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/56\">",
"       Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/57\">",
"       Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005; 293:463.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/58\">",
"       Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7:268.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/59\">",
"       Simpson S Jr, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:1132.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/60\">",
"       Hern&aacute;n MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999; 53:1711.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/61\">",
"       Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61:504.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/62\">",
"       van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327:316.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/63\">",
"       Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007; 69:381.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/64\">",
"       Orton SM, Wald L, Confavreux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011; 76:425.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/65\">",
"       Ramagopalan SV, Handel AE, Giovannoni G, et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011; 76:1410.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/66\">",
"       Salzer J, Hallmans G, Nystr&ouml;m M, et al. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012; 79:2140.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/67\">",
"       Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/68\">",
"       Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72:234.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/69\">",
"       Franklin GM, Nelson L. Environmental risk factors in multiple sclerosis: causes, triggers, and patient autonomy. Neurology 2003; 61:1032.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/70\">",
"       Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003; 61:1122.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/71\">",
"       Hern&aacute;n MA, Jick SS, Logroscino G, et al. Cigarette smoking and the progression of multiple sclerosis. Brain 2005; 128:1461.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/72\">",
"       Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66:858.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/73\">",
"       Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009; 73:504.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/74\">",
"       Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005; 330:120.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/75\">",
"       Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37:1108.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/76\">",
"       International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:851.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/77\">",
"       Friese MA, Jakobsen KB, Friis L, et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008; 14:1227.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/78\">",
"       De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41:776.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/79\">",
"       Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009; 41:824.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/80\">",
"       International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476:214.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/81\">",
"       Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39:1083.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/82\">",
"       Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39:1108.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/83\">",
"       Ramagopalan SV, Anderson C, Sadovnick AD, Ebers GC. Genomewide study of multiple sclerosis. N Engl J Med 2007; 357:2199.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/84\">",
"       International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. Lancet Neurol 2008; 7:567.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/85\">",
"       Rubio JP, Stankovich J, Field J, et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 2008; 9:624.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/86\">",
"       Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009; 5:e1000369.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/87\">",
"       Nolan D, Castley A, Tschochner M, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology 2012; 79:538.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/88\">",
"       Sadovnick AD, Armstrong H, Rice GP, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33:281.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/89\">",
"       Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: a nationwide cohort study. Am J Epidemiol 2005; 162:774.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/90\">",
"       Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004; 363:1773.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/91\">",
"       Hupperts R, Broadley S, Mander A, et al. Patterns of disease in concordant parent-child pairs with multiple sclerosis. Neurology 2001; 57:290.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/92\">",
"       Kantarci OH, Barcellos LF, Atkinson EJ, et al. Men transmit MS more often to their children vs women: the Carter effect. Neurology 2006; 67:305.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/93\">",
"       Herrera BM, Ramagopalan SV, Orton S, et al. Parental transmission of MS in a population-based Canadian cohort. Neurology 2007; 69:1208.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/94\">",
"       Hoppenbrouwers IA, Liu F, Aulchenko YS, et al. Maternal transmission of multiple sclerosis in a dutch population. Arch Neurol 2008; 65:345.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/95\">",
"       Herrera BM, Ramagopalan SV, Lincoln MR, et al. Parent-of-origin effects in MS: observations from avuncular pairs. Neurology 2008; 71:799.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/96\">",
"       Kantarci OH, Spurkland A. Parent of origin in multiple sclerosis: understanding inheritance in complex neurologic diseases. Neurology 2008; 71:786.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/97\">",
"       Burwick RM, Ramsay PP, Haines JL, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006; 66:1373.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/98\">",
"       van der Walt A, Stankovich J, Bahlo M, et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009; 73:1018.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/99\">",
"       Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:392.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/100\">",
"       Simka M, Kostecki J, Zaniewski M, et al. Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis. Int Angiol 2010; 29:109.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/101\">",
"       Al-Omari MH, Rousan LA. Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int Angiol 2010; 29:115.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/102\">",
"       Zivadinov R, Marr K, Cutter G, et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011; 77:138.",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/44/32458/abstract/103\">",
"       Doepp F, Paul F, Valdueza JM, et al. No cerebrocervical venous congestion in patients with",
"      </a>",
"     </li>",
"    </ol>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var script_f31_44_32458=[""].join("\n");
var outline_f31_44_32458=null;
var title_f31_44_32459="Pain assoc interventions";
var content_f31_44_32459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute pain syndromes associated with diagnostic and therapeutic interventions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute pain syndromes associated with diagnostic interventions:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lumbar puncture-associated and post-lumbar puncture headache",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arterial or venous blood sampling",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endoscopy and biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endometrial biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transrectal prostate biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Percutaneous biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bone marrow biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute pain syndromes associated with therapeutic interventions:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pleurodesis/chest tube insertions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Percutaneous biliary stents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal paracentesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vascular embolization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Suprapubic catheterization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nephrostomy tube insertion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute pain syndromes associated with analgesic techniques:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Injection-related pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Opioid hyperalgesia syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epidural injection pain",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32459=[""].join("\n");
var outline_f31_44_32459=null;
var title_f31_44_32460="Paget dz breast surg XRT";
var content_f31_44_32460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Paget disease of the breast with breast conserving surgery and radiation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Local Recurrence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median F/U (mos)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fourquet A; 1987",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        <p>",
"         No mass",
"        </p>",
"        <p>",
"         Normal mammogram",
"        </p>",
"       </td>",
"       <td>",
"        Biopsy + radiation",
"       </td>",
"       <td>",
"        3 (18 percent)",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulens P; 1990",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        No mass",
"       </td>",
"       <td>",
"        Biopsy + radiation",
"       </td>",
"       <td>",
"        0 (0 percent)",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stockdale AD; 1989",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        <p>",
"         No mass",
"        </p>",
"        <p>",
"         Normal mammogram",
"        </p>",
"       </td>",
"       <td>",
"        Biopsy + radiation",
"       </td>",
"       <td>",
"        3 (16 percent)",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        <p>",
"         No mass",
"        </p>",
"        <p>",
"         Abnormal/unknown mammogram",
"        </p>",
"       </td>",
"       <td>",
"        Biopsy + radiation",
"       </td>",
"       <td>",
"        5 (8 percent)",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rissanen PM; 1969",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Local surgery + radiation",
"       </td>",
"       <td>",
"        3 (38 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bijker N; 2001",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        <p>",
"         No mass, 97 percent",
"        </p>",
"        <p>",
"         Normal mammogram, 84 percent",
"        </p>",
"       </td>",
"       <td>",
"        Complete nipple-areolar resection + radiation",
"       </td>",
"       <td>",
"        4 (6 percent)",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marshall JK; 2003",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        <p>",
"         No mass",
"        </p>",
"        <p>",
"         Normal mammogram",
"        </p>",
"       </td>",
"       <td>",
"        Partial nipple-areolar resection + radiation (n = 9); complete nipple-areolar resection + radiation (n = 25)",
"       </td>",
"       <td>",
"        4 (11 percent)",
"       </td>",
"       <td>",
"        113",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Fourquet A, et al. Int J Radiat Oncol Biol Phys 1987; 13:1463. Bulens P, et al. Radiother Oncol 1990; 17:305. Stockdale AD, et al. Lancet 1989; 2:664 Rissanen PM, et al. Oncology 1969; 23:209 Bijker N, et al. Cancer 2001: 91:472 Marshall JK, et al. Cancer 2003; 97:2142.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32460=[""].join("\n");
var outline_f31_44_32460=null;
var title_f31_44_32461="AED nonAED drug interactions";
var content_f31_44_32461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiepileptic drug-nonantiepileptic drug interactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nonantiepileptic drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antiepileptic drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome of drug interaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antacids",
"       </td>",
"       <td>",
"        Phenobarbital, phenytoin, carbamazepine, and gabapentin",
"       </td>",
"       <td>",
"        Reduced gut absorption of the AEDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticancer agents",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        AEDs can increase the metabolism of anticancer agents and reduce therapeutic efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiviral agents that are metabolized by CYP3A4",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        AEDs can increase the metabolism and reduce the plasma concentrations of antiviral agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Carbamazepine, phenytoin, and phenobarbital",
"       </td>",
"       <td>",
"        Increases metabolism and decreases plasma concentrations of benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine",
"       </td>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Inhibition of phenytoin metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Inhibition of AED metabolism and increased plasma concentrations of carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroids",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        Increased metabolism of the corticosteroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        AEDs can increase the metabolism and reduce the plasma concentrations of cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td>",
"        Phenytoin, topiramate",
"       </td>",
"       <td>",
"        Decreased plasma concentrations of digoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Inhibition of the metabolism of the AEDs and increased plasma concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Inhibition of phenytoin metabolism with a possible increase in phenytoin plasma concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoxetine",
"       </td>",
"       <td>",
"        Carbamazepine and phenytoin",
"       </td>",
"       <td>",
"        Inhibition of AED metabolism and increased plasma concentrations of carbamazepine and phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Griseofulvin",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        Increased metabolism of griseofulvin and reduced plasma concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haloperidol",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        Increased metabolism of haloperidol with a subsequent decrease in plasma concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Omeprazole",
"       </td>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Inhibition of phenytoin metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptive pill",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital, felbamate, oxcarbazepine, perampanel&nbsp;and topiramate)",
"       </td>",
"       <td>",
"        Increased metabolism of the contraceptive pill and reduced hormone levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propofol&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Valproate",
"       </td>",
"       <td>",
"        Valproate reduces the dose of propofol required for sedation*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline",
"       </td>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        Inhibition of AED metabolism and increased plasma concentrations of lamotrigine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        Carbamazepine, phenytoin, perampanel",
"       </td>",
"       <td>",
"        The metabolism of carbamazepine, phenytoin and perampanel&nbsp;may be increased by St. John's wort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        Increased metabolism of theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants (TCAs)",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        Bidirectional interaction with TCA concentrations reducing and AED concentrations increasing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin",
"       </td>",
"       <td>",
"        Enzyme-inducing AEDs (eg, carbamazepine, phenytoin, phenobarbital and others, see text)",
"       </td>",
"       <td>",
"        Increased metabolism of warfarin and reduced anticoagulant activity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Ishii M, Higuchi H, Maeda S, et al. The influence of oral VPA on the required dose of propofol for sedation during dental treatment in patients with mental retardation: A prospective observer-blinded cohort study. Epilepsia 2012, 53:e13.",
"     <br>",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Patsalos PN, Froscher W, Pisani F, van Rijn CM, Epilepsia 2002; 43:365.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32461=[""].join("\n");
var outline_f31_44_32461=null;
var title_f31_44_32462="Abnormal leukocyte movement in LAD II";
var content_f31_44_32462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/59192/ldd_stim_conv.mp4?title=Abnormal+leukocyte+movement+in+LAD+II\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal leukocyte movement in leukocyte adhesion deficiency II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Amos Etzioni.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32462=[""].join("\n");
var outline_f31_44_32462=null;
var title_f31_44_32463="Sensation anterolateral thigh";
var content_f31_44_32463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sensation over the anterolateral thigh",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Sensory testing is performed in patients with suspected lateral femoral cutaneous nerve entrapment (meralgia paresthetica) to assess the anterolateral thigh. The skin is tested for light touch, pinprick, and deep pain sensation. Loss of sensation (hypesthesia) or a feeling of heightened sensation (dysesthesia) is characteristic of meralgia paresthetica.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Andrson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_44_32463=[""].join("\n");
var outline_f31_44_32463=null;
